Name	BrandName	Applicants	CHEMBL_ID	Canonical_Smiles	Chirality	First_Approval	Phase	SC_Patent	Synonyms	Indications	Type	targets_id	inchi	stdInchikey	csid	Links	LinkName	lig_pdbID	pdbID	indicationG2P	indicationDB	uniprotId	MW	HBA	HBD	NRB	TPSA	LogP	RoF	Melting point	Targets	Kinase families	FDA_approved
Abemaciclib	Verzenio;Verzenios	Eli Lilly	CHEMBL3301610	CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F	Achiral Molecule	2017	4.0	US-7855211-B2	ABEMACICLIB | LY-2835219 | LY2835219 | VERZENIO | VERZENIOS	On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for  women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.	1	P11802|Q00534	InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)	UZWDCWONPYILKI-UHFFFAOYSA-N	29340700	|http://www.chemspider.com/Chemical-Structure.29340700.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301610|http://pubchem.ncbi.nlm.nih.gov/compound/46220502|http://www.drugbank.ca/drugs/DB12001| http://www.rcsb.org/ligand/6ZV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6ZV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7382|http://zinc15.docking.org/substances/ZINC000072318121|https://precision.fda.gov/uniisearch/srs/unii/60UAB198HK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50110183	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'6ZV'	5l2s 7o7j 7o7k 7sj3		"Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with <a href=""https://go.drugbank.com/drugs/DB00947"">Fulvestrant</a>. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma."	P11802|Q00534|P08684|P05177|P20813|P10632|P11712|P10635	506.3	8	1	7	75.0	4.9	1		CDK4; CDK6	CMGC	Y
Abivertinib		ACEA Biosciences	CHEMBL4297865	CN1CCN(CC1)c2ccc(cc2F)Nc3nc4c(cc[nH]4)c(n3)Oc5cccc(c5)NC(=O)C=C	Achiral Molecule	nan	3.0	None	A610 | ABIVERTINIB | AC-0010 | AC0010 | ACEA100610 | AVITINIB | EX-ACEA0010	"AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [<a href='javascript:callRef(""ReferenceDisplayForward?referenceId=35960&displayId=2"", 960, 600)' title=""2. Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B, Xu R, Fang X, Liu J, Fang C et al.. (2016) Mol. Cancer Ther. 15 (11): 2586-2597"">2</a>]. It may also inhibit BTK, thus offering extended clinical utility [<a href='javascript:callRef(""ReferenceDisplayForward?referenceId=35961&displayId=3"", 960, 600)' title=""3. Yan X, Zhou Y, Huang S, Li X, Yu M, Huang J, Wang J, Ma Z, Jin J, Pan J et al.. (2018) J. Cancer Res. Clin. Oncol. 144 (4): 697-706"">3</a>]. We show the structure for the free base form of the compound."	nan	nan	InChI=1S/C26H26FN7O2/c1-3-23(35)29-17-5-4-6-19(15-17)36-25-20-9-10-28-24(20)31-26(32-25)30-18-7-8-22(21(27)16-18)34-13-11-33(2)12-14-34/h3-10,15-16H,1,11-14H2,2H3,(H,29,35)(H2,28,30,31,32)	UOFYSRZSLXWIQB-UHFFFAOYSA-N	57490375	|http://www.chemspider.com/Chemical-Structure.57490375.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297865|http://pubchem.ncbi.nlm.nih.gov/compound/72734520|http://www.drugbank.ca/drugs/DB15327|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10044|http://zinc15.docking.org/substances/ZINC000142081723|https://precision.fda.gov/uniisearch/srs/unii/CER0OPG92L|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=294480	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Abivertinib is a tyrosine kinase inhibitor targeted against mutant forms of both human epidermal growth factor receptor (EGFR) and Bruton&#39;s tyrosine kinase (BTK).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Sorrento Therapeutics: Abivertinib"" href=""#reference-L17383"">1</a></sup> It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies. In binding to and inhibiting EGFR and BTK receptors, abivertinib exerts immunomodulatory effects by preventing the production and release of pro-inflammatory cytokines (e.g. TNF-alpha, interleukins).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Sorrento Therapeutics: Abivertinib COVID-19 Trial"" href=""#reference-L17388"">2</a></sup></p><p>Abivertinib&#39;s potential to depress cytokine production has led to its investigation in the treatment of hospitalized patients with moderate-to-severe COVID-19.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Sorrento Therapeutics: Abivertinib COVID-19 Trial"" href=""#reference-L17388"">2</a>,<a class=""reference-popover-link"" data-content=""NCT04440007: Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19 (SOC)"" href=""#reference-L17393"">3</a></sup> The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). The study is expected to be completed in March 2021.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Targeted Oncology: FDA Clears Phase 2 Study of Abivertinib in Hospitalized Patients With COVID-19"" href=""#reference-L17398"">4</a></sup>"	P00533|Q06187	487.2	7	3	7	98.4	4.5	0		nan		
Abrocitinib	Cibinqo	Pfizer	CHEMBL3655081	CCCS(=O)(=O)NC1CC(C1)N(C)c2c3cc[nH]c3ncn2	Single Stereoisomer	2022	4.0	US-9035074-B2	|PF-04965842|CIBINQO|ABROCITINIB	On January 2022, FDA approved abrocitinib to treat refractory, moderate-to-severe atopic dermatitis	nan	nan	InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)	IUEWXNHSKRWHDY-UHFFFAOYSA-N	68006894	|http://www.chemspider.com/Chemical-Structure.68006894.html|http://pubchem.ncbi.nlm.nih.gov/compound/78323835	|ChemSpider|PubChem						323.1	5	2	6	91.0	1.3	0		nan		Y
Acalabrutinib	Calquence	Astrazeneca	CHEMBL3707348	CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5	Single Stereoisomer	2017	4.0	US-7459554-B2	ACALABRUTINIB | ACP-196 | CALQUENCE	Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy	nan	Q06187	InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1	WDENQIQQYWYTPO-IBGZPJMESA-N	36764951	|http://www.chemspider.com/Chemical-Structure.36764951.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3707348|http://pubchem.ncbi.nlm.nih.gov/compound/71226662|http://www.drugbank.ca/drugs/DB11703|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8912|http://zinc15.docking.org/substances/ZINC000208774715|https://precision.fda.gov/uniisearch/srs/unii/I42748ELQW|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50175583	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.</p><p>As of October 31, 2017 the FDA approved Astra Zeneca&#39;s orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules"" href=""#reference-L10241"">6</a></sup> In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Calquence (acalabrutinib) tablets for oral use"" href=""#reference-L42795"">7</a>,<a class=""reference-popover-link"" data-content=""Bloomberg: CALQUENCE (acalabrutinib) tablet formulation approved in the US across current indications"" href=""#reference-L42800"">8</a></sup> Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules"" href=""#reference-L10241"">6</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Calquence (acalabrutinib) tablets for oral use"" href=""#reference-L42795"">7</a></sup></p><p>Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK.</p><p>Nevertheless, acalabrutinib was approved under the FDA&#39;s accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib&#39;s currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials.</p><p>Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Astra Zeneca Press Release: US FDA Approves Astrazeneca&#39;s Calquence for Adult Patients with Previously-Treated Mantle Cell Lymphoma"" href=""#reference-L1009"">5</a></sup>."	Q06187|P08684|P20815|P08684|Q9HB55|P20815|P24462|P02768|P02763|P19652	465.2	7	2	4	118.5	3.3	0		BTK	Tyr	Y
Acalisib		Gilead Sciences	CHEMBL4303323	C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4	Single Stereoisomer	nan	2.0	None	ACALISIB | CAL-120 | CAL120 | GS-9820 | GS9820	nan	nan	P42336	InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1	DOCINCLJNAXZQF-LBPRGKRZSA-N	9793017	|http://www.chemspider.com/Chemical-Structure.9793017.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303323|http://pubchem.ncbi.nlm.nih.gov/compound/11618268|http://www.drugbank.ca/drugs/DB15407|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10096|http://zinc15.docking.org/substances/ZINC000035943170|https://precision.fda.gov/uniisearch/srs/unii/OVW60IDW1D|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=217352	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						401.1	7	2	4	101.4	3.4	0		PIK3CA	Atypical	
Acumapimod		Mereo BioPharma	CHEMBL3545226	Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4	Single Stereoisomer	nan	2.0	None	|ACUMAPIMOD	nan	nan	Q16539|Q15759|O15264|P53778	InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29)	VGUSQKZDZHAAEE-UHFFFAOYSA-N	9513071	|http://www.chemspider.com/Chemical-Structure.9513071.html|http://pubchem.ncbi.nlm.nih.gov/compound/11338127|http://www.drugbank.ca/drugs/DB15448|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9203|http://zinc15.docking.org/substances/ZINC000116024237|https://precision.fda.gov/uniisearch/srs/unii/2F16KW647L	|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						385.2	6	2	5	113.8	2.8	0		MAPK14; MAPK11; MAPK13; MAPK12	CMGC	
Adavosertib		Astrazeneca	CHEMBL1976040	CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O	Achiral Molecule	nan	2.0	None	ADAVOSERTIB | AZD 1775 | AZD-1775 | AZD1775 | MK-1775 | MK1775	nan	1	P30291	InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)	BKWJAKQVGHWELA-UHFFFAOYSA-N	24808590	|http://www.chemspider.com/Chemical-Structure.24808590.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1976040|http://pubchem.ncbi.nlm.nih.gov/compound/24856436|http://www.drugbank.ca/drugs/DB11740| http://www.rcsb.org/ligand/8X7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8X7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7702|http://zinc15.docking.org/substances/ZINC000063539231|https://precision.fda.gov/uniisearch/srs/unii/K2T6HJX3I3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50240826	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'8X7'	5v5y 5vd0 5vdk 8bjt		MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.	P30291	500.3	10	2	7	104.3	2.9	1		WEE1	Other	
Afatinib	Gilotrif;Giotrif	Boehringer Ingelheim	CHEMBL1173655	CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F	Single Stereoisomer	2013	4.0	US-RE43431-E1	AFATINIB | BIBW 2992 | BIBW-2992 | BIBW2992 | GILOTRIF | GIOTRIF | NSC-750691 | TOMTOVOK | TOVOK	Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.	1	P00533|P04626|Q15303	InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1	ULXXDDBFHOBEHA-CWDCEQMOSA-N	8360155	|http://www.chemspider.com/Chemical-Structure.8360155.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1173655|http://pubchem.ncbi.nlm.nih.gov/compound/10184653|http://www.drugbank.ca/drugs/DB08916| http://www.rcsb.org/ligand/0WM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0WM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5667|http://zinc15.docking.org/substances/ZINC03976838|https://precision.fda.gov/uniisearch/srs/unii/41UD74L59M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50322823	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'0WM'	4g5j		"Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim&#39;s brand name Gilotrif <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Official drug label"" href=""#label-reference"">Label</a></sup>. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Boehringer Ingelheim: FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC"" href=""#reference-L2939"">4</a></sup>. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Boehringer Ingelheim: FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC"" href=""#reference-L2939"">4</a></sup>."	P00533|P04626|Q15303	485.2	7	2	8	88.6	4.4	0		EGFR; ERBB2; ERBB4	Tyr	Y
Afuresertib		GlaxoSmithKline	CHEMBL2219422	Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN	Single Stereoisomer	nan	2.0	None	AFURESERTIB | ASB-183 | ASB183 | GSK-2110183 | GSK-2110183C | GSK2110183 | GSK2110183C	nan	nan	P31749|P31751|Q9Y243	InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1	AFJRDFWMXUECEW-LBPRGKRZSA-N	28651809	|http://www.chemspider.com/Chemical-Structure.28651809.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2219422|http://pubchem.ncbi.nlm.nih.gov/compound/46843057|http://www.drugbank.ca/drugs/DB11648|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7890|http://zinc15.docking.org/substances/ZINC000043197674|https://precision.fda.gov/uniisearch/srs/unii/8739X25QI3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50502477	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						426.0	5	2	6	72.9	3.9	0		AKT1; AKT2; AKT3	AGC	
Agerafenib		Ignyta	CHEMBL2029988	CC(C)(c1cc(no1)NC(=O)Nc2cccc(c2)Oc3c4cc(c(cc4ncn3)OC)OC)C(F)(F)F	Achiral Molecule	nan	1.0	None	AB-024 | AC-013773 | AGERAFENIB | CEP-32496 | RXDX 105 | RXDX-105	nan	nan	nan	InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33)	DKNUPRMJNUQNHR-UHFFFAOYSA-N	28506650	|http://www.chemspider.com/Chemical-Structure.28506650.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2029988|http://pubchem.ncbi.nlm.nih.gov/compound/56846693|http://www.drugbank.ca/drugs/DB15068|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7880|http://zinc15.docking.org/substances/ZINC000043207440|https://precision.fda.gov/uniisearch/srs/unii/78I4VEX88N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50382959	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						517.2	8	2	7	120.6	5.9	2		nan		
Alectinib	Alecensa	Hoffmann-La Roche	CHEMBL1738797	CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C	Achiral Molecule	2015	4.0	US-9126931-B2	AF-802 | AF802 | ALECENSA | ALECTINIB | CH-5424802 | CH5424802 | RO-5424802 | RO5424802	Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.	1	Q9UM73	InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3	KDGFLJKFZUIJMX-UHFFFAOYSA-N	26326738	|http://www.chemspider.com/Chemical-Structure.26326738.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738797|http://pubchem.ncbi.nlm.nih.gov/compound/49806720|http://www.drugbank.ca/drugs/DB11363| http://www.rcsb.org/ligand/EMH|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EMH|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7739|http://zinc15.docking.org/substances/ZINC000066166864|https://precision.fda.gov/uniisearch/srs/unii/LIJ4CT1Z3Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50362781	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'EMH'	3aox 5xv7		Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. </p><p>Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance.	Q9UM73	482.3	5	1	3	72.4	4.8	0		ALK	Tyr	Y
Alflutinib		Allist Pharmaceuticals	CHEMBL4297258	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C	Achiral Molecule	nan	3.0	None	ALFLUTINIB | AST-2818 | AST2818 | FURMONERTINIB	nan	nan	nan	InChI=1S/C28H31F3N8O2/c1-6-24(40)33-21-15-22(26(41-17-28(29,30)31)36-25(21)38(4)14-13-37(2)3)35-27-32-12-11-20(34-27)19-16-39(5)23-10-8-7-9-18(19)23/h6-12,15-16H,1,13-14,17H2,2-5H3,(H,33,40)(H,32,34,35)	GHKOONMJXNWOIW-UHFFFAOYSA-N	81367235	|http://www.chemspider.com/Chemical-Structure.81367235.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297258|http://pubchem.ncbi.nlm.nih.gov/compound/118861389|http://www.drugbank.ca/drugs/DB16087|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10477|https://precision.fda.gov/uniisearch/srs/unii/A49A7A5YN4	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						568.3	9	2	11	100.4	4.8	1		nan		
Alisertib		Millennium Pharmaceuticals	CHEMBL483158	COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F	Achiral Molecule	nan	3.0	None	ALISERTIB | MLN 8237 | MLN-8237 | MLN8237	For the treatment of various forms of cancer.	1	O14965	InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)	ZLHFILGSQDJULK-UHFFFAOYSA-N	24700147	|http://www.chemspider.com/Chemical-Structure.24700147.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL483158|http://pubchem.ncbi.nlm.nih.gov/compound/24771867|http://www.drugbank.ca/drugs/DB05220| http://www.rcsb.org/ligand/A5B|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/A5B|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7790|http://zinc15.docking.org/substances/ZINC40939534|https://precision.fda.gov/uniisearch/srs/unii/T66ES73M18|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50277545	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'A5B'	5ia0		Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.	O14965	518.1	7	2	6	105.9	5.7	2		AURKA	Other	
Allitinib		Allist Pharmaceuticals	CHEMBL1947204	C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F	Achiral Molecule	nan	2.0	None	ALL-3 | ALLITINIB | ALS 1306 | AST 1306 | AST-1306 | AST1306	nan	nan	P04626|P00533	InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)	MVZGYPSXNDCANY-UHFFFAOYSA-N	25027184	|http://www.chemspider.com/Chemical-Structure.25027184.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1947204|http://pubchem.ncbi.nlm.nih.gov/compound/24739943|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9912|http://zinc15.docking.org/substances/ZINC000052509434|https://precision.fda.gov/uniisearch/srs/unii/CX0M5RO7CY	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS						448.1	5	2	7	76.1	5.9	1		ERBB2; EGFR	Tyr	
Alofanib		Russian Pharmaceutical Technologies	CHEMBL4594436	Cc1cc([N+](=O)[O-])c(NS(=O)(=O)c2cccc(C(=O)O)c2)cc1-c1cccnc1	Achiral Molecule	nan	1.0	None	ALOFANIB	nan	nan	nan	InChI=1S/C19H15N3O6S/c1-12-8-18(22(25)26)17(10-16(12)14-5-3-7-20-11-14)21-29(27,28)15-6-2-4-13(9-15)19(23)24/h2-11,21H,1H3,(H,23,24)	QUQGQIASFYWKAB-UHFFFAOYSA-N	44208820	|http://www.chemspider.com/Chemical-Structure.44208820.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594436|http://pubchem.ncbi.nlm.nih.gov/compound/86280646|http://zinc15.docking.org/substances/ZINC000219244618|https://precision.fda.gov/uniisearch/srs/unii/LQX7RFK8MZ	|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS						413.1	6	2	6	139.5	3.5	0		nan		
Alpelisib	Piqray;Vijoice	Novartis	CHEMBL2396661	Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F	Single Stereoisomer	2019	4.0	US-8227462-B2	ALPELISIB | BYL-719 | BYL719 | NVP-BYL719 | PIQRAY | VIJOICE	On may 2019, FDA approved alpelisib to treat breast cancer	nan	P42336	InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1	STUWGJZDJHPWGZ-LBPRGKRZSA-N	28424123	|http://www.chemspider.com/Chemical-Structure.28424123.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2396661|http://pubchem.ncbi.nlm.nih.gov/compound/56649450|http://www.drugbank.ca/drugs/DB12015| http://www.rcsb.org/ligand/1LT|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1LT|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955|http://zinc15.docking.org/substances/ZINC000068198368|https://precision.fda.gov/uniisearch/srs/unii/08W5N2C97Q|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50436459	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'1LT'	4jps 7myo 7pg6 8gua 8gub 8gud		"Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T: A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3. (PubMed ID 30167089)"" href=""#reference-A179203"">2</a></sup>, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Yang X, Zhang X, Huang M, Song K, Li X, Huang M, Meng L, Zhang J: New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kalpha Complexed with a Potent Lead Compound. Sci Rep. 2017 Nov 6;7(1):14572. doi: 10.1038/s41598-017-15260-5. (PubMed ID 29109464)"" href=""#reference-A179209"">3</a></sup> </p><p>There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as <a href=""https://go.drugbank.com/drugs/DB09054"">idelalisib</a> used for chronic lymphocytic leukemia (CLL).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Yang X, Zhang X, Huang M, Song K, Li X, Huang M, Meng L, Zhang J: New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kalpha Complexed with a Potent Lead Compound. Sci Rep. 2017 Nov 6;7(1):14572. doi: 10.1038/s41598-017-15260-5. (PubMed ID 29109464)"" href=""#reference-A179209"">3</a></sup> Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with <a href=""https://go.drugbank.com/drugs/DB00947"">fulvestrant</a> for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O&#39;Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D&#39;Andrea AD, Winer E, Wulf GM, Matulonis UA: Olaparib and alpha-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14. (PubMed ID 30880072)"" href=""#reference-A179200"">1</a></sup> and colorectal cancer <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T: A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. eCollection 2018 Aug 3. (PubMed ID 30167089)"" href=""#reference-A179203"">2</a></sup>, are under ongoing investigations.</p><p>Alpelisib was granted FDA approval on 24 May 2019.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: PIQRAY (alpelisib) tablets, for oral use"" href=""#reference-L6652"">7</a></sup> In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: VIJOICE (alpelisib) tablets, for oral use"" href=""#reference-L41384"">8</a></sup>"	P42336|P08684|P11712|P10632|P33261|Q9UNQ0|P08183	441.1	5	2	4	101.2	3.8	0		PIK3CA	Atypical	Y
Altiratinib		Deciphera Pharmaceuticals	CHEMBL3545365	c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F	Achiral Molecule	nan	1.0	None	ALTIRATINIB | DCC-2701 | DP-5164	nan	nan	P08581|Q02763|P35968|P04629	InChI=1S/C26H21F3N4O4/c27-15-3-5-16(6-4-15)31-24(35)26(8-9-26)25(36)32-20-12-19(29)21(13-18(20)28)37-17-7-10-30-22(11-17)33-23(34)14-1-2-14/h3-7,10-14H,1-2,8-9H2,(H,31,35)(H,32,36)(H,30,33,34)	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	33427355	|http://www.chemspider.com/Chemical-Structure.33427355.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545365|http://pubchem.ncbi.nlm.nih.gov/compound/54576299|http://www.drugbank.ca/drugs/DB17191| http://www.rcsb.org/ligand/A9I|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/A9I|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9174|http://zinc15.docking.org/substances/ZINC000113198271|https://precision.fda.gov/uniisearch/srs/unii/T678746713|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193395	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'A9I'	7q4a				510.2	5	3	8	109.4	5.0	1		MET; TEK; KDR; NTRK1	Tyr	
Alvocidib		Sanofi	CHEMBL428690	CN1CC[C@@H]([C@@H](C1)O)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O	Single Stereoisomer	nan	3.0	None	ALVOCIDIB | ALVOCIDIB FREEBASE | FLAVOPIRIDOL | HL 275 | HL-275 | HMR 1275 | HMR-1275 | L 86 8275 | L-868275 | L86-8275 | MDL 107,826A | MDL-107826A | NSC-649890	Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).	nan	nan	InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1	BIIVYFLTOXDAOV-YVEFUNNKSA-N	4450222	|http://www.chemspider.com/Chemical-Structure.4450222.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL428690|http://pubchem.ncbi.nlm.nih.gov/compound/5287969|http://www.drugbank.ca/drugs/DB03496| http://www.rcsb.org/ligand/CPB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CPB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5680|http://zinc15.docking.org/substances/ZINC000021288966|https://precision.fda.gov/uniisearch/srs/unii/45AD6X575G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5655	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'CPB'	1c8k 1e1y 3blr 3ebp 4o71		Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.	P11216|P06737|P11217|P50613|Q00535|P50750|P06493|Q00534|P00533|P11802|P49336|P24941|P22309|Q9UNQ0	401.1	6	3	2	94.1	3.3	0		nan		
Amcasertib		Boston Biomedical	CHEMBL3707349	CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C	Achiral Molecule	nan	2.0	None	AMCASERTIB | BBI-503 | BBI503	nan	nan	P16234	InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-	QDWKGEFGLQMDAM-ULJHMMPZSA-N	44208821	|http://www.chemspider.com/Chemical-Structure.44208821.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3707349|http://pubchem.ncbi.nlm.nih.gov/compound/25190990|http://www.drugbank.ca/drugs/DB14866|http://zinc15.docking.org/substances/ZINC000059029686|https://precision.fda.gov/uniisearch/srs/unii/GLY8ABW25V	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS						539.2	5	3	9	90.1	6.0	2		PDGFRA	Tyr	
Amuvatinib		Supergen	CHEMBL2103851	c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6	Achiral Molecule	nan	2.0	None	AMUVATINIB | HPK 56 | HPK-56 | HPK56 | MP 470 | MP-470 | MP470	"Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp
onent of double-stranded DNA repair in cancer cells."	nan	P10721|P08581|P07949|P36888|P09619	InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)	FOFDIMHVKGYHRU-UHFFFAOYSA-N	9457280	|http://www.chemspider.com/Chemical-Structure.9457280.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103851|http://pubchem.ncbi.nlm.nih.gov/compound/11282283|http://www.drugbank.ca/drugs/DB12742|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7932|http://zinc15.docking.org/substances/ZINC34951302|https://precision.fda.gov/uniisearch/srs/unii/SO9S6QZB4R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172081	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.	P10721|P08581|P07949|P16234|P36888|Q06609	447.1	7	1	3	75.9	3.3	0		KIT; MET; RET; FLT3; PDGFRB	Tyr	
Anizatrectinib		Array BioPharma	CHEMBL5095088	CC1C(=NN(C=1NC(=O)N[C@@H]1CN(C[C@H]1C1C=C(F)C=CC=1)CCOC)C1C=CC=CC=1)C1=CN=C(C)N=C1	Single Stereoisomer	nan	-1.0	None		nan	nan	nan	InChI=1S/C29H32FN7O2/c1-19-27(22-15-31-20(2)32-16-22)35-37(24-10-5-4-6-11-24)28(19)34-29(38)33-26-18-36(12-13-39-3)17-25(26)21-8-7-9-23(30)14-21/h4-11,14-16,25-26H,12-13,17-18H2,1-3H3,(H2,33,34,38)/t25-,26+/m0/s1	BGKSBHPSVMJTFL-IZZNHLLZSA-N	115009485	|http://www.chemspider.com/Chemical-Structure.115009485.html|http://pubchem.ncbi.nlm.nih.gov/compound/92135967|http://zinc15.docking.org/substances/ZINC000606301420	|ChemSpider|PubChem|ZINC						529.3	7	2	8	97.2	4.3	1		nan		
Anlotinib		Advenchen Laboratories		Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC		nan	4.0		AL 3818 | AL-3818 | AL3818 | ANLOTINIB | CATEQUENTINIB	Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.	nan	P35968|P35916	InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3	KSMZEXLVHXZPEF-UHFFFAOYSA-N	45743493	|http://www.chemspider.com/Chemical-Structure.45743493.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303201|http://pubchem.ncbi.nlm.nih.gov/compound/25017411|http://www.drugbank.ca/drugs/DB11885|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9601|http://zinc15.docking.org/substances/ZINC000117924202|https://precision.fda.gov/uniisearch/srs/unii/GKF8S4C432	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						407.2	5	2	6	82.4	4.8	0		KDR; FLT4	Tyr	N
Ansornitinib		Angion Biomedica	CHEMBL5095090	COC(=O)c1ccc2c(n1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1	Achiral Molecule		-1.0	None					InChI=1S/C30H32N6O4/c1-34-15-17-36(18-16-34)19-25(37)35(2)22-11-9-21(10-12-22)31-27(20-7-5-4-6-8-20)26-23-13-14-24(30(39)40-3)32-28(23)33-29(26)38/h4-14,31H,15-19H2,1-3H3,(H,32,33,38)/b27-26-	OABALTWKAJWHEA-RQZHXJHFSA-N		|http://www.chemspider.com/Chemical-Structure..html|http://pubchem.ncbi.nlm.nih.gov/compound/71654874	|ChemSpider|PubChem						540.2	8	2	7	107.1	3.0	1		nan	(*)	
Apatinib		Bukwang Pharmaceutical		N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C		2014	4.0		|APATINIB GROUP|CARBOPLATIN|5-FLUOROURACIL|PLATINU|APATINIB TABLETS|APATINIB 750MG|RIVOCERANIB|NAVELBINE+AITAN|APATINIB 500MG|VP-16|H20140103|STUDY DRUG|YN968D1,(AITAN®|ALBUMIN PACLITAXEL|NO.|APATINIB MESYLAS|YN968D1|CAPECITABINE|ATAN|EMOZOLOMIDE|SPA|APATINIB|ARGET THERAPY|S1|OXALIPLATIN|AI TAN|IE CHEMOTHERAPY|DOCETAXEL|REATMENT GROUP|SHR-1210|EMOZOLOMIDE（TMZ）|APATINIBMESYLATE|EGAFUR|ARM A|PACLITAXOL|XELOX|IRINOTECAN|S-1|AITAN|APATINIB MESYLATE|YEW|SURGERY|ESYLATE APATINIB|CRYOABLATION|PEMETREXED|APA PLUS C	Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.	nan	P35968	InChI=1S/C24H23N5O/c1-17-10-14-26-15-21(17)29-22-20(5-4-13-27-22)23(30)28-19-8-6-18(7-9-19)24(16-25)11-2-3-12-24/h4-10,13-15H,2-3,11-12H2,1H3,(H,27,29)(H,28,30)	MGZNERAVOCFMCU-UHFFFAOYSA-N	34980756	|http://www.chemspider.com/Chemical-Structure.34980756.html|http://pubchem.ncbi.nlm.nih.gov/compound/66577012|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7648|http://zinc15.docking.org/substances/ZINC000083291412	|ChemSpider|PubChem|Guide to Pharmacology|ZINC						397.2	5	2	5	90.7	5.1	1		KDR	Tyr	N
Apitolisib		Hoffmann-La Roche	CHEMBL1922094	Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O	Single Stereoisomer	nan	2.0	None	APITOLISIB | G-038390 | G-038390.1 | GDC-0980 | GDC-0980.1 | GNE-390 | RG-7422 | RG7422	nan	nan	P42336|P42345	InChI=1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1	YOVVNQKCSKSHKT-HNNXBMFYSA-N	26325996	|http://www.chemspider.com/Chemical-Structure.26325996.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1922094|http://pubchem.ncbi.nlm.nih.gov/compound/25254071|http://www.drugbank.ca/drugs/DB12180| http://www.rcsb.org/ligand/980|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/980|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888|http://zinc15.docking.org/substances/ZINC000059224388|https://precision.fda.gov/uniisearch/srs/unii/1C854K1MIJ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50358204	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'980'	3tl5				498.2	11	2	5	133.8	0.9	1		PIK3CA; MTOR	Atypical	
Asciminib		Novartis	CHEMBL4208229	c1cc(ccc1NC(=O)c2cc(c(nc2)N3CC[C@H](C3)O)c4ccn[nH]4)OC(F)(F)Cl	Single Stereoisomer	2021	4.0	US-8829195-B2	ABL-001 | ABL001 | ABL001-NX | ASCIMINIB | NVP-ABL001	On October 2021, FDA approved asciminib To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria	nan	nan	InChI=1S/C20H18ClF2N5O3/c21-20(22,23)31-15-3-1-13(2-4-15)26-19(30)12-9-16(17-5-7-25-27-17)18(24-10-12)28-8-6-14(29)11-28/h1-5,7,9-10,14,29H,6,8,11H2,(H,25,27)(H,26,30)/t14-/m1/s1	VOVZXURTCKPRDQ-CQSZACIVSA-N	52085218	|http://www.chemspider.com/Chemical-Structure.52085218.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4208229|http://pubchem.ncbi.nlm.nih.gov/compound/72165228|http://www.drugbank.ca/drugs/DB12597| http://www.rcsb.org/ligand/AY7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AY7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8962|http://zinc15.docking.org/substances/ZINC000150275965|https://precision.fda.gov/uniisearch/srs/unii/L1F3R18W77|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50459091	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'AY7'	5mo4		"Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Scemblix (asciminib) tablets for oral use"" href=""#reference-L38995"">6</a></sup> which serves as a driver of CML proliferation in most patients with the disease.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""NIH National Cancer Institute: BCR-ABL fusion gene"" href=""#reference-L39005"">8</a></sup> It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.</p><p>Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain (<a href=""https://go.drugbank.com/drugs/DB01254"">dasatinib</a>, <a href=""https://go.drugbank.com/drugs/DB06616"">bosutinib</a>) and those that target the inactive kinase domain (<a href=""https://go.drugbank.com/drugs/DB00619"">imatinib</a>, <a href=""https://go.drugbank.com/drugs/DB04868"">nilotinib</a>, <a href=""https://go.drugbank.com/drugs/DB08901"">ponatinib</a>).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Khatri A, Wang J, Pendergast AM: Multifunctional Abl kinases in health and disease. J Cell Sci. 2016 Jan 1;129(1):9-16. doi: 10.1242/jcs.175521. (PubMed ID 26729027)"" href=""#reference-A241065"">5</a></sup> Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Scemblix (asciminib) tablets for oral use"" href=""#reference-L38995"">6</a>,<a class=""reference-popover-link"" data-content=""Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021 Apr 21;14(1):66. doi: 10.1186/s13045-021-01077-3. (PubMed ID 33879198)"" href=""#reference-A241055"">3</a></sup></p><p>Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News Release: FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia"" href=""#reference-L39000"">7</a></sup>"	P00519|P08684|P16662|O75795|P22309|P33261|P11712|Q9UNQ0|P08183|Q9Y6L6|Q9NPD5|O15245	449.1	6	3	6	103.4	3.5	0		nan		Y
Asnuciclib			CHEMBL2347597	CNc1nc(C)c(-c2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2F)s1	Achiral Molecule	nan	-1.0	None	ASNUCICLIB | CDKI-73 | CDKI73	nan	nan	nan	InChI=1S/C15H15FN6O2S2/c1-8-13(25-15(18-2)20-8)12-11(16)7-19-14(22-12)21-9-4-3-5-10(6-9)26(17,23)24/h3-7H,1-2H3,(H,18,20)(H2,17,23,24)(H,19,21,22)	GAIOPWBQKZMUNO-UHFFFAOYSA-N	29407664	|http://www.chemspider.com/Chemical-Structure.29407664.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2347597|http://pubchem.ncbi.nlm.nih.gov/compound/71561915|http://zinc15.docking.org/substances/ZINC000095605236|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50431360	|ChemSpider|ChEMBL|PubChem|ZINC|BindingDB						394.1	8	3	5	122.9	2.5	0		nan		
Atinvicitinib		Intervet International BV	CHEMBL4066193	COc1cc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc(F)n1	Single Stereoisomer	nan	-1.0	None	ATINVICITINIB	nan	nan	nan	InChI=1S/C16H17FN6O3/c1-25-14-5-10(4-13(17)21-14)20-16-11(15(19)24)7-23(22-16)12-8-26-3-2-9(12)6-18/h4-5,7,9,12H,2-3,8H2,1H3,(H2,19,24)(H,20,21,22)/t9-,12+/m1/s1	PRQMBGDYXWVEHE-SKDRFNHKSA-N	76784061	|http://www.chemspider.com/Chemical-Structure.76784061.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4066193|http://pubchem.ncbi.nlm.nih.gov/compound/135138184|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50250929	|ChemSpider|ChEMBL|PubChem|BindingDB						360.1	8	2	5	128.1	1.4	0		nan		
Atuveciclib		Bayer	CHEMBL4439321	COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1	Single Stereoisomer	nan	1.0	None	ATUVECICLIB	nan	nan	nan	InChI=1S/C18H18FN5O2S/c1-26-16-9-13(19)6-7-15(16)17-21-11-22-18(24-17)23-14-5-3-4-12(8-14)10-27(2,20)25/h3-9,11,20H,10H2,1-2H3,(H,21,22,23,24)/t27-/m1/s1	ACWKGTGIJRCOOM-HHHXNRCGSA-N	58827829	|http://www.chemspider.com/Chemical-Structure.58827829.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4439321|http://pubchem.ncbi.nlm.nih.gov/compound/121488167|http://zinc15.docking.org/substances/ZINC000207637501|https://precision.fda.gov/uniisearch/srs/unii/63Q7F59W0V|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50528818	|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS|BindingDB						387.1	7	2	6	100.9	3.6	0		nan		
Aumolertinib	Ameile;Amerol	Jiangsu Hansoh Pharmaceutical	CHEMBL4761468	CN(C)CCN(C)C1C=C(OC)C(=CC=1NC(=O)C=C)NC1N=C(C=CN=1)C1=CN(C2CC2)C2C=CC=CC=21	Achiral Molecule	nan	3.0	None	ALMONERTINIB | AMEILE | AMEROL | AUMOLERTINIB | EGFR T790M INHIBITOR HS-10296 | EQ-143 | EQ143 | HS 10296 | HS-10206 | HS-10296	nan	nan	nan	InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34)	DOEOECWDNSEFDN-UHFFFAOYSA-N	75535991	|http://www.chemspider.com/Chemical-Structure.75535991.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4761468|http://pubchem.ncbi.nlm.nih.gov/compound/121280087|http://www.drugbank.ca/drugs/DB16640|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11136|https://precision.fda.gov/uniisearch/srs/unii/T4RS462G19	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS				"Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S: Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9. (PubMed ID 32916310)"" href=""#reference-A231859"">1</a>,<a class=""reference-popover-link"" data-content=""Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI: Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2020 Dec 15. pii: S1556-0864(20)31105-9. doi: 10.1016/j.jtho.2020.11.028. (PubMed ID 33338652)"" href=""#reference-A231864"">2</a>,<a class=""reference-popover-link"" data-content=""Jiang T, Luo Y, Wang B: Almonertinib-induced interstitial lung disease: A case report. Medicine (Baltimore). 2021 Jan 22;100(3):e24393. doi: 10.1097/MD.0000000000024393. (PubMed ID 33546082)"" href=""#reference-A231869"">3</a></sup> It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Jiang T, Luo Y, Wang B: Almonertinib-induced interstitial lung disease: A case report. Medicine (Baltimore). 2021 Jan 22;100(3):e24393. doi: 10.1097/MD.0000000000024393. (PubMed ID 33546082)"" href=""#reference-A231869"">3</a></sup>"	Q504U8	525.3	8	2	11	87.6	5.3	2		nan		
Avapritinib	Ayvakit	Blueprint Medicines	CHEMBL4204794	C[C@](c1ccc(cc1)F)(c2cnc(nc2)N3CCN(CC3)c4c5cc(cn5ncn4)c6cnn(c6)C)N	Single Stereoisomer	2020	4.0	US-9200002-B2	70C366 | AVAPRITINIB | AYVAKIT | BLU-285 | C-366 | X-720776 | X720776	On January 2020 FDA approved avapritinib to treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)	nan	nan	InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1	DWYRIWUZIJHQKQ-SANMLTNESA-N	58828673	|http://www.chemspider.com/Chemical-Structure.58828673.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4204794|http://pubchem.ncbi.nlm.nih.gov/compound/118023034|http://www.drugbank.ca/drugs/DB15233|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10368|https://precision.fda.gov/uniisearch/srs/unii/513P80B4YJ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=469269	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB				"Avapritinib, or BLU-285,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV: Avapritinib: A Selective Inhibitor of KIT and PDGFRalpha that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4. (PubMed ID 31117741)"" href=""#reference-A189327"">1</a></sup> is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B: New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019 May 17;11:1758835919841946. doi: 10.1177/1758835919841946. eCollection 2019. (PubMed ID 31205499)"" href=""#reference-A189339"">2</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: AYVAKIT (avapritinib) tablets, for oral use"" href=""#reference-L40363"">4</a></sup> It is one of the first medications available for the treatment of multidrug resistant cancers.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV: Avapritinib: A Selective Inhibitor of KIT and PDGFRalpha that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16(7):3040-3052. doi: 10.1021/acs.molpharmaceut.9b00274. Epub 2019 Jun 4. (PubMed ID 31117741)"" href=""#reference-A189327"">1</a></sup> Avapritinib shares a similar mechanism with <a href=""https://go.drugbank.com/drugs/DB14840"">ripretinib</a>.</p><p>Avapritinib was granted FDA approval on 9 January 2020 <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: AYVAKIT (avapritinib) tablets, for oral use"" href=""#reference-L40363"">4</a></sup> and EMA approval on 24 September 2020.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""EMA Approved Drug Products: AYVAKYT (avapritinib) Oral Tablets"" href=""#reference-L41464"">3</a></sup>"	P10721|P08684|P11712|P08183|Q9UNQ0|O95342|Q96FL8|Q86VL8	498.2	10	1	5	106.3	2.6	0		nan		Y
Avotaciclib		BeyondBio	CHEMBL4650328	NC1N=C(C=CN=1)C1=CC=C(O)C(=N1)C1C=CN=C(N)N=1	Achiral Molecule	nan	1.0	None	AVOTACICLIB | BEY-1107 | BEY1107 | CDK1 INHIBITOR BEY1107	nan	nan	nan	InChI=1S/C13H11N7O/c14-12-16-5-3-8(19-12)7-1-2-10(21)11(18-7)9-4-6-17-13(15)20-9/h1-6,21H,(H2,14,16,19)(H2,15,17,20)	VFVAQKKPFOPZEA-UHFFFAOYSA-N	115006923	|http://www.chemspider.com/Chemical-Structure.115006923.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650328|http://pubchem.ncbi.nlm.nih.gov/compound/137150099|http://www.drugbank.ca/drugs/DB16652|https://precision.fda.gov/uniisearch/srs/unii/Z6BYC0F36E	|ChemSpider|ChEMBL|PubChem|DrugBank|FDA SRS				Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer).	P06493	281.1	8	3	2	136.7	0.9	0		nan		
Avutometinib		Verastem	CHEMBL3264002	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	Achiral Molecule	nan	1.0	None	AVUTOMETINIB | CH-5126766 | CH5126766 | CKI-27 | R-7304 | RG-7304 | RO 5126766 | RO-5126766 | VS-6766	nan	nan	nan	InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)	LMMJFBMMJUMSJS-UHFFFAOYSA-N	17623621	|http://www.chemspider.com/Chemical-Structure.17623621.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3264002|http://pubchem.ncbi.nlm.nih.gov/compound/16719221|http://www.drugbank.ca/drugs/DB15254| http://www.rcsb.org/ligand/CHU|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CHU|http://zinc15.docking.org/substances/ZINC000068247388|https://precision.fda.gov/uniisearch/srs/unii/D0D4252V97|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50010462	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB	'CHU'	3wig 7m0z 7mfd				471.1	8	2	7	136.3	2.7	0		nan		
Axitinib	Inlyta	Pfizer	CHEMBL1289926	CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4	Achiral Molecule	2012	4.0	US-6534524-B1	AG-013736 | AG-13736 | AXITINIB | INLYTA | NSC-757441	Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.	2	P17948|P35968|P35916	InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+	RITAVMQDGBJQJZ-FMIVXFBMSA-N	4953153	|http://www.chemspider.com/Chemical-Structure.4953153.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289926|http://pubchem.ncbi.nlm.nih.gov/compound/6450551|http://www.drugbank.ca/drugs/DB06626| http://www.rcsb.org/ligand/AXI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AXI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5659|http://zinc15.docking.org/substances/ZINC03816287|https://precision.fda.gov/uniisearch/srs/unii/C9LVQ0YUXG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25117	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'AXI'	4ag8 4agc 4twp 4wa9		"Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""DRUG NAME: Axitinib - BC Cancer"" href=""#reference-L6676"">7</a></sup> Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""DRUG NAME: Axitinib - BC Cancer"" href=""#reference-L6676"">7</a></sup> Axitinib is an indazole derivative.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Gross-Goupil M, Francois L, Quivy A, Ravaud A: Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 2013 Oct 29;7:269-77. doi: 10.4137/CMO.S10594. (PubMed ID 24250243)"" href=""#reference-A179398"">6</a></sup> It is most commonly marketed under the name Inlyta® and is available in oral formulations."	P17948|P35968|P35916|P08684|P20815|P05177|P33261|P22309|P08183|Q9Y6L6	386.1	4	2	5	70.7	4.6	0		FLT1; KDR; FLT4	Tyr	Y
Azenosertib		Zentalis Pharmaceuticals	CHEMBL5095036	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)[C@@](O)(CC)CC2	Single Stereoisomer	nan	2.0	None	ZN-C3|	nan	nan	nan	InChI=1S/C29H34N8O2/c1-4-14-36-27(38)23-19-30-28(31-21-7-9-22(10-8-21)35-17-15-34(3)16-18-35)33-26(23)37(36)24-11-6-20-12-13-29(39,5-2)25(20)32-24/h4,6-11,19,39H,1,5,12-18H2,2-3H3,(H,30,31,33)/t29-/m1/s1	OXTSYWDBUVRXFF-GDLZYMKVSA-N	114826635	|http://www.chemspider.com/Chemical-Structure.114826635.html|http://pubchem.ncbi.nlm.nih.gov/compound/139467635| http://www.rcsb.org/ligand/05J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/05J|https://precision.fda.gov/uniisearch/srs/unii/9J13XU96Z1	|ChemSpider|PubChem|RCSB|PDBe|FDA SRS	'05J'	7n3u				526.3	10	2	7	104.3	3.2	1		nan		
Bafetinib		Innovive Pharmaceuticals	CHEMBL206834	Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C	Single Stereoisomer	nan	2.0	None	BAFETINIB | CNS-9 | INNO-406 | NS-187	nan	2	P07948|P00519	InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	9562515	|http://www.chemspider.com/Chemical-Structure.9562515.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL206834|http://pubchem.ncbi.nlm.nih.gov/compound/11387605|http://www.drugbank.ca/drugs/DB11851| http://www.rcsb.org/ligand/406|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/406|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906|http://zinc15.docking.org/substances/ZINC000022940637|https://precision.fda.gov/uniisearch/srs/unii/NVW4Z03I9B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50178612	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'406'	2e2b				576.3	8	2	8	99.2	5.4	2		LYN; ABL1	Tyr	
Balamapimod		Wyeth	CHEMBL2104954	Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC	Achiral Molecule	nan	1.0	None	BALAMAPIMOD | MKI-833	nan	nan	P04049|Q02750|P36507	InChI=1S/C30H32ClN7OS/c1-36-14-9-33-30(36)40-28-6-5-21(15-24(28)31)35-29-20(18-32)19-34-25-17-26(27(39-2)16-23(25)29)38-12-7-22(8-13-38)37-10-3-4-11-37/h5-6,9,14-17,19,22H,3-4,7-8,10-13H2,1-2H3,(H,34,35)	CVAKNHIXTWLGJO-UHFFFAOYSA-N	9653509	|http://www.chemspider.com/Chemical-Structure.9653509.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2104954|http://pubchem.ncbi.nlm.nih.gov/compound/11478684|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9925|http://zinc15.docking.org/substances/ZINC000011726212|https://precision.fda.gov/uniisearch/srs/unii/7Y0IV7N95Q	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS						573.2	9	1	7	82.2	6.5	2		RAF1; MAP2K1; MAP2K2	TKL<br>STE	
Barasertib		Astrazeneca	CHEMBL415049	CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O	Achiral Molecule	nan	3.0	None	AZD 1152 | AZD-1152 | AZD1152 | BARASERTIB | BARASERTIB (WHO-DD)	nan	nan	Q96GD4	InChI=1S/C26H31FN7O6P/c1-2-34(10-12-40-41(36,37)38)9-4-11-39-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(35)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17H,2,4,9-12,15H2,1H3,(H,30,35)(H2,36,37,38)(H2,28,29,31,32,33)	GBJVVSCPOBPEIT-UHFFFAOYSA-N	9672789	|http://www.chemspider.com/Chemical-Structure.9672789.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL415049|http://pubchem.ncbi.nlm.nih.gov/compound/11497983|http://www.drugbank.ca/drugs/DB11747|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7332|http://zinc15.docking.org/substances/ZINC000043129461|https://precision.fda.gov/uniisearch/srs/unii/16XC2U7W8N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50241089	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						587.2	9	5	15	174.8	3.6	1		AURKB	Other	
Baricitinib	Olumiant	Eli Lilly	CHEMBL2105759	CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3	Achiral Molecule	2017	4.0	US-8158616-B2	BARICITINIB | BARICITINIB PHOSPHATE | BARICITINIB PHOSPHATE SALT | INCB-028050 | INCB-28050 | INCB028050 | LY-3009104 | LY3009104 | OLUMIANT	Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.	1	P23458|O60674	InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)	XUZMWHLSFXCVMG-UHFFFAOYSA-N	26373084	|http://www.chemspider.com/Chemical-Structure.26373084.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105759|http://pubchem.ncbi.nlm.nih.gov/compound/44205240|http://www.drugbank.ca/drugs/DB11817| http://www.rcsb.org/ligand/3JW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3JW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7792|http://zinc15.docking.org/substances/ZINC000073069247|https://precision.fda.gov/uniisearch/srs/unii/ISP4442I3Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021656	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'3JW'	4w9x 6vn8 6wto		"Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: OLUMIANT (baricitinib) tablets, for oral use"" href=""#reference-L41760"">9</a></sup></p><p>Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Markham A: Baricitinib: First Global Approval. Drugs. 2017 Apr;77(6):697-704. doi: 10.1007/s40265-017-0723-3. (PubMed ID 28290136)"" href=""#reference-A248395"">4</a></sup> and was later approved by the FDA in 2018.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Mayence A, Vanden Eynde JJ: Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases. Pharmaceuticals (Basel). 2019 Mar 12;12(1). pii: ph12010037. doi: 10.3390/ph12010037. (PubMed ID 30871014)"" href=""#reference-A248400"">5</a></sup> The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A: Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients. Healthcare (Basel). 2021 Nov 18;9(11). pii: healthcare9111575. doi: 10.3390/healthcare9111575. (PubMed ID 34828623)"" href=""#reference-A248405"">6</a></sup> While baricitinib was granted emergency use as a treatment for COVID-19 in combination with <a href=""https://go.drugbank.com/drugs/DB14761"">remdesivir</a> under the Emergency Use Authorization (EUA) in November 2020,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA: Emergency Use Authorization for Baricitinib in Combination with Remdesivir for COVID-19"" href=""#reference-L22619"">8</a></sup> the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: OLUMIANT (baricitinib) tablets, for oral use"" href=""#reference-L41760"">9</a></sup>"	P23458|O60674|P52333|P29597|P08684|Q8TCC7|Q9UNQ0|Q86VL8|Q4U2R8|O15244|Q9NPD5|P08183	371.1	7	1	5	120.6	1.1	0		JAK1; JAK2	Tyr	Y
Befotertinib		InventisBio	CHEMBL5095167	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(CC(F)(F)F)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C	Achiral Molecule	nan	2.0	None	|D-0316|D0316	nan	nan	nan	InChI=1S/C29H32F3N7O2/c1-6-27(40)34-22-15-23(26(41-5)16-25(22)38(4)14-13-37(2)3)36-28-33-12-11-21(35-28)20-17-39(18-29(30,31)32)24-10-8-7-9-19(20)24/h6-12,15-17H,1,13-14,18H2,2-5H3,(H,34,40)(H,33,35,36)	USOCZVZOXKTJTI-UHFFFAOYSA-N	115006925	|http://www.chemspider.com/Chemical-Structure.115006925.html|http://pubchem.ncbi.nlm.nih.gov/compound/130412842|https://precision.fda.gov/uniisearch/srs/unii/0XT2CPR891	|ChemSpider|PubChem|FDA SRS						567.3	8	2	11	87.5	5.5	2		nan		
Belumosudil		Surface logix	CHEMBL2005186	CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5	Achiral Molecule	2021	4.0	US-8357693-B2	BELUMOSUDIL | KD-025 | KD025 | ROCK2 INHIBITOR KD025 | SLX-2119 | SLX-2119 FREE BASE	On July 2021, FDA approved belumosudil to treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy	nan	nan	InChI=1S/C26H24N6O2/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31)	GKHIVNAUVKXIIY-UHFFFAOYSA-N	103836147	|http://www.chemspider.com/Chemical-Structure.103836147.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2005186|http://pubchem.ncbi.nlm.nih.gov/compound/11950170|http://www.drugbank.ca/drugs/DB16703| http://www.rcsb.org/ligand/ICQ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/ICQ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9558|http://zinc15.docking.org/substances/ZINC000063298464|https://precision.fda.gov/uniisearch/srs/unii/834YJF89WO|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=322155	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'ICQ'	7z39		"Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Yamamura A, Nayeem MJ, Sato M: The Rho kinase 2 (ROCK2)-specific inhibitor KD025 ameliorates the development of pulmonary arterial hypertension. Biochem Biophys Res Commun. 2021 Jan 1;534:795-801. doi: 10.1016/j.bbrc.2020.10.106. Epub 2020 Nov 5. (PubMed ID 33160621)"" href=""#reference-A236634"">4</a></sup> It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC<sub>50</sub> 100 nM vs. 3 μM, respectively).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Rezurock (belumosudil) tablets for oral use"" href=""#reference-L34749"">5</a></sup> In the treatment of GVHD, a condition in which donor T-cells begin to attack recipient tissues following allogeneic hematopoeitic stem cell transplantation (HSCT), belumosudil helps to resolve immune dysregulation by shifting the balance between Th17 cells and T-regulatory cells, thereby dampening the inflammatory cascade that can occasionally be fatal.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ferrara JL, Reddy P: Pathophysiology of graft-versus-host disease. Semin Hematol. 2006 Jan;43(1):3-10. doi: 10.1053/j.seminhematol.2005.09.001. (PubMed ID 16412784)"" href=""#reference-A236644"">3</a>,<a class=""reference-popover-link"" data-content=""Kadmon: Belumosudil Mechanism of Action"" href=""#reference-L34759"">7</a></sup></p><p>Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines of systemic therapy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News Release: FDA approves belumosudil for chronic graft-versus-host disease"" href=""#reference-L34754"">6</a></sup> In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Health Canada News Release: Health Canada approves belumosudil for chronic graft-versus-host disease"" href=""#reference-L42925"">10</a></sup>"	O75116|Q13464|P08684|P10632|P10635|O60656|P05177|P33261|P22309|P02768|P02763|P08183|Q9UNQ0|Q9Y6L6	452.2	6	3	7	104.8	4.8	0		nan		Y
Belvarafenib		Hanmi Pharmaceutical	CHEMBL3977543	CC1=C(C2=C(C=C1)C(=NC=C2)NC3=C(C(=CC=C3)Cl)F)NC(=O)C4=CSC5=C4N=CN=C5N	Achiral Molecule	nan	2.0	None	BELVARAFENIB	nan	nan	nan	InChI=1S/C23H16ClFN6OS/c1-11-5-6-13-12(7-8-27-22(13)30-16-4-2-3-15(24)17(16)25)18(11)31-23(32)14-9-33-20-19(14)28-10-29-21(20)26/h2-10H,1H3,(H,27,30)(H,31,32)(H2,26,28,29)	KVCQTKNUUQOELD-UHFFFAOYSA-N	64878400	|http://www.chemspider.com/Chemical-Structure.64878400.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3977543|http://pubchem.ncbi.nlm.nih.gov/compound/89655386| http://www.rcsb.org/ligand/V1Y|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/V1Y|https://precision.fda.gov/uniisearch/srs/unii/31M3WLJ3KG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185591	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|FDA SRS|BindingDB	'V1Y'	6xfp				478.1	7	3	4	105.8	5.9	1		nan		
Bemcentinib		BerGenBio	CHEMBL3809489	c1ccc-2c(c1)CCCc3c2nnc(c3)n4c(nc(n4)Nc5ccc6c(c5)CC[C@H](CC6)N7CCCC7)N	Single Stereoisomer	nan	2.0	None	BEMCENTINIB | BGB 324 | BGB-324 | BGB324 | CS-1046 | HY-15150 | KB-80319 | QC-11751 | R 428 | R-428 | R428 | SYN-1131 | SYN1131 | W-5845	nan	nan	P30530	InChI=1S/C30H34N8/c31-29-33-30(32-24-13-10-20-11-14-25(15-12-22(20)18-24)37-16-3-4-17-37)36-38(29)27-19-23-8-5-7-21-6-1-2-9-26(21)28(23)35-34-27/h1-2,6,9-10,13,18-19,25H,3-5,7-8,11-12,14-17H2,(H3,31,32,33,36)/t25-/m0/s1	KXMZDGSRSGHMMK-VWLOTQADSA-N	28637805	|http://www.chemspider.com/Chemical-Structure.28637805.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3809489|http://pubchem.ncbi.nlm.nih.gov/compound/46215462|http://www.drugbank.ca/drugs/DB12411| http://www.rcsb.org/ligand/Q8U|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/Q8U|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10478|http://zinc15.docking.org/substances/ZINC000051951669|https://precision.fda.gov/uniisearch/srs/unii/0ICW2LX8AS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172079	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'Q8U'	8ba3 8ba4		Bemcentinib has been investigated for the treatment of Non-Small Cell Lung Cancer.	P0DTC2	506.3	8	2	4	97.8	4.9	1		AXL	Tyr	
Bentamapimod		PregLem	CHEMBL3545213	N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5	Racemic Mixture	nan	2.0	None	AS-602801 | AS602801 | BENTAMAPIMOD | PGL-5001 | PGL5001	nan	nan	P45983|P45984	InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2	XCPPIJCBCWUBNT-UHFFFAOYSA-N	8370750	|http://www.chemspider.com/Chemical-Structure.8370750.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545213|http://pubchem.ncbi.nlm.nih.gov/compound/10195250|http://www.drugbank.ca/drugs/DB16851|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9926|https://precision.fda.gov/uniisearch/srs/unii/TT3L4B4U0N	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						457.2	8	0	7	84.2	4.2	0		MAPK8; MAPK9	CMGC	
Berzosertib		Vertex Pharmaceuticals	CHEMBL3989870	CC(C)S(=O)(=O)c1ccc(cc1)c2cnc(c(n2)c3cc(no3)c4ccc(cc4)CNC)N	Achiral Molecule	nan	2.0	None	BERZOSERTIB | M-6620 | M6620 | VE-822 | VX-970 | VX970	nan	nan	nan	InChI=1S/C24H25N5O3S/c1-15(2)33(30,31)19-10-8-18(9-11-19)21-14-27-24(25)23(28-21)22-12-20(29-32-22)17-6-4-16(5-7-17)13-26-3/h4-12,14-15,26H,13H2,1-3H3,(H2,25,27)	JZCWLJDSIRUGIN-UHFFFAOYSA-N	30773968	|http://www.chemspider.com/Chemical-Structure.30773968.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989870|http://pubchem.ncbi.nlm.nih.gov/compound/59472121|http://www.drugbank.ca/drugs/DB11794|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8003|http://zinc15.docking.org/substances/ZINC000096170459|https://precision.fda.gov/uniisearch/srs/unii/L423PRV3V3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50226746	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						463.2	8	2	7	124.0	3.9	0		nan		
Bezuclastinib		Plexxikon	CHEMBL5095229	Cc1[nH]nc(C(=O)Nc2cnc3[nH]c(-c4ccccc4)cc3c2)c1C	Achiral Molecule	nan	3.0	None	|CGT9486	nan	nan	nan	InChI=1S/C19H17N5O/c1-11-12(2)23-24-17(11)19(25)21-15-8-14-9-16(22-18(14)20-10-15)13-6-4-3-5-7-13/h3-10H,1-2H3,(H,20,22)(H,21,25)(H,23,24)	NVSHVYGIYPBTEZ-UHFFFAOYSA-N	115007996	|http://www.chemspider.com/Chemical-Structure.115007996.html|http://pubchem.ncbi.nlm.nih.gov/compound/75593308| http://www.rcsb.org/ligand/WEJ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/WEJ|https://precision.fda.gov/uniisearch/srs/unii/2ROQ545LAG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=392363	|ChemSpider|PubChem|RCSB|PDBe|FDA SRS|BindingDB	'WEJ'	7khk				331.1	3	3	3	86.5	3.8	0		nan		
Bimiralisib		Piqur Therapeutics	CHEMBL4084907	c1c(c(c[nH]c1=N)c2nc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F	Achiral Molecule	nan	2.0	None	BIMIRALISIB | NC-B5 | NCB5 | PI3K-IN-2 | PQR-309 | PQR309	Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent.	nan	nan	InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)	ADGGYDAFIHSYFI-UHFFFAOYSA-N	35033288	|http://www.chemspider.com/Chemical-Structure.35033288.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4084907|http://pubchem.ncbi.nlm.nih.gov/compound/58507717|http://www.drugbank.ca/drugs/DB14846| http://www.rcsb.org/ligand/A3W|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/A3W|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8383|http://zinc15.docking.org/substances/ZINC000068203488|https://precision.fda.gov/uniisearch/srs/unii/6Z3QHB00LB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50240975	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'A3W'	5oq4				411.2	8	2	3	103.2	1.0	0		nan		
Binimetinib	Mektovi	Novartis	CHEMBL3187723	Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO	Achiral Molecule	2018	4.0	US-7777050-B2	ARRY 438162 | ARRY-162 | ARRY-438162 | BINIMETINIB | MEK-162 | MEK162 | MEKTOVI | NVP-MEK162	On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	nan	Q02750	InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)	ACWZRVQXLIRSDF-UHFFFAOYSA-N	8463660	|http://www.chemspider.com/Chemical-Structure.8463660.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3187723|http://pubchem.ncbi.nlm.nih.gov/compound/10288191|http://www.drugbank.ca/drugs/DB11967| http://www.rcsb.org/ligand/QO7|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QO7|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921|http://zinc15.docking.org/substances/ZINC000038460704|https://precision.fda.gov/uniisearch/srs/unii/181R97MR71	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS	'QO7'	7m0u		"Binimetinib, also known as <em>Mektovi</em>, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with <a href=""https://go.drugbank.com/drugs/DB11718"">Encorafenib</a> <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, Weekes CD, Tan BR, Khan GN, Zalupski MM, Infante JR, Jones S, Papadopoulos KP, Tolcher AW, Chavira RE, Christy-Bittel JL, Barrett E, Patnaik A: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer. 2017 Feb 28;116(5):575-583. doi: 10.1038/bjc.2017.10. Epub 2017 Feb 2. (PubMed ID 28152546)"" href=""#reference-A34275"">4</a>,<a class=""reference-popover-link"" data-content=""FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations"" href=""#reference-L3335"">8</a></sup>.</p><p>On June 27, 2018, the Food and Drug Administration approved the combination of <a href=""https://go.drugbank.com/drugs/DB11718"">Encorafenib</a> and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations"" href=""#reference-L3335"">8</a></sup>"	Q13233|P36507|P05231|P01375|P01584|P22309|P05177|P33261	440.0	6	3	6	88.4	3.0	0		MAP2K1	STE	Y
Bosutinib	Bosulif	Wyeth	CHEMBL288441	CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC	Achiral Molecule	2012	4.0	US-7417148-B2	BOSULIF | BOSUTINIB | BOSUTINIB (AS MONOHYDRATE) | BOSUTINIB HYDRATE | BOSUTINIB MONOHYDRATE | SK-606 | SKI-606	Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.	1	P11274|P00519|P07948|P08631|P12931|P24941|Q02750|P36507|Q9Y2U5|Q13555	InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)	UBPYILGKFZZVDX-UHFFFAOYSA-N	4486102	|http://www.chemspider.com/Chemical-Structure.4486102.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL288441|http://pubchem.ncbi.nlm.nih.gov/compound/5328940|http://www.drugbank.ca/drugs/DB06616| http://www.rcsb.org/ligand/DB8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/DB8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710|http://zinc15.docking.org/substances/ZINC000022448983|https://precision.fda.gov/uniisearch/srs/unii/5018V4AEZ0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4552	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'DB8'	3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4qmn 5ajq 5i9x 5vc3 5vcy 6fdy 6op9		Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.	P11274|P00519|P07948|P08631|P12931|P24941|Q02750|P36507|Q9Y2U5|Q13555|P08684|P10632|P08183	529.2	8	1	9	82.9	5.2	2		BCR; ABL1; LYN; HCK; SRC; CDK2; MAP2K1; MAP2K2; MAP3K2; CAMK2G	CAMK<br>STE<br>Tyr<br>CMGC<br>Atypical	Y
Branebrutinib		Bristol Myers Squibb	CHEMBL4297674	CC#CC(=O)N[C@H]1CCCN(C1)c2c(cc(c3c2c(c([nH]3)C)C)C(=O)N)F	Single Stereoisomer	nan	2.0	None	BMS-986195 | BRANEBRUTINIB	nan	nan	nan	InChI=1S/C20H23FN4O2/c1-4-6-16(26)24-13-7-5-8-25(10-13)19-15(21)9-14(20(22)27)18-17(19)11(2)12(3)23-18/h9,13,23H,5,7-8,10H2,1-3H3,(H2,22,27)(H,24,26)/t13-/m0/s1	VJPPLCNBDLZIFG-ZDUSSCGKSA-N	64835069	|http://www.chemspider.com/Chemical-Structure.64835069.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297674|http://pubchem.ncbi.nlm.nih.gov/compound/121293929|http://www.drugbank.ca/drugs/DB15347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9869|https://precision.fda.gov/uniisearch/srs/unii/7LBRZUYSHU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=164638	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB				Branebrutinib is under investigation in clinical trial NCT02705989 (Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects).	Q06187	370.2	3	3	3	91.2	2.1	0		nan		
Brepocitinib		Pfizer	CHEMBL4297477	Cn1cc(cn1)Nc2nccc(n2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F	Single Stereoisomer	nan	3.0	None	BREPOCITINIB | PF-06700841	nan	nan	nan	InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1	BUWBRTXGQRBBHG-MJBXVCDLSA-N	71107316	|http://www.chemspider.com/Chemical-Structure.71107316.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297477|http://pubchem.ncbi.nlm.nih.gov/compound/118878093|http://www.drugbank.ca/drugs/DB15003| http://www.rcsb.org/ligand/G4J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/G4J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10459|http://zinc15.docking.org/substances/ZINC000526061580|https://precision.fda.gov/uniisearch/srs/unii/3X8387Q25N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=329924	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'G4J'	6dbm 6dbn				389.2	7	1	4	79.2	1.8	0		nan		
Brigatinib	Alunbrig	Ariad Pharmaceuticals	CHEMBL3545311	CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl	Achiral Molecule	2017	4.0	US-9012462-B2	ALUNBRIG | AP-26113 | AP26113 | BRIGATINIB	The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.	1	Q9UM73|P00533	InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)	AILRADAXUVEEIR-UHFFFAOYSA-N	34982928	|http://www.chemspider.com/Chemical-Structure.34982928.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545311|http://pubchem.ncbi.nlm.nih.gov/compound/68165256|http://www.drugbank.ca/drugs/DB12267| http://www.rcsb.org/ligand/6GY|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6GY|http://zinc15.docking.org/substances/ZINC000148723177|https://precision.fda.gov/uniisearch/srs/unii/HYW8DB273J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50185140	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB	'6GY'	6mx8 7aem 7zym		"Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C: Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13. (PubMed ID 23239810)"" href=""#reference-A31311"">1</a></sup> It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D: Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015 Feb 27;8:17. doi: 10.1186/s13045-015-0122-8. (PubMed ID 25888090)"" href=""#reference-A31313"">2</a></sup> Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News and Events"" href=""#reference-L1026"">9</a></sup>"	Q9UM73|P00533|P00519|P08069|P36888|P06213|P08581|Q15303|P04626|P10632|P08684|P08684|Q9HB55|P20815|P24462|Q2M3G0|Q9UNQ0|O15245|Q96FL8|Q86VL8	583.3	9	2	8	85.9	5.1	2		ALK; EGFR	Tyr	Y
Brivanib		Bristol Myers Squibb	CHEMBL270995	Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C	Single Stereoisomer	nan	3.0	None	BMS-540215 | BRIVANIB	nan	nan	P35968	InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1	WCWUXEGQKLTGDX-LLVKDONJSA-N	9409099	|http://www.chemspider.com/Chemical-Structure.9409099.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL377300|http://pubchem.ncbi.nlm.nih.gov/compound/11234052|http://www.drugbank.ca/drugs/DB11958|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5671|http://zinc15.docking.org/substances/ZINC13684256|https://precision.fda.gov/uniisearch/srs/unii/DDU33B674I|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50184807	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						370.1	6	2	5	84.7	3.5	0		KDR	Tyr	
Brivanib alaninate		Bristol Myers Squibb		Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		nan	3.0		BMS-582664 | BMS-582664-02 | BRIVANIB ALANINATE | BRIVANIB L-ALANINE ESTER	nan	nan	nan	InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1	LTEJRLHKIYCEOX-OCCSQVGLSA-N	9330033	|http://www.chemspider.com/Chemical-Structure.9330033.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL270995|http://pubchem.ncbi.nlm.nih.gov/compound/11154925|http://www.drugbank.ca/drugs/DB11865|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8097|http://zinc15.docking.org/substances/ZINC29134440|https://precision.fda.gov/uniisearch/srs/unii/U2Y5OFN795	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						441.2	8	2	7	116.8	3.4	0		nan		
Buparlisib		Novartis	CHEMBL2017974	c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F	Achiral Molecule	nan	3.0	None	BKM-120 | BKM-120NX | BKM120-NX | BUPARLISIB | NVP-BKM-120 | NVP-BKM120	nan	1	P42336	InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)	CWHUFRVAEUJCEF-UHFFFAOYSA-N	17588300	|http://www.chemspider.com/Chemical-Structure.17588300.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2017974|http://pubchem.ncbi.nlm.nih.gov/compound/16654980|http://www.drugbank.ca/drugs/DB11666| http://www.rcsb.org/ligand/SD5|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/SD5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7878|http://zinc15.docking.org/substances/ZINC43154039|https://precision.fda.gov/uniisearch/srs/unii/0ZM2Z182GD|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50380363	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'SD5'	3sd5 5m7e 7r26				410.2	8	1	3	89.6	1.8	0		PIK3CA	Atypical	
Cabozantinib	Cabometyx;Cometriq	Exelixis	CHEMBL2105717	COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F	Achiral Molecule	2012	4.0	US-7579473-B2	BMS-907351 | BMS-907351 FREE BASE | CABOMETYX | CABOZANTINIB | COMETRIQ | XL-184 | XL-184 FREE BASE | XL184	For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.	2	P08581|P35968|P07949	InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)	ONIQOQHATWINJY-UHFFFAOYSA-N	25948202	|http://www.chemspider.com/Chemical-Structure.25948202.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105717|http://pubchem.ncbi.nlm.nih.gov/compound/25102847|http://www.drugbank.ca/drugs/DB08875|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5887|http://zinc15.docking.org/substances/ZINC000070466416|https://precision.fda.gov/uniisearch/srs/unii/1C39JW444G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021574	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Cometriq (cabozantinib) oral capsules"" href=""#reference-L15123"">6</a></sup> In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Cabometyx (cabozantinib) oral tablets"" href=""#reference-L15128"">7</a>,<a class=""reference-popover-link"" data-content=""Health Canada Product Monograph: Cabometyx (cabozantinib) oral tablets"" href=""#reference-L15133"">8</a></sup>"	P08581|P35968|P07949|P08684|P11712|P10632	501.2	6	2	8	98.8	5.5	2		MET; KDR; RET	Tyr	Y
Camonsertib		Repare Therapeutics	CHEMBL5095260	C[C@@H]1COCCN1c1cc([C@]2(O)C[C@H]3CC[C@@H](C2)O3)c2cnn(-c3cc[nH]n3)c2n1	Single Stereoisomer		2.0	None	RP-3500|RP3500|				InChI=1S/C21H26N6O3/c1-13-12-29-7-6-26(13)19-8-17(21(28)9-14-2-3-15(10-21)30-14)16-11-23-27(20(16)24-19)18-4-5-22-25-18/h4-5,8,11,13-15,28H,2-3,6-7,9-10,12H2,1H3,(H,22,25)/t13-,14-,15+,21+/m1/s1	YIHHYCIYAIVQKX-MBIULKOWSA-N	115009619	|http://www.chemspider.com/Chemical-Structure.115009619.html	|ChemSpider						410.2	8	2	3	101.3	1.9	0		nan	(*)	
Canertinib		Pfizer	CHEMBL31965	C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F	Achiral Molecule	nan	3.0	None	CANERTINIB | CI-1033	Investigated for use/treatment in breast cancer and lung cancer.	nan	P00533	InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)	OMZCMEYTWSXEPZ-UHFFFAOYSA-N	137741	|http://www.chemspider.com/Chemical-Structure.137741.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL31965|http://pubchem.ncbi.nlm.nih.gov/compound/156414|http://www.drugbank.ca/drugs/DB05424|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5675|http://zinc15.docking.org/substances/ZINC27439698|https://precision.fda.gov/uniisearch/srs/unii/C78W1K5ASF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4779	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.	P00533	485.2	7	2	9	88.6	4.4	0		EGFR	Tyr	
Capivasertib		Astrazeneca	CHEMBL2325741	c1cc(ccc1[C@H](CCO)NC(=O)C2(CCN(CC2)c3c4cc[nH]c4ncn3)N)Cl	Single Stereoisomer	nan	3.0	None	AZC5363 | AZD 5363 | AZD-5363 | AZD5363 | CAPIVASERTIB	nan	nan	P31749	InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1	JDUBGYFRJFOXQC-KRWDZBQOSA-N	28189073	|http://www.chemspider.com/Chemical-Structure.28189073.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2325741|http://pubchem.ncbi.nlm.nih.gov/compound/25227436|http://www.drugbank.ca/drugs/DB12218| http://www.rcsb.org/ligand/0XZ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0XZ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7709|http://zinc15.docking.org/substances/ZINC000043204023|https://precision.fda.gov/uniisearch/srs/unii/WFR23M21IE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50427349	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'0XZ'	4gv1				428.2	6	4	6	120.2	2.1	0		AKT1	AGC	
Capmatinib		Novartis	CHEMBL3188267	CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5	Achiral Molecule	2020	4.0	US-7767675-B2	CAPMATINIB | INC-280 | INC280 | INCB-28060 | INCB-28060 FREE BASE | NVP-INC280 | NVP-INC280-NX | NYP-INC280-NX	On may 2020 FDA approved capmatinib to treat patients with non small cell lung cancer	nan	P08581	InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)	LIOLIMKSCNQPLV-UHFFFAOYSA-N	25069712	|http://www.chemspider.com/Chemical-Structure.25069712.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3188267|http://pubchem.ncbi.nlm.nih.gov/compound/25145656|http://www.drugbank.ca/drugs/DB11791|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7904|http://zinc15.docking.org/substances/ZINC000043195321|https://precision.fda.gov/uniisearch/srs/unii/TY34L4F9OZ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50146167	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)"" href=""#reference-A199122"">2</a></sup> Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)"" href=""#reference-A199122"">2</a></sup> Mutations in <em>MET</em> have been detected in non-small cell lung cancer (NSCLC), and the prevalence of <em>MET</em> amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Kim S, Kim TM, Kim DW, Kim S, Kim M, Ahn YO, Keam B, Heo DS: Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat. 2019 Jul;51(3):951-962. doi: 10.4143/crt.2018.052. Epub 2018 Oct 10. (PubMed ID 30309221)"" href=""#reference-A199122"">2</a></sup> This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.</p><p>Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approvals and Databases: FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer"" href=""#reference-L13380"">4</a></sup> for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets"" href=""#reference-L13347"">3</a></sup> The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approvals and Databases: FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer"" href=""#reference-L13380"">4</a></sup> As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib&#39;s benefit in confirmatory trials.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets"" href=""#reference-L13347"">3</a></sup> Capmatinib was approved by Health Canada on June 8, 2022.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Cision PR Newswire: Health Canada approves (Pr)Tabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations"" href=""#reference-L42015"">7</a></sup>"	P08581|P08684|Q06278|P05177|P08183|Q96FL8|Q86VL8|Q9UNQ0	412.1	6	1	4	85.1	3.4	0		MET	Tyr	Y
Cediranib	Recentin	Astrazeneca	CHEMBL491473	Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC	Achiral Molecule	nan	3.0	None	AZD-2171 | AZD2171 | CEDIRANIB | RECENTIN | ZD-2171	For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.	nan	P35968	InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3	XXJWYDDUDKYVKI-UHFFFAOYSA-N	8109103	|http://www.chemspider.com/Chemical-Structure.8109103.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL491473|http://pubchem.ncbi.nlm.nih.gov/compound/9933475|http://www.drugbank.ca/drugs/DB04849|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5664|http://zinc15.docking.org/substances/ZINC000003948085|https://precision.fda.gov/uniisearch/srs/unii/NQU9IPY4K9|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331096	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.	P35968	450.2	6	1	8	72.5	5.2	1		KDR	Tyr	
Cenisertib		EMD Serono	CHEMBL1967878	Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F	Racemic Mixture	nan	1.0	None	AS-703569 | R-763	nan	nan	O14965|Q96GD4|Q9UQB9	InChI=1S/C24H30FN7O/c1-14-11-17(5-6-19(14)32-9-7-31(2)8-10-32)28-24-27-13-18(25)23(30-24)29-21-16-4-3-15(12-16)20(21)22(26)33/h3-6,11,13,15-16,20-21H,7-10,12H2,1-2H3,(H2,26,33)(H2,27,28,29,30)/t15-,16+,20+,21-/m1/s1	KSOVGRCOLZZTPF-QMKUDKLTSA-N	9744737	|http://www.chemspider.com/Chemical-Structure.9744737.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614709|http://pubchem.ncbi.nlm.nih.gov/compound/11569967|http://www.drugbank.ca/drugs/DB06347|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9927|http://zinc15.docking.org/substances/ZINC000063298059|https://precision.fda.gov/uniisearch/srs/unii/5277GPA358|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50389967	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Cenisertib is an aurora kinase inhibitor.	O14965	451.2	7	3	6	99.4	2.5	0		AURKA; AURKB; AURKC	Other	
Ceralasertib		Astrazeneca	CHEMBL4285417	CC1COCCN1c2cc(nc(n2)c3cncc4c3cc[nH]4)C5(CC5)S(=N)(=O)C	Single Stereoisomer	nan	3.0	None	AZD6738|AZD-6738	Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.	nan	nan	InChI=1S/C20H24N6O2S/c1-13-12-28-8-7-26(13)18-9-17(20(4-5-20)29(2,21)27)24-19(25-18)15-10-22-11-16-14(15)3-6-23-16/h3,6,9-11,13,21,23H,4-5,7-8,12H2,1-2H3	DTTJKLNXNZAVSM-UHFFFAOYSA-N	64879993	|http://www.chemspider.com/Chemical-Structure.64879993.html|http://pubchem.ncbi.nlm.nih.gov/compound/76189946	|ChemSpider|PubChem						412.2	7	2	4	107.8	2.9	0		nan		
Cerdulatinib		Portola pharmaceuticals	CHEMBL4116008	CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N	Achiral Molecule	nan	2.5	None	CERDULATINIB | PRT-062070 | PRT-2070 | RVT-502	nan	nan	P23458|P43405	InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)	BGLPECHZZQDNCD-UHFFFAOYSA-N	32822046	|http://www.chemspider.com/Chemical-Structure.32822046.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4116008|http://pubchem.ncbi.nlm.nih.gov/compound/44595079|http://www.drugbank.ca/drugs/DB15499|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8957|http://zinc15.docking.org/substances/ZINC000114483165|https://precision.fda.gov/uniisearch/srs/unii/D1LXQ45S1O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468574	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						445.2	8	3	8	133.6	1.4	0		JAK1; SYK	Tyr	
Ceritinib	Zykadia	Novartis	CHEMBL2403108	Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl	Achiral Molecule	2014	4.0	US-7893074-B2	CERITINIB | CERITINIB[MI] | LDK-378 | LDK378 | NVP-LDK-378-NX | NVP-LDK378-NX | ZYKADIA	Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.	1	Q9UM73	InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)	VERWOWGGCGHDQE-UHFFFAOYSA-N	29315053	|http://www.chemspider.com/Chemical-Structure.29315053.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2403108|http://pubchem.ncbi.nlm.nih.gov/compound/57379345|http://www.drugbank.ca/drugs/DB09063| http://www.rcsb.org/ligand/4MK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/4MK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397|http://zinc15.docking.org/substances/ZINC000096272772|https://precision.fda.gov/uniisearch/srs/unii/K418KG2GET|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50436850	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'4MK'	4mkc		Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key &quot;gatekeeper&quot; residues of the enzyme. This occurrence led to development of novel second-generation ALK inhibitors such as ceritinib to overcome crizotinib resistance. The FDA approved ceritinib in April 2014 due to a surprisingly high response rate (56%) towards crizotinib-resistant tumours and has designated it with orphan drug status.	Q9UM73|P11712|P08684	557.2	8	3	9	105.2	6.4	2		ALK	Tyr	Y
Chiauranib		Chipscreen Biosciences		COC1=CC=C2C(=CC=NC2=C1)OC1=CC2=CC=CC(C(=O)NC3=CC=CC=C3N)=C2C=C1		nan	3.0		|CHIAURANIB CAPSULES|CS-2164|CS2164	nan	nan	nan	InChI=1S/C27H21N3O3/c1-32-18-9-12-22-25(16-18)29-14-13-26(22)33-19-10-11-20-17(15-19)5-4-6-21(20)27(31)30-24-8-3-2-7-23(24)28/h2-16H,28H2,1H3,(H,30,31)	BRKWREZNORONDU-UHFFFAOYSA-N	81367270	|http://www.chemspider.com/Chemical-Structure.81367270.html|http://pubchem.ncbi.nlm.nih.gov/compound/49779393|http://www.drugbank.ca/drugs/DB16124|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10475|https://precision.fda.gov/uniisearch/srs/unii/F40IRN5981	|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						435.2	5	2	5	86.5	6.0	1		nan		
Cobimetinib	Cotellic	Hoffmann-La Roche	CHEMBL2146883	c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I	Single Stereoisomer	2015	4.0	US-7803839-B2	COBIMETINIB | COTELLIC | GDC 0623 | GDC 0973 | GDC-0623 | GDC-0973 | RG 7420 | RG-7420 | RG-7421 | RG7420 | XL 518 | XL-518 | XL518	For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.	3	Q02750	InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1	BSMCAPRUBJMWDF-KRWDZBQOSA-N	17349374	|http://www.chemspider.com/Chemical-Structure.17349374.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2146883|http://pubchem.ncbi.nlm.nih.gov/compound/16222096|http://www.drugbank.ca/drugs/DB05239| http://www.rcsb.org/ligand/EUI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EUI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7626|http://zinc15.docking.org/substances/ZINC000060325170|https://precision.fda.gov/uniisearch/srs/unii/ER29L26N1X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50391802	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'EUI'	4an2 4lmn 7juy 7m0v		Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.	Q02750|P08684|P16662|P10635|P20815|P02763|Q9Y6L6|Q9NPD5|Q9UNQ0|P08183	531.1	4	3	4	64.6	3.8	1		MAP2K1	STE	Y
Conteltinib		Centaurus Biopharma	CHEMBL3899477	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2	Unknown	nan	1.0	None	CONTELTINIB 	nan	nan	nan	InChI=1S/C32H45N9O3S/c1-22(2)38-45(42,43)29-8-6-5-7-27(29)34-31-25-11-14-33-30(25)36-32(37-31)35-26-10-9-24(21-28(26)44-4)40-15-12-23(13-16-40)41-19-17-39(3)18-20-41/h5-10,21-23,38H,11-20H2,1-4H3,(H3,33,34,35,36,37)	NPJCURIANJMFEO-UHFFFAOYSA-N	61732963	|http://www.chemspider.com/Chemical-Structure.61732963.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3899477|http://pubchem.ncbi.nlm.nih.gov/compound/89860551|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9763|https://precision.fda.gov/uniisearch/srs/unii/URX2UMQ8XV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=245641	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS|BindingDB						635.3	11	4	10	127.0	3.8	2		nan		
Copanlisib	Aliqopa	Bayer	CHEMBL3218576	COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5	Achiral Molecule	2017	4.0	US-7511041-B2	BAY 80-6946 | BAY-80-6946 | BAY80-6946 | COPANLISIB	Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.	1	P42336|P42338	InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)	PZBCKZWLPGJMAO-UHFFFAOYSA-N	25069683	|http://www.chemspider.com/Chemical-Structure.25069683.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3218576|http://pubchem.ncbi.nlm.nih.gov/compound/24989044|http://www.drugbank.ca/drugs/DB12483| http://www.rcsb.org/ligand/6E2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6E2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7875|http://zinc15.docking.org/substances/ZINC000068247389|https://precision.fda.gov/uniisearch/srs/unii/WI6V529FZ9|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50204093	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'6E2'	5g2n		Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase) inhibitor that was first developed by Bayer Healthcare Pharmaceuticals, Inc. The drug targets the enzyme that plays a role in regulating cell growth and survival. Copanlisib was granted accelerated approval on September 14, 2017 under the market name Aliqopa for the treatment of adult patients with relapsed follicular lymphoma and a treatment history of at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that is caused by unregulated proliferation and growth of lymphocytes. The active ingredient in Aliquopa intravenous therapy is copanlisib dihydrochloride.	P42336|O00329	480.2	11	2	7	139.8	0.7	1		PIK3CA; PIK3CB	Atypical	Y
Crenolanib		Arog Pharmaceuticals	CHEMBL2105728	CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N	Achiral Molecule	nan	3.0	None	ARO 002 | ARO-002 | CP 868596 | CP-868,596 | CP-868596 | CRENOLANIB	nan	1	P36888|P16234|P09619	InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3	DYNHJHQFHQTFTP-UHFFFAOYSA-N	8541584	|http://www.chemspider.com/Chemical-Structure.8541584.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2105728|http://pubchem.ncbi.nlm.nih.gov/compound/10366136|http://www.drugbank.ca/drugs/DB11832| http://www.rcsb.org/ligand/6T2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6T2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7882|http://zinc15.docking.org/substances/ZINC000003820043|https://precision.fda.gov/uniisearch/srs/unii/LQF7I567TQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185149	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'6T2'	5lby 6bqp 6joi 6joj				443.2	7	1	5	78.4	3.9	0		FLT3; PDGFRA; PDGFRB	Tyr	
Crizotinib	Xalkori	Pfizer	CHEMBL601719	C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4	Single Stereoisomer	2011	4.0	US-7230098-B2	CRIZOTINIB | NSC-756645 | PF-02341066 | PF-2341066 | XALKORI	Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.	1	Q9UM73|P08581	InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1	KTEIFNKAUNYNJU-GFCCVEGCSA-N	9801307	|http://www.chemspider.com/Chemical-Structure.9801307.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL601719|http://pubchem.ncbi.nlm.nih.gov/compound/11626560|http://www.drugbank.ca/drugs/DB08865| http://www.rcsb.org/ligand/VGH|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VGH|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4903|http://zinc15.docking.org/substances/ZINC000035902489|https://precision.fda.gov/uniisearch/srs/unii/53AH36668S|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50306682	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'VGH'	2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 6imz		"Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: XALKORI (crizotinib) capsules for oral use"" href=""#reference-L42460"">4</a></sup> By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Heigener DF, Reck M: Crizotinib. Recent Results Cancer Res. 2018;211:57-65. doi: 10.1007/978-3-319-91442-8_4. (PubMed ID 30069759)"" href=""#reference-A250785"">3</a></sup> Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Heigener DF, Reck M: Crizotinib. Recent Results Cancer Res. 2018;211:57-65. doi: 10.1007/978-3-319-91442-8_4. (PubMed ID 30069759)"" href=""#reference-A250785"">3</a></sup> Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: XALKORI (crizotinib) capsules for oral use"" href=""#reference-L42460"">4</a></sup>"	Q9UM73|P08581|P08922|Q04912|P08684|P20815|P20813|P08684|Q9HB55|P20815|P24462|P02768|P02763|P19652|P08183	449.1	6	2	5	78.0	5.0	1		ALK; MET	Tyr	Y
Crozbaciclib			CHEMBL4277900	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2	Achiral Molecule	nan	-1.0	None	CROZBACICLIB	nan	nan	nan	InChI=1S/C28H30F2N6/c1-17-28(9-3-4-10-28)21-13-20(14-22(29)26(21)33-17)25-23(30)16-32-27(35-25)34-24-6-5-19(15-31-24)18-7-11-36(2)12-8-18/h5-6,13-16,18H,3-4,7-12H2,1-2H3,(H,31,32,34,35)	AEFFENQISAXIKE-UHFFFAOYSA-N	71117313	|http://www.chemspider.com/Chemical-Structure.71117313.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4277900|http://pubchem.ncbi.nlm.nih.gov/compound/129202507|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50464606	|ChemSpider|ChEMBL|PubChem|BindingDB						488.3	6	1	4	66.3	6.3	1		nan		
Culmerciclib			CHEMBL5095094	CC(C)c1c2cc(-c3nc(Nc4ccc(N5CCNCC5)cn4)ncc3F)ccc2nn1C	Achiral Molecule	nan	-1.0	None		nan	nan	nan	InChI=1S/C24H27FN8/c1-15(2)23-18-12-16(4-6-20(18)31-32(23)3)22-19(25)14-28-24(30-22)29-21-7-5-17(13-27-21)33-10-8-26-9-11-33/h4-7,12-15,26H,8-11H2,1-3H3,(H,27,28,29,30)	LLFOBMRPWNABCB-UHFFFAOYSA-N		|http://www.chemspider.com/Chemical-Structure..html|http://pubchem.ncbi.nlm.nih.gov/compound/122544510	|ChemSpider|PubChem						446.2	8	2	5	83.8	3.8	0		nan		
Dabrafenib	Tafinlar	GlaxoSmithKline	CHEMBL2028663	CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F	Achiral Molecule	2013	4.0	US-7994185-B2	DABRAFENIB | GSK-2118436 | GSK-2118436A | GSK2118436 | GSK2118436A | TAFINLAR	Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.	1.5	P15056|P04049|P57059|Q8NG66|P53667	InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)	BFSMGDJOXZAERB-UHFFFAOYSA-N	25948204	|http://www.chemspider.com/Chemical-Structure.25948204.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2028663|http://pubchem.ncbi.nlm.nih.gov/compound/44462760|http://www.drugbank.ca/drugs/DB08912| http://www.rcsb.org/ligand/P06|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P06|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494|http://zinc15.docking.org/substances/ZINC000068153186|https://precision.fda.gov/uniisearch/srs/unii/QGP4HA4G1B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50428286	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'P06'	4xv2 5csw 5hie 6hj2 6v2u 7riv		"Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Proucts: TAFINLAR® (dabrafenib) capsules, for oral use"" href=""#reference-L41955"">20</a></sup> It was also used for metastatic non-small cell lung cancer with the same mutation.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Proucts: TAFINLAR® (dabrafenib) capsules, for oral use"" href=""#reference-L41955"">20</a></sup></p><p>In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (<a href=""https://go.drugbank.com/drugs/DB08911"">Trametinib</a>), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Proucts: TAFINLAR® (dabrafenib) capsules, for oral use"" href=""#reference-L41955"">20</a></sup>"	P15056|P04049|P57059|Q8NG66|P53667|P08684|P10632|P20813|P11712|P33261|P05177|P22309|P02768|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|P46721|Q4U2R8|Q8TCC7|O15244	519.1	7	2	5	110.9	5.4	2		BRAF; RAF1; SIK1; NEK11; LIMK1	TKL<br>CAMK<br>NEK	Y
Dacomitinib	Vizimpro	Pfizer	CHEMBL2110732	COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F	Achiral Molecule	2018	4.0	US-7772243-B2	DACOMITINIB | PF-00299804	On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer	1	P00533	InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+	LVXJQMNHJWSHET-AATRIKPKSA-N	9685914	|http://www.chemspider.com/Chemical-Structure.9685914.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2110732|http://pubchem.ncbi.nlm.nih.gov/compound/11511120|http://www.drugbank.ca/drugs/DB11963| http://www.rcsb.org/ligand/1C9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1C9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422|http://zinc15.docking.org/substances/ZINC000072266312|https://precision.fda.gov/uniisearch/srs/unii/2XJX250C20|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=112499	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'1C9'	4i23 4i24		"Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Brzezniak C, Carter CA, Giaccone G: Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2013 Feb;14(2):247-53. doi: 10.1517/14656566.2013.758714. Epub 2013 Jan 7. (PubMed ID 23294134)"" href=""#reference-A40009"">2</a></sup></p><p>Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA approval"" href=""#reference-L4810"">14</a></sup> Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, Sabourinejad Z, Alishahi Z, Yousefi H, Ghasemi R, Dardaei L, Bashash D, Chahardouli B, Dehpour AR, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH: Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Sci Rep. 2017 Jun 23;7(1):4204. doi: 10.1038/s41598-017-04147-0. (PubMed ID 28646172)"" href=""#reference-A39624"">1</a></sup>, although further investigations are needed."	P00533|P10635|P08684|P11712|P22309	469.2	6	2	7	79.4	5.2	1	184-187 ºC	EGFR	Tyr	Y
Dactolisib		Novartis	CHEMBL1879463	CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5	Achiral Molecule	nan	3.0	None	BEZ-235 | BEZ235 | DACTOLISIB | NSC-751249 | NVP-BEZ-235 | NVP-BEZ235 | NVP-BEZ235-NX | RTB-101 | RTB101	nan	nan	P42336|P42338|P48736|O00329|P42345	InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	10151099	|http://www.chemspider.com/Chemical-Structure.10151099.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1879463|http://pubchem.ncbi.nlm.nih.gov/compound/11977753|http://www.drugbank.ca/drugs/DB11651|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950|http://zinc15.docking.org/substances/ZINC24760115|https://precision.fda.gov/uniisearch/srs/unii/RUJ6Z9Y0DT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=92862	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						469.2	6	0	3	76.5	5.9	1		PIK3CA; PIK3CB; PIK3CG; PIK3CD; MTOR	Atypical	
Dalmelitinib		Jiangsu Hansoh Pharmaceutical	CHEMBL3818247	CN1C(=O)COc2c1cnc1ccc(Sc3nnc4c(F)cc(-c5cnn(C)c5)cn34)cc21	Achiral Molecule	nan	-1.0	None	DALMELITINIB	nan	nan	nan	InChI=1S/C22H16FN7O2S/c1-28-9-13(7-25-28)12-5-16(23)21-26-27-22(30(21)10-12)33-14-3-4-17-15(6-14)20-18(8-24-17)29(2)19(31)11-32-20/h3-10H,11H2,1-2H3	MFEXYTURXUZOID-UHFFFAOYSA-N	58880647	|http://www.chemspider.com/Chemical-Structure.58880647.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3818247|http://pubchem.ncbi.nlm.nih.gov/compound/86302574|http://zinc15.docking.org/substances/ZINC000221146611|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50182493	|ChemSpider|ChEMBL|PubChem|ZINC|BindingDB						461.1	9	0	3	90.4	3.3	0		nan		
Dalpiciclib		Jiangsu Hengrui Medicine	CHEMBL4802161	CC(=O)c1c(C)c2cnc(Nc3ccc(C4CCNCC4)cn3)nc2n(C2CCCC2)c1=O	Achiral Molecule	nan	2.0	None	DALPICICLIB | SHR-6390	nan	nan	nan	InChI=1S/C25H30N6O2/c1-15-20-14-28-25(29-21-8-7-18(13-27-21)17-9-11-26-12-10-17)30-23(20)31(19-5-3-4-6-19)24(33)22(15)16(2)32/h7-8,13-14,17,19,26H,3-6,9-12H2,1-2H3,(H,27,28,29,30)	SGJLSPUSUBJWHO-UHFFFAOYSA-N	114951729	|http://www.chemspider.com/Chemical-Structure.114951729.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4802161|http://pubchem.ncbi.nlm.nih.gov/compound/86279927|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11189|https://precision.fda.gov/uniisearch/srs/unii/5ZHA5P4PFX	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS						446.2	8	2	5	101.8	4.0	0		nan		
Danusertib		Nerviano Medical Sciences	CHEMBL402548	CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC	Single Stereoisomer	nan	2.0	None	DANUSERTIB | PHA-739358	nan	1	O14965|Q96GD4|Q9UQB9	InChI=1S/C26H30N6O3/c1-30-12-14-31(15-13-30)20-10-8-19(9-11-20)25(33)27-24-21-16-32(17-22(21)28-29-24)26(34)23(35-2)18-6-4-3-5-7-18/h3-11,23H,12-17H2,1-2H3,(H2,27,28,29,33)/t23-/m1/s1	XKFTZKGMDDZMJI-HSZRJFAPSA-N	9617754	|http://www.chemspider.com/Chemical-Structure.9617754.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL402548|http://pubchem.ncbi.nlm.nih.gov/compound/11442891|http://www.drugbank.ca/drugs/DB11778| http://www.rcsb.org/ligand/627|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/627|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7937|http://zinc15.docking.org/substances/ZINC000006718723|https://precision.fda.gov/uniisearch/srs/unii/M3X659D0FY|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=209858	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'627'	2j50 2v7a 4qo9 5i9z				474.2	6	2	6	93.8	2.6	0		AURKA; AURKB; AURKC	Other	
Darovasertib		Novartis	CHEMBL3982723	CC1(N)CCN(c2cccnc2NC(=O)c2nc(-c3ncccc3C(F)(F)F)cnc2N)CC1	Achiral Molecule	nan	2.0	None	DAROVASERTIB | IDE-196 | IDE196 | LXS-196 | LXS196 | NVP-LXS-196	nan	nan	nan	InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)	XXJXHXJWQSCNPX-UHFFFAOYSA-N	57617794	|http://www.chemspider.com/Chemical-Structure.57617794.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3982723|http://pubchem.ncbi.nlm.nih.gov/compound/118873253|http://www.drugbank.ca/drugs/DB16059|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11186|http://zinc15.docking.org/substances/ZINC000584641445|https://precision.fda.gov/uniisearch/srs/unii/E0YF0M8O09|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=251460	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						472.2	8	3	4	135.9	3.1	0		nan		
Dasatinib	Dasatinib;Sprycel	Bristol Myers Squibb	CHEMBL1421	Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl	Achiral Molecule	2006	4.0	US-7491725-B2	BMS-354825 | BMS-354825 HYDRATE | BMS-354825-03 | DASATINIB | DASATINIB ANHYDROUS | DASATINIB HYDRATE | DASATINIB MONOHYDRATE | NSC-759877 | SPRYCEL	For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.	1	P00519|P12931|P29317|P06239|P07947|P10721|P09619|P42684|P06241	InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	2323020	|http://www.chemspider.com/Chemical-Structure.2323020.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1421|http://pubchem.ncbi.nlm.nih.gov/compound/3062316|http://www.drugbank.ca/drugs/DB01254| http://www.rcsb.org/ligand/1N1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1N1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678|http://zinc15.docking.org/substances/ZINC21982951|https://precision.fda.gov/uniisearch/srs/unii/X78UG0A0RN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13216	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'1N1'	2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 6bsd 6fnm 7erk 7n9g		"Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. (PubMed ID 17154512)"" href=""#reference-A2224"">1</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (February 2023)"" href=""#reference-L45171"">7</a></sup> Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. (PubMed ID 20072833)"" href=""#reference-A11377"">5</a>,<a class=""reference-popover-link"" data-content=""Aguilera DG, Tsimberidou AM: Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag. 2009 Apr;5(2):281-9. Epub 2009 May 4. (PubMed ID 19536317)"" href=""#reference-A33432"">6</a></sup> Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. (PubMed ID 20072833)"" href=""#reference-A11377"">5</a></sup> </p><p>Unlike <a href=""https://go.drugbank.com/drugs/DB00619"">imatinib</a>, another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O&#39;Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. (PubMed ID 16775234)"" href=""#reference-A2226"">2</a>,<a class=""reference-popover-link"" data-content=""Lindauer M, Hochhaus A: Dasatinib. Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. (PubMed ID 20072833)"" href=""#reference-A11377"">5</a></sup> Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O&#39;Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41. (PubMed ID 16775234)"" href=""#reference-A2226"">2</a></sup> The use of dasatinib was first approved by the FDA in 2006.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (February 2023)"" href=""#reference-L45171"">7</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Sprycel (dasatinib) tablets for oral use (June 2006)"" href=""#reference-L45186"">9</a></sup>"	P00519|P12931|P29317|P06239|P07947|P10721|P09619|P51692|P42684|P06241|Q06187|Q92570|P11274|P41240|P54756|P54760|P09769|P42685|P11142|P07948|Q9NYL2|Q16539|Q06203|P04798|P05177|Q16678|P20815|P31513|P08684|P08183|Q9UNQ0	487.2	9	3	7	106.5	3.3	0	280-286 °C	ABL1; SRC; EPHA2; LCK; YES1; KIT; PDGFRB; ABL2; FYN	Tyr	Y
Decernotinib		Vertex Pharmaceuticals	CHEMBL3039513	CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3	Single Stereoisomer	nan	2.0	None	ADELATINIB | DECERNOTINIB | VRT-831509 | VX-509	nan	1	P52333	InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1	ASUGUQWIHMTFJL-QGZVFWFLSA-N	30843790	|http://www.chemspider.com/Chemical-Structure.30843790.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039513|http://pubchem.ncbi.nlm.nih.gov/compound/59422203|http://www.drugbank.ca/drugs/DB12566| http://www.rcsb.org/ligand/VJK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VJK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8309|http://zinc15.docking.org/substances/ZINC000096941867|https://precision.fda.gov/uniisearch/srs/unii/MZK2GP0RHK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50021655	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'VJK'	4yti				392.2	5	3	6	95.6	3.3	0		JAK3	Tyr	
Defactinib		Verastem	CHEMBL3137331	CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F	Achiral Molecule	nan	2.0	None	DEFACTINIB | PF-04554878 | VS-6063	nan	1	Q05397|Q14289	InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)	FWLMVFUGMHIOAA-UHFFFAOYSA-N	32695161	|http://www.chemspider.com/Chemical-Structure.32695161.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3137331|http://pubchem.ncbi.nlm.nih.gov/compound/25117126|http://www.drugbank.ca/drugs/DB12282| http://www.rcsb.org/ligand/7KD|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/7KD|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7910|http://zinc15.docking.org/substances/ZINC000103297739|https://precision.fda.gov/uniisearch/srs/unii/53O87HA2QU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=418817	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'7KD'	5mah				510.1	9	3	8	142.1	2.4	1		PTK2; PTK2B	Tyr	
Delgocitinib		Japan Tobacco	CHEMBL4297507	CC1CN(C12CCN(C2)c3c4cc[nH]c4ncn3)C(=O)CC#N	Single Stereoisomer	nan	3.0	None		nan	nan	nan	InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)	LOWWYYZBZNSPDT-UHFFFAOYSA-N	34960249	|http://www.chemspider.com/Chemical-Structure.34960249.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3689518|http://pubchem.ncbi.nlm.nih.gov/compound/50913622|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=109868	|ChemSpider|ChEMBL|PubChem|BindingDB						310.2	5	1	2	88.9	1.3	0		nan		
Denfivontinib		Genosco	CHEMBL4544478	CN1CCC(Nc2nc(Nc3ccc(Oc4ccccc4)cc3)c3c(=O)[nH]cc(Br)c3n2)CC1	Achiral Molecule	nan	-1.0	None	DENFIVONTINIB | G-749	nan	nan	nan	InChI=1S/C25H25BrN6O2/c1-32-13-11-17(12-14-32)29-25-30-22-20(26)15-27-24(33)21(22)23(31-25)28-16-7-9-19(10-8-16)34-18-5-3-2-4-6-18/h2-10,15,17H,11-14H2,1H3,(H,27,33)(H2,28,29,30,31)	SXWMIXPJPNCXQQ-UHFFFAOYSA-N	32813334	|http://www.chemspider.com/Chemical-Structure.32813334.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4544478|http://pubchem.ncbi.nlm.nih.gov/compound/78357765|http://www.drugbank.ca/drugs/DB17159|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8108|http://zinc15.docking.org/substances/ZINC000095644293|https://precision.fda.gov/uniisearch/srs/unii/B06W426B66	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						520.1	7	3	6	95.2	5.1	2		nan		
Derazantinib		ArQule	CHEMBL4297187	COCCNCCc1cccc(c1)Nc2ncc3c(n2)-c4ccccc4[C@@H](C3)c5ccccc5F	Single Stereoisomer	nan	2.0	None	ARQ 087 | ARQ-087 | ARQ087 | DERAZANTINIB	Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity.	nan	nan	InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1	KPJDVVCDVBFRMU-AREMUKBSSA-N	59718644	|http://www.chemspider.com/Chemical-Structure.59718644.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297187|http://pubchem.ncbi.nlm.nih.gov/compound/46834118|http://www.drugbank.ca/drugs/DB14889|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9785|https://precision.fda.gov/uniisearch/srs/unii/N9B0H171MJ	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						468.2	5	2	9	59.1	5.5	1		nan		
Deucravacitinib		Bristol Myers Squibb	CHEMBL4596392	C[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC	Achiral Molecule	2022	4.0	None	BMS-986165 | DEUCRAVACITINIB | SOTYKTU	On September 2022, FDA approved deucravacitinib to treat moderate-to-severe plaque psoriasis	nan	P29597	InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3	BZZKEPGENYLQSC-FIBGUPNXSA-N	72380005	|http://www.chemspider.com/Chemical-Structure.72380005.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4435170|http://pubchem.ncbi.nlm.nih.gov/compound/134821691|http://www.drugbank.ca/drugs/DB16650|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10432|https://precision.fda.gov/uniisearch/srs/unii/N0A21N6RAU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50507816	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB				"Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S: Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Mar 3. pii: annrheumdis-2021-221664. doi: 10.1136/annrheumdis-2021-221664. (PubMed ID 35241426)"" href=""#reference-A246938"">1</a>,<a class=""reference-popover-link"" data-content=""Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, Patel A, Shen J, Girgis IG, Banerjee S, Throup J: Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30. (PubMed ID 34471993)"" href=""#reference-A246943"">2</a></sup> This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and triglyceride levels and liver and kidney dysfunction.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, Patel A, Shen J, Girgis IG, Banerjee S, Throup J: Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30. (PubMed ID 34471993)"" href=""#reference-A246943"">2</a></sup> </p><p>Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: SOTYKTU (deucravacitinib) tablets, for oral use"" href=""#reference-L43150"">5</a></sup> It was later approved by Health Canada in November 2022 <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Health Canada Approved Drug Products: SOTYKTU (deucravacitinib) Oral Tablets"" href=""#reference-L44216"">6</a></sup> and by the European Medicines Agency in March 2023.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Bristol Myers Squibb: Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis"" href=""#reference-L45788"">8</a></sup>"	P29597|P05177|P20813|P10635|O00748|O60656|P08183|Q9UNQ0|O15245|Q9NPD5	425.2	8	3	7	139.2	1.2	0		TYK2	Tyr	Y
Dezapelisib		Incyte Corporation	CHEMBL2216863	Cc1csc2n1c(=O)c(c(n2)[C@H](C)Nc3c4c([nH]cn4)ncn3)c5cccc(c5)F	Single Stereoisomer	nan	0.0	None	DEZAPELISIB | INCB040093	nan	nan	nan	InChI=1S/C20H16FN7OS/c1-10-7-30-20-27-15(11(2)26-18-16-17(23-8-22-16)24-9-25-18)14(19(29)28(10)20)12-4-3-5-13(21)6-12/h3-9,11H,1-2H3,(H2,22,23,24,25,26)/t11-/m0/s1	RSIWALKZYXPAGW-NSHDSACASA-N	28651137	|http://www.chemspider.com/Chemical-Structure.28651137.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216863|http://pubchem.ncbi.nlm.nih.gov/compound/58111426|http://www.drugbank.ca/drugs/DB16137|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9728|http://zinc15.docking.org/substances/ZINC000095564453|https://precision.fda.gov/uniisearch/srs/unii/2K59L7G59M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004547	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						421.1	8	2	4	100.9	3.7	0		nan		
Dilmapimod		GlaxoSmithKline	CHEMBL2103838	Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F	Achiral Molecule	nan	2.0	None	DILMAPIMOD | GW-681323 | SB-681323 | SB681323	Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.	nan	Q16539|Q15759|O15264|P53778	InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)	ORVNHOYNEHYKJG-UHFFFAOYSA-N	8473450	|http://www.chemspider.com/Chemical-Structure.8473450.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103838|http://pubchem.ncbi.nlm.nih.gov/compound/10297982|http://www.drugbank.ca/drugs/DB12140|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7815|http://zinc15.docking.org/substances/ZINC000034997404|https://precision.fda.gov/uniisearch/srs/unii/Q3238VQW0N	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS				Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}	P01375|P01584|P05231	456.1	7	3	6	100.3	2.9	0		MAPK14; MAPK11; MAPK13; MAPK12	CMGC	
Dinaciclib		Schering-Plough	CHEMBL2103840	CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO	Single Stereoisomer	nan	3.0	None	DINACICLIB | MK-7965 | SCH 727965 | SCH-727965	nan	nan	P11802|Q00534|Q58F21	InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1	PIMQWRZWLQKKBJ-SFHVURJKSA-N	25027387	|http://www.chemspider.com/Chemical-Structure.25027387.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103840|http://pubchem.ncbi.nlm.nih.gov/compound/46926350|http://www.drugbank.ca/drugs/DB12021|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7379|http://zinc15.docking.org/substances/ZINC000034894449|https://precision.fda.gov/uniisearch/srs/unii/4V8ECV0NBQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50139171	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						396.2	7	2	7	92.6	2.3	0		CDK4; CDK6; BRDT	CMGC<br>(*)	
Doramapimod		Boehringer Ingelheim	CHEMBL103667	Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5	Achiral Molecule	nan	2.0	None	BIRB 796 BS | BIRB-796 | BIRB-796 BS | DORAMAPIMOD	nan	2	Q16539	InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	137746	|http://www.chemspider.com/Chemical-Structure.137746.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL103667|http://pubchem.ncbi.nlm.nih.gov/compound/156422|http://www.drugbank.ca/drugs/DB03044| http://www.rcsb.org/ligand/B96|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/B96|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5668|http://zinc15.docking.org/substances/ZINC24044436|https://precision.fda.gov/uniisearch/srs/unii/HO1A8B3YVV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13533	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'B96'	1kv2 3fzs 3npc 4jvg 4twn 5n66 6gtt		Doramapimod is a P38 MAP kinase inhibitor.	Q16539	527.3	6	2	7	80.7	6.0	2		MAPK14	CMGC	
Dovitinib		Novartis	CHEMBL522892	CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N	Achiral Molecule	nan	3.0	None	CHIR-258 | DOVITINIB | GFKI-258 | NVP-TKI258 | TKI-258	nan	1	P22607|P15692|P11362|P16234|P10721|P07333	InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)	PIQCTGMSNWUMAF-UHFFFAOYSA-N	11530944	|http://www.chemspider.com/Chemical-Structure.11530944.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL522892|http://pubchem.ncbi.nlm.nih.gov/compound/135398510|http://www.drugbank.ca/drugs/DB05928| http://www.rcsb.org/ligand/38O|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/38O|http://zinc15.docking.org/substances/ZINC000003816310|https://precision.fda.gov/uniisearch/srs/unii/I35H55G906|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25118	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB	'38O'	4tyi 5a46 5am6 5am7 5owq 7akg 7qq6		Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.	O75469|P04798|P05177|P35503|P16662|P33261|P08684|O15438|Q9UNQ0|Q9Y6L6|O94956|Q9NPD5|P08183	392.2	5	3	2	94.0	2.5	0		FGFR3; VEGFA; FGFR1; PDGFRA; KIT; CSF1R	(*)<br>Tyr	
Dubermatinib		Tolero Pharmaceuticals	CHEMBL2022968	CN1CCN(CC1)Cc2ccc(cc2)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)N(C)C)Cl	Achiral Molecule	nan	1.5	None	DUBERMATINIB | HCL-2084 | TP 0903 | TP-0903 | TP0903	nan	nan	nan	InChI=1S/C24H30ClN7O2S/c1-30(2)35(33,34)22-7-5-4-6-21(22)28-23-20(25)16-26-24(29-23)27-19-10-8-18(9-11-19)17-32-14-12-31(3)13-15-32/h4-11,16H,12-15,17H2,1-3H3,(H2,26,27,28,29)	YUAALFPUEOYPNX-UHFFFAOYSA-N	28516684	|http://www.chemspider.com/Chemical-Structure.28516684.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2022968|http://pubchem.ncbi.nlm.nih.gov/compound/56839178|http://www.drugbank.ca/drugs/DB15187|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8863|http://zinc15.docking.org/substances/ZINC000084617535|https://precision.fda.gov/uniisearch/srs/unii/14D65TV20J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50382425	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						515.2	8	2	8	93.7	3.6	1		nan		
Duvelisib	Copiktra	Infinity Pharmacueticals	CHEMBL3039502	C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4	Single Stereoisomer	2018	4.0	US-8193182-B2	COPIKTRA | DUVELISIB | DUVELISIB HYDRATE | DUVELISIB MONOHYDRATE | INK-1147 | INK-1197 | IPI-145	On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma	nan	O00329|P48736	InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1	SJVQHLPISAIATJ-ZDUSSCGKSA-N	28637766	|http://www.chemspider.com/Chemical-Structure.28637766.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039502|http://pubchem.ncbi.nlm.nih.gov/compound/50905713|http://www.drugbank.ca/drugs/DB11952|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7795|http://zinc15.docking.org/substances/ZINC000088346058|https://precision.fda.gov/uniisearch/srs/unii/610V23S0JI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193013	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL: PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7. (PubMed ID 24211136)"" href=""#reference-A39025"">1</a></sup> Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA news"" href=""#reference-L4585"">7</a></sup>"	P48736|O00329|P08684	416.1	6	2	4	88.5	4.5	0	>190 ºC	PIK3CD; PIK3CG	Atypical	Y
Ebvaciclib		Pfizer	CHEMBL4446357	C[C@@]1(O)CCC[C@H]1n1c(=O)c(C(F)F)cc2cnc(NC3CCN(S(C)(=O)=O)CC3)nc21	Single Stereoisomer	nan	2.0	None	EBVACICLIB | PF-06873600	nan	nan	nan	InChI=1S/C20H27F2N5O4S/c1-20(29)7-3-4-15(20)27-17-12(10-14(16(21)22)18(27)28)11-23-19(25-17)24-13-5-8-26(9-6-13)32(2,30)31/h10-11,13,15-16,29H,3-9H2,1-2H3,(H,23,24,25)/t15-,20-/m1/s1	QIEKHLDZKRQLLN-FOIQADDNSA-N	71061508	|http://www.chemspider.com/Chemical-Structure.71061508.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4446357|http://pubchem.ncbi.nlm.nih.gov/compound/134247638| http://www.rcsb.org/ligand/WG1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/WG1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10426|https://precision.fda.gov/uniisearch/srs/unii/3B512HJD65|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=370121	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB	'WG1'	7kjs				471.2	8	2	5	117.4	2.0	0		nan		
Eciruciclib		Glixx Labs Inc	CHEMBL5095060	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4ccc5nn(C)c(C(C)C)c5c4)n3)nc2)CC1	Achiral Molecule	nan	-1.0	None		nan	nan	nan	InChI=1S/C27H33FN8/c1-5-35-10-12-36(13-11-35)17-19-6-9-24(29-15-19)31-27-30-16-22(28)25(32-27)20-7-8-23-21(14-20)26(18(2)3)34(4)33-23/h6-9,14-16,18H,5,10-13,17H2,1-4H3,(H,29,30,31,32)	RLRQXKXWZNPYRB-UHFFFAOYSA-N	103836221	|http://www.chemspider.com/Chemical-Structure.103836221.html|http://pubchem.ncbi.nlm.nih.gov/compound/118687700	|ChemSpider|PubChem						488.3	8	1	7	75.0	4.6	0		nan		
Eclitasertib		Sanofi	CHEMBL4861471	CN1C(=O)[C@@H](NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2cccnc21	Single Stereoisomer	nan	2.0	None	DNL-758 | DNL758 | ECLITASERTIB | SAR-443122 | SAR443122	nan	nan	nan	InChI=1S/C19H18N6O3/c1-25-17-14(8-5-9-20-17)28-11-13(19(25)27)21-18(26)16-22-15(23-24-16)10-12-6-3-2-4-7-12/h2-9,13H,10-11H2,1H3,(H,21,26)(H,22,23,24)/t13-/m0/s1	XUZICJHIIJCKQQ-ZDUSSCGKSA-N	115009121	|http://www.chemspider.com/Chemical-Structure.115009121.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4861471|http://pubchem.ncbi.nlm.nih.gov/compound/130298939|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11308|https://precision.fda.gov/uniisearch/srs/unii/975AT1P9J6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=356271	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS|BindingDB						378.1	6	2	4	113.1	0.9	0		nan		
Edecesertib		Gilead Sciences	CHEMBL5095097	C[C@H](C#N)Nc1cc(-c2ccc3cc(C#N)cnn23)ncc1C(=O)NC[C@@H](F)C(C)(C)O	Single Stereoisomer	nan	-1.0	None		nan	nan	nan	InChI=1S/C22H22FN7O2/c1-13(8-24)29-17-7-18(19-5-4-15-6-14(9-25)10-28-30(15)19)26-11-16(17)21(31)27-12-20(23)22(2,3)32/h4-7,10-11,13,20,32H,12H2,1-3H3,(H,26,29)(H,27,31)/t13-,20-/m1/s1	HORBHQPSWJRDSV-ZUOKHONESA-N		|http://www.chemspider.com/Chemical-Structure..html|http://pubchem.ncbi.nlm.nih.gov/compound/147817927	|ChemSpider|PubChem						435.2	8	3	7	139.1	2.4	0		nan		
Edicotinib		Janssen	CHEMBL3674570	CC1(CCC(=CC1)c2c(ccc(n2)C3CC(OC(C3)(C)C)(C)C)NC(=O)c4[nH]c(cn4)C#N)C	Achiral Molecule	nan	2.0	None	EDICOTINIB | JNJ-40346527	nan	nan	nan	InChI=1S/C27H35N5O2/c1-25(2)11-9-17(10-12-25)22-21(32-24(33)23-29-16-19(15-28)30-23)8-7-20(31-22)18-13-26(3,4)34-27(5,6)14-18/h7-9,16,18H,10-14H2,1-6H3,(H,29,30)(H,32,33)	BNVPFDRNGHMRJS-UHFFFAOYSA-N	34951020	|http://www.chemspider.com/Chemical-Structure.34951020.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3674570|http://pubchem.ncbi.nlm.nih.gov/compound/25230468|http://www.drugbank.ca/drugs/DB12504|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8942|http://zinc15.docking.org/substances/ZINC000043208574|https://precision.fda.gov/uniisearch/srs/unii/3NU609VYNF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=98634	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						461.3	5	2	4	103.7	6.0	1		nan		
Edralbrutinib		Eternity Bioscience	CHEMBL4650338	CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1	Single Stereoisomer	nan	2.0	None	EDRALBRUTINIB | SHR-1459 | SHR1459 | TG 1701 | TG-1701 | TG1701	nan	nan	nan	InChI=1S/C26H21F2N5O3/c1-2-4-21(34)32-12-11-16(13-32)33-14-18(22-23(33)26(35)31-30-25(22)29)15-7-9-17(10-8-15)36-24-19(27)5-3-6-20(24)28/h3,5-10,14,16H,11-13H2,1H3,(H2,29,30)(H,31,35)/t16-/m1/s1	DNPOFZXZJJDQLB-MRXNPFEDSA-N	94287367	|http://www.chemspider.com/Chemical-Structure.94287367.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650338|http://pubchem.ncbi.nlm.nih.gov/compound/118649391|https://precision.fda.gov/uniisearch/srs/unii/SG5I5QTR4E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=390081	|ChemSpider|ChEMBL|PubChem|FDA SRS|BindingDB						489.2	6	2	4	106.2	3.8	0		nan		
Eganelisib		Intellikine	CHEMBL3984425	C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)C#Cc4cnn(c4)C)NC(=O)c5c(nn6c5nccc6)N	Single Stereoisomer	nan	2.0	None	EGANELISIB | IPI-549 | PI3K-GAMMA INHIBITOR IPI-549	nan	nan	nan	InChI=1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1	XUMALORDVCFWKV-IBGZPJMESA-N	60600433	|http://www.chemspider.com/Chemical-Structure.60600433.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3984425|http://pubchem.ncbi.nlm.nih.gov/compound/91933883|http://www.drugbank.ca/drugs/DB16296| http://www.rcsb.org/ligand/V7Y|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/V7Y|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9563|http://zinc15.docking.org/substances/ZINC000584906867|https://precision.fda.gov/uniisearch/srs/unii/FOF5155FMZ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50192880	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'V7Y'	6xrl 7jwz				528.2	9	2	4	125.1	3.2	1		nan		
Elimusertib		Bayer	CHEMBL4647810	CC1COCCN1c2cc(c3ccnc(c3n2)c4ccn[nH]4)c5ccnn5C	Single Stereoisomer	nan	1.5	None	BAY1895344||BAY-1895344|BAY 1895344	nan	nan	nan	InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)	YBXRSCXGRPSTMW-UHFFFAOYSA-N	64879752	|http://www.chemspider.com/Chemical-Structure.64879752.html|http://pubchem.ncbi.nlm.nih.gov/compound/134446438	|ChemSpider|PubChem						375.2	7	1	3	84.8	2.6	0		nan		
Elsubrutinib		Abbvie	CHEMBL4594348	C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1	Single Stereoisomer	nan	2.0	None	ABBV-105 | ABBV105 | ELSUBRUTINIB	nan	nan	nan	InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1	UNHZLHSLZZWMNP-LLVKDONJSA-N	72380148	|http://www.chemspider.com/Chemical-Structure.72380148.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594348|http://pubchem.ncbi.nlm.nih.gov/compound/117773770|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10464|http://zinc15.docking.org/substances/ZINC000220885814|https://precision.fda.gov/uniisearch/srs/unii/1487U1Q3IQ	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS						297.1	2	2	3	79.2	2.2	0		nan		
Elzovantinib		TP Therapeutics	CHEMBL5095061	CCN1Cc2c(ccc(F)c2C#N)O[C@@H](C)CNC(=O)c2c(N)nn3ccc1nc23	Single Stereoisomer	nan	-1.0	None		nan	nan	nan	InChI=1S/C20H20FN7O2/c1-3-27-10-13-12(8-22)14(21)4-5-15(13)30-11(2)9-24-20(29)17-18(23)26-28-7-6-16(27)25-19(17)28/h4-7,11H,3,9-10H2,1-2H3,(H2,23,26)(H,24,29)/t11-/m0/s1	UUDPUQDMSHQSKH-NSHDSACASA-N	72380105	|http://www.chemspider.com/Chemical-Structure.72380105.html|http://pubchem.ncbi.nlm.nih.gov/compound/137455315	|ChemSpider|PubChem						409.2	8	2	1	121.6	1.9	0		nan		
Emavusertib		Aurigene Discovery Technologies	CHEMBL4783351	Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1	Single Stereoisomer	nan	1.5	None	AU-4948 | CA-4948 | EMAVUSERTIB	nan	nan	nan	InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1	SJHNWSAWWOAWJH-MRXNPFEDSA-N	29395146	|http://www.chemspider.com/Chemical-Structure.29395146.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4783351|http://pubchem.ncbi.nlm.nih.gov/compound/118224491| http://www.rcsb.org/ligand/FJ0|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FJ0|https://precision.fda.gov/uniisearch/srs/unii/MH5DMF9JKY	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|FDA SRS	'FJ0'	7c2v				491.2	11	2	5	142.9	2.2	1		nan		
Empesertib		Bayer	CHEMBL4303241	C[C@H](c1ccc(cc1)F)C(=O)Nc2ccc(cc2)c3ccc4nc(nn4c3)Nc5ccc(cc5OC)S(=O)(=O)C	Single Stereoisomer	nan	1.0	None	(-)-BAY-1161909 | BAY 1161909 | BAY-1161909 | EMPESERTIB | MPS1-IN-5	nan	nan	nan	InChI=1S/C29H26FN5O4S/c1-18(19-4-9-22(30)10-5-19)28(36)31-23-11-6-20(7-12-23)21-8-15-27-33-29(34-35(27)17-21)32-25-14-13-24(40(3,37)38)16-26(25)39-2/h4-18H,1-3H3,(H,31,36)(H,32,34)/t18-/m1/s1	NRJKIOCCERLIDG-GOSISDBHSA-N	35308224	|http://www.chemspider.com/Chemical-Structure.35308224.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303241|http://pubchem.ncbi.nlm.nih.gov/compound/71599640| http://www.rcsb.org/ligand/8QW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8QW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9427|http://zinc15.docking.org/substances/ZINC000206769279|https://precision.fda.gov/uniisearch/srs/unii/02Y3Z2756M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=329334	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'8QW'	5n9s 6tnb				559.2	8	2	8	114.7	5.4	2		nan		
Emprumapimod		Pfizer	CHEMBL4802251	CC(C)CN1C2=CC(C(N[C@H](C(N)=O)CCN(C)C)=O)=C(OC3=C(C=C(C=C3)F)F)C=C2C=N1	Single Stereoisomer	nan	1.0	None	PF-07265803||PF-06802861	nan	nan	nan	InChI=1S/C24H29F2N5O3/c1-14(2)13-31-20-11-17(24(33)29-19(23(27)32)7-8-30(3)4)22(9-15(20)12-28-31)34-21-6-5-16(25)10-18(21)26/h5-6,9-12,14,19H,7-8,13H2,1-4H3,(H2,27,32)(H,29,33)/t19-/m0/s1	JOOOJNJPZINWHM-IBGZPJMESA-N	115010416	|http://www.chemspider.com/Chemical-Structure.115010416.html|http://pubchem.ncbi.nlm.nih.gov/compound/67411502|https://precision.fda.gov/uniisearch/srs/unii/4JG61K4659	|ChemSpider|PubChem|FDA SRS						473.2	6	2	10	102.5	3.3	0		nan		
Enbezotinib		TP Therapeutics	CHEMBL5095062	C[C@H]1CNC(=O)c2cnn3cc4c(nc23)N(Cc2cc(F)cnc2O1)[C@@H]1CCC[C@@H]1O4	Single Stereoisomer	nan	-1.0	None		nan	nan	nan	InChI=1S/C21H21FN6O3/c1-11-6-23-20(29)14-8-25-28-10-17-19(26-18(14)28)27(15-3-2-4-16(15)31-17)9-12-5-13(22)7-24-21(12)30-11/h5,7-8,10-11,15-16H,2-4,6,9H2,1H3,(H,23,29)/t11-,15+,16-/m0/s1	BYYQDEOVMILBQT-XZJROXQQSA-N	115010417	|http://www.chemspider.com/Chemical-Structure.115010417.html|http://pubchem.ncbi.nlm.nih.gov/compound/146662764	|ChemSpider|PubChem						424.2	8	1	0	93.9	2.1	0		nan		
Encorafenib	Braftovi	Novartis	CHEMBL3301612	C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC	Single Stereoisomer	2018	4.0	US-8501758-B2	BRAFTOVI | ENCORAFENIB | LGX-818 | LGX818 | NVP-LGX-818-NXA | NVP-LGX818 | NVP-LGX818-NXA	On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.	nan	P15056	InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1	CMJCXYNUCSMDBY-ZDUSSCGKSA-N	28536139	|http://www.chemspider.com/Chemical-Structure.28536139.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301612|http://pubchem.ncbi.nlm.nih.gov/compound/50922675|http://www.drugbank.ca/drugs/DB11718|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7908|http://zinc15.docking.org/substances/ZINC000068249103|https://precision.fda.gov/uniisearch/srs/unii/8L7891MRB6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=221688	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Encorafenib, also known as <em>BRAFTOVI</em>, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Braftovi (encorafenib) oral capsules"" href=""#reference-L12216"">8</a></sup> This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""BRAF B-Raf proto-oncogene, serine/threonine kinase [ Homo sapiens (human) ]"" href=""#reference-L3344"">6</a></sup>.</p><p>On June 27, 2018, the Food and Drug Administration approved encorafenib and <a href=""https://go.drugbank.com/drugs/DB11967"">binimetinib</a> (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Braftovi (encorafenib) oral capsules"" href=""#reference-L12216"">8</a></sup>"	P15056|P24385|P08684|P33261|P10635	539.2	9	3	9	140.1	3.9	1		BRAF	TKL	Y
Ensartinib		Xcovery	CHEMBL4113131	C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl	Single Stereoisomer	nan	3.0	None	ENSARTINIB | X-396	nan	nan	Q9UM73	InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1	GLYMPHUVMRFTFV-QLFBSQMISA-N	58828042	|http://www.chemspider.com/Chemical-Structure.58828042.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4113131|http://pubchem.ncbi.nlm.nih.gov/compound/56960363|http://www.drugbank.ca/drugs/DB14860|http://zinc15.docking.org/substances/ZINC000199407645|https://precision.fda.gov/uniisearch/srs/unii/SMA5ZS5B22|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=179297	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB						560.2	7	3	6	122.5	4.7	1		ALK	Tyr	
Entospletinib		Gilead Sciences	CHEMBL3265032	c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6	Achiral Molecule	nan	3.0	None	ENTOSPLETINIB | GS-9973 | SYK INHIBITOR GS-9973	nan	1	P43405	InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	31042596	|http://www.chemspider.com/Chemical-Structure.31042596.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3265032|http://pubchem.ncbi.nlm.nih.gov/compound/59473233|http://www.drugbank.ca/drugs/DB12121| http://www.rcsb.org/ligand/CG9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CG9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7889|http://zinc15.docking.org/substances/ZINC000098208742|https://precision.fda.gov/uniisearch/srs/unii/6I3O3W6O3B|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015448	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'CG9'	4puz		Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.	P43405	411.2	7	2	4	83.4	3.9	0		SYK	Tyr	
Entrectinib	Rozlytrek	Ignyta	CHEMBL1983268	CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F	Achiral Molecule	2019	4.0	US-8299057-B2	ENTRECTINIB | NMS-E628 | ROZLYTREK | RXDX-101	On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and to treat adult and pediatric patients 12 years of age and older with solid tumors	1	P04629|Q16620|Q16288|P08922|Q9UM73	InChI=1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40)	HAYYBYPASCDWEQ-UHFFFAOYSA-N	24808589	|http://www.chemspider.com/Chemical-Structure.24808589.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1983268|http://pubchem.ncbi.nlm.nih.gov/compound/25141092|http://www.drugbank.ca/drugs/DB11986| http://www.rcsb.org/ligand/YMX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/YMX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8290|http://zinc15.docking.org/substances/ZINC000043204146|https://precision.fda.gov/uniisearch/srs/unii/L5ORF0AN1I|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=158154	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'YMX'	5fto 5kvt		"Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Productsl: Rozlytrek (entrectinib) capsules for oral use"" href=""#reference-L8081"">7</a></sup> It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Announcement: Entrectinib Approval"" href=""#reference-L8207"">9</a></sup> Entrectinib&#39;s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as <a href=""https://go.drugbank.com/drugs/DB11363"">alectinib</a>, <a href=""https://go.drugbank.com/drugs/DB09063"">ceritinib</a>, and <a href=""https://go.drugbank.com/drugs/DB12130"">lorlatinib</a> due to a wider range of targets.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Pacenta HL, Macy ME: Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma. Drug Des Devel Ther. 2018 Oct 23;12:3549-3561. doi: 10.2147/DDDT.S147384. eCollection 2018. (PubMed ID 30425456)"" href=""#reference-A183929"">6</a></sup>"	P04629|Q16288|P08922|Q16620|O60674|Q07912|P08684|P08183	560.3	6	3	7	85.5	5.0	2		NTRK1; NTRK2; NTRK3; ROS1; ALK	Tyr	Y
Enzastaurin	Kinenza	Eli Lilly	CHEMBL300138	Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7	Achiral Molecule	nan	3.0	None	DB-102 | DB102 | ENZASTAURIN | KINENZA | LY-317615 | LY317615	nan	nan	nan	InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)	AXRCEOKUDYDWLF-UHFFFAOYSA-N	153463	|http://www.chemspider.com/Chemical-Structure.153463.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL300138|http://pubchem.ncbi.nlm.nih.gov/compound/176167|http://www.drugbank.ca/drugs/DB06486|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693|http://zinc15.docking.org/substances/ZINC000001494900|https://precision.fda.gov/uniisearch/srs/unii/UC96G28EQF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50128285	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.	P05771|Q96GD4|O14965|Q96Q40|O14757|O96017|P31749|P27986	515.2	6	1	5	72.2	4.9	1		nan		
Epitinib		Hutchison MediPharma	CHEMBL3545121	CCN1CCN(CC1)C(=O)NC2=C(C=C3C(=C2)C(=NC=N3)NC4=CC=CC(=C4)C#C)OC CCN1CCN(CC1)C(=O)NC1=CC2=C(NC3C=C(C=CC=3)C#C)N=CN=C2C=C1OC	Single Stereoisomer	nan	1.0	None	|HMPL-813	nan	nan	nan	InChI=1S/C24H26N6O2/c1-4-17-7-6-8-18(13-17)27-23-19-14-21(22(32-3)15-20(19)25-16-26-23)28-24(31)30-11-9-29(5-2)10-12-30/h1,6-8,13-16H,5,9-12H2,2-3H3,(H,28,31)(H,25,26,27)	DQAZPZIYEOGZAF-UHFFFAOYSA-N	107561648	|http://www.chemspider.com/Chemical-Structure.107561648.html|http://pubchem.ncbi.nlm.nih.gov/compound/59142777|http://zinc15.docking.org/substances/ZINC000202963740|https://precision.fda.gov/uniisearch/srs/unii/WZ97ZE4UUG	|ChemSpider|PubChem|ZINC|FDA SRS						430.2	6	2	5	82.6	3.5	0		nan		
Erdafitinib	Balversa	Janssen	CHEMBL3545376	CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC	Achiral Molecule	2019	4.0	US-8895601-B2	BALVERSA | ERDAFITINIB | JNJ-42756493	On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer	1	P11362	InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3	OLAHOMJCDNXHFI-UHFFFAOYSA-N	35308353	|http://www.chemspider.com/Chemical-Structure.35308353.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545376|http://pubchem.ncbi.nlm.nih.gov/compound/67462786|http://www.drugbank.ca/drugs/DB12147| http://www.rcsb.org/ligand/5SF|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/5SF|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9039|http://zinc15.docking.org/substances/ZINC000168520308|https://precision.fda.gov/uniisearch/srs/unii/890E37NHMV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50525939	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'5SF'	5ew8		"In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies&#39; brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release"" href=""#reference-L5956"">4</a>,<a class=""reference-popover-link"" data-content=""First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval"" href=""#reference-L5959"">5</a></sup> At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release"" href=""#reference-L5956"">4</a>,<a class=""reference-popover-link"" data-content=""First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval"" href=""#reference-L5959"">5</a></sup>.</p><p>Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient&#39;s specific genetic mutation.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release"" href=""#reference-L5956"">4</a>,<a class=""reference-popover-link"" data-content=""First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval"" href=""#reference-L5959"">5</a></sup> Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""NHS Evidence Briefing On: Erdafitinib capsules for metastatic or surgically unresectable urothelial cancer with FGFR gene aberrations – second line therapy"" href=""#reference-F4372"">9</a></sup></p><p>Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma: Press Release"" href=""#reference-L5956"">4</a>,<a class=""reference-popover-link"" data-content=""First Targeted Therapy for Metastatic Bladder Cancer Receives FDA Approval"" href=""#reference-L5959"">5</a></sup>"	P11362|P21802|P22607|P22455|O43519|P07333|P16234|P09619|P10721|P35968|P11712|P08684|P02763|P19652|P08183|O15244	446.2	8	1	9	77.3	4.2	0		FGFR1	Tyr	Y
Erlotinib	Tarceva	Osi Pharmaceuticals	CHEMBL553	COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C	Achiral Molecule	2004	4.0	None	CP-358,774 | CP-358774 | CP-35877401 | ERLOTINIB | OSI-774 | R-1415 | RG-1415 | RO-508231 | TARCEVA	For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.	1.5	P00533|O75469	InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)	AAKJLRGGTJKAMG-UHFFFAOYSA-N	154044	|http://www.chemspider.com/Chemical-Structure.154044.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL553|http://pubchem.ncbi.nlm.nih.gov/compound/176870|http://www.drugbank.ca/drugs/DB00530| http://www.rcsb.org/ligand/AQ4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AQ4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920|http://zinc15.docking.org/substances/ZINC01546066|https://precision.fda.gov/uniisearch/srs/unii/J4T82NDH7E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5446	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'AQ4'	1m17 4hjo 6dwn		Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.	O75469|P00533|P08684|P20815|P05177|P04798|P10635|P10632|Q16678|P22309|P00533|P02768|P02763	393.2	7	1	10	74.7	3.4	0		EGFR; NR1I2	(*)<br>Tyr	Y
Evobrutinib		Merck	CHEMBL4072833	C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4	Achiral Molecule	nan	3.0	None	EVOBRUTINIB | M-2951 | MSC-2364447C | MSC2364447C	nan	nan	Q06187	InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)	QUIWHXQETADMGN-UHFFFAOYSA-N	58827807	|http://www.chemspider.com/Chemical-Structure.58827807.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4072833|http://pubchem.ncbi.nlm.nih.gov/compound/71479709|http://www.drugbank.ca/drugs/DB15170| http://www.rcsb.org/ligand/MZJ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MZJ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9752|http://zinc15.docking.org/substances/ZINC000205623965|https://precision.fda.gov/uniisearch/srs/unii/ZA45457L1K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=291522	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'MZJ'	6omu		Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).	Q06187	429.2	6	2	7	93.4	4.4	0		BTK	Tyr	
Exarafenib		Kinnate Biopharma	CHEMBL5095099	Cc1ccc(NC(=O)N2CC[C@@H](CC(F)(F)F)C2)cc1-c1cc(N[C@H](C)CO)nc(N2CCOCC2)c1	Single Stereoisomer	nan	1.0	None		nan	nan	nan	InChI=1S/C26H34F3N5O3/c1-17-3-4-21(31-25(36)34-6-5-19(15-34)14-26(27,28)29)13-22(17)20-11-23(30-18(2)16-35)32-24(12-20)33-7-9-37-10-8-33/h3-4,11-13,18-19,35H,5-10,14-16H2,1-2H3,(H,30,32)(H,31,36)/t18-,19+/m1/s1	GZMYLSJUNSCMTD-MOPGFXCFSA-N	115277132	|http://www.chemspider.com/Chemical-Structure.115277132.html|http://pubchem.ncbi.nlm.nih.gov/compound/156297592	|ChemSpider|PubChem						521.3	6	3	7	90.0	4.5	1		nan		
Fadraciclib		Cyclacel pharmaceuticals	CHEMBL4297930	CC[C@@H]([C@@H](C)O)Nc1nc(c2c(n1)n(cn2)C(C)C)NCc3cnc(cc3C)C	Unknown	nan	1.5	None		nan	nan	nan	InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1	DLPIYBKBHMZCJI-WBVHZDCISA-N	34957698	|http://www.chemspider.com/Chemical-Structure.34957698.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3655762|http://pubchem.ncbi.nlm.nih.gov/compound/24983461|http://www.drugbank.ca/drugs/DB15425|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10461|http://zinc15.docking.org/substances/ZINC000096177788|https://precision.fda.gov/uniisearch/srs/unii/YET2XNU791|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=106950	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						397.3	8	3	8	100.8	3.6	0		nan		
Famitinib		Jiangsu Hengrui Medicine	CHEMBL1278146	CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O	Achiral Molecule	nan	3.0	None	FAMITINIB | SHR-1020 | SHR1020	nan	nan	P10721|P35968|P35916|P16234|P09619|P17948|P36888	InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-	GKEYKDOLBLYGRB-LGMDPLHJSA-N	17595500	|http://www.chemspider.com/Chemical-Structure.17595500.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1278146|http://pubchem.ncbi.nlm.nih.gov/compound/16662431|http://www.drugbank.ca/drugs/DB11741|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7886|http://zinc15.docking.org/substances/ZINC000064453767|https://precision.fda.gov/uniisearch/srs/unii/768FW21J3L|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331023	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						410.2	3	2	6	68.4	3.3	0		KIT; KDR; FLT4; PDGFRA; PDGFRB; FLT1; FLT3	Tyr	
Fasudil		Asahi Kasei Pharma Corp	CHEMBL38380	c1cc2cnccc2c(c1)S(=O)(=O)N3CCCNCC3	Achiral Molecule	nan	4.0	None	AT 877 | AT-877 | FASUDIL | HA 1077 | HA-1077 | NSC-759827 | ZK-258594	Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.	nan	nan	InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2	NGOGFTYYXHNFQH-UHFFFAOYSA-N	3426	|http://www.chemspider.com/Chemical-Structure.3426.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL38380|http://pubchem.ncbi.nlm.nih.gov/compound/3547|http://www.drugbank.ca/drugs/DB08162| http://www.rcsb.org/ligand/M77|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/M77|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181|http://zinc15.docking.org/substances/ZINC000000006486|https://precision.fda.gov/uniisearch/srs/unii/Q0CH43PGXS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=14027	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'M77'	1q8w 2esm 2f2u 2gni 3tku 5lcp 5nw8 5o0e 5ok3 5vef 6em2 6erw 6i2a 6i2c 6yna		Fasudil has been investigated in Carotid Stenosis.	P61925|P17612|Q13464|O75116	291.1	4	1	2	62.3	1.2	0		nan		N
Fedratinib	Inrebic	Sanofi	CHEMBL1287853	Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4	Achiral Molecule	2019	4.0	US-7528143-B2	FEDRATINIB | SAR-302503 | SAR302503 | TG-101348 | TG101348	On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis	nan	O60674|P36888|O60885	InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)	JOOXLOJCABQBSG-UHFFFAOYSA-N	17626393	|http://www.chemspider.com/Chemical-Structure.17626393.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1287853|http://pubchem.ncbi.nlm.nih.gov/compound/16722836|http://www.drugbank.ca/drugs/DB12500| http://www.rcsb.org/ligand/2TA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2TA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716|http://zinc15.docking.org/substances/ZINC000019862646|https://precision.fda.gov/uniisearch/srs/unii/6L1XP550I6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50332294	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'2TA'	4ogj 4ps5 6vne		"Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O: Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10;13:294. doi: 10.1186/s12967-015-0644-4. (PubMed ID 26357842)"" href=""#reference-A183176"">2</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Fedratinib Oral Capsules"" href=""#reference-L8090"">7</a></sup> It is an anilinopyrimidine derivative.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Roskoski R Jr: Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26. (PubMed ID 27473820)"" href=""#reference-A183188"">6</a></sup></p><p>Fedratinib was granted FDA approval on August 16, 2019.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Fedratinib Oral Capsules"" href=""#reference-L8090"">7</a></sup>"	O60674|P36888|P23458|P08684|P33261|P31513|P10635|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|P09086|Q96FL8|Q86VL8	524.3	8	3	10	108.5	4.8	1		JAK2; FLT3; BRD4	(*)<br>Tyr	Y
Fenebrutinib		Genentech	CHEMBL4065122	C[C@H]1CN(CCN1c2ccc(nc2)Nc3cc(cn(c3=O)C)c4ccnc(c4CO)N5CCn6c(cc7c6CC(C7)(C)C)C5=O)C8COC8	Single Stereoisomer	nan	3.0	None	FENEBRUTINIB | G-02599853 | G02599853 | GDC-0853 | RG-7845 | RG7845 | RO-7010939 | RO7010939	nan	nan	nan	InChI=1S/C37H44N8O4/c1-23-18-42(27-21-49-22-27)9-10-43(23)26-5-6-33(39-17-26)40-30-13-25(19-41(4)35(30)47)28-7-8-38-34(29(28)20-46)45-12-11-44-31(36(45)48)14-24-15-37(2,3)16-32(24)44/h5-8,13-14,17,19,23,27,46H,9-12,15-16,18,20-22H2,1-4H3,(H,39,40)/t23-/m0/s1	WNEODWDFDXWOLU-QHCPKHFHSA-N	58145210	|http://www.chemspider.com/Chemical-Structure.58145210.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4065122|http://pubchem.ncbi.nlm.nih.gov/compound/86567195|http://www.drugbank.ca/drugs/DB14785| http://www.rcsb.org/ligand/9AJ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9AJ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9299|http://zinc15.docking.org/substances/ZINC000220197997|https://precision.fda.gov/uniisearch/srs/unii/E9L2885WUL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50244440	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'9AJ'	5vfi		Fenebrutinib is under investigation in clinical trial NCT03174041 (A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin).	Q06187	664.3	11	2	7	121.0	3.6	2		nan		
Fidrisertib		Blueprint Medicines	CHEMBL4802133	CCOC1(c2ccc(-c3cc4c(N5CCN(C(=O)O[C@@H]6CCOC6)CC5)ccnn4c3)nc2)CCN(C(C)C)CC1	Single Stereoisomer	nan	1.0	None	BLU-782 | FIDRISERTIB	nan	nan	nan	InChI=1S/C31H42N6O4/c1-4-40-31(9-12-34(13-10-31)23(2)3)25-5-6-27(32-20-25)24-19-29-28(7-11-33-37(29)21-24)35-14-16-36(17-15-35)30(38)41-26-8-18-39-22-26/h5-7,11,19-21,23,26H,4,8-10,12-18,22H2,1-3H3/t26-/m1/s1	SWVYYNLRVIYURK-AREMUKBSSA-N	72380177	|http://www.chemspider.com/Chemical-Structure.72380177.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4802133|http://pubchem.ncbi.nlm.nih.gov/compound/132026427|https://precision.fda.gov/uniisearch/srs/unii/KF4ZI0CJ7M	|ChemSpider|ChEMBL|PubChem|FDA SRS						562.3	9	0	7	84.7	4.2	1		nan		
Filgotinib		Galapagos	CHEMBL3301607	c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5	Single Stereoisomer	nan	4.0	None	FILGOTINIB | G-146034 | G146034 | GLPG-0634 | GLPG0634 | GS-6034 FREE BASE	nan	1	P23458	InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27)	RIJLVEAXPNLDTC-UHFFFAOYSA-N	28189566	|http://www.chemspider.com/Chemical-Structure.28189566.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301607|http://pubchem.ncbi.nlm.nih.gov/compound/49831257|http://www.drugbank.ca/drugs/DB14845| http://www.rcsb.org/ligand/2HB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2HB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913|http://zinc15.docking.org/substances/ZINC000096174616|https://precision.fda.gov/uniisearch/srs/unii/3XVL385Q0M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=103727	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'2HB'	4p7e 5ut5		"Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Wasserman AM: Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011 Dec 1;84(11):1245-52. (PubMed ID 22150658)"" href=""#reference-A221451"">4</a>,<a class=""reference-popover-link"" data-content=""Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018. (PubMed ID 29736302)"" href=""#reference-A221456"">5</a></sup> The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)"" href=""#reference-A189165"">3</a></sup> 50-70% of patients with RA are unable to achieve sustained clinical remission despite the availability of several treatments including disease-modifying anti-rheumatic drugs (DMARDS) like <a href=""https://go.drugbank.com/drugs/DB00563"">methotrexate</a>, interleukin-6 (IL-6) blockers, and tumor necrosis factor (TNF) inhibitors.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)"" href=""#reference-A189165"">3</a></sup> New therapeutic developments target other inflammatory pathways implicated in RA including the Janus kinase (JAK) signaling pathway as seen with filgotinib.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15. doi: 10.1038/s41413-018-0016-9. eCollection 2018. (PubMed ID 29736302)"" href=""#reference-A221456"">5</a></sup> </p><p>There are four JAK subtypes which include JAK1, JAK2, JAK3, and tyrosine kinase 2.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)"" href=""#reference-A189165"">3</a></sup> Non-selective JAK inhibitors like <a href=""https://go.drugbank.com/drugs/DB08895"">tofacitinib</a> target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)"" href=""#reference-A189165"">3</a></sup> JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity for JAK1 aims to improve the safety profile of filgotinib while maintaining clinical efficacy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)"" href=""#reference-A189165"">3</a></sup> Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""EMA Summary of Product Characteristics: Jyseleca (filgotinib) film-coated tablets for oral use"" href=""#reference-L16616"">10</a></sup>"	P23458|O00748|P23141|P08183	425.2	7	1	5	96.7	2.0	0		JAK1	Tyr	N
Fisogatinib		Blueprint Medicines	CHEMBL4514636	C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1	Single Stereoisomer	nan	1.0	None	BLU-111362 | BLU-554 | BLU111362 | FISOGATINIB | X-439161 | X439161	nan	nan	nan	InChI=1S/C24H24Cl2N4O4/c1-4-20(31)28-16-7-8-34-12-17(16)30-24-27-11-14-9-13(5-6-15(14)29-24)21-22(25)18(32-2)10-19(33-3)23(21)26/h4-6,9-11,16-17H,1,7-8,12H2,2-3H3,(H,28,31)(H,27,29,30)/t16-,17+/m0/s1	MGZKYOAQVGSSGC-DLBZAZTESA-N	58828666	|http://www.chemspider.com/Chemical-Structure.58828666.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4514636|http://pubchem.ncbi.nlm.nih.gov/compound/91885617|http://www.drugbank.ca/drugs/DB16167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10220|https://precision.fda.gov/uniisearch/srs/unii/5Q7R99CKV2	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						502.1	7	2	7	94.6	4.5	1		nan		
Flonoltinib		Chengdu Zenitar Biomedical Technology		CN(CCO)C1CCN(CC1)C1=CC=C(C=C1F)NC1N=C(C2C=NN(C=2)C(C)C)C(C)=CN=1		nan	1.0			nan	nan	nan	InChI=1S/C25H34FN7O/c1-17(2)33-16-19(15-28-33)24-18(3)14-27-25(30-24)29-20-5-6-23(22(26)13-20)32-9-7-21(8-10-32)31(4)11-12-34/h5-6,13-17,21,34H,7-12H2,1-4H3,(H,27,29,30)	CVLXNRIQVFIVGY-UHFFFAOYSA-N	103835539	|http://www.chemspider.com/Chemical-Structure.103835539.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4447631|http://pubchem.ncbi.nlm.nih.gov/compound/139600335| http://www.rcsb.org/ligand/36H|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/36H|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10549|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50505817	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|BindingDB	'36H'	7f7w				467.3	8	2	8	82.3	4.0	0		nan		
Flumatinib		Jiangsu Hengrui Medicine		Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5		nan	4.0		FLUMATINIB | FLUMBATINIB | HH-GV678 | HHGV-678	nan	nan	P11274|P00519|P09619|P10721	InChI=1S/C29H29F3N8O/c1-19-26(38-28-34-9-7-25(37-28)21-4-3-8-33-16-21)15-23(17-35-19)36-27(41)20-5-6-22(24(14-20)29(30,31)32)18-40-12-10-39(2)11-13-40/h3-9,14-17H,10-13,18H2,1-2H3,(H,36,41)(H,34,37,38)	BJCJYEYYYGBROF-UHFFFAOYSA-N	25069687	|http://www.chemspider.com/Chemical-Structure.25069687.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545413|http://pubchem.ncbi.nlm.nih.gov/compound/46848036|http://www.drugbank.ca/drugs/DB11904|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9913|http://zinc15.docking.org/substances/ZINC000068244727|https://precision.fda.gov/uniisearch/srs/unii/R4009Y24AI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50529313	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						562.2	8	2	7	99.2	5.0	2		BCR; ABL1; PDGFRB; KIT	Atypical<br>Tyr	N
Foretinib		GlaxoSmithKline	CHEMBL1230609	COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F	Achiral Molecule	nan	2.0	None	EXEL-2880 | FORETINIB | GSK-089 | GSK-1363089 | GSK-1363089G | GSK089 | GSK1363089 | GSK1363089G | XL-880 | XL880	nan	2	P08581|P35968	InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)	CXQHYVUVSFXTMY-UHFFFAOYSA-N	24608641	|http://www.chemspider.com/Chemical-Structure.24608641.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1230609|http://pubchem.ncbi.nlm.nih.gov/compound/42642645|http://www.drugbank.ca/drugs/DB12307| http://www.rcsb.org/ligand/88Z|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/88Z|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5679|http://zinc15.docking.org/substances/ZINC43204048|https://precision.fda.gov/uniisearch/srs/unii/81FH7VK1C4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399540	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'88Z'	3lq8 5ia4 6i2y 6sd9 6sdc		Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits the activation of MET, RON, ERK and AKT, decreased proliferation and increased apoptosis.	P14210|P35968	632.2	8	2	12	111.2	5.8	2		MET; KDR	Tyr	
Foslinanib		TaiRx	CHEMBL1615993	COc1ccc2c(c1OP(=O)(O)O)c(=O)cc([nH]2)c3cccc(c3)F	Achiral Molecule	nan	2.0	None	CVM-1118 | CVM-1118 FREE ACID | FOSLINANIB | TRX 818 | TRX-818 | TRX-818 FREE ACID	nan	nan	nan	InChI=1S/C16H13FNO6P/c1-23-14-6-5-11-15(16(14)24-25(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9/h2-8H,1H3,(H,18,19)(H2,20,21,22)	ZDWFMAHQGDEALT-UHFFFAOYSA-N	26374637	|http://www.chemspider.com/Chemical-Structure.26374637.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1615993|http://pubchem.ncbi.nlm.nih.gov/compound/49840582|http://www.drugbank.ca/drugs/DB16172|http://zinc15.docking.org/substances/ZINC000064447756|https://precision.fda.gov/uniisearch/srs/unii/2X2DNM7NGX	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS						365.0	4	3	4	108.8	2.8	0		nan		
Fostamatinib	Tavalisse	Rigel Pharmaceuticals	CHEMBL2103830	CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C	Achiral Molecule	2018	4.0	US-7449458-B2	FOSTAMATINIB | R-788 | R-788 FREE ACID | R-935788 | R-935788 FREE ACID | R788 FREE ACID | R935788 FREE ACID	Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment	nan	P43405	InChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)	GKDRMWXFWHEQQT-UHFFFAOYSA-N	9846198	|http://www.chemspider.com/Chemical-Structure.9846198.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103830|http://pubchem.ncbi.nlm.nih.gov/compound/11671467|http://www.drugbank.ca/drugs/DB12010| http://www.rcsb.org/ligand/2RC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2RC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7796|http://zinc15.docking.org/substances/ZINC000043131420|https://precision.fda.gov/uniisearch/srs/unii/SQ8A3S5101|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50431381	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'2RC'	4o75		"Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Fostamatinib FDA Approval"" href=""#reference-L2644"">11</a>,<a class=""reference-popover-link"" data-content=""Official drug label"" href=""#label-reference"">Label</a></sup>. Fostamatinib has also been granted orphan drug status by the FDA <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Fostamatinib FDA Approval"" href=""#reference-L2644"">11</a></sup>.</p><p>Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, Suffredini AF, Childs RW, Chertow DS: Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. J Infect Dis. 2021 Mar 29;223(6):981-984. doi: 10.1093/infdis/jiaa789. (PubMed ID 33367731)"" href=""#reference-A235008"">8</a>,<a class=""reference-popover-link"" data-content=""Kost-Alimova M, Sidhom EH, Satyam A, Chamberlain BT, Dvela-Levitt M, Melanson M, Alper SL, Santos J, Gutierrez J, Subramanian A, Byrne PJ, Grinkevich E, Reyes-Bricio E, Kim C, Clark AR, Watts AJB, Thompson R, Marshall J, Pablo JL, Coraor J, Roignot J, Vernon KA, Keller K, Campbell A, Emani M, Racette M, Bazua-Valenti S, Padovano V, Weins A, McAdoo SP, Tam FWK, Ronco L, Wagner F, Tsokos GC, Shaw JL, Greka A: A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Rep Med. 2020 Oct 29;1(8):100137. doi: 10.1016/j.xcrm.2020.100137. eCollection 2020 Nov 17. (PubMed ID 33294858)"" href=""#reference-A235013"">9</a>,<a class=""reference-popover-link"" data-content=""Authors unspecified: High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med. 2021 May 11. pii: scitranslmed.abf8654. doi: 10.1126/scitranslmed.abf8654. (PubMed ID 33979301)"" href=""#reference-A235018"">10</a></sup>"	P43405|P0DMS8|Q99870|O00519|Q99808|P22309|O76074|P09917|P25774|P07711|P00519|P62344|P9WI81|Q9UK32|P29597|Q8NI60|P23458|P08581|Q8IY84|Q9P289|P17612|Q9Y6E0|Q13188|P42680|Q9BYT3|Q8TDR2|Q9NRP7|Q15208|Q9Y2H1|Q9UEW8|Q7L7X3|Q9UL54|Q9H2K8|Q9UHD2|Q02763|Q15569|P36897|P37173|P35590|Q9UKI8|Q86UE8|Q9UKE5|Q13470|Q07912|Q59H18|Q9BXA7|P33981|P42681|Q06418|O75385|Q8IYT8|Q6PHR2|P30291|P07947|Q56UN5|Q9NYL2|P43403|Q2M2I8|P42684|Q04771|P36896|Q96D53|Q9UM73|Q8NFD2|O14965|Q96GD4|Q9UQB9|P30530|P51451|Q9NSY1|O00238|Q13873|P51813|P15056|Q06187|Q14012|Q8IU85|Q96NX5|Q9UQM7|Q13554|Q13557|Q13555|Q8N5S9|Q96RR4|O14936|P07498|P06493|Q6DT37|P11802|Q00532|Q92772|O14757|O96017|O14578|P49759|P49760|P49761|Q9HAZ1|P07333|P41240|P48729|P68400|P19784|P53355|Q9UIK4|O43293|O15075|Q8N568|Q9C098|Q08345|Q16832|Q13627|Q9Y463|P00533|Q9BQI3|P19525|Q9P2K8|P21709|P29317|P29320|P54764|P54756|Q9UF33|Q15375|P29322|P54762|P29323|P54760|O15197|P04626|Q15303|O75460|P16591|P07332|P11362|P21802|P22607|P09769|P17948|P36888|P35916|P42345|P42685|P06241|O14976|P49840|P49841|P08631|Q9H2X6|Q9H422|Q9UPZ9|O14920|Q14164|P06213|P14616|P51617|Q9Y616|Q9NWZ3|Q08881|O60674|P52333|P35968|Q9Y2K2|P10721|O95835|P06239|P53667|P53671|Q5S007|P29376|P07948|P36507|P46734|Q13163|P52564|Q13233|Q02779|Q16584|Q12852|O43283|Q6ZN16|Q9Y2U5|Q99759|Q9Y6R4|O95382|P80192|Q92918|Q12851|Q8IVH8|O95819|Q9Y4K4|P53779|O15264|Q16539|Q8TD08|P31152|Q13164|P45984|Q8IW41|Q9P0L2|Q7KZI7|P27448|Q96L34|Q7Z460|Q9Y2H9|P42679|Q14680|Q12866|Q8N4C8|Q9BUB5|Q9HBH9|Q04912|O15146|Q15746|Q9H1R3|Q32MK0|Q86YV6|Q8NEV4|Q96PY6|Q8NG66|P51955|P51956|P51957|Q6P3R8|Q8TD19|P04629|Q16620|Q16288|O60285|Q9H093|O95747|Q13153|Q13177|O75914|O96013|Q9NQU5|Q9P286|Q00536|Q00537|P16234|P09619|O15530|Q96Q40|Q16816|Q9UBF8|O00750|O75747|O00329|P48736|P11309|Q86V86|P78356|Q8TBX8|Q99640|Q16512|Q16513|P53350|Q9NYY3|Q9H4B4|O00444|Q13131|Q13131|P54646|Q9Y478|O43741|P54619|Q9UGJ0|Q9UGI9|P22694|Q05655|Q02156|P05129|P41743|Q04759|Q15139|Q13237|Q13523|Q05397|Q14289|Q13882|P04049|P07949|Q9BRS2|Q9BVS4|O14730|Q13546|O43353|P57078|O75116|P08922|Q15418|P51812|Q52WX2|P0C264|Q96BR1|P57059|Q9H0K1|Q9H2G2|Q9NRH2|P12931|Q9H3Y6|O94804|O75716|Q9UEE5|O94768|Q8WU08|P08684|O60656	580.1	12	4	10	186.7	3.1	2		SYK	Tyr	Y
Fruquintinib		Hutchison MediPharma	CHEMBL4303214	Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC	Achiral Molecule	nan	3.0	None	FRUQUINTINIB | HMPL-013 | HMPL013	nan	nan	P17948|P35968|P35916	InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)	BALLNEJQLSTPIO-UHFFFAOYSA-N	39625837	|http://www.chemspider.com/Chemical-Structure.39625837.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4303214|http://pubchem.ncbi.nlm.nih.gov/compound/44480399|http://www.drugbank.ca/drugs/DB11679|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9428|http://zinc15.docking.org/substances/ZINC000114898570|https://precision.fda.gov/uniisearch/srs/unii/49DXG3M5ZW	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						393.1	7	1	5	95.7	3.9	0		FLT1; KDR; FLT4	Tyr	
Futibatinib	Lytgobi	Taiho Pharmaceutical	CHEMBL3701238	COc1cc(cc(c1)OC)C#Cc2c3c(ncnc3n(n2)C4CCN(C4)C(=O)C=C)N	Single Stereoisomer	2022	4.0	None		On September 2022, FDA approved futibatinib to treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements	nan	P11362|P21802|P22607|P22455	InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)	KEIPNCCJPRMIAX-UHFFFAOYSA-N	58877815	|http://www.chemspider.com/Chemical-Structure.58877815.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3701237|http://pubchem.ncbi.nlm.nih.gov/compound/78137072|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=161388	|ChemSpider|ChEMBL|PubChem|BindingDB						418.2	8	1	4	108.4	1.8	0		FGFR1; FGFR2; FGFR3; FGFR4	Tyr	Y
Galunisertib		Eli Lilly	CHEMBL2364611	Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N	Achiral Molecule	nan	2.0	None	GALUNISERTIB | LY-2157299 | LY2157299	nan	nan	P36897	InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)	IVRXNBXKWIJUQB-UHFFFAOYSA-N	8266022	|http://www.chemspider.com/Chemical-Structure.8266022.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2364611|http://pubchem.ncbi.nlm.nih.gov/compound/10090485|http://www.drugbank.ca/drugs/DB11911|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7797|http://zinc15.docking.org/substances/ZINC03959536|https://precision.fda.gov/uniisearch/srs/unii/3OKH1W5LZE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015640	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						369.2	5	1	3	86.7	3.5	0		TGFBR1	TKL	
Gandotinib		Eli Lilly	CHEMBL2107823	Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5	Achiral Molecule	nan	2.0	None	GANDOTINIB | LY-2784544 | LY2784544	nan	nan	O60674	InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)	SQSZANZGUXWJEA-UHFFFAOYSA-N	25027412	|http://www.chemspider.com/Chemical-Structure.25027412.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2107823|http://pubchem.ncbi.nlm.nih.gov/compound/46213929|http://www.drugbank.ca/drugs/DB13040|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909|http://zinc15.docking.org/substances/ZINC68245097|https://precision.fda.gov/uniisearch/srs/unii/ANC71R916O	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						469.2	7	2	6	83.4	4.0	0		JAK2	Tyr	
Gartisertib		Vertex Pharmaceuticals	CHEMBL4650286	Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(C(=O)N2CCN(C3COC3)CC2)CC1	Achiral Molecule	nan	1.0	None	GARTISERTIB | M 4344 | M-4344 | M4344 | VX-803	nan	nan	nan	InChI=1S/C25H29F2N9O3/c26-16-9-30-23-20(22(28)32-36(23)12-16)24(37)31-19-11-29-10-18(27)21(19)34-3-1-15(2-4-34)25(38)35-7-5-33(6-8-35)17-13-39-14-17/h9-12,15,17H,1-8,13-14H2,(H2,28,32)(H,31,37)	QAYHKBLKSXWOEO-UHFFFAOYSA-N	64866821	|http://www.chemspider.com/Chemical-Structure.64866821.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650286|http://pubchem.ncbi.nlm.nih.gov/compound/86720912|https://precision.fda.gov/uniisearch/srs/unii/7OM98IUD1O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=412060	|ChemSpider|ChEMBL|PubChem|FDA SRS|BindingDB						541.2	10	2	5	134.2	1.0	1		nan		
Gedatolisib		Pfizer	CHEMBL592445	CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6	Achiral Molecule	nan	3.0	None	GEDATOLISIB | PF-05212384 | PKI-587	nan	nan	P42336|P42338|P48736|O00329|P42345	InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)	DWZAEMINVBZMHQ-UHFFFAOYSA-N	24644946	|http://www.chemspider.com/Chemical-Structure.24644946.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL592445|http://pubchem.ncbi.nlm.nih.gov/compound/44516953|http://www.drugbank.ca/drugs/DB11896| http://www.rcsb.org/ligand/VL1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VL1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940|http://zinc15.docking.org/substances/ZINC000049757175|https://precision.fda.gov/uniisearch/srs/unii/96265TNH2R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50308135	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'VL1'	7jwe				615.3	10	2	7	128.3	3.0	1		PIK3CA; PIK3CB; PIK3CG; PIK3CD; MTOR	Atypical	
Gefitinib	Iressa	Astrazeneca	CHEMBL939	COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F	Achiral Molecule	2003	4.0	None	GEFITINIB | IRESSA | NSC-759856 | ZD-1839 | ZD1839	For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.	1.5	P00533	InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)	XGALLCVXEZPNRQ-UHFFFAOYSA-N	110217	|http://www.chemspider.com/Chemical-Structure.110217.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL939|http://pubchem.ncbi.nlm.nih.gov/compound/123631|http://www.drugbank.ca/drugs/DB07998| http://www.rcsb.org/ligand/IRE|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/IRE|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4941|http://zinc15.docking.org/substances/ZINC19632614|https://precision.fda.gov/uniisearch/srs/unii/S65743JHBS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5447	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'IRE'	2ito 2ity 2itz 3ug2 4i22 4wkq 5y7z 5y80		Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.	P00533|P20815|P04798|P11712|P33261|P08684|P10635|P02768|P02763	446.2	7	1	8	68.7	4.3	0		EGFR	Tyr	Y
Gilmelisib		Medshine Discovery Inc	CHEMBL5095067	COc1ncc(-c2ccc3ncc(OCCN(C)C)c(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1Cl	Achiral Molecule	nan	-1.0	None		nan	nan	nan	InChI=1S/C24H23ClFN5O5S/c1-30(2)8-9-36-20-13-27-22-7-4-15(14-31(22)24(20)32)16-10-19(23(35-3)28-12-16)29-37(33,34)21-6-5-17(26)11-18(21)25/h4-7,10-14,29H,8-9H2,1-3H3	BXKBZQAZYOZHJY-UHFFFAOYSA-N	115007130	|http://www.chemspider.com/Chemical-Structure.115007130.html|http://pubchem.ncbi.nlm.nih.gov/compound/118612873	|ChemSpider|PubChem						547.1	9	1	9	115.1	3.3	1		nan		
Gilteritinib	Xospata	Astellas Pharma	CHEMBL3301622	CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5	Achiral Molecule	2018	4.0	US-8969336-B2	ASP-2215 | ASP2215 | GILTERITINIB	On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML)	nan	P36888|P30530|Q9UM73	InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)	GYQYAJJFPNQOOW-UHFFFAOYSA-N	32055842	|http://www.chemspider.com/Chemical-Structure.32055842.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301622|http://pubchem.ncbi.nlm.nih.gov/compound/49803313|http://www.drugbank.ca/drugs/DB12141| http://www.rcsb.org/ligand/C6F|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/C6F|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8708|http://zinc15.docking.org/substances/ZINC000113476229|https://precision.fda.gov/uniisearch/srs/unii/66D92MGC8M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=144315	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'C6F'	6jqr 7ab1		"Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Stone RM: What FLT3 inhibitor holds the greatest promise? Best Pract Res Clin Haematol. 2018 Dec;31(4):401-404. doi: 10.1016/j.beha.2018.09.008. Epub 2018 Sep 20. (PubMed ID 30466756)"" href=""#reference-A40036"">1</a></sup> It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Lee LY, Hernandez D, Rajkhowa T, Smith SC, Raman JR, Nguyen B, Small D, Levis M: Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017 Jan 12;129(2):257-260. doi: 10.1182/blood-2016-10-745133. Epub 2016 Dec 1. (PubMed ID 27908881)"" href=""#reference-A40044"">5</a></sup> Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA news"" href=""#reference-L4830"">7</a></sup>"	P36888|P30530|Q9UM73|P08908|P28222|P28221|P28566|P30939|P28223|P41595|P28335|P46098|O95264|Q8WXA8|Q70Z44|A5X5Y0|Q13639|P50406|P34969|P08684|P02768|P08183|Q96FL8|Q9UNQ0|O15245	552.4	10	3	9	121.1	2.7	1		FLT3; AXL; ALK	Tyr	Y
Glesatinib		Mirati Therapeutics	CHEMBL3989914	COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F	Achiral Molecule	nan	2.0	None	GLESATINIB | MG-90265 | MG-90265X | MG90265 | MG90265GLY | MG90265H9 | MG90265X | MGCD-265 | MGCD265	nan	nan	P08581|Q02763|P17948|P35968|P35916|Q04912	InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)	YRCHYHRCBXNYNU-UHFFFAOYSA-N	52084900	|http://www.chemspider.com/Chemical-Structure.52084900.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989914|http://pubchem.ncbi.nlm.nih.gov/compound/25181472|http://www.drugbank.ca/drugs/DB06302|http://zinc15.docking.org/substances/ZINC000113139653|https://precision.fda.gov/uniisearch/srs/unii/7Q29OXD98N	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS						619.2	8	3	11	97.4	6.2	2		MET; TEK; FLT1; KDR; FLT4; MST1R	Tyr	
Glumetinib		HaiHe Phaemaceutical		Cn1cc(-c2cnc3cnn(S(=O)(=O)c4cnc5ccc(-c6cnn(C)c6)cn45)c3c2)cn1		nan	1.0		GLUMETINIB | GUMARONTINIB | SC-C244 | SCC244	nan	nan	nan	InChI=1S/C21H17N9O2S/c1-27-11-16(7-24-27)14-3-4-20-23-10-21(29(20)13-14)33(31,32)30-19-5-15(6-22-18(19)9-26-30)17-8-25-28(2)12-17/h3-13H,1-2H3	RYBLECYFLJXEJX-UHFFFAOYSA-N	68006902	|http://www.chemspider.com/Chemical-Structure.68006902.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594400|http://pubchem.ncbi.nlm.nih.gov/compound/117797905|http://www.drugbank.ca/drugs/DB15630|https://precision.fda.gov/uniisearch/srs/unii/7JTT036WGX	|ChemSpider|ChEMBL|PubChem|DrugBank|FDA SRS						459.1	11	0	4	117.8	2.1	1		nan		
Golidocitinib		Astrazeneca	CHEMBL4577523	COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1	Single Stereoisomer	nan	2.0	None	AZD-4205 | AZD4205 | GOLIDOCITINIB	nan	nan	nan	InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1	CVCVOSPZEVINRM-MRXNPFEDSA-N	71117616	|http://www.chemspider.com/Chemical-Structure.71117616.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4577523|http://pubchem.ncbi.nlm.nih.gov/compound/126715380|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10744|https://precision.fda.gov/uniisearch/srs/unii/3BY9Z3M34G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=264212	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS|BindingDB						489.3	9	3	7	116.2	2.7	0		nan		
Golvatinib		Eisai	CHEMBL3039525	CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F	Achiral Molecule	nan	2.0	None	E-7050 | E7050 | GOLVATINIB	nan	2	P08581|P35968	InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)	UQRCJCNVNUFYDX-UHFFFAOYSA-N	17275597	|http://www.chemspider.com/Chemical-Structure.17275597.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039525|http://pubchem.ncbi.nlm.nih.gov/compound/16118392|http://www.drugbank.ca/drugs/DB11977| http://www.rcsb.org/ligand/GV0|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/GV0|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7956|http://zinc15.docking.org/substances/ZINC000043195317|https://precision.fda.gov/uniisearch/srs/unii/516Z3YP58E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50100615	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'GV0'	5ia5				633.3	7	3	8	119.1	4.8	1		MET; KDR	Tyr	
Gusacitinib		Asana BioSciences	CHEMBL4594275	N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1	Achiral Molecule	nan	2.0	None	ASN-002 | ASN002 | EN-3351 | EN3351 | GUSACITINIB	nan	nan	nan	InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29)	NLFLXLJXEIUQDL-UHFFFAOYSA-N	71117451	|http://www.chemspider.com/Chemical-Structure.71117451.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594275|http://pubchem.ncbi.nlm.nih.gov/compound/71269142|http://www.drugbank.ca/drugs/DB15670|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10000|https://precision.fda.gov/uniisearch/srs/unii/4801QYW816	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						460.2	9	3	5	134.1	2.5	0		nan		
Henatinib		Jiangsu Hengrui Medicine	CHEMBL1277072	Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F	Single Stereoisomer	nan	1.0	None	HENATINIB	nan	nan	P35968	InChI=1S/C25H29FN4O4/c1-15-22(12-19-18-11-16(26)4-5-20(18)28-24(19)32)27-21-3-2-6-30(25(33)23(15)21)14-17(31)13-29-7-9-34-10-8-29/h4-5,11-12,17,27,31H,2-3,6-10,13-14H2,1H3,(H,28,32)/b19-12-/t17-/m1/s1	MCTXSDCWFQAGFS-UEXNTNOUSA-N	26354883	|http://www.chemspider.com/Chemical-Structure.26354883.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1277072|http://pubchem.ncbi.nlm.nih.gov/compound/25116064|http://www.drugbank.ca/drugs/DB13019|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9930|http://zinc15.docking.org/substances/ZINC000064454147|https://precision.fda.gov/uniisearch/srs/unii/TE20GB753F|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331032	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						468.2	5	3	5	97.9	2.0	0		KDR	Tyr	
Ibcasertib		Chipscreen Biosciences	CHEMBL5095033	COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1	Achiral Molecule	nan	3.0	None	|CS-2164|CS2164	nan	nan	nan	InChI=1S/C27H21N3O3/c1-32-18-9-12-22-25(16-18)29-14-13-26(22)33-19-10-11-20-17(15-19)5-4-6-21(20)27(31)30-24-8-3-2-7-23(24)28/h2-16H,28H2,1H3,(H,30,31)	BRKWREZNORONDU-UHFFFAOYSA-N	81367270	|http://www.chemspider.com/Chemical-Structure.81367270.html|http://pubchem.ncbi.nlm.nih.gov/compound/49779393|http://www.drugbank.ca/drugs/DB16124|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10475|https://precision.fda.gov/uniisearch/srs/unii/F40IRN5981	|ChemSpider|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						435.2	5	2	5	86.5	6.0	1		nan		
Ibrutinib	Imbruvica	Pharmacyclics	CHEMBL1873475	C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N	Single Stereoisomer	2013	4.0	US-7514444-B2	CRA-032765 | IBRUTINIB | IMBRUVICA | PC-32765 | PCI 32765 | PCI-32765 | PCI-32765-00	Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia	1.5	Q06187	InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1	XYFPWWZEPKGCCK-GOSISDBHSA-N	26637187	|http://www.chemspider.com/Chemical-Structure.26637187.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1873475|http://pubchem.ncbi.nlm.nih.gov/compound/24821094|http://www.drugbank.ca/drugs/DB09053| http://www.rcsb.org/ligand/1E8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/1E8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912|http://zinc15.docking.org/substances/ZINC35328014|https://precision.fda.gov/uniisearch/srs/unii/1X70OSD4VX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50357312	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'1E8'	4ifg 4rz7 5p9i 5yu9 6l8l 6yg2 6yz4		"Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton&#39;s tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. (PubMed ID 26111359)"" href=""#reference-A32299"">4</a></sup> Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Imbruvica (ibrutinib) oral capsules"" href=""#reference-L12228"">16</a></sup> however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""BioSpace: AbbVie, J&amp;J Pull Two Accelerated Approvals for Imbruvica"" href=""#reference-L45894"">21</a></sup></p><p>Ibrutinib was approved by the EMA in October 2014 <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""EMA Approved Drug Products: Imbruvica (ibrutinib) Oral Capsules or Tablets"" href=""#reference-L45884"">19</a></sup> and by Health Canada in November 2014.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Health Canada Approved Drug Products: IMBRUVICA (ibrutinib) Oral Capsules or Tablets"" href=""#reference-L45889"">20</a></sup> It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström&#39;s Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Imbruvica (ibrutinib) oral capsules"" href=""#reference-L12228"">16</a></sup> Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Janssen Biotech: IMBRUVICA for Previously Treated cGVHD in Children 1 Year and Older"" href=""#reference-L43020"">18</a></sup>"	Q06187|P08684|P20815|P10635|P02768|P02763|P19652	440.2	7	1	5	99.2	4.2	0	149-158ºC	BTK	Tyr	Y
Icotinib		Zhejiang Beta Pharma	CHEMBL2087361	C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4	Achiral Molecule	2011	4.0	None	BPI-2009 | BPI-2009H | ICOTINIB	Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.	nan	P00533	InChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)	QQLKULDARVNMAL-UHFFFAOYSA-N	10762174	|http://www.chemspider.com/Chemical-Structure.10762174.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2087361|http://pubchem.ncbi.nlm.nih.gov/compound/22024915|http://www.drugbank.ca/drugs/DB11737|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7641|http://zinc15.docking.org/substances/ZINC000043207566|https://precision.fda.gov/uniisearch/srs/unii/9G6U5L461Q|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50391089	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).	P00533|P08684|P05177|P20815	391.2	7	1	2	74.7	3.2	0		EGFR	Tyr	N
Idelalisib	Zydelig	Gilead Sciences	CHEMBL2216870	CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4	Single Stereoisomer	2014	4.0	US-RE44599-E1	CAL-101 | GS-1101 | GS-11CAL-101 | IDELALISIB | ZYDELIG	Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.	1	O00329	InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1	IFSDAJWBUCMOAH-HNNXBMFYSA-N	9800565	|http://www.chemspider.com/Chemical-Structure.9800565.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216870|http://pubchem.ncbi.nlm.nih.gov/compound/11625818|http://www.drugbank.ca/drugs/DB09054| http://www.rcsb.org/ligand/40L|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/40L|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741|http://zinc15.docking.org/substances/ZINC13986658|https://precision.fda.gov/uniisearch/srs/unii/YG57I8T5M0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50403068	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'40L'	4xe0		Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.	O00329	415.2	7	2	5	101.4	3.8	0		PIK3CD	Atypical	Y
Ifidancitinib		Rigel Pharmaceuticals	CHEMBL4594441	COc1cc(Nc2ncc(C)c(Nc3ccc4oc(=O)[nH]c4c3)n2)cc(C)c1F	Achiral Molecule	nan	2.0	None	A-301 | ATI-502 | IFIDANCITINIB	nan	nan	nan	InChI=1S/C20H18FN5O3/c1-10-6-13(8-16(28-3)17(10)21)24-19-22-9-11(2)18(26-19)23-12-4-5-15-14(7-12)25-20(27)29-15/h4-9H,1-3H3,(H,25,27)(H2,22,23,24,26)	OYFMQDVLFYKOPZ-UHFFFAOYSA-N	88297766	|http://www.chemspider.com/Chemical-Structure.88297766.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594441|http://pubchem.ncbi.nlm.nih.gov/compound/46851625|http://www.drugbank.ca/drugs/DB16191|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10638|https://precision.fda.gov/uniisearch/srs/unii/R105E71J13	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						395.1	7	3	5	105.1	4.2	0		nan		
Ilginatinib		Nippon Shinyaku	CHEMBL3545217	CC(c1ccc(cc1)F)Nc2cc(cc(n2)Nc3cnccn3)c4cnn(c4)C	Single Stereoisomer	nan	2.0	None	|NS-018	nan	nan	nan	InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)	UQTPDWDAYHAZNT-UHFFFAOYSA-N	64880076	|http://www.chemspider.com/Chemical-Structure.64880076.html|http://pubchem.ncbi.nlm.nih.gov/compound/75236651	|ChemSpider|PubChem						389.2	7	2	6	80.6	4.3	0		nan		
Ilorasertib	ABT-348, A-968660;Abt-348, a-968660	Abbott Laboratories	CHEMBL1980297	c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N	Achiral Molecule	nan	2.0	None	A-968660 | A-968660.0 | ABBOTT-968660 | ABT-348 | ABT-348, A-968660 | ILORASERTIB	nan	nan	O14965|Q96GD4|Q9UQB9|P17948|P16234|P09619	InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)	WPHKIQPVPYJNAX-UHFFFAOYSA-N	24809095	|http://www.chemspider.com/Chemical-Structure.24809095.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1980297|http://pubchem.ncbi.nlm.nih.gov/compound/46207586|http://www.drugbank.ca/drugs/DB11694|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9914|http://zinc15.docking.org/substances/ZINC000063298074|https://precision.fda.gov/uniisearch/srs/unii/6L5D03D975|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50381716	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						488.1	7	4	6	118.1	5.2	1		AURKA; AURKB; AURKC; FLT1; PDGFRA; PDGFRB	Tyr<br>Other	
Ilunocitinib		Elanco Animal Health	CHEMBL4802241	N#CCC1(CN(C1)S(=O)(=O)C1CC1)N1C=C(C=N1)C1N=CN=C2NC=CC=12	Achiral Molecule	nan	0.0	None	ILUNOCITINIB | LY-3411067 | LY3411067	nan	nan	nan	InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)	RVOUEXFKIYNODQ-UHFFFAOYSA-N	115006748	|http://www.chemspider.com/Chemical-Structure.115006748.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4802241|http://pubchem.ncbi.nlm.nih.gov/compound/44231134|https://precision.fda.gov/uniisearch/srs/unii/N3TB5AH8B9	|ChemSpider|ChEMBL|PubChem|FDA SRS						383.1	7	1	5	120.6	1.2	0		nan		
Imatinib	Gleevec	Novartis	CHEMBL941	Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C	Achiral Molecule	2001	4.0	None	GLAMOX | GLEEVEC | IMATINIB | NSC-743414 | NSC-759854 | STI-571	For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).	2	P10721|P07949|P04629|P07333|P16234|Q08345|P00519|P09619	InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)	KTUFNOKKBVMGRW-UHFFFAOYSA-N	5101	|http://www.chemspider.com/Chemical-Structure.5101.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL941|http://pubchem.ncbi.nlm.nih.gov/compound/5291|http://www.drugbank.ca/drugs/DB03261| http://www.rcsb.org/ligand/STI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/STI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687|http://zinc15.docking.org/substances/ZINC19632618|https://precision.fda.gov/uniisearch/srs/unii/BKJ8M8G5HI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13530	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'STI'	1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 6hd4 6hd6 6jol 6ktn 6npe 6npu 6npv 6vxh 7n9g		"Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Iqbal N, Iqbal N: Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. doi: 10.1155/2014/357027. Epub 2014 May 19. (PubMed ID 24963404)"" href=""#reference-A249305"">10</a></sup> It was deemed a &quot;miracle drug&quot; due to its clinical success, as oncologist Dr. Brian noted that &quot;complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy&quot;.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996 May;2(5):561-6. doi: 10.1038/nm0596-561. (PubMed ID 8616716)"" href=""#reference-A249315"">12</a></sup>. The discovery of imatinib also established a new group of therapy called &quot;targeted therapy&quot;, since treatment can be tailored specifically to the unique cancer genetics of each patient.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""How Imatinib Transformed Leukemia Treatment and Cancer Research"" href=""#reference-L42220"">16</a></sup>"	P11274|P10721|O43519|P04629|P07333|P16234|Q08345|P00519|P09619|Q16832|P08684|P20815|P24462|P05177|P11712|P10635|P33261|P10632|P02768|P02763|O15245|P08183|O15244|Q9UNQ0|Q99758|O95342|Q92887|P33527|O76082|Q9NPD5|O15439|P46721	493.3	7	2	7	86.3	4.6	0	226°C (mesylate salt)	KIT; RET; NTRK1; CSF1R; PDGFRA; DDR1; ABL1; PDGFRB	Tyr	Y
Inavolisib		Genentech	CHEMBL4650215	C[C@@H](C(=N)O)Nc1ccc-2c(c1)OCCn3c2nc(c3)N4[C@@H](COC4=O)C(F)F	Single Stereoisomer	nan	3.0	None	GDC-0077 | GDC0077 | INAVOLISIB | RG-6114 | RG6114 | RO-7113755 | RO7113755	nan	nan	nan	InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1	SGEUNORSOZVTOL-CABZTGNLSA-N	59718498	|http://www.chemspider.com/Chemical-Structure.59718498.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650215|http://pubchem.ncbi.nlm.nih.gov/compound/124173720|http://www.drugbank.ca/drugs/DB15275| http://www.rcsb.org/ligand/X3N|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/X3N|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9636|http://zinc15.docking.org/substances/ZINC000669678973|https://precision.fda.gov/uniisearch/srs/unii/L4C1UY2NYH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=295665	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'X3N'	8exv				407.1	7	3	5	112.7	2.9	0		nan		
Infigratinib		Novartis	CHEMBL1852688	CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl	Achiral Molecule	2021	4.0	US-8552002-B2	BGJ-398 | BGJ398 | INFIGRATINIB | MVP-BGJ398 | NVP-BGJ398	On May 2021, FDA approved infigratinib to treat adults with cholangiocarcinoma whose disease meets certain criteria	1	P11362|P21802|P22607	InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)	QADPYRIHXKWUSV-UHFFFAOYSA-N	26333103	|http://www.chemspider.com/Chemical-Structure.26333103.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1852688|http://pubchem.ncbi.nlm.nih.gov/compound/53235510|http://www.drugbank.ca/drugs/DB11886| http://www.rcsb.org/ligand/07J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/07J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7877|http://zinc15.docking.org/substances/ZINC000072105034|https://precision.fda.gov/uniisearch/srs/unii/A4055ME1VK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355393	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'07J'	3tt0		"Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Botrus G, Raman P, Oliver T, Bekaii-Saab T: Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. Expert Opin Investig Drugs. 2021 Apr;30(4):309-316. doi: 10.1080/13543784.2021.1864320. Epub 2021 Jan 4. (PubMed ID 33307867)"" href=""#reference-A235174"">1</a></sup> Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568. (PubMed ID 27928095)"" href=""#reference-A198963"">2</a></sup> Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Botrus G, Raman P, Oliver T, Bekaii-Saab T: Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. Expert Opin Investig Drugs. 2021 Apr;30(4):309-316. doi: 10.1080/13543784.2021.1864320. Epub 2021 Jan 4. (PubMed ID 33307867)"" href=""#reference-A235174"">1</a></sup> </p><p>On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Drug Approvals and Databases: FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma"" href=""#reference-L34304"">5</a></sup> This approval follows <a href=""https://go.drugbank.com/drugs/DB15102"">pemigatinib</a>, another FGFR inhibitor approved by the FDA for the same therapeutic indication."	P11362|P21802|P22607|P22455|P08684|P31513|P02647|P02652|P06727|P04114|P02655|P02656|P05090|P02649|O14791|O95445|P08519|P08183|Q9UNQ0|Q96FL8|O95342|O15245|O15244|Q86VL8|Q9Y6L6|Q9NPD5	559.2	8	2	8	95.1	5.4	2		FGFR1; FGFR2; FGFR3	Tyr	Y
Inixaciclib		GiraFPharma	CHEMBL5095102	CC(C)N1CCOc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc21	Achiral Molecule	nan	-1.0	None		nan	nan	nan	InChI=1S/C26H30F2N6O/c1-16(2)34-10-11-35-25-20(27)12-19(13-22(25)34)24-21(28)15-30-26(32-24)31-23-5-4-18(14-29-23)17-6-8-33(3)9-7-17/h4-5,12-17H,6-11H2,1-3H3,(H,29,30,31,32)	YZSCPLGKKMSBMV-UHFFFAOYSA-N		|http://www.chemspider.com/Chemical-Structure..html|http://pubchem.ncbi.nlm.nih.gov/compound/139390026	|ChemSpider|PubChem						480.2	7	1	5	66.4	5.0	0		nan		
Ipatasertib		Hoffmann-La Roche	CHEMBL2177390	C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O	Single Stereoisomer	nan	4.0	None	GDC-0068 | IPATASERTIB | RG-7440 | RG7440	nan	1	P31749|P31751|Q9Y243	InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1	GRZXWCHAXNAUHY-NSISKUIASA-N	28189084	|http://www.chemspider.com/Chemical-Structure.28189084.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2177390|http://pubchem.ncbi.nlm.nih.gov/compound/24788740|http://www.drugbank.ca/drugs/DB11743| http://www.rcsb.org/ligand/0RF|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0RF|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7887|http://zinc15.docking.org/substances/ZINC000068250459|https://precision.fda.gov/uniisearch/srs/unii/524Y3IB4HQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50398379	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'0RF'	4ekl				457.2	6	2	6	81.6	3.1	0		AKT1; AKT2; AKT3	AGC	Y
Itacitinib		Incyte Corporation	CHEMBL3622820	c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N	Achiral Molecule	nan	3.0	None	INCB-039110 | INCB-39110 | INCB039110 | ITACITINIB	nan	nan	P23458	InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)	KTBSXLIQKWEBRB-UHFFFAOYSA-N	35033258	|http://www.chemspider.com/Chemical-Structure.35033258.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3622820|http://pubchem.ncbi.nlm.nih.gov/compound/53380437|http://www.drugbank.ca/drugs/DB12154|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8364|http://zinc15.docking.org/substances/ZINC000118795962|https://precision.fda.gov/uniisearch/srs/unii/19J3781LPM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=246868	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						553.2	8	1	5	119.6	3.6	1		JAK1	Tyr	
Ivarmacitinib		Jiangsu Hengrui Medicine	CHEMBL5095398	CN(C1C[C@@H]2CN(C[C@@H]2C1)C(=O)NC1=NC(=NS1)OC)C1=NC=NC2NC=CC=21	Single Stereoisomer	nan	2.0	None	|IVARMACITINIB|SHR0302 base	nan	nan	nan	InChI=1S/C18H22N8O2S/c1-25(15-13-3-4-19-14(13)20-9-21-15)12-5-10-7-26(8-11(10)6-12)18(27)23-17-22-16(28-2)24-29-17/h3-4,9-12H,5-8H2,1-2H3,(H,19,20,21)(H,22,23,24,27)/t10-,11+,12?	DNBCBAXDWNDRNO-FOSCPWQOSA-N	114935320	|http://www.chemspider.com/Chemical-Structure.114935320.html|http://pubchem.ncbi.nlm.nih.gov/compound/71622431	|ChemSpider|PubChem						414.2	8	2	4	112.2	2.2	0		nan		
Izencitinib		Theravance Biopharma	CHEMBL4650343	Cc1cc(Nc2cc3ncccc3c(N[C@H]3C[C@@H]4CC[C@H](C3)N4CCC#N)n2)n[nH]1	Single Stereoisomer	nan	2.0	None	IZENCITINIB | TD-1473 | TD1473	nan	nan	nan	InChI=1S/C22H26N8/c1-14-10-21(29-28-14)26-20-13-19-18(4-2-8-24-19)22(27-20)25-15-11-16-5-6-17(12-15)30(16)9-3-7-23/h2,4,8,10,13,15-17H,3,5-6,9,11-12H2,1H3,(H3,25,26,27,28,29)/t15-,16-,17+	DADAEARVGOQWHV-OSYLJGHBSA-N	75536963	|http://www.chemspider.com/Chemical-Structure.75536963.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650343|http://www.drugbank.ca/drugs/DB16660|https://precision.fda.gov/uniisearch/srs/unii/2ZT81PV5UM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=277390	|ChemSpider|ChEMBL|DrugBank|FDA SRS|BindingDB						402.2	7	3	6	105.6	3.7	0		nan		
Izorlisib		Menarini Pharma	CHEMBL1684984	CS(=O)(=O)N1CCc2c1nc(nc2c3cnc(nc3)N)N4CCOCC4	Achiral Molecule	nan	1.0	None	CH 5132799 | CH-5132799 | CH5132799 | IZORLISIB | PA-799 | PA799	nan	nan	nan	InChI=1S/C15H19N7O3S/c1-26(23,24)22-3-2-11-12(10-8-17-14(16)18-9-10)19-15(20-13(11)22)21-4-6-25-7-5-21/h8-9H,2-7H2,1H3,(H2,16,17,18)	JEGHXKRHKHPBJD-UHFFFAOYSA-N	26328046	|http://www.chemspider.com/Chemical-Structure.26328046.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1684984|http://pubchem.ncbi.nlm.nih.gov/compound/49784945|http://www.drugbank.ca/drugs/DB13051| http://www.rcsb.org/ligand/MMD|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MMD|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7743|http://zinc15.docking.org/substances/ZINC000066074200|https://precision.fda.gov/uniisearch/srs/unii/JCL936W835|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50338197	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'MMD'	3apc				377.1	9	1	3	127.4	-0.3	0		nan		
Lapatinib	Tykerb;Tyverb	GlaxoSmithKline	CHEMBL554	CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F	Achiral Molecule	2007	4.0	US-8821927-B2	GSK-572016 | GW-2016 | GW-572016 | GW-572016X | GW572016 | LAPATINIB | TYVERB	Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.	1.5	P00533|P04626	InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)	BCFGMOOMADDAQU-UHFFFAOYSA-N	181006	|http://www.chemspider.com/Chemical-Structure.181006.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL554|http://pubchem.ncbi.nlm.nih.gov/compound/208908|http://www.drugbank.ca/drugs/DB02584| http://www.rcsb.org/ligand/FMM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FMM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5692|http://zinc15.docking.org/substances/ZINC000001550477|https://precision.fda.gov/uniisearch/srs/unii/0VUA21238F|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5445	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'FMM'	1xkk 3bbt		Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.	P00533|P04626|P08684|P20815|P10632|P33261|P08183|Q03518	580.1	8	2	11	106.4	6.1	2		EGFR; ERBB2	Tyr	Y
Larotrectinib	Vitrakvi	Array BioPharma	CHEMBL3889654	c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F	Single Stereoisomer	2018	4.0	US-8513263-B2	ARRY-470 | BAY-2757556 | BAY2757556 | LAROTRECTINIB | LOXO-101	On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker)	nan	P04629|Q16620|Q16288	InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1	NYNZQNWKBKUAII-KBXCAEBGSA-N	44210503	|http://www.chemspider.com/Chemical-Structure.44210503.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3889654|http://pubchem.ncbi.nlm.nih.gov/compound/46188928|http://www.drugbank.ca/drugs/DB14723|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8909|http://zinc15.docking.org/substances/ZINC000118399834|https://precision.fda.gov/uniisearch/srs/unii/PF9462I9HX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=136597	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Larotrectinib is an orally administered tropomyosin receptor kinase (Trk) inhibitor with demonstrated antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.</p><p>Originally discovered by Array BioPharma, the agent was ultimately licensed to Loxo Oncology in 2013. Larotrectinib is another example of innovative new cancer therapy medications that target key, specific genetic biomarker drivers of cancer rather than particular types of tumors <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Larotrectinib FDA Approval Press Release"" href=""#reference-L4847"">6</a></sup>."	P04629|Q16620|Q16288	428.2	6	2	3	86.0	2.9	0		NTRK1; NTRK2; NTRK3	Tyr	Y
Lazertinib		Genosco	CHEMBL4558324	CN(C)Cc1cn(nc1c2ccccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N5CCOCC5)NC(=O)C=C	Achiral Molecule	nan	3.0	None	C-18112003-G | GNS-1480 | GNS1480 | JNJ-73841937-AAA | LAZERTINIB | YH-25448 | YH25448	Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation for antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.	nan	nan	InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)	RRMJMHOQSALEJJ-UHFFFAOYSA-N	64835231	|http://www.chemspider.com/Chemical-Structure.64835231.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4558324|http://pubchem.ncbi.nlm.nih.gov/compound/121269225|http://www.drugbank.ca/drugs/DB16216|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10136|https://precision.fda.gov/uniisearch/srs/unii/4A2Y23XK11	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						554.3	10	2	10	109.7	4.1	1		nan		
Leniolisib		Novartis	CHEMBL3643413	CCC(=O)N1CC[C@@H](C1)Nc2c3c(ncn2)CCN(C3)c4cc(c(nc4)OC)C(F)(F)F	Single Stereoisomer	2023	4.0	None	CDZ-173 FREE BASE | CDZ-173-NX | CDZ173 FREE BASE | CDZ173-NX | LENIOLISIB	On March 2023, FDA approved Leniolosib to treat activated phosphoinositide 3-kinase delta syndrome	nan	nan	InChI=1S/C21H25F3N6O2/c1-3-18(31)30-6-4-13(10-30)28-19-15-11-29(7-5-17(15)26-12-27-19)14-8-16(21(22,23)24)20(32-2)25-9-14/h8-9,12-13H,3-7,10-11H2,1-2H3,(H,26,27,28)/t13-/m0/s1	MWKYMZXCGYXLPL-ZDUSSCGKSA-N	52083264	|http://www.chemspider.com/Chemical-Structure.52083264.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3643413|http://pubchem.ncbi.nlm.nih.gov/compound/57495353|http://www.drugbank.ca/drugs/DB16217| http://www.rcsb.org/ligand/9NQ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9NQ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9424|http://zinc15.docking.org/substances/ZINC000113570569|https://precision.fda.gov/uniisearch/srs/unii/L22772Z9CP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=118299	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'9NQ'	5o83		"Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News: FDA approves first treatment for activated phosphoinositide 3-kinase delta syndrome"" href=""#reference-L45758"">10</a></sup> APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Michalovich D, Nejentsev S: Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy. Front Immunol. 2018 Feb 27;9:369. doi: 10.3389/fimmu.2018.00369. eCollection 2018. (PubMed ID 29535736)"" href=""#reference-A258473"">1</a>,<a class=""reference-popover-link"" data-content=""Rao VK, Webster S, Dalm VASH, Sediva A, van Hagen PM, Holland S, Rosenzweig SD, Christ AD, Sloth B, Cabanski M, Joshi AD, de Buck S, Doucet J, Guerini D, Kalis C, Pylvaenaeinen I, Soldermann N, Kashyap A, Uzel G, Lenardo MJ, Patel DD, Lucas CL, Burkhart C: Effective &quot;activated PI3Kdelta syndrome&quot;-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316. doi: 10.1182/blood-2017-08-801191. Epub 2017 Sep 29. (PubMed ID 28972011)"" href=""#reference-A258463"">2</a></sup> Leniolisib works to inhibit hyperactive PI3Kδ.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: JOENJA (leniolisib) tablets, for oral use"" href=""#reference-L45753"">9</a></sup> Investigations for using leniolisib in primary Sjögren’s syndrome are ongoing.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Hoegenauer K, Soldermann N, Zecri F, Strang RS, Graveleau N, Wolf RM, Cooke NG, Smith AB, Hollingworth GJ, Blanz J, Gutmann S, Rummel G, Littlewood-Evans A, Burkhart C: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med Chem Lett. 2017 Aug 25;8(9):975-980. doi: 10.1021/acsmedchemlett.7b00293. eCollection 2017 Sep 14. (PubMed ID 28947947)"" href=""#reference-A258468"">3</a></sup>"	O00329|P05177|P08684|P20815|P10635|P04798|Q9UNQ0|Q9Y6L6|Q9NPD5|P08183	450.2	7	1	5	83.5	2.9	0		nan		Y
Lenvatinib	Kisplyx;Lenvima	Eisai	CHEMBL1289601	COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4	Achiral Molecule	2015	4.0	US-7253286-B2	E-7080 | ER-203492-00 | KISPLYX | LENVATINIB | LENVIMA	Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.	1.5	P17948|P35968|P35916|P11362|P21802|P22607|P22455|P10721	InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)	WOSKHXYHFSIKNG-UHFFFAOYSA-N	7999567	|http://www.chemspider.com/Chemical-Structure.7999567.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289601|http://pubchem.ncbi.nlm.nih.gov/compound/9823820|http://www.drugbank.ca/drugs/DB09078| http://www.rcsb.org/ligand/LEV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LEV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7426|http://zinc15.docking.org/substances/ZINC03816292|https://precision.fda.gov/uniisearch/srs/unii/EE083865G2|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331094	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'LEV'	3wzd 5zv2		Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.</p><p>Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.	P17948|P35968|P35916|P11362|P21802|P22607|P22455|P16234|P07949|P10721|P08684|Q06278|P10632|P11712|P05177|P20813|P33261|P10635	426.1	5	3	6	115.6	4.1	0		FLT1; KDR; FLT4; FGFR1; FGFR2; FGFR3; FGFR4; KIT	Tyr	Y
Lerociclib		G1 Therapeutics	CHEMBL3904602	CC(C)N1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O	Achiral Molecule	nan	3.0	None	G1T-38 | G1T38 | G1T38 FREE BASE | LEROCICLIB	nan	nan	nan	InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)	YPJRHEKCFKOVRT-UHFFFAOYSA-N	68007293	|http://www.chemspider.com/Chemical-Structure.68007293.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3904602|http://pubchem.ncbi.nlm.nih.gov/compound/86269224|http://www.drugbank.ca/drugs/DB16218|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10313|https://precision.fda.gov/uniisearch/srs/unii/WBH8AY6ENB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=253941	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						474.3	8	2	4	91.2	3.5	0		nan		
Lestaurtinib		Cephalon	CHEMBL603469	C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O	Single Stereoisomer	nan	3.0	None	A-154475 | A-154475.0 | CEP-701 | KT-555 | KT-5555 | KT5555 | LESTAURTINIB | SP-924 | SP924 | SPM-924	nan	nan	P36888	InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1	UIARLYUEJFELEN-LROUJFHJSA-N	112457	|http://www.chemspider.com/Chemical-Structure.112457.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL603469|http://pubchem.ncbi.nlm.nih.gov/compound/126565| http://www.rcsb.org/ligand/2V9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2V9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5672|http://zinc15.docking.org/substances/ZINC03781738|https://precision.fda.gov/uniisearch/srs/unii/DO989GC5D1|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50308060	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'2V9'	4otg 5wnj				439.2	6	3	1	88.7	3.5	0		FLT3	Tyr	
Lifirafenib		BeiGene	CHEMBL4209157	c1cc2c(cc1C(F)(F)F)[nH]c(n2)[C@H]3[C@H]4[C@@H]3Oc5c4cc(cc5)Oc6ccnc7c6CCC(=O)N7	Single Stereoisomer	nan	1.0	None	BEIGENE-283 | BGB 283 | BGB-283 | LIFIRAFENIB	nan	nan	nan	InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1	NGFFVZQXSRKHBM-FKBYEOEOSA-N	58145118	|http://www.chemspider.com/Chemical-Structure.58145118.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4209157|http://pubchem.ncbi.nlm.nih.gov/compound/89670174|http://www.drugbank.ca/drugs/DB14773| http://www.rcsb.org/ligand/3K3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3K3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8958|http://zinc15.docking.org/substances/ZINC000068764621|https://precision.fda.gov/uniisearch/srs/unii/8762XZS5ZF|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50453816	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'3K3'	4r5y				478.1	5	2	3	89.1	5.3	1		nan		
Linifanib		Abbott Laboratories	CHEMBL223360	Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F	Achiral Molecule	nan	3.0	None	A-741439 | ABT-869 | AL-39324 | LINIFANIB | RG-3635	nan	nan	P36888|P07333|P35968	InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)	MPVGZUGXCQEXTM-UHFFFAOYSA-N	9660475	|http://www.chemspider.com/Chemical-Structure.9660475.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL223360|http://pubchem.ncbi.nlm.nih.gov/compound/11485656|http://www.drugbank.ca/drugs/DB06080|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5657|http://zinc15.docking.org/substances/ZINC06718813|https://precision.fda.gov/uniisearch/srs/unii/CO93X137CW|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21079	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.	P36888|P17948|P35968|P35916|P10721|P07333	375.1	3	4	3	95.8	4.9	0		FLT3; CSF1R; KDR	Tyr	
Linperlisib		Shanghai Yingli Pharmaceutical		CC(C)(C1CCN(CC1)Cc2cc(cc3c2nc(nc3c4cc(c(nc4)OC)NS(=O)(=O)C)N5CCOCC5)F)O		nan	1.5			nan	nan	nan	InChI=1S/C28H37FN6O5S/c1-28(2,36)20-5-7-34(8-6-20)17-19-13-21(29)15-22-24(31-27(32-25(19)22)35-9-11-40-12-10-35)18-14-23(33-41(4,37)38)26(39-3)30-16-18/h13-16,20,33,36H,5-12,17H2,1-4H3	NVWKNQGHVMMAJW-UHFFFAOYSA-N	67886313	|http://www.chemspider.com/Chemical-Structure.67886313.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4574601|http://pubchem.ncbi.nlm.nih.gov/compound/91754520|http://www.drugbank.ca/drugs/DB17235|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10466|https://precision.fda.gov/uniisearch/srs/unii/05HYK3CV9N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=309960	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						588.3	10	2	8	130.0	3.0	1		nan		
Linsitinib		Osi Pharmaceuticals	CHEMBL1091644	C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O	Single Stereoisomer	nan	3.0	None	ASP-7487 | LINSITINIB | OSI-906 | OSI-906AA	nan	nan	P08069	InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+	PKCDDUHJAFVJJB-VLZXCDOPSA-N	21391708	|http://www.chemspider.com/Chemical-Structure.21391708.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1091644|http://www.drugbank.ca/drugs/DB06075|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7423|http://zinc15.docking.org/substances/ZINC000100071817|https://precision.fda.gov/uniisearch/srs/unii/15A52GPT8T|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50315887	|ChemSpider|ChEMBL|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.	P06213|P08069	421.2	6	2	3	89.3	4.8	0		IGF1R	Tyr	
Lorlatinib	Lorbrena	Pfizer	CHEMBL3286830	C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F	Single Stereoisomer	2018	4.0	US-8680111-B2	LORBRENA | LORLATINIB | PF-06463922	On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer	1	Q9UM73|P08922	InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1	IIXWYSCJSQVBQM-LLVKDONJSA-N	32813339	|http://www.chemspider.com/Chemical-Structure.32813339.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3286830|http://pubchem.ncbi.nlm.nih.gov/compound/71731823|http://www.drugbank.ca/drugs/DB12130| http://www.rcsb.org/ligand/5P8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/5P8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7476|http://zinc15.docking.org/substances/ZINC000098208524|https://precision.fda.gov/uniisearch/srs/unii/OSP71S83EU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50018830	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'5P8'	4cli 4clj 4uxl 5a9u 5aa8 5aa9		"Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Lorbrena (lorlatinib) tablets for oral use"" href=""#reference-L39905"">11</a></sup> which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""EMA Summary of Product Characteristics: Lorviqua (lorlatinib) film-coated tablets for oral use"" href=""#reference-L13580"">12</a></sup>"	Q9UM73	406.2	7	1	0	110.1	2.8	0		ALK; ROS1	Tyr	Y
Lorpucitinib		Janssen		CC(C)(O)CNC(=O)CC1=NC2=CNC3=NC=CC3=C2N1[C@@H]1CC[C@@H](CC#N)CC1		nan	1.0		|LORPUCITINIB	nan	nan	nan	InChI=1S/C22H28N6O2/c1-22(2,30)13-26-19(29)11-18-27-17-12-25-21-16(8-10-24-21)20(17)28(18)15-5-3-14(4-6-15)7-9-23/h8,10,12,14-15,30H,3-7,11,13H2,1-2H3,(H,24,25)(H,26,29)/t14-,15-	NJKMSBSVJSQUBU-UHFFFAOYSA-N	88297963	|http://www.chemspider.com/Chemical-Structure.88297963.html|http://pubchem.ncbi.nlm.nih.gov/compound/134611548|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=505107	|ChemSpider|PubChem|BindingDB						408.2	6	3	6	119.6	2.9	0		nan		
Losmapimod		GlaxoSmithKline	CHEMBL1088752	Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C	Achiral Molecule	nan	3.0	None	FTX-1821 | FTX1821 | GSK-AHAB | GSKAHAB | GW-856553 | GW-856553X | GW856553 | GW856553X | LOSMAPIMOD	nan	nan	Q16539|Q15759|O15264|P53778	InChI=1S/C22H26FN3O2/c1-13-17(9-15(10-18(13)23)21(28)26-16-6-7-16)19-8-5-14(11-24-19)20(27)25-12-22(2,3)4/h5,8-11,16H,6-7,12H2,1-4H3,(H,25,27)(H,26,28)	KKYABQBFGDZVNQ-UHFFFAOYSA-N	9727484	|http://www.chemspider.com/Chemical-Structure.9727484.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1088752|http://pubchem.ncbi.nlm.nih.gov/compound/11552706|http://www.drugbank.ca/drugs/DB12270|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7835|http://zinc15.docking.org/substances/ZINC000035793138|https://precision.fda.gov/uniisearch/srs/unii/F2DQF16BXE|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50418610	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						383.2	3	2	5	71.1	3.9	0		MAPK14; MAPK11; MAPK13; MAPK12	CMGC	
Lucitanib		Clovis Oncology	CHEMBL2220486	CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC	Achiral Molecule	nan	2.0	None	AL-3810 | CO-3810 | E-3810 | LUCITANIB | S 80881 | S-80881	nan	1	P17948|P35968|P35916|P11362|P21802	InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)	CUDVHEFYRIWYQD-UHFFFAOYSA-N	28189586	|http://www.chemspider.com/Chemical-Structure.28189586.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2220486|http://pubchem.ncbi.nlm.nih.gov/compound/25031915|http://www.drugbank.ca/drugs/DB11845| http://www.rcsb.org/ligand/3ZC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3ZC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7649|http://zinc15.docking.org/substances/ZINC000077024213|https://precision.fda.gov/uniisearch/srs/unii/PP449XA4BH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399539	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'3ZC'	4rwl				443.2	6	2	7	95.7	4.4	0		FLT1; KDR; FLT4; FGFR1; FGFR2	Tyr	
Luvixasertib		University Health Network	CHEMBL4469414	Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1	Single Stereoisomer	nan	1.0	None	CFI-402257 | CFI402257 | LUVIXASERTIB	nan	nan	nan	InChI=1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,30,36H,6-7,12-14H2,1-2H3,(H,32,35)/t18-,28+	PMQUGSPFUBGJCZ-CHOKWEPUSA-N	60600040	|http://www.chemspider.com/Chemical-Structure.60600040.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4469414|https://precision.fda.gov/uniisearch/srs/unii/HE97PTK3Q6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50512456	|ChemSpider|ChEMBL|FDA SRS|BindingDB						498.2	8	3	8	113.7	4.4	0		nan		
Luxeptinib		CrystalGenomics	CHEMBL4594420	Cc1c[nH]c(-c2ccc(-c3ccc(NC(=O)Nc4c(F)cc(F)cc4F)cc3F)c3c2C(=O)NC3)n1	Achiral Molecule	nan	1.0	None	CG'806 | CG-026806 | CG-806 | CG026806 | CG806 | LUXEPTINIB	nan	nan	nan	InChI=1S/C25H17F4N5O2/c1-11-9-30-23(32-11)16-5-4-14(17-10-31-24(35)21(16)17)15-3-2-13(8-18(15)27)33-25(36)34-22-19(28)6-12(26)7-20(22)29/h2-9H,10H2,1H3,(H,30,32)(H,31,35)(H2,33,34,36)	MWHHJYUHCZWSLS-UHFFFAOYSA-N	81367387	|http://www.chemspider.com/Chemical-Structure.81367387.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594420|http://pubchem.ncbi.nlm.nih.gov/compound/118480924|https://precision.fda.gov/uniisearch/srs/unii/TQ6PBX1JU0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=340031	|ChemSpider|ChEMBL|PubChem|FDA SRS|BindingDB						495.1	3	4	4	98.9	5.5	1		nan		
Masitinib	Kinavet;Masivet	AB Science	CHEMBL1908391	Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C	Achiral Molecule	nan	4.0	None	AB-1010 | AB1010 | KINAVET | MASICAN | MASITINIB | MASITINIB MESILATE | MASITINIB MESYLATE | MASITINIB METHANESULFONATE | MASIVET | MASIVIERA	nan	nan	P10721|P16234|P09619|P11362|P21802|P22607	InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)	WJEOLQLKVOPQFV-UHFFFAOYSA-N	8250179	|http://www.chemspider.com/Chemical-Structure.8250179.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1908391|http://pubchem.ncbi.nlm.nih.gov/compound/10074640|http://www.drugbank.ca/drugs/DB11526| http://www.rcsb.org/ligand/G65|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/G65|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5656|http://zinc15.docking.org/substances/ZINC34177219|https://precision.fda.gov/uniisearch/srs/unii/M59NC4E26P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355495	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'G65'	5mql 7ju7 7tvx				498.2	7	2	7	73.4	5.3	1		KIT; PDGFRA; PDGFRB; FGFR1; FGFR2; FGFR3	Tyr	Y
Mavelertinib		Pfizer	CHEMBL3989970	Cn1cc(c(n1)OC)Nc2c3c(nc(n2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)n(cn3)C	Single Stereoisomer	nan	2.0	None	EGFR T790M INHIBITOR PF-06747775 | MAVELERTINIB | PF-06747775	nan	nan	nan	InChI=1S/C18H22FN9O2/c1-5-13(29)21-11-8-28(6-10(11)19)18-23-15(14-16(24-18)26(2)9-20-14)22-12-7-27(3)25-17(12)30-4/h5,7,9-11H,1,6,8H2,2-4H3,(H,21,29)(H,22,23,24)/t10-,11-/m1/s1	JYIUNVOCEFIUIU-GHMZBOCLSA-N	49070873	|http://www.chemspider.com/Chemical-Structure.49070873.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989970|http://pubchem.ncbi.nlm.nih.gov/compound/91668194|http://www.drugbank.ca/drugs/DB16228|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9765|http://zinc15.docking.org/substances/ZINC000231225813|https://precision.fda.gov/uniisearch/srs/unii/YXX2180047|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50450870	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						415.2	10	2	6	115.0	0.7	0		nan		
Merestinib		Eli Lilly	CHEMBL3545307	Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C	Achiral Molecule	nan	2.0	None	LY-2801653 | LY2801653 | MERESTINIB	nan	2	P08581	InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)	QHADVLVFMKEIIP-UHFFFAOYSA-N	29361338	|http://www.chemspider.com/Chemical-Structure.29361338.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545307|http://pubchem.ncbi.nlm.nih.gov/compound/44603533|http://www.drugbank.ca/drugs/DB12381| http://www.rcsb.org/ligand/L1X|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/L1X|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9841|http://zinc15.docking.org/substances/ZINC000095926668|https://precision.fda.gov/uniisearch/srs/unii/5OGS5K699E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50172078	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'L1X'	4eev 7aay				552.2	7	2	6	106.8	5.7	2		MET	Tyr	
Midostaurin	Rydapt	Novartis Pharmaceuticals Corp	CHEMBL608533	C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC	Single Stereoisomer	2017	4.0	US-7973031-B2	CGP 41251 | CGP-41251 | MIDOSTAURIN | NSC-656576 | NVP-PKC412 | PKC 412 | PKC-412 | RYDAPT	On april 28 , 2017, the FDA approved midostaurin to  treat acute myeloid leukemia	nan	nan	InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1	BMGQWWVMWDBQGC-IIFHNQTCSA-N	8005258	|http://www.chemspider.com/Chemical-Structure.8005258.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL608533|http://pubchem.ncbi.nlm.nih.gov/compound/9829523|http://www.drugbank.ca/drugs/DB06595| http://www.rcsb.org/ligand/2K2|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2K2|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5702|http://zinc15.docking.org/substances/ZINC000100013130|https://precision.fda.gov/uniisearch/srs/unii/ID912S5VON|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50326053	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'2K2'	4nct		"Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Gallogly MM, Lazarus HM: Midostaurin: an emerging treatment for acute myeloid leukemia patients. J Blood Med. 2016 Apr 19;7:73-83. doi: 10.2147/JBM.S100283. eCollection 2016. (PubMed ID 27186148)"" href=""#reference-A19108"">4</a></sup>. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents."	P17252|P35968|P16234|P09619|P36888|P10721|P08684|Q9HB55|P20815|P24462|P05177|P20813|P10632|P11712|P33261|P10635|P05181|P08684|P20815|P24462|Q9HB55	570.2	6	1	3	77.7	5.9	2	235-260	nan		Y
Milciclib		Nerviano Medical Sciences	CHEMBL564829	CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C	Achiral Molecule	nan	2.0	None	MILCICLIB | PHA 848125 | PHA-848125	nan	1	P06493|P04629	InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)	RXZMYLDMFYNEIM-UHFFFAOYSA-N	16788113	|http://www.chemspider.com/Chemical-Structure.16788113.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL564829|http://pubchem.ncbi.nlm.nih.gov/compound/16718576|http://www.drugbank.ca/drugs/DB16232| http://www.rcsb.org/ligand/P48|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P48|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7938|http://zinc15.docking.org/substances/ZINC000053119602|https://precision.fda.gov/uniisearch/srs/unii/688000M8S8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31545	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'P48'	2wih 5vc6 5vd1				460.3	8	2	4	91.2	2.6	0		CDK1; NTRK1	CMGC<br>Tyr	
Miransertib		Merck	CHEMBL4297188	c1ccc(cc1)c2ccc3c(n2)n(c(n3)c4cccnc4N)c5ccc(cc5)C6(CCC6)N	Achiral Molecule	nan	2.0	None	ARQ 092 | ARQ 092 FREE BASE | ARQ-092 | MIRANSERTIB	nan	nan	nan	InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)	HNFMVVHMKGFCMB-UHFFFAOYSA-N	57251282	|http://www.chemspider.com/Chemical-Structure.57251282.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297188|http://pubchem.ncbi.nlm.nih.gov/compound/53262401|http://www.drugbank.ca/drugs/DB14982| http://www.rcsb.org/ligand/6S1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6S1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9429|http://zinc15.docking.org/substances/ZINC000072315647|https://precision.fda.gov/uniisearch/srs/unii/T1DQI1B52Y	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS	'6S1'	5kcv				432.2	6	2	4	95.6	5.1	1		nan		
Mirdametinib		Pfizer	CHEMBL507361	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	Single Stereoisomer	nan	2.0	None	MIRDAMETINIB | PD 0325901 | PD 03525901 | PD 901 | PD-0325901	nan	nan	nan	InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1	SUDAHWBOROXANE-SECBINFHSA-N	8002271	|http://www.chemspider.com/Chemical-Structure.8002271.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL507361|http://pubchem.ncbi.nlm.nih.gov/compound/9826528|http://www.drugbank.ca/drugs/DB07101| http://www.rcsb.org/ligand/4BM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/4BM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7935|http://zinc15.docking.org/substances/ZINC03938683|https://precision.fda.gov/uniisearch/srs/unii/86K0J5AK6M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=104963	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'4BM'	3eqg 3vvh 7juu 7jv0 7m0x		PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.	Q02750	482.0	5	4	7	90.8	2.5	0		nan		
Mivavotinib		Takeda	CHEMBL3979920	Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1	Single Stereoisomer	nan	2.0	None	CB-659 | MIVAVOTINIB | TAK-659F	nan	nan	nan	InChI=1S/C17H21FN6O/c1-24-8-9(6-21-24)15-13-10(7-20-17(13)25)14(18)16(23-15)22-12-5-3-2-4-11(12)19/h6,8,11-12H,2-5,7,19H2,1H3,(H,20,25)(H,22,23)/t11-,12+/m0/s1	MJHOMTRKVMKCNE-NWDGAFQWSA-N	57583808	|http://www.chemspider.com/Chemical-Structure.57583808.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3979920|http://pubchem.ncbi.nlm.nih.gov/compound/53252276|http://www.drugbank.ca/drugs/DB16849| http://www.rcsb.org/ligand/7KG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/7KG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9600|https://precision.fda.gov/uniisearch/srs/unii/8QR88H79VX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50204290	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB	'7KG'	5tr6				344.2	6	3	3	97.9	1.5	0		nan		
Mobocertinib		Takeda	CHEMBL4650319	C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C	Achiral Molecule	2021	4.0	US-9796712-B2	AP-32788 | AP32788 | MOBOCERTINIB | TAK-788	On September 2021, FDA approved mobocertinib to treat ocally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations	nan	nan	InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)	AZSRSNUQCUDCGG-UHFFFAOYSA-N	84455481	|http://www.chemspider.com/Chemical-Structure.84455481.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650319|http://pubchem.ncbi.nlm.nih.gov/compound/118607832|http://www.drugbank.ca/drugs/DB16390|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10468|https://precision.fda.gov/uniisearch/srs/unii/39HBQ4A67L|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=368374	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB				"Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the <em>EGFR</em> gene,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News Release: FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations"" href=""#reference-L38368"">8</a></sup> which are typically associated with a poorer prognosis (as compared to &quot;classical&quot; <em>EGFR</em> mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Vyse S, Huang PH: Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019 Mar 8;4:5. doi: 10.1038/s41392-019-0038-9. eCollection 2019. (PubMed ID 30854234)"" href=""#reference-A238828"">6</a></sup> Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on <em>EGFR</em> exon 20 insertion mutant variants at concentrations 1.5- to 10-fold lower than those required to inhibit wild-type EGFR.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Exkivity (mobocertinib) capsules for oral use"" href=""#reference-L38319"">7</a></sup></p><p>Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic NSCLC in patients with <em>EGFR</em> exon 20 insertion mutations who have failed previous therapies.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News Release: FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations"" href=""#reference-L38368"">8</a></sup>"	P00533|P08684|P20815|P24462|P08183|Q9UNQ0	585.3	10	2	12	113.8	5.1	2		nan		Y
Momelotinib		Ym Biosciences Australia	CHEMBL1078178	c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N	Achiral Molecule	nan	3.0	None	CYT-0387 | CYT-11387 | CYT-387 | CYT387 | GS-0387 | MOMELOTINIB	nan	nan	P23458|O60674|P52333	InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	24676202	|http://www.chemspider.com/Chemical-Structure.24676202.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1078178|http://pubchem.ncbi.nlm.nih.gov/compound/25062766|http://www.drugbank.ca/drugs/DB11763| http://www.rcsb.org/ligand/C87|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/C87|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7791|http://zinc15.docking.org/substances/ZINC43199890|https://precision.fda.gov/uniisearch/srs/unii/6O01GMS00P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50311017	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'C87'	6fdz 7nns				414.2	7	2	6	103.2	3.0	0		JAK1; JAK2; JAK3	Tyr	
Motesanib		Amgen	CHEMBL572881	CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C	Achiral Molecule	nan	3.0	None	AMG 706 | AMG-706 | MOTESANIB	nan	2	P17948|P35968|P35916|P16234|P09619|P10721|P07949	InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)	RAHBGWKEPAQNFF-UHFFFAOYSA-N	9842625	|http://www.chemspider.com/Chemical-Structure.9842625.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL572881|http://pubchem.ncbi.nlm.nih.gov/compound/11667893|http://www.drugbank.ca/drugs/DB05575| http://www.rcsb.org/ligand/706|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/706|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5660|http://zinc15.docking.org/substances/ZINC18710082|https://precision.fda.gov/uniisearch/srs/unii/U1JK633AYI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=24773	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'706'	3efl				373.2	5	3	5	78.9	4.0	0		FLT1; KDR; FLT4; PDGFRA; PDGFRB; KIT; RET	Tyr	
Mubritinib		Takeda	CHEMBL1614707	c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F	Achiral Molecule	nan	1.0	None	MUBRITINIB | TAK-165	nan	nan	P00533|P04626	InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+	ZTFBIUXIQYRUNT-MDWZMJQESA-N	4948554	|http://www.chemspider.com/Chemical-Structure.4948554.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614707|http://pubchem.ncbi.nlm.nih.gov/compound/6444692|http://www.drugbank.ca/drugs/DB12682|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6011|http://zinc15.docking.org/substances/ZINC11679877|https://precision.fda.gov/uniisearch/srs/unii/V734AZP9BR	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						468.2	6	0	10	66.0	6.1	1		EGFR; ERBB2	Tyr	
Naporafenib		Novartis	CHEMBL4583691	Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1	Achiral Molecule	nan	2.0	None	LXH 254 | LXH-254 | LXH254 | NAPORAFENIB | PAN-RAF INHIBITOR LXH254	nan	nan	nan	InChI=1S/C25H25F3N4O4/c1-16-2-3-19(30-24(34)17-4-5-29-21(12-17)25(26,27)28)15-20(16)18-13-22(32-6-9-35-10-7-32)31-23(14-18)36-11-8-33/h2-5,12-15,33H,6-11H2,1H3,(H,30,34)	UEPXBTCUIIGYCY-UHFFFAOYSA-N	67886371	|http://www.chemspider.com/Chemical-Structure.67886371.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4583691|http://pubchem.ncbi.nlm.nih.gov/compound/90456533| http://www.rcsb.org/ligand/K81|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/K81|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10658|https://precision.fda.gov/uniisearch/srs/unii/15JL80DG6H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=88120	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB	'K81'	6n0p 8f7p				502.2	7	2	7	96.8	3.9	1		nan		
Naquotinib		Astellas Pharma	CHEMBL3663929	CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C	Single Stereoisomer	nan	3.0	None	ASP-8273 | ASP8273 | NAQUOTINIB	nan	nan	P00533	InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1	QKDCLUARMDUUKN-XMMPIXPASA-N	44210447	|http://www.chemspider.com/Chemical-Structure.44210447.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3663929|http://pubchem.ncbi.nlm.nih.gov/compound/71667668|http://www.drugbank.ca/drugs/DB12036| http://www.rcsb.org/ligand/8RC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8RC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9248|http://zinc15.docking.org/substances/ZINC000205341959|https://precision.fda.gov/uniisearch/srs/unii/47DD4548PB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=170514	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'8RC'	5y9t 7lg8				562.3	9	2	9	120.2	2.3	1		EGFR	Tyr	
Narazaciclib		Onconova Therapeutics	CHEMBL3115681	CN1CCN(CC1)c2ccc(cc2)Nc3ncc4cc(c(=O)n(c4n3)C5CCCC5)C#N	Achiral Molecule	nan	1.5	None	NARAZACICLIB | ON-123300 | ON123300	nan	nan	nan	InChI=1S/C24H27N7O/c1-29-10-12-30(13-11-29)20-8-6-19(7-9-20)27-24-26-16-18-14-17(15-25)23(32)31(22(18)28-24)21-4-2-3-5-21/h6-9,14,16,21H,2-5,10-13H2,1H3,(H,26,27,28)	VADOZMZXXRBXNY-UHFFFAOYSA-N	31140969	|http://www.chemspider.com/Chemical-Structure.31140969.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3115681|http://pubchem.ncbi.nlm.nih.gov/compound/56649281|http://zinc15.docking.org/substances/ZINC000103269269|https://precision.fda.gov/uniisearch/srs/unii/QJ8RO3296G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50447512	|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS|BindingDB						429.2	8	1	4	90.1	3.3	0		nan		
Nazartinib		Novartis	CHEMBL3787344	Cc1cc(ccn1)C(=O)Nc2nc3cccc(c3n2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)Cl	Single Stereoisomer	nan	3.0	None	EGF-816 | EGF816 | NAZARTINIB | NVP-EGF816-NX	nan	nan	nan	InChI=1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1	IOMMMLWIABWRKL-WUTDNEBXSA-N	35308229	|http://www.chemspider.com/Chemical-Structure.35308229.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3787344|http://pubchem.ncbi.nlm.nih.gov/compound/72703790|http://www.drugbank.ca/drugs/DB16250|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9204|http://zinc15.docking.org/substances/ZINC000210610738|https://precision.fda.gov/uniisearch/srs/unii/KE7K32EME8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50160870	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						494.2	6	1	6	83.4	4.3	0		nan		
Nedisertib		Merck	CHEMBL4297629	COc1ccc(nn1)C(c2cc(c(cc2Cl)F)c3c4ccc(cc4ncn3)N5CCOCC5)O	Single Stereoisomer	nan	1.5	None	MSC 2490484A|MSC-2490484A|M3814|M-3814|MSC2490484A	nan	nan	nan	InChI=1S/C24H21ClFN5O3/c1-33-22-5-4-20(29-30-22)24(32)16-11-17(19(26)12-18(16)25)23-15-3-2-14(10-21(15)27-13-28-23)31-6-8-34-9-7-31/h2-5,10-13,24,32H,6-9H2,1H3	MOWXJLUYGFNTAL-UHFFFAOYSA-N	68007068	|http://www.chemspider.com/Chemical-Structure.68007068.html|http://pubchem.ncbi.nlm.nih.gov/compound/117696445|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=315705	|ChemSpider|PubChem|BindingDB						481.1	8	1	5	93.5	3.8	0		nan		
Neflamapimod		EIP Pharma	CHEMBL119385	c1cc(c(c(c1)Cl)c2c3ccc(nn3cnc2=O)Sc4ccc(cc4F)F)Cl	Achiral Molecule	nan	2.0	None	745 | NEFLAMAPIMOD | VD-31 | VD-31,745 | VD-31745 | VRT-031745 | VX-745	nan	nan	Q16539	InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H	VEPKQEUBKLEPRA-UHFFFAOYSA-N	2302086	|http://www.chemspider.com/Chemical-Structure.2302086.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL119385|http://pubchem.ncbi.nlm.nih.gov/compound/3038525|http://www.drugbank.ca/drugs/DB07138| http://www.rcsb.org/ligand/52P|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/52P|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5719|http://zinc15.docking.org/substances/ZINC13493055|https://precision.fda.gov/uniisearch/srs/unii/TYL52QM320|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=15244	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'52P'	3fc1 3hp5 3zsi		Neflamapimod has been used in trials studying the treatment of Alzheimer&#39;s Disease and Mild Cognitive Impairment.	Q16539	435.0	5	0	3	47.3	5.5	1		MAPK14	CMGC	
Nemiralisib		GlaxosmithKline	CHEMBL2216859	CC(C)N1CCN(CC1)Cc2cnc(o2)c3cc(cc4c3cn[nH]4)c5cccc6c5cc[nH]6	Achiral Molecule	nan	2.0	None	GSK-2269557 | GSK-2269557 FREE BASE | GSK-2269557A | GSK2269557A | NEMIRALISIB	nan	nan	nan	InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)	MCIDWGZGWVSZMK-UHFFFAOYSA-N	28651123	|http://www.chemspider.com/Chemical-Structure.28651123.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2216859|http://pubchem.ncbi.nlm.nih.gov/compound/49784002|http://www.drugbank.ca/drugs/DB16253| http://www.rcsb.org/ligand/VVX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VVX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9425|http://zinc15.docking.org/substances/ZINC000095564436|https://precision.fda.gov/uniisearch/srs/unii/OEP8JJ3OZR|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004529	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'VVX'	5ae8				440.2	5	2	5	77.0	4.9	0		nan		
Nemtabrutinib		Merck	CHEMBL4756476	c1ccc(cc1)Oc2ccc(c(c2)Cl)C(=O)c3c[nH]c4c3c(ncn4)N[C@@H]5CC[C@H](OC5)CO	Single Stereoisomer	nan	2.0	None	ARQ-531 | NEMTABRUTINIB	nan	nan	nan	InChI=1S/C25H23ClN4O4/c26-21-10-17(34-16-4-2-1-3-5-16)8-9-19(21)23(32)20-11-27-24-22(20)25(29-14-28-24)30-15-6-7-18(12-31)33-13-15/h1-5,8-11,14-15,18,31H,6-7,12-13H2,(H2,27,28,29,30)/t15-,18+/m1/s1	JSFCZQSJQXFJDS-QAPCUYQASA-N	64854483	|http://www.chemspider.com/Chemical-Structure.64854483.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4756476|http://pubchem.ncbi.nlm.nih.gov/compound/129045720| http://www.rcsb.org/ligand/HRA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/HRA|https://precision.fda.gov/uniisearch/srs/unii/JTZ51LIXN4	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|FDA SRS	'HRA'	6e4f				478.1	7	3	7	109.4	4.6	0		nan		
Neratinib	Nerlynx	Puma Biotechnology	CHEMBL180022	CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4	Achiral Molecule	2017	4.0	US-7399865-B2	CDP-820 | HKI-272 | NERATINIB | WAY-179272	For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy	nan	P04626|P00533	InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+	JWNPDZNEKVCWMY-VQHVLOKHSA-N	8091392	|http://www.chemspider.com/Chemical-Structure.8091392.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL180022|http://pubchem.ncbi.nlm.nih.gov/compound/9915743|http://www.drugbank.ca/drugs/DB11828|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5686|http://zinc15.docking.org/substances/ZINC000003916214|https://precision.fda.gov/uniisearch/srs/unii/JJH94R3PWB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50161957	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.	P00533	556.2	8	2	11	112.4	5.9	2		ERBB2; EGFR	Tyr	Y
Netarsudil	Rhopressa	Aerie Pharmaceutical	CHEMBL4594250	Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3	Single Stereoisomer	2017	4.0	US-8394826-B2	AR-11324 FREE BASE | AR-13324 | NETARSUDIL	On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension	nan	nan	InChI=1S/C28H27N3O3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32)/t26-/m1/s1	OURRXQUGYQRVML-AREMUKBSSA-N	34980598	|http://www.chemspider.com/Chemical-Structure.34980598.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4594250|http://pubchem.ncbi.nlm.nih.gov/compound/66599893|http://www.drugbank.ca/drugs/DB13931|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9322|http://zinc15.docking.org/substances/ZINC000113149554|https://precision.fda.gov/uniisearch/srs/unii/W6I5QDT7QI	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS				A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous</p><p>As of December 18, 2017 the FDA approved Aerie Pharmaceutical&#39;s Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.	Q13464|O75116|P23975	453.2	5	2	7	94.3	4.9	0		nan		Y
Nezulcitinib		Theravance Biopharma	CHEMBL4802163	CN(C)C1CN(C1)C(=O)[C@@H]1CC2NC(=NC=2CN1C(C)C)C1=NNC2=CC(=CC=C21)C1C=CC(O)=CC=1CC	Single Stereoisomer	nan	2.0	None	NEZULCITINIB | TD-0903 | THRX-136377	nan	nan	nan	InChI=1S/C30H37N7O2/c1-6-18-11-21(38)8-10-22(18)19-7-9-23-24(12-19)33-34-28(23)29-31-25-13-27(37(17(2)3)16-26(25)32-29)30(39)36-14-20(15-36)35(4)5/h7-12,17,20,27,38H,6,13-16H2,1-5H3,(H,31,32)(H,33,34)/t27-/m0/s1	VQIIUJSNIKEMCK-MHZLTWQESA-N	115009351	|http://www.chemspider.com/Chemical-Structure.115009351.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4802163|http://pubchem.ncbi.nlm.nih.gov/compound/146421275|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11304|https://precision.fda.gov/uniisearch/srs/unii/CXA4I8AH6A	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS						527.3	6	3	6	104.4	3.8	1		nan		
Nilotinib	Tasigna	Novartis	CHEMBL255863	Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F	Achiral Molecule	2007	4.0	US-7169791-B2	AMN 107 | AMN-107 | AMN107 | NILOTINIB | NSC-747599 | TASIGNA	For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).	2	P00519|P10721	InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)	HHZIURLSWUIHRB-UHFFFAOYSA-N	559260	|http://www.chemspider.com/Chemical-Structure.559260.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL255863|http://pubchem.ncbi.nlm.nih.gov/compound/644241|http://www.drugbank.ca/drugs/DB04868| http://www.rcsb.org/ligand/NIL|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/NIL|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697|http://zinc15.docking.org/substances/ZINC06716957|https://precision.fda.gov/uniisearch/srs/unii/F41401512X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50237710	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'NIL'	3cs9 3gp0 5mo4		Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.	P00519|P10721|P08684|P10632|P11712|P10635|P20813|P08183|Q9UNQ0|P22309|Q9Y6L6	529.2	7	2	6	97.6	6.4	2		ABL1; KIT	Tyr	Y
Ningetinib		HEC Pharm	CHEMBL3984441	Cc1c(c(=O)n(n1C)c2ccccc2)C(=O)Nc3ccc(c(c3)F)Oc4ccnc5c4ccc(c5)OCC(C)(C)O	Achiral Molecule	nan	1.5	None	CT-053 FREE BASE | CT-053-PTSA FREE BASE | CT053PTSA FREE BASE | NINGETINIB	Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration.	nan	nan	InChI=1S/C31H29FN4O5/c1-19-28(30(38)36(35(19)4)21-8-6-5-7-9-21)29(37)34-20-10-13-27(24(32)16-20)41-26-14-15-33-25-17-22(11-12-23(25)26)40-18-31(2,3)39/h5-17,39H,18H2,1-4H3,(H,34,37)	VQYYQSZNRVQLIS-UHFFFAOYSA-N	61719564	|http://www.chemspider.com/Chemical-Structure.61719564.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3984441|http://pubchem.ncbi.nlm.nih.gov/compound/60165029|http://www.drugbank.ca/drugs/DB16256|http://zinc15.docking.org/substances/ZINC000143426755|https://precision.fda.gov/uniisearch/srs/unii/PW3Q92Z6A4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=180270	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB						556.2	8	2	8	107.6	5.4	2		nan		
Nintedanib	Ofev;Vargatef	Boehringer Ingelheim	CHEMBL502835	CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5	Achiral Molecule	2014	4.0	US-6762180-B1	BIBF 1120 | BIBF-1120 | BIBF1120 | INTEDANIB | NINTEDANIB | OFEV | VARGATEF	Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).	1	P17948|P35968|P35916|P11362|P21802|P22607|P36888|P06239|P07948|P12931	InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-	XZXHXSATPCNXJR-ZIADKAODSA-N	7985471	|http://www.chemspider.com/Chemical-Structure.7985471.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL502835|http://pubchem.ncbi.nlm.nih.gov/compound/9809715|http://www.drugbank.ca/drugs/DB09079| http://www.rcsb.org/ligand/XIN|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/XIN|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5936|http://zinc15.docking.org/substances/ZINC000100014909|https://precision.fda.gov/uniisearch/srs/unii/G6HRD2P839|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50026612	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'XIN'	3c7q 5maf 5te0 6nec		"Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Ofev (nintedanib) capsules for oral use"" href=""#reference-L8453"">8</a>,<a class=""reference-popover-link"" data-content=""EMA Summary of Product Characteristics: Vargatef (nintedanib) soft capsules for oral use"" href=""#reference-L8459"">9</a></sup> It was first approved for use in the United States in 2014.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Ofev (nintedanib) capsules for oral use"" href=""#reference-L8453"">8</a></sup> Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being <a href=""https://go.drugbank.com/drugs/DB04951"">Pirfenidone</a>) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Richeldi L, Collard HR, Jones MG: Idiopathic pulmonary fibrosis. Lancet. 2017 May 13;389(10082):1941-1952. doi: 10.1016/S0140-6736(17)30866-8. Epub 2017 Mar 30. (PubMed ID 28365056)"" href=""#reference-A185237"">6</a></sup> As a chemotherapeutic agent for NSCLC, nintedanib, in combination with <a href=""https://go.drugbank.com/drugs/DB01248"">Docetaxel</a>, is reserved for patients who have tried and failed first-line chemotherapeutic options.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""EMA Summary of Product Characteristics: Vargatef (nintedanib) soft capsules for oral use"" href=""#reference-L8459"">9</a></sup>"	P17948|P35968|P35916|P16234|P09619|P11362|P21802|P22607|P36888|P06239|P07948|P12931|P22309|Q9HAW7|Q9HAW9|Q9HAW8|P08684|P02768|P08183|O15245|Q9UNQ0	539.3	7	2	7	94.2	3.6	1		FLT1; KDR; FLT4; FGFR1; FGFR2; FGFR3; FLT3; LCK; LYN; SRC	Tyr	Y
Oclacitinib		Pfizer	CHEMBL2103874	CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C	Single Stereoisomer	nan	0.0	None	JAK-I | JAKI | OCLACITINIB | PF 03394197 | PF-03394197	nan	nan	P23458|O60674|P52333	InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-	HJWLJNBZVZDLAQ-HAQNSBGRSA-N	28528036	|http://www.chemspider.com/Chemical-Structure.28528036.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103874|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9696|https://precision.fda.gov/uniisearch/srs/unii/99GS5XTB51|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185700	|ChemSpider|ChEMBL|Guide to Pharmacology|FDA SRS|BindingDB						337.2	5	2	5	91.0	1.5	0		JAK1; JAK2; JAK3	Tyr	
Olafertinib		Suzhou NeuPharma	CHEMBL4297486	C=CC(=O)Nc1cccc(-c2cccc3cnc(Nc4ccc(N5CCN(CCO)CC5)c(F)c4F)nc23)c1	Achiral Molecule	nan	1.0	None	CK-101 | OLAFERTINIB | RX-518	nan	nan	nan	InChI=1S/C29H28F2N6O2/c1-2-25(39)33-21-7-3-5-19(17-21)22-8-4-6-20-18-32-29(35-28(20)22)34-23-9-10-24(27(31)26(23)30)37-13-11-36(12-14-37)15-16-38/h2-10,17-18,38H,1,11-16H2,(H,33,39)(H,32,34,35)	IDRGFNPZDVBSSE-UHFFFAOYSA-N	57490372	|http://www.chemspider.com/Chemical-Structure.57490372.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297486|http://pubchem.ncbi.nlm.nih.gov/compound/117909640|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9863|http://zinc15.docking.org/substances/ZINC000514250913|https://precision.fda.gov/uniisearch/srs/unii/708TLB8J3Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=318916	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						530.2	7	3	8	93.6	4.6	1		nan		
Olmutinib		Hanmi Pharmaceutical	CHEMBL3786343	CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C	Achiral Molecule	nan	2.0	None	BI 1482694 | BI-1482694 | HM-61713 | HM61713 | OLMUTINIB	For use in treatment of metastatic T790M mutation positive non-small cell lung cancer	nan	P00533	InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)	FDMQDKQUTRLUBU-UHFFFAOYSA-N	45743494	|http://www.chemspider.com/Chemical-Structure.45743494.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3786343|http://pubchem.ncbi.nlm.nih.gov/compound/54758501|http://www.drugbank.ca/drugs/DB13164|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9196|http://zinc15.docking.org/substances/ZINC000198970879|https://precision.fda.gov/uniisearch/srs/unii/CHL9B67L95|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50160871	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Kim ES: Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7. doi: 10.1007/s40265-016-0606-z. (PubMed ID 27357069)"" href=""#reference-A19196"">4</a></sup>. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016."	P00533	486.2	8	2	7	82.6	5.1	1		EGFR	Tyr	
Olverembatinib		Guangzhou Institutes of Biomedicine and Health	CHEMBL2316582	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1	Achiral Molecule	nan	3.0	None	D-824 | D-824 DIMESYLATE | GZD-824 | GZD-824 DIMESYLATE | HQP-1351 | HQP-1351 DIMESYLATE | HQP1351 | HQP1351 DIMESYLATE | OLVEREMBATINIB | OLVEREMBATINIB DIMESYLATE	nan	nan	nan	InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)	TZKBVRDEOITLRB-UHFFFAOYSA-N	29395146	|http://www.chemspider.com/Chemical-Structure.29395146.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2316582|http://pubchem.ncbi.nlm.nih.gov/compound/51038269|http://www.drugbank.ca/drugs/DB16185|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10630|http://zinc15.docking.org/substances/ZINC000095594040|https://precision.fda.gov/uniisearch/srs/unii/KV1M7Q3CBP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50425780	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						532.2	5	2	4	77.2	4.7	1		nan		
Omipalisib		GlaxosmithKline	CHEMBL1236962	COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F	Achiral Molecule	nan	1.0	None	GSK-2126458 | GSK2126458 | OMIPALISIB	nan	1	P42336|P42345	InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3	CGBJSGAELGCMKE-UHFFFAOYSA-N	25027388	|http://www.chemspider.com/Chemical-Structure.25027388.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1236962|http://pubchem.ncbi.nlm.nih.gov/compound/25167777|http://www.drugbank.ca/drugs/DB12703| http://www.rcsb.org/ligand/ZIG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/ZIG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8974|http://zinc15.docking.org/substances/ZINC43208634|https://precision.fda.gov/uniisearch/srs/unii/1X8F5A3NA0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50145416	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'ZIG'	3l08				505.1	7	1	6	107.0	4.8	1		PIK3CA; MTOR	Atypical	
Onatasertib		Celgene	CHEMBL3586404	CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1	Single Stereoisomer	nan	2.0	None	ATG-008 | CC-223 | ONATASERTIB	nan	nan	nan	InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24)/t14-,15-	UFKLYTOEMRFKAD-SHTZXODSSA-N	35308326	|http://www.chemspider.com/Chemical-Structure.35308326.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3586404|http://www.drugbank.ca/drugs/DB12570|http://zinc15.docking.org/substances/ZINC000114617828|https://precision.fda.gov/uniisearch/srs/unii/I8RA3543SY|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50092783	|ChemSpider|ChEMBL|DrugBank|ZINC|FDA SRS|BindingDB						397.2	7	2	4	100.5	2.5	0		nan		
Onvansertib		Cardiff Oncology	CHEMBL1738758	CN1CCN(CC1)c2ccc(c(c2)Nc3ncc4c(n3)-c5c(c(nn5CCO)C(=O)N)CC4)OC(F)(F)F	Achiral Molecule	nan	2.0	None	NMS-1286937 | NMS-P937 | ONVANSERTIB | PCM-075	nan	nan	nan	InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	26325993	|http://www.chemspider.com/Chemical-Structure.26325993.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738758|http://pubchem.ncbi.nlm.nih.gov/compound/49792852|http://www.drugbank.ca/drugs/DB15110| http://www.rcsb.org/ligand/937|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/937|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7918|http://zinc15.docking.org/substances/ZINC000043196885|https://precision.fda.gov/uniisearch/srs/unii/67RM91WDHQ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50343559	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'937'	2yac				532.2	10	3	7	134.7	1.9	1		nan		
Opaganib		RedHill Biopharma	CHEMBL2158685	c1cc(ccc1C23CC4CC(C2)CC(C4)(C3)C(=O)NCc5ccncc5)Cl	Achiral Molecule	nan	2.5	None	ABC 294640 | ABC-294640 | ABC294640 | OPAGANIB	nan	nan	nan	InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)	CAOTVXGYTWCKQE-UHFFFAOYSA-N	13079494	|http://www.chemspider.com/Chemical-Structure.13079494.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2158685|http://pubchem.ncbi.nlm.nih.gov/compound/15604015|http://www.drugbank.ca/drugs/DB12764|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624|https://precision.fda.gov/uniisearch/srs/unii/DRG21OQ517|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50393642	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB				"Opaganib, also known as ABC294640, is a selective <a href=""https://go.drugbank.com/polypeptides/Q9NRA0"">sphingosine kinase-2 (SK2)</a> inhibitor that is orally administered.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Opaganib (Yeliva®, ABC294640)"" href=""#reference-L27436"">2</a></sup> This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19."	Q9NRA0	380.2	2	1	4	42.0	4.9	0		nan		
Orantinib		Pfizer	CHEMBL274654	Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O	Achiral Molecule	nan	3.0	None	NSC-702827 | ORANTINIB | SU-6668 | TSU-68	nan	1	P35968|P09619|P11362	InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	4486261	|http://www.chemspider.com/Chemical-Structure.4486261.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL274654|http://pubchem.ncbi.nlm.nih.gov/compound/5329099|http://www.drugbank.ca/drugs/DB12072| http://www.rcsb.org/ligand/SU6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/SU6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7816|http://zinc15.docking.org/substances/ZINC000003834032|https://precision.fda.gov/uniisearch/srs/unii/9RL37ZZ665|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4811	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'SU6'	4jlc 5yvc				310.1	2	3	4	82.2	3.1	0		KDR; PDGFRB; FGFR1	Tyr	
Orelabrutinib	Innobruka	InnoCare Pharma	CHEMBL4650321	C=CC(=O)N1CCC(CC1)C1=CC=C(C(N)=O)C(=N1)C1C=CC(=CC=1)OC1C=CC=CC=1	Achiral Molecule	nan	3.0	None	ICP-022 | INNOBRUKA | ORELABRUTINIB	nan	nan	nan	InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31)	MZPVEMOYADUARK-UHFFFAOYSA-N	82956396	|http://www.chemspider.com/Chemical-Structure.82956396.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650321|http://pubchem.ncbi.nlm.nih.gov/compound/91667513|http://www.drugbank.ca/drugs/DB16272|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10629|https://precision.fda.gov/uniisearch/srs/unii/WJA5UO9E10|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=389631	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						427.2	4	1	6	85.5	4.5	0		nan		
Osimertinib	Tagrisso	Astrazeneca	CHEMBL3353410	Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C	Achiral Molecule	2015	4.0	US-8946235-B2	AZD-9291 | AZD-9291 FREE BASE | AZD9291 | MERELETINIB | OSIMERTINIB | TAGRISSO	Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.	1	P00533	InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)	DUYJMQONPNNFPI-UHFFFAOYSA-N	31042598	|http://www.chemspider.com/Chemical-Structure.31042598.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3353410|http://pubchem.ncbi.nlm.nih.gov/compound/71496458|http://www.drugbank.ca/drugs/DB09330| http://www.rcsb.org/ligand/YY3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/YY3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7719|http://zinc15.docking.org/substances/ZINC000098023177|https://precision.fda.gov/uniisearch/srs/unii/3C06JJ0Z2O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50029668	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'YY3'	4zau 6jwl 6jx0 6jx4 6jxt 6lud 7jxm 7jxp 7jxw 7k1h		"Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Xu M, Xie Y, Ni S, Liu H: The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med. 2015 May;3(7):96. doi: 10.3978/j.issn.2305-5839.2015.03.60. (PubMed ID 26015938)"" href=""#reference-A7926"">1</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: TAGRISSO (osimertinib) tablets for oral use"" href=""#reference-L43453"">9</a></sup> Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Tan CS, Gilligan D, Pacey S: Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015 Sep;16(9):e447-59. doi: 10.1016/S1470-2045(15)00246-6. (PubMed ID 26370354)"" href=""#reference-A7927"">2</a></sup> More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ayeni D, Politi K, Goldberg SB: Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. Clin Cancer Res. 2015 Sep 1;21(17):3818-20. doi: 10.1158/1078-0432.CCR-15-1211. Epub 2015 Jul 13. (PubMed ID 26169963)"" href=""#reference-A7928"">3</a></sup></p><p>Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Xu M, Xie Y, Ni S, Liu H: The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC). Ann Transl Med. 2015 May;3(7):96. doi: 10.3978/j.issn.2305-5839.2015.03.60. (PubMed ID 26015938)"" href=""#reference-A7926"">1</a>,<a class=""reference-popover-link"" data-content=""Tan CS, Gilligan D, Pacey S: Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015 Sep;16(9):e447-59. doi: 10.1016/S1470-2045(15)00246-6. (PubMed ID 26370354)"" href=""#reference-A7927"">2</a>,<a class=""reference-popover-link"" data-content=""Shea M, Costa DB, Rangachari D: Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis. 2016 Apr;10(2):113-29. doi: 10.1177/1753465815617871. Epub 2015 Nov 30. (PubMed ID 26620497)"" href=""#reference-A7931"">6</a></sup>"	P00533|P08684|P05177|P08183|Q9UNQ0	499.3	8	2	10	87.6	4.5	0		EGFR	Tyr	Y
Pacritinib		Cell Therapeutics	CHEMBL2035187	c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5	Achiral Molecule	2022	4.0	US-8153632-B2	ONX-0803 | PACRITINIB | SB-1518 | SB1518	On February 2022, FDA approved pacritinib to treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets	1	O60674	InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+	HWXVIOGONBBTBY-ONEGZZNKSA-N	28518965	|http://www.chemspider.com/Chemical-Structure.28518965.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2035187|http://pubchem.ncbi.nlm.nih.gov/compound/46216796|http://www.drugbank.ca/drugs/DB11697| http://www.rcsb.org/ligand/6T3|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6T3|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7793|http://zinc15.docking.org/substances/ZINC000043153645|https://precision.fda.gov/uniisearch/srs/unii/G22N65IL3O|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50400312	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'6T3'	5lbz		"Myelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""National Organization for Rare Disorders: Primary Myelofibrosis"" href=""#reference-L40793"">3</a></sup> The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia vera or essential thrombocythemia.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""National Organization for Rare Disorders: Primary Myelofibrosis"" href=""#reference-L40793"">3</a></sup> While some patients may remain asymptomatic, typical symptoms of MF arise from abnormalities in blood cell production and may therefore include various cytopenias, infections, splenomegaly, and general systemic symptoms such as fever.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""National Organization for Rare Disorders: Primary Myelofibrosis"" href=""#reference-L40793"">3</a></sup> Approximately 50% of patients with primary MF have a mutation of the <em>JAK2</em> gene, which is also commonly mutated in patients with polycythemia vera or essential thrombocythemia.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""National Organization for Rare Disorders: Primary Myelofibrosis"" href=""#reference-L40793"">3</a></sup> JAK2 signaling is important for hematopoiesis and proper immune functioning,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Vonjo (pacritinib) capsules for oral use"" href=""#reference-L40754"">2</a></sup> and while the precise role it plays in the pathogenesis of MF remains unclear, its clear association with MF has made it a desirable therapeutic target in MF treatment.</p><p>Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment of both primary and secondary MF in patients with platelet counts &lt; 50 x 10<sup>9</sup>/L.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Vonjo (pacritinib) capsules for oral use"" href=""#reference-L40754"">2</a></sup> It provides a treatment option for patients who have MF with severe thrombocytopenia, which occurs in approximately one-third of MF patients and carries with it a particularly poor prognosis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""BioSpace News: CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia"" href=""#reference-L40709"">4</a></sup>"	O60674|P36888|P08684|P05177|P33261|P08183|Q9UNQ0|O15245|O15244	472.2	7	1	4	68.7	5.0	0		JAK2	Tyr	Y
Padnarsertib		Karyopharm Therapeutics	CHEMBL4297467	Nc1ccc(/C=C/C(=O)NCc2cc3cc(-c4ccc(C(=O)N5CCC(F)(F)CC5)cc4)cc(-c4ccc(F)cc4)c3o2)cn1	Achiral Molecule	nan	1.0	None	KPT 9274 | KPT-9274 | PADNARSERTIB | PAK4-IN-1	nan	nan	nan	InChI=1S/C35H29F3N4O3/c36-28-9-7-24(8-10-28)30-19-26(23-3-5-25(6-4-23)34(44)42-15-13-35(37,38)14-16-42)17-27-18-29(45-33(27)30)21-41-32(43)12-2-22-1-11-31(39)40-20-22/h1-12,17-20H,13-16,21H2,(H2,39,40)(H,41,43)/b12-2+	MRFOPLWJZULAQD-SWGQDTFXSA-N	38772371	|http://www.chemspider.com/Chemical-Structure.38772371.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297467|http://pubchem.ncbi.nlm.nih.gov/compound/117779453| http://www.rcsb.org/ligand/96Q|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/96Q|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10593|http://zinc15.docking.org/substances/ZINC000253387914|https://precision.fda.gov/uniisearch/srs/unii/9T56TV18X7	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS	'96Q'	5nsd				610.2	5	2	7	101.5	7.1	2		nan		
Palbociclib	Ibrance	Pfizer	CHEMBL189963	Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5	Achiral Molecule	2015	4.0	US-6936612-B2	IBRANCE | PALBOCICLIB | PD-0332991	Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.	1	P11802|Q00534	InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)	AHJRHEGDXFFMBM-UHFFFAOYSA-N	4487437	|http://www.chemspider.com/Chemical-Structure.4487437.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL189963|http://pubchem.ncbi.nlm.nih.gov/compound/5330286|http://www.drugbank.ca/drugs/DB09073| http://www.rcsb.org/ligand/LQQ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LQQ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380|http://zinc15.docking.org/substances/ZINC000003938686|https://precision.fda.gov/uniisearch/srs/unii/G9ZF61LE7G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=6309	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'LQQ'	2euf 5l2i 7n7o		"Palbociclib is a piperazine pyridopyrimidine<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, Zirkelbach JF, Yu J, Liu Q, Zhao L, Crich J, Chen XH, Hughes M, Bloomquist E, Tang S, Sridhara R, Kluetz PG, Kim G, Ibrahim A, Pazdur R, Cortazar P: FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1;21(21):4760-6. doi: 10.1158/1078-0432.CCR-15-1185. Epub 2015 Aug 31. (PubMed ID 26324739)"" href=""#reference-A176792"">3</a></sup> that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Rocca A, Schirone A, Maltoni R, Bravaccini S, Cecconetto L, Farolfi A, Bronte G, Andreis D: Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105. doi: 10.1177/1758834016677961. Epub 2016 Nov 21. (PubMed ID 28203301)"" href=""#reference-A176798"">4</a></sup> selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Cadoo KA, Gucalp A, Traina TA: Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2014 Aug 4;6:123-33. doi: 10.2147/BCTT.S46725. eCollection 2014. (PubMed ID 25177151)"" href=""#reference-A176810"">5</a></sup></p><p>Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Pfizer history"" href=""#reference-L5867"">8</a></sup> It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Apadaz (benzhydrocodone and acetaminophen) tablets"" href=""#reference-L4894"">7</a></sup>"	P11802|Q00534|P08684|Q06520|P02768|P08183|Q9UNQ0|O15245	447.2	9	2	5	105.0	3.0	0	263-266 ºC	CDK4; CDK6	CMGC	Y
Paltimatrectinib		Pyramid Biosciences	CHEMBL5095076	C[C@]1(O)C[C@@](N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1	Single Stereoisomer	nan	-1.0	None	PIFUSERTIB | TAS 117 | TAS-117	nan	nan	nan	InChI=1S/C26H24N4O2/c1-25(31)14-26(27,15-25)19-9-7-17(8-10-19)22-23(18-5-3-2-4-6-18)30-16-32-21-11-12-28-13-20(21)24(30)29-22/h2-13,31H,14-16,27H2,1H3/t25-,26-	AIFGVDXMHWGOGJ-DIVCQZSQSA-N	64854605	|http://www.chemspider.com/Chemical-Structure.64854605.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297329|http://www.drugbank.ca/drugs/DB15054|https://precision.fda.gov/uniisearch/srs/unii/QI52W1ZIIB	|ChemSpider|ChEMBL|DrugBank|FDA SRS						424.2	6	2	3	86.2	4.3	0		nan		
Pamapimod		Hoffmann-La Roche	CHEMBL1090089	Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO	Achiral Molecule	nan	2.0	None	PAMAPIMOD | R-1503 | R1503 | RO 4402257 | RO-4402257	nan	1	Q16539|Q15759	InChI=1S/C19H20F2N4O4/c1-25-17-11(10-22-19(24-17)23-13(4-6-26)5-7-27)8-16(18(25)28)29-15-3-2-12(20)9-14(15)21/h2-3,8-10,13,26-27H,4-7H2,1H3,(H,22,23,24)	JYYLVUFNAHSSFE-UHFFFAOYSA-N	17347490	|http://www.chemspider.com/Chemical-Structure.17347490.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1090089|http://pubchem.ncbi.nlm.nih.gov/compound/16220188| http://www.rcsb.org/ligand/FLW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FLW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9915|http://zinc15.docking.org/substances/ZINC30691792|https://precision.fda.gov/uniisearch/srs/unii/8S2C9V11K4|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50314070	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'FLW'	3flw				406.1	8	3	8	109.5	1.9	0		MAPK14; MAPK11	CMGC	
Pamufetinib		Taiho Pharmaceutical	CHEMBL3545144	CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=C(C=C(C=C3)NC(=S)NC(=O)CC4=CC=CC=C4)F	Single Stereoisomer	nan	1.0	None		nan	nan	nan	InChI=1S/C27H23FN4O4S/c1-29-26(34)19-14-18-21(15-24(19)35-2)30-11-10-22(18)36-23-9-8-17(13-20(23)28)31-27(37)32-25(33)12-16-6-4-3-5-7-16/h3-11,13-15H,12H2,1-2H3,(H,29,34)(H2,31,32,33,37)	ORRNXRYWGDUDOG-UHFFFAOYSA-N	58796450	|http://www.chemspider.com/Chemical-Structure.58796450.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3764045|http://pubchem.ncbi.nlm.nih.gov/compound/44247727|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10460|http://zinc15.docking.org/substances/ZINC000115306389|https://precision.fda.gov/uniisearch/srs/unii/H2OL3Q4XRD|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50146163	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						518.1	6	3	7	101.6	4.6	1		nan		
Panulisib		Piramal Enterprises	CHEMBL5095025	CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F	Single Stereoisomer	nan	1.0	None		nan	nan	P42336|P42345	InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)	VJLRLTSXTLICIR-UHFFFAOYSA-N	29165869	|http://www.chemspider.com/Chemical-Structure.29165869.html|http://pubchem.ncbi.nlm.nih.gov/compound/56947515|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9916|http://zinc15.docking.org/substances/ZINC000301055099	|ChemSpider|PubChem|Guide to Pharmacology|ZINC						527.2	9	1	3	134.5	4.8	1		PIK3CA; MTOR	Atypical	
Parsaclisib		Incyte Corporation	CHEMBL4297615	CCOc1c(cc(c(c1[C@H]2CC(=O)NC2)F)Cl)[C@H](C)n3c4c(c(n3)C)c(ncn4)N	Single Stereoisomer	nan	3.0	None	INCB-050465 | INCB050465 | PARSACLISIB	"Parsaclisib (INCB050465) is a PI3K&delta; inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [<a href='javascript:callRef(""ReferenceDisplayForward?referenceId=36232&displayId=1"", 960, 600)' title=""1. Li Y-L, Yao W, Combs AP, Yue EW, Mei S, Zhu W, Glenn J Jr, Maduskuie TP, Sparks RB, Douty B, He C. (2014) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS. Patent no. WO2014134426A1."">1</a>]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency <i>vs</i>. PI3K&delta; and 347 was tested <i>in vivo</i> [<a href='javascript:callRef(""ReferenceDisplayForward?referenceId=36233&displayId=2"", 960, 600)' title=""2. Li Y-L, Yao W, Combs AP, Yue EW, Mei S, Zhu W, Glenn J, Maduskuie TP Jr, Sparks RB, Douty B. (2013) Heterocyclylamines as pi3k inhibitors. Patent no. WO2013033569A1."">2</a>]."	nan	nan	InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1	ZQPDJCIXJHUERQ-QWRGUYRKSA-N	64835232	|http://www.chemspider.com/Chemical-Structure.64835232.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297615|http://pubchem.ncbi.nlm.nih.gov/compound/86677874|http://www.drugbank.ca/drugs/DB14867|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10098|https://precision.fda.gov/uniisearch/srs/unii/OS7097575K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=272573	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						432.1	7	2	5	107.9	3.1	0		nan		
Paxalisib		Genentech	CHEMBL3813842	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12	Achiral Molecule	nan	2.0	None	G-02441729 | G02441729 | GDC-0084 | GDC0084 | PAXALISIB | RG-7666	nan	nan	nan	InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)	LGWACEZVCMBSKW-UHFFFAOYSA-N	57251291	|http://www.chemspider.com/Chemical-Structure.57251291.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3813842|http://pubchem.ncbi.nlm.nih.gov/compound/57384863|http://www.drugbank.ca/drugs/DB15186|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10097|http://zinc15.docking.org/substances/ZINC000149645112|https://precision.fda.gov/uniisearch/srs/unii/P5DKZ70636|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50177662	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						382.2	10	1	2	117.1	1.0	0		nan		
Pazopanib	Votrient	GlaxoSmithKline	CHEMBL477772	Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C	Achiral Molecule	2009	4.0	US-7105530-B2	GW786034 | NSC-752782 | PAZOPANIB | VOTRIENT	Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)	1	P17948|P35968|P35916|P16234|P09619|P10721|P22607|Q08881|P11362	InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)	CUIHSIWYWATEQL-UHFFFAOYSA-N	8289501	|http://www.chemspider.com/Chemical-Structure.8289501.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL477772|http://pubchem.ncbi.nlm.nih.gov/compound/10113978|http://www.drugbank.ca/drugs/DB06589|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5698|http://zinc15.docking.org/substances/ZINC000011617039|https://precision.fda.gov/uniisearch/srs/unii/7RN5DR86CK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=26474	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.	P17948|P35968|P35916|P16234|P09619|P10721|P22607|Q08881|P05230|Q9UQQ2|P10635|P10632|P05177|P08684|P08183|Q9UNQ0|Q9Y6L6|P22309	437.2	8	2	5	119.0	3.1	0		FLT1; KDR; FLT4; PDGFRA; PDGFRB; KIT; FGFR3; ITK; FGFR1	Tyr	Y
Peficitinib		Astellas Pharma	CHEMBL3137308	c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O	Racemic Mixture	nan	3.0	None		nan	nan	P23458|O60674|P52333|P29597	InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9-,10-,11+,14-,18-	DREIJXJRTLTGJC-ZKVNVPQCSA-N	32742439	|http://www.chemspider.com/Chemical-Structure.32742439.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4536840| http://www.rcsb.org/ligand/9T6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/9T6|http://zinc15.docking.org/substances/ZINC000146784326	|ChemSpider|ChEMBL|RCSB|PDBe|ZINC	'9T6'	6aah 6aaj 6aak 6aam				326.2	4	4	3	104.0	2.0	0		JAK1; JAK2; JAK3; TYK2	Tyr	
Pegcantratinib		Cephalon	CHEMBL4297182	COCCN1C(=O)O[C@@]2(C[C@H]3O[C@]2(C)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)C1=O	Single Stereoisomer	nan	2.0	None	CT-327 | CT327 | PEGCANTRATINIB | SNA-120	nan	nan	nan	InChI=1S/C30H24N4O6/c1-29-30(27(36)32(11-12-38-2)28(37)40-30)13-20(39-29)33-18-9-5-3-7-15(18)22-23-17(14-31-26(23)35)21-16-8-4-6-10-19(16)34(29)25(21)24(22)33/h3-10,20H,11-14H2,1-2H3,(H,31,35)/t20-,29+,30+/m1/s1	SHWPFRVVBIKGAT-LYWBODIJSA-N	88293788	|http://www.chemspider.com/Chemical-Structure.88293788.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297182|http://pubchem.ncbi.nlm.nih.gov/compound/91824201	|ChemSpider|ChEMBL|PubChem						536.2	8	1	3	104.0	4.1	1		nan		
Pelitinib		Wyeth	CHEMBL607707	CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F	Achiral Molecule	nan	2.0	None	EKB-569 | PELITINIB | WAY-EKB-569	nan	1	P00533|P04626	InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+	WVUNYSQLFKLYNI-AATRIKPKSA-N	4949255	|http://www.chemspider.com/Chemical-Structure.4949255.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL607707|http://pubchem.ncbi.nlm.nih.gov/compound/6445562|http://www.drugbank.ca/drugs/DB05524| http://www.rcsb.org/ligand/93J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/93J|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7644|http://zinc15.docking.org/substances/ZINC000000602803|https://precision.fda.gov/uniisearch/srs/unii/X5DWL380Z6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=31090	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'93J'	5vcw 7axm		Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.	P00533	467.2	6	2	8	90.3	5.1	1		EGFR; ERBB2	Tyr	
Pemigatinib	Pemazyre	Incyte Corporation	CHEMBL4297522	CCN1c2c3cc([nH]c3ncc2CN(C1=O)c4c(c(cc(c4F)OC)OC)F)CN5CCOCC5	Achiral Molecule	2020	4.0	US-9611267-B2	FGFR INHIBITOR INCB054828 | INCB-054828 | INCB054828 | PEMAZYRE | PEMIGATINIB	On April 2020, FDA approved pemigatinib to treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts.	nan	nan	InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)	HCDMJFOHIXMBOV-UHFFFAOYSA-N	68007304	|http://www.chemspider.com/Chemical-Structure.68007304.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297522|http://pubchem.ncbi.nlm.nih.gov/compound/86705695|http://www.drugbank.ca/drugs/DB15102| http://www.rcsb.org/ligand/8ZF|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8ZF|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9767|https://precision.fda.gov/uniisearch/srs/unii/Y6BX7BL23K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=301310	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB	'8ZF'	7wcl		"Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, Pal SK, De Giorgi U: Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther Adv Med Oncol. 2019 Nov 25;11:1758835919890285. doi: 10.1177/1758835919890285. eCollection 2019. (PubMed ID 31803255)"" href=""#reference-A193719"">1</a></sup> FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Roskoski R Jr: The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. doi: 10.1016/j.phrs.2019.104567. Epub 2019 Nov 23. (PubMed ID 31770593)"" href=""#reference-A198984"">4</a></sup> Deregulated FGFR signalling pathway can lead the development of oncogenes and tumour-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of cell death.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G: INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One. 2020 Apr 21;15(4):e0231877. doi: 10.1371/journal.pone.0231877. eCollection 2020. (PubMed ID 32315352)"" href=""#reference-A193716"">2</a></sup></p><p>In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Resources for Information | Approved Drugs: FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion"" href=""#reference-L13068"">6</a></sup> Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Blechacz B: Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568. (PubMed ID 27928095)"" href=""#reference-A198963"">3</a></sup> The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. Pemigatinib is marketed under the brand name Pemazyre, and it is available as oral tablets.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use"" href=""#reference-L13050"">5</a></sup>"	P11362|P21802|P22607|P22455|P08684|P08183|Q9UNQ0|O15244|Q96FL8	487.2	6	1	6	83.2	3.7	0		nan		Y
Peposertib		Merck		COCCOc1c(cc(cc1OC)Cc2cnc(nc2N)N)OC		nan	1.5		TETROXOPRIM	nan	nan	nan	InChI=1S/C16H22N4O4/c1-21-4-5-24-14-12(22-2)7-10(8-13(14)23-3)6-11-9-19-16(18)20-15(11)17/h7-9H,4-6H2,1-3H3,(H4,17,18,19,20)	WSWJIZXMAUYHOE-UHFFFAOYSA-N	58910	|http://www.chemspider.com/Chemical-Structure.58910.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL32039|http://pubchem.ncbi.nlm.nih.gov/compound/65450|http://www.drugbank.ca/drugs/DB15976|http://zinc15.docking.org/substances/ZINC000002020087|https://precision.fda.gov/uniisearch/srs/unii/5R6712AY0K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50029760	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB						334.2	8	2	8	114.7	1.3	0		nan		
Pexidartinib	Turalio	Daiichi Sankyo	CHEMBL3813873	c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F	Achiral Molecule	2019	4.0	US-7893075-B2	CML-261 | PEXIDARTINIB | PLX-3397 | PLX3397	On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor	2	P36888|P10721|P07333	InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29)	JGWRKYUXBBNENE-UHFFFAOYSA-N	35308322	|http://www.chemspider.com/Chemical-Structure.35308322.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3813873|http://pubchem.ncbi.nlm.nih.gov/compound/25151352|http://www.drugbank.ca/drugs/DB12978| http://www.rcsb.org/ligand/P31|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P31|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8710|http://zinc15.docking.org/substances/ZINC000115705166|https://precision.fda.gov/uniisearch/srs/unii/6783M2LV5X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50177716	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'P31'	4r7h 7khg		"Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA approves first therapy for rare joint tumor - FDA News Release"" href=""#reference-L7901"">11</a></sup> Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Giustini N, Bernthal NM, Bukata SV, Singh AS: Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature. Clin Sarcoma Res. 2018 Jul 10;8:14. doi: 10.1186/s13569-018-0101-2. eCollection 2018. (PubMed ID 30002809)"" href=""#reference-A182240"">1</a>,<a class=""reference-popover-link"" data-content=""FDA approves first therapy for rare joint tumor - FDA News Release"" href=""#reference-L7901"">11</a></sup> Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA approves first therapy for rare joint tumor - FDA News Release"" href=""#reference-L7901"">11</a></sup></p><p>While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""TURALIO (PEXIDARTINIB) CAPSULES - Daiichi Sankyo, Inc. - FDA Oncologic Drugs Advisory Committee Briefing Document"" href=""#reference-L7895"">10</a></sup> Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martin-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ: Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Jun 19. pii: S0140-6736(19)30764-0. doi: 10.1016/S0140-6736(19)30764-0. (PubMed ID 31229240)"" href=""#reference-A182243"">2</a></sup> Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA approves first therapy for rare joint tumor - FDA News Release"" href=""#reference-L7901"">11</a></sup>"	P07333|P10721|P36888|P09619|P08684|P22310|P20813|P11712|P22309|P02768|P02763|Q96FL8|Q86VL8|Q9Y6L6|Q9NPD5|O94956	417.1	4	2	5	66.5	5.2	1		FLT3; KIT; CSF1R	Tyr	Y
Pexmetinib		Array BioPharma	CHEMBL3991932	Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F	Achiral Molecule	nan	1.0	None	ARRY-614 | PEXMETINIB	nan	nan	Q16539|Q02763	InChI=1S/C31H33FN6O3/c1-20-5-8-24(9-6-20)38-29(17-28(36-38)31(2,3)4)35-30(40)33-18-22-15-23(32)7-12-27(22)41-25-10-11-26-21(16-25)19-34-37(26)13-14-39/h5-12,15-17,19,39H,13-14,18H2,1-4H3,(H2,33,35,40)	LNMRSSIMGCDUTP-UHFFFAOYSA-N	32702049	|http://www.chemspider.com/Chemical-Structure.32702049.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3991932|http://pubchem.ncbi.nlm.nih.gov/compound/24765037|http://www.drugbank.ca/drugs/DB16294|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9917|http://zinc15.docking.org/substances/ZINC000041747181|https://precision.fda.gov/uniisearch/srs/unii/3750D0U8B5	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						556.3	7	3	8	106.2	6.1	2		MAPK14; TEK	CMGC<br>Tyr	
Pictilisib		Hoffmann-La Roche	CHEMBL521851	CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6	Achiral Molecule	nan	2.0	None	CDC-0941 | GDC 0941 | GDC-0941 | PICTILISIB | PICTRELISIB | RG-7321	nan	1	P42336|P42338|O00329|P48736	InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)	LHNIIDJUOCFXAP-UHFFFAOYSA-N	21437049	|http://www.chemspider.com/Chemical-Structure.21437049.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL521851|http://pubchem.ncbi.nlm.nih.gov/compound/17755052|http://www.drugbank.ca/drugs/DB11663| http://www.rcsb.org/ligand/GD9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/GD9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682|http://zinc15.docking.org/substances/ZINC16052714|https://precision.fda.gov/uniisearch/srs/unii/ICY00EMP8P|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=25028	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'GD9'	2wxp 2y3a 3dbs				513.2	9	1	5	107.6	2.1	1		PIK3CA; PIK3CB; PIK3CD; PIK3CG	Atypical	
Pifusertib			CHEMBL4297329	C[C@]1(O)C[C@@](N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1	Single Stereoisomer		2.0	None	PIFUSERTIB | TAS 117 | TAS-117				InChI=1S/C26H24N4O2/c1-25(31)14-26(27,15-25)19-9-7-17(8-10-19)22-23(18-5-3-2-4-6-18)30-16-32-21-11-12-28-13-20(21)24(30)29-22/h2-13,31H,14-16,27H2,1H3/t25-,26-	AIFGVDXMHWGOGJ-DIVCQZSQSA-N	64854605	|http://www.chemspider.com/Chemical-Structure.64854605.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297329|http://www.drugbank.ca/drugs/DB15054|https://precision.fda.gov/uniisearch/srs/unii/QI52W1ZIIB	|ChemSpider|ChEMBL|DrugBank|FDA SRS						424.2	6	2	3	86.2	4.3	0		nan	(*)	
Pilaralisib		Sanofi	CHEMBL3360203	CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N	Achiral Molecule	nan	2.0	None	PILARALISIB | SAR-245408 | SAR245408 | XL-147 | XL147	nan	nan	P42336|P42338|O00329|P48736	InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)	QINPEPAQOBZPOF-UHFFFAOYSA-N	29340997	|http://www.chemspider.com/Chemical-Structure.29340997.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3360203|http://pubchem.ncbi.nlm.nih.gov/compound/56599306|http://www.drugbank.ca/drugs/DB11772|http://zinc15.docking.org/substances/ZINC000100472223|https://precision.fda.gov/uniisearch/srs/unii/60ES45KTMK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50197062	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB				Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.	P42336	540.1	8	4	8	148.3	4.5	1		PIK3CA; PIK3CB; PIK3CD; PIK3CG	Atypical	
Pimasertib	 as703026; emd 1036239;AS703026;EMD 1036239;MSC1936369A;Msc1936369a;Msc1936369a; as703026; emd 1036239;as703026	Merck	CHEMBL2107832	c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O	Single Stereoisomer	nan	2.0	None	AS 703026 | AS-703026 | AS703026 | EMD 1036239 | EMD-1036239 | G-02443714 | MSC-1936369 | MSC-1936369A | MSC-1936369B | MSC1936369A | MSC1936369A; AS703026; EMD 1036239 | PIMASERTIB	nan	nan	Q02750|P36507	InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1	VIUAUNHCRHHYNE-JTQLQIEISA-N	24747378	|http://www.chemspider.com/Chemical-Structure.24747378.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2107832|http://pubchem.ncbi.nlm.nih.gov/compound/44187362|http://www.drugbank.ca/drugs/DB14904| http://www.rcsb.org/ligand/QOA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QOA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7872|http://zinc15.docking.org/substances/ZINC38226009|https://precision.fda.gov/uniisearch/srs/unii/6ON9RK82AL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50014412	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'QOA'	7m0w		Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).	Q02750|P36507|P46734|P45985|Q13163|P52564|O14733	431.0	5	4	6	94.5	1.7	0		MAP2K1; MAP2K2	STE	
Pirotinib		XuanZhu Pharma		CN1CCC2(CC1)CC(C2)COc3cc4c(cc3NC(=O)C=C)c(ncn4)Nc5ccc(c(c5)Cl)F		nan	2.0		|KBP-5209	nan	nan	nan	InChI=1S/C27H29ClFN5O2/c1-3-25(35)33-23-11-19-22(30-16-31-26(19)32-18-4-5-21(29)20(28)10-18)12-24(23)36-15-17-13-27(14-17)6-8-34(2)9-7-27/h3-5,10-12,16-17H,1,6-9,13-15H2,2H3,(H,33,35)(H,30,31,32)	KJBZQIKLKWQVLL-UHFFFAOYSA-N	58810202	|http://www.chemspider.com/Chemical-Structure.58810202.html|http://pubchem.ncbi.nlm.nih.gov/compound/56933206|https://precision.fda.gov/uniisearch/srs/unii/M8R6ETA52F|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=333466	|ChemSpider|PubChem|FDA SRS|BindingDB						509.2	6	2	7	79.4	5.8	2		nan		
Pirtobrutinib		Loxo Oncology	CHEMBL4650485	COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1	Single Stereoisomer	2023	4.0	None	LOXO-305 | LY-3527727 | LY3527727 | PIRTOBRUTINIB | RXC-005	On January 2023, FDA approved Pirtobrutinib to treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor	nan	nan	InChI=1S/C22H21F4N5O3/c1-11(22(24,25)26)31-19(27)17(20(28)32)18(30-31)13-5-3-12(4-6-13)10-29-21(33)15-9-14(23)7-8-16(15)34-2/h3-9,11H,10,27H2,1-2H3,(H2,28,32)(H,29,33)/t11-/m0/s1	FWZAWAUZXYCBKZ-NSHDSACASA-N	114875989	|http://www.chemspider.com/Chemical-Structure.114875989.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650485|http://pubchem.ncbi.nlm.nih.gov/compound/129269915| http://www.rcsb.org/ligand/Y7W|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/Y7W|https://precision.fda.gov/uniisearch/srs/unii/JNA39I7ZVB	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|FDA SRS	'Y7W'	8fll 8fln				479.2	6	3	7	125.3	3.4	0		nan		Y
Ponatinib	Iclusig	Ariad Pharmaceuticals	CHEMBL1171837	Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C	Achiral Molecule	2012	4.0	US-8114874-B2	AP-24534 | AP24534 | ICLUSIG | PONATINIB	Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.	2	P00519|P11274|P10721|P07949|Q02763|P36888|P11362|P21802|P22607|P22455|P06239|P12931|P07948|P35968|P16234	InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)	PHXJVRSECIGDHY-UHFFFAOYSA-N	24747381	|http://www.chemspider.com/Chemical-Structure.24747381.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1171837|http://pubchem.ncbi.nlm.nih.gov/compound/24826799|http://www.drugbank.ca/drugs/DB08901| http://www.rcsb.org/ligand/0LI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/0LI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5890|http://zinc15.docking.org/substances/ZINC36701290|https://precision.fda.gov/uniisearch/srs/unii/4340891KFS|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50322535	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'0LI'	3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 6eg9 6p3d 6tu9 7ote 7wf5		Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.	P00519|P11274|P10721|P07949|Q02763|P36888|P11362|P21802|P22607|P22455|P06239|P12931|P07948|P35968|P16234|P08684|P10632|P10635|P20815|P08183|Q9UNQ0	532.2	6	1	4	65.8	4.5	1		ABL1; BCR; KIT; RET; TEK; FLT3; FGFR1; FGFR2; FGFR3; FGFR4; LCK; SRC; LYN; KDR; PDGFRA	Atypical<br>Tyr	Y
Poseltinib		Hanmi Pharmaceutical	CHEMBL4163691	CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccoc4c(n3)Oc5cccc(c5)NC(=O)C=C	Achiral Molecule	nan	2.0	None	HM-71224 | HM71224 | LY3337641 | POSELTINIB	nan	nan	nan	InChI=1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)	LZMJNVRJMFMYQS-UHFFFAOYSA-N	58826582	|http://www.chemspider.com/Chemical-Structure.58826582.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4163691|http://pubchem.ncbi.nlm.nih.gov/compound/56644522|http://www.drugbank.ca/drugs/DB16299|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9862|https://precision.fda.gov/uniisearch/srs/unii/D01E4B1U35|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50369724	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						470.2	8	2	7	95.8	4.6	0		nan		
Povorcitinib		Incyte Corporation	CHEMBL5095079	CC1NN=C(C)C=1C1C=NN(C=1)C1(CN(C1)C1C=C(F)C(=CC=1F)C(=O)N[C@@H](C)C(F)(F)F)CC#N	Single Stereoisomer	nan	2.0	None	|POVORCITINIB	nan	nan	nan	InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1	MSGYSFWCPOBHEV-AWEZNQCLSA-N	115010428	|http://www.chemspider.com/Chemical-Structure.115010428.html|http://pubchem.ncbi.nlm.nih.gov/compound/86280672|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=246853	|ChemSpider|PubChem|BindingDB						507.2	6	2	6	102.6	4.0	1		nan		
Poziotinib		Hanmi Pharmaceutical	CHEMBL3545154	COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl	Achiral Molecule	nan	3.0	None	HM 781-36 | HM 781-36B | HM-781-36 | HM-781-36B | HM781-36B | NOV-1201 | NOV-120101 | POZIOTINIB	nan	nan	P00533	InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)	LPFWVDIFUFFKJU-UHFFFAOYSA-N	30687714	|http://www.chemspider.com/Chemical-Structure.30687714.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545154|http://pubchem.ncbi.nlm.nih.gov/compound/25127713|http://www.drugbank.ca/drugs/DB12114|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7903|http://zinc15.docking.org/substances/ZINC000095930125|https://precision.fda.gov/uniisearch/srs/unii/OEI6OOU6IK|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468247	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Poziotinib has been used in trials studying the treatment of Breast Cancer, Metastatic Breast Cancer, Increased Drug Resistance, Adenocarcinoma of Lung Stage IV, and Adenocarcinoma of Lung Stage IIIB, among others.	P00533	490.1	6	1	6	76.6	5.4	1		EGFR	Tyr	
Pralsetinib	Gavreto	Blueprint Medicines	CHEMBL4582651	Cc1[nH]nc(c1)Nc2nc(nc(c2)C)[C@H]3CC[C@@](CC3)(OC)C(=O)N[C@H](c4cnc(cc4)n5ncc(c5)F)C	Single Stereoisomer	2020	4.0	US-10030005-B2	RG6396|BLU123244|RO7499790|GAVRETO|X581238|BLU-123244|GAVRETO (US|X-581238|BLU-667	Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs	nan	nan	InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27-/m0/s1	GBLBJPZSROAGMF-BATDWUPUSA-N	71060332	|http://www.chemspider.com/Chemical-Structure.71060332.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297597|http://www.drugbank.ca/drugs/DB15822| http://www.rcsb.org/ligand/Q4J|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/Q4J|https://precision.fda.gov/uniisearch/srs/unii/1WPE73O1WV	|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|FDA SRS	'Q4J'	7du9 7ju5		"Pralsetinib, similar to the previously approved <a href=""https://go.drugbank.com/drugs/DB15685"">selpercatinib</a>, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)"" href=""#reference-A202055"">3</a>,<a class=""reference-popover-link"" data-content=""Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK: Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. (PubMed ID 29657135)"" href=""#reference-A219751"">5</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules"" href=""#reference-L15986"">9</a></sup> Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including <a href=""https://go.drugbank.com/drugs/DB08875"">cabozantinib</a>, <a href=""https://go.drugbank.com/drugs/DB08901"">ponatinib</a>, <a href=""https://go.drugbank.com/drugs/DB00398"">sorafenib</a>, <a href=""https://go.drugbank.com/drugs/DB01268"">sunitinib</a>, and <a href=""https://go.drugbank.com/drugs/DB05294"">vandetanib</a>, have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)"" href=""#reference-A202055"">3</a></sup> Pralsetinib (BLU-667) and <a href=""https://go.drugbank.com/drugs/DB15685"">selpercatinib</a> (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R, Rolfo C: New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). Curr Oncol Rep. 2020 Apr 16;22(5):48. doi: 10.1007/s11912-020-00909-8. (PubMed ID 32296961)"" href=""#reference-A202049"">1</a>,<a class=""reference-popover-link"" data-content=""Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)"" href=""#reference-A202055"">3</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules"" href=""#reference-L15986"">9</a></sup></p><p>Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment of metastatic RET-fusion positive non-small cell lung cancer. It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules"" href=""#reference-L15986"">9</a></sup>"	P07949|Q08345|Q16288|P36888|P23458|O60674|P04629|P35968|P09619|P11362|P21802|P08684|P20815|P10635|P05177|P10632|P11712|P08183|Q9UNQ0|Q9Y6L6|Q9NPD5|Q4U2R8|Q96FL8|Q86VL8|O95342	533.3	9	3	8	135.5	4.2	1		nan		Y
Prexasertib		Eli Lilly	CHEMBL3544911	COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN	Achiral Molecule	nan	2.0	None	LY2606368 | PREXASERTIB	nan	nan	O14757|O96017	InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)	DOTGPNHGTYJDEP-UHFFFAOYSA-N	32738771	|http://www.chemspider.com/Chemical-Structure.32738771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544911|http://pubchem.ncbi.nlm.nih.gov/compound/46700756|http://www.drugbank.ca/drugs/DB12008|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9549|http://zinc15.docking.org/substances/ZINC000095837013|https://precision.fda.gov/uniisearch/srs/unii/820NH671E6|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50524300	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, BREAST CANCER, and Ovarian Cancer, among others.	O14757	365.2	8	3	8	134.8	2.2	0		CHEK1; CHEK2	CAMK	
Puquitinib		Zhejiang Medicine	CHEMBL3545088	c1cc2cc(ccc2nc1)Nc3nc4c(c(n3)NC5CC5)[nH]cn4	Single Stereoisomer	nan	1.0	None		nan	nan	nan	InChI=1S/C17H15N7/c1-2-10-8-12(5-6-13(10)18-7-1)22-17-23-15-14(19-9-20-15)16(24-17)21-11-3-4-11/h1-2,5-9,11H,3-4H2,(H3,19,20,21,22,23,24)	QUTFBURLXCODBH-UHFFFAOYSA-N	13114568	|http://www.chemspider.com/Chemical-Structure.13114568.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4596972|http://pubchem.ncbi.nlm.nih.gov/compound/15983184|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9928|https://precision.fda.gov/uniisearch/srs/unii/WFG29AB872	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS						317.1	6	3	4	91.4	3.2	0		nan		
Pyrotinib		Hengrui Therapeutics	CHEMBL3544956	CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5	Single Stereoisomer	nan	3.0	None		nan	nan	P00533|P04626	InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1	SADXACCFNXBCFY-IYNHSRRRSA-N	52083721	|http://www.chemspider.com/Chemical-Structure.52083721.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3647420|http://pubchem.ncbi.nlm.nih.gov/compound/51039030|http://www.drugbank.ca/drugs/DB14993|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9662|http://zinc15.docking.org/substances/ZINC000068250550|https://precision.fda.gov/uniisearch/srs/unii/CJN36EQM0H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=139991	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						582.2	8	2	10	112.4	6.5	2		EGFR; ERBB2	Tyr	
Quizartinib		Ambit Biosciences	CHEMBL576982	CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6	Achiral Molecule	nan	3.0	None	AC-010220 | AC-220 | AC010220 | AC220 | ASP-2689 | QUIZARTINIB	nan	2	P36888|P07333|P10721	InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)	CVWXJKQAOSCOAB-UHFFFAOYSA-N	24640357	|http://www.chemspider.com/Chemical-Structure.24640357.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL576982|http://pubchem.ncbi.nlm.nih.gov/compound/24889392|http://www.drugbank.ca/drugs/DB12874| http://www.rcsb.org/ligand/P30|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/P30|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5658|http://zinc15.docking.org/substances/ZINC43204002|https://precision.fda.gov/uniisearch/srs/unii/7LA4O6Q0D3|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50300690	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'P30'	4rt7 4xuf		Quizartinib is under investigation in Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies. It is a potent inhibitor of FLT3.	P36888	560.2	9	2	7	106.2	5.9	2		FLT3; CSF1R; KIT	Tyr	
Rabusertib		Eli Lilly	CHEMBL3039517	Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3	Single Stereoisomer	nan	2.0	None	IC-83 | LY-2603618 | LY2603618 | RABUSERTIB	nan	nan	O14757	InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1	SYYBDNPGDKKJDU-ZDUSSCGKSA-N	10130131	|http://www.chemspider.com/Chemical-Structure.10130131.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3039517|http://pubchem.ncbi.nlm.nih.gov/compound/11955855|http://www.drugbank.ca/drugs/DB11662|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7960|http://zinc15.docking.org/substances/ZINC000070466463|https://precision.fda.gov/uniisearch/srs/unii/3S9L1NU6U7|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50524309	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						435.1	6	3	5	97.4	2.9	0		CHEK1	CAMK	
Radotinib		Il-Yang Pharmaceutical	CHEMBL4297524	Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F	Achiral Molecule	nan	3.0	None	IY5511 | RADOTINIB	Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.	nan	P00519|P09619	InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)	DUPWHXBITIZIKZ-UHFFFAOYSA-N	17222861	|http://www.chemspider.com/Chemical-Structure.17222861.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297524|http://pubchem.ncbi.nlm.nih.gov/compound/16063245|http://www.drugbank.ca/drugs/DB12323|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7814|http://zinc15.docking.org/substances/ZINC000059749972|https://precision.fda.gov/uniisearch/srs/unii/I284LJY110	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS				Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.	P00519	530.2	8	2	6	110.5	5.8	2		ABL1; PDGFRB	Tyr	
Ralimetinib		Eli Lilly	CHEMBL2364626	CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N	Achiral Molecule	nan	2.0	None	LSN-2322600 FREE BASE | LSN2322600 FREE BASE | LY-2228820 | LY2228820 | LY22288220 | RALIMETINIB	nan	nan	Q16539|Q15759	InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)	XPPBBJCBDOEXDN-UHFFFAOYSA-N	9713805	|http://www.chemspider.com/Chemical-Structure.9713805.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2364626|http://pubchem.ncbi.nlm.nih.gov/compound/11539025|http://www.drugbank.ca/drugs/DB11787|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959|http://zinc15.docking.org/substances/ZINC34630490|https://precision.fda.gov/uniisearch/srs/unii/73I34XW4HD	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						420.2	5	2	3	85.4	5.6	1		MAPK14; MAPK11	CMGC	
Ravoxertinib		Genentech	CHEMBL3544964	Cn1c(ccn1)Nc2nccc(n2)c3ccn(c(=O)c3)[C@H](CO)c4ccc(c(c4)F)Cl	Single Stereoisomer	nan	1.0	None	GDC-0994 | GDC0994 | RAVOXERTINIB | RG-7842	nan	nan	nan	InChI=1S/C21H18ClFN6O2/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14/h2-11,18,30H,12H2,1H3,(H,24,26,27)/t18-/m1/s1	RZUOCXOYPYGSKL-GOSISDBHSA-N	32501977	|http://www.chemspider.com/Chemical-Structure.32501977.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544964|http://pubchem.ncbi.nlm.nih.gov/compound/71727581|http://www.drugbank.ca/drugs/DB15281| http://www.rcsb.org/ligand/6QB|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6QB|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9229|http://zinc15.docking.org/substances/ZINC000144904566|https://precision.fda.gov/uniisearch/srs/unii/R6AXV96CRH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=120095	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'6QB'	5k4i 5k4j 6oph				440.1	8	2	6	97.9	3.2	0		nan		
Rebastinib	DP-1919;Dp-1919	Deciphera Pharmaceuticals	CHEMBL1738757	CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC	Achiral Molecule	nan	2.0	None	DCC-2036 | DCC-2036 FREE BASE | DP-1919 | REBASTINIB	nan	2	P36888|Q02763|P35968|P07948|P11274|P00519|P04629	InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)	WVXNSAVVKYZVOE-UHFFFAOYSA-N	26325986	|http://www.chemspider.com/Chemical-Structure.26325986.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1738757|http://pubchem.ncbi.nlm.nih.gov/compound/25066467|http://www.drugbank.ca/drugs/DB13005| http://www.rcsb.org/ligand/919|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/919|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9173|http://zinc15.docking.org/substances/ZINC63933734|https://precision.fda.gov/uniisearch/srs/unii/75017Q6I97|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=185674	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'919'	3qri 3qrj 5g6v 6cnh 6mwe				553.2	7	3	6	123.1	6.0	2		FLT3; TEK; KDR; LYN; BCR; ABL1; NTRK1	Atypical<br>Tyr	
Recilisib	Ex-RAD;Ex-rad	Onconova Therapeutics	CHEMBL2219421	c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl	Achiral Molecule	nan	1.0	None	EX-RAD | ON 01210 | ON 01210.NA | ON-01210 | RECILISIB	nan	nan	nan	InChI=1S/C16H13ClO4S/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19/h1-10H,11H2,(H,18,19)/b10-9+	KBEKQQJUNVQLDZ-MDZDMXLPSA-N	8059894	|http://www.chemspider.com/Chemical-Structure.8059894.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2219421|http://pubchem.ncbi.nlm.nih.gov/compound/9884220|http://zinc15.docking.org/substances/ZINC000034007613|https://precision.fda.gov/uniisearch/srs/unii/F5V4K11SYV	|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS						336.0	3	1	5	71.4	3.6	0		nan		
Refametinib		Bayer	CHEMBL1236682	COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F	Single Stereoisomer	nan	2.0	None	BAY 869766 | BAY 8697661 | BAY-86-9766 | BAY-869766 | BAY-8697661 | BAY86-9766 | RDEA 119 | RDEA-119 | RDEA119 | REFAMETINIB	nan	nan	Q02750	InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1	RDSACQWTXKSHJT-NSHDSACASA-N	25058723	|http://www.chemspider.com/Chemical-Structure.25058723.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1236682|http://pubchem.ncbi.nlm.nih.gov/compound/44182295|http://www.drugbank.ca/drugs/DB06309| http://www.rcsb.org/ligand/VRA|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VRA|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942|http://zinc15.docking.org/substances/ZINC39187987|https://precision.fda.gov/uniisearch/srs/unii/JPX07AFM0N	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS	'VRA'	3e8n				572.0	6	4	9	107.9	3.5	1		MAP2K1	STE	
Regorafenib	Stivarga	Bayer	CHEMBL1946170	CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl	Achiral Molecule	2012	4.0	US-7351834-B1	BAY 73-4506 | BAY 73-4506 MONOHYDRATE | BAY-73-4506 | BAY-734506 | REGORAFENIB | REGORAFENIB ANHYDROUS | REGORAFENIB HYDRATE | REGORAFENIB MONOHYDRATE | STIVARGA	Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	2	P17948|P35968|P35916|P10721|P16234|P09619|P11362|P21802|Q02763|Q16832|P04629|P29317|P04049|P15056|Q15759|P42685|P00519|P07949	InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)	FNHKPVJBJVTLMP-UHFFFAOYSA-N	9342697	|http://www.chemspider.com/Chemical-Structure.9342697.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1946170|http://pubchem.ncbi.nlm.nih.gov/compound/11167602|http://www.drugbank.ca/drugs/DB08896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5891|http://zinc15.docking.org/substances/ZINC06745272|https://precision.fda.gov/uniisearch/srs/unii/24T2A1DOYB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50363397	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.	P17948|P35968|P35916|P10721|P16234|P09619|P11362|P21802|Q02763|Q16832|P04629|P29317|P04049|P15056|Q15759|P42685|P00519|P07949	482.1	4	3	5	92.3	5.7	1		FLT1; KDR; FLT4; KIT; PDGFRA; PDGFRB; FGFR1; FGFR2; TEK; DDR2; NTRK1; EPHA2; RAF1; BRAF; MAPK11; FRK; ABL1; RET	TKL<br>CMGC<br>Tyr	Y
Remibrutinib		Novartis	CHEMBL4483575	CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C	Achiral Molecule	nan	3.0	None	LOU064-NXA | NVP-LOU064-NXA | REMIBRUTINIB	nan	nan	nan	InChI=1S/C27H27F2N5O3/c1-4-23(35)34(3)9-10-37-25-24(31-14-32-26(25)30)20-12-18(28)13-22(15(20)2)33-27(36)19-8-7-17(11-21(19)29)16-5-6-16/h4,7-8,11-14,16H,1,5-6,9-10H2,2-3H3,(H,33,36)(H2,30,31,32)	CUABMPOJOBCXJI-UHFFFAOYSA-N	78317000	|http://www.chemspider.com/Chemical-Structure.78317000.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4483575|http://pubchem.ncbi.nlm.nih.gov/compound/118107483|http://www.drugbank.ca/drugs/DB16852|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10457|https://precision.fda.gov/uniisearch/srs/unii/I7MVZ8HDNU|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=259407	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						507.2	6	2	9	110.4	4.5	1		nan		
Repotrectinib		TP Therapeutics	CHEMBL4298138	CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C	Single Stereoisomer	nan	1.5	None	REPOTRECTINIB | TPX-0005 | TRX-0005	nan	nan	nan	InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11,21H,8H2,1-2H3,(H,20,25)/b22-16-	FIKPXCOQUIZNHB-WDEREUQCSA-N	71084199	|http://www.chemspider.com/Chemical-Structure.71084199.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4298138|http://pubchem.ncbi.nlm.nih.gov/compound/135565923|http://www.drugbank.ca/drugs/DB16826| http://www.rcsb.org/ligand/7GI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/7GI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10316|https://precision.fda.gov/uniisearch/srs/unii/08O3FQ4UNP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=374727	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB	'7GI'	7vkn 7vko				355.1	6	2	0	80.6	2.6	0		nan		
Ribociclib	Kisqali	Novartis	CHEMBL3545110	CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5	Achiral Molecule	2017	4.0	US-8324225-B2	LEE-011 | LEE-011A | LEE011 | LEE011A | NVP-LEE011 | RIBOCICLIB	Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.	1	P11802|Q00534	InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)	RHXHGRAEPCAFML-UHFFFAOYSA-N	30798107	|http://www.chemspider.com/Chemical-Structure.30798107.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545110|http://pubchem.ncbi.nlm.nih.gov/compound/44631912|http://www.drugbank.ca/drugs/DB11730| http://www.rcsb.org/ligand/6ZZ|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6ZZ|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7383|http://zinc15.docking.org/substances/ZINC000072316335|https://precision.fda.gov/uniisearch/srs/unii/TK8ERE8P56|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=148264	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'6ZZ'	5l2t		Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.	P11802|Q00534|P08684	434.3	8	2	5	91.2	2.8	0		CDK4; CDK6	CMGC	Y
Rigosertib		Onconova Therapeutics	CHEMBL1241855	COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC	Achiral Molecule	nan	3.0	None	ON 01910 | RIGOSERTIB	nan	3	P42336|P53350	InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+	OWBFCJROIKNMGD-BQYQJAHWSA-N	5293927	|http://www.chemspider.com/Chemical-Structure.5293927.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1241855|http://pubchem.ncbi.nlm.nih.gov/compound/6918736|http://www.drugbank.ca/drugs/DB12146| http://www.rcsb.org/ligand/6FS|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/6FS|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7833|http://zinc15.docking.org/substances/ZINC000003942646|https://precision.fda.gov/uniisearch/srs/unii/67DOW7F9GL|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50060917	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'6FS'	5j18 5j2r 5ov7				451.1	8	2	11	120.4	2.8	0		PIK3CA; PLK1	Atypical<br>Other	
Rilzabrutinib		Principia Biopharma	CHEMBL3702854	CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1	Single Stereoisomer	nan	3.0	None	PRN-1008 | PRN1008 | RILZABRUTINIB	nan	nan	nan	InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)/b24-18+/	LCFFREMLXLZNHE-GBOLQPHISA-N	58893525	|http://www.chemspider.com/Chemical-Structure.58893525.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3702854|http://pubchem.ncbi.nlm.nih.gov/compound/73388818| http://www.rcsb.org/ligand/R1L|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/R1L|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9993|http://zinc15.docking.org/substances/ZINC000207730864|https://precision.fda.gov/uniisearch/srs/unii/5G1WE425BI	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS	'R1L'	7l5o 7l5p				665.3	11	1	8	138.7	4.4	2		nan		
Ripasudil		Kowa Pharmaceutical	CHEMBL3426621	C[C@H]1CNCCCN1S(=O)(=O)c2cccc3c2c(cnc3)F	Single Stereoisomer	nan	3.0	None	RIPASUDIL	nan	nan	nan	InChI=1S/C15H18FN3O2S/c1-11-8-17-6-3-7-19(11)22(20,21)14-5-2-4-12-9-18-10-13(16)15(12)14/h2,4-5,9-11,17H,3,6-8H2,1H3/t11-/m0/s1	QSKQVZWVLOIIEV-NSHDSACASA-N	8039366	|http://www.chemspider.com/Chemical-Structure.8039366.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3426621|http://pubchem.ncbi.nlm.nih.gov/compound/9863672|http://www.drugbank.ca/drugs/DB13165|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10423|http://zinc15.docking.org/substances/ZINC000003940873|https://precision.fda.gov/uniisearch/srs/unii/11978226XX|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50087135	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. Ripasudil is a well tolerated medication that is used when other drugs have been proven to be non-effective or cannot be administered.	Q13464|O75116	323.1	4	1	2	62.3	1.7	0		nan		
Ripretinib	Qinlock	Deciphera Pharmaceuticals	CHEMBL4216467	CCn1c2cc(ncc2cc(c1=O)c3cc(c(cc3Br)F)NC(=O)Nc4ccccc4)NC	Achiral Molecule	2020	4.0	US-8188113-B2	DCC-2618 | QINLOCK | RIPRETINIB	Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFR&alpha; kinase inhibitor being developed by Dicephera Pharmaceuticals.  It is in clinical development for the treatment of  malignancies that are driven by KIT and/or PDGFR&alpha;, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.	nan	nan	InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)	CEFJVGZHQAGLHS-UHFFFAOYSA-N	67886378	|http://www.chemspider.com/Chemical-Structure.67886378.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4216467|http://pubchem.ncbi.nlm.nih.gov/compound/71584930|http://www.drugbank.ca/drugs/DB14840|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9175|https://precision.fda.gov/uniisearch/srs/unii/9XW757O13D	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS				"Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as <a href=""https://go.drugbank.com/drugs/DB01268"">sunitinib</a> and <a href=""https://go.drugbank.com/drugs/DB00619"">imatinib</a>. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Qinlock (ripretinib) tablets for oral use"" href=""#reference-L13769"">7</a></sup> </p><p>It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approves First Drug for Fourth-Line Treatment of Advanced Gastrointestinal Stromal Tumors"" href=""#reference-L13778"">8</a></sup>"	P10721|P09619|Q02763|P35968|P15056|P16234|P10632|P16234|P08684|P10635|P05181|P02768|P02763|P19652|P08183|Q9UNQ0|Q96FL8	509.1	5	3	5	88.0	5.7	2		nan		Y
Ritlecitinib		Pfizer	CHEMBL4085457	C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C	Single Stereoisomer	nan	3.0	None	PF-06651600 | RITLECITINIB	nan	nan	nan	InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1	CBRJPFGIXUFMTM-WDEREUQCSA-N	59718512	|http://www.chemspider.com/Chemical-Structure.59718512.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4085457|http://pubchem.ncbi.nlm.nih.gov/compound/118115473|http://www.drugbank.ca/drugs/DB14924|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9559|http://zinc15.docking.org/substances/ZINC000526061581|https://precision.fda.gov/uniisearch/srs/unii/2OYE00PC25|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=209866	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: LITFULO (ritlecitinib) capsules for oral use (June 2023)"" href=""#reference-L47092"">5</a>,<a class=""reference-popover-link"" data-content=""Business Wire: FDA Approves Pfizer’s LITFULO (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata"" href=""#reference-L47127"">6</a></sup> Ritlecitinib is administered orally and is the first member of its class.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ramirez-Marin HA, Tosti A: Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata. Drug Des Devel Ther. 2022 Feb 17;16:363-374. doi: 10.2147/DDDT.S334727. eCollection 2022. (PubMed ID 35210753)"" href=""#reference-A260122"">1</a>,<a class=""reference-popover-link"" data-content=""Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y, Crouse K, Dickinson C, Symanowicz P, Hegen M, Banker ME, Vincent F, Unwalla R, Liang S, Gilbert AM, Brown MF, Hayward M, Montgomery J, Yang X, Bauman J, Trujillo JI, Casimiro-Garcia A, Vajdos FF, Leung L, Geoghegan KF, Quazi A, Xuan D, Jones L, Hett E, Wright K, Clark JD, Thorarensen A: Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol. 2016 Dec 16;11(12):3442-3451. doi: 10.1021/acschembio.6b00677. Epub 2016 Nov 10. (PubMed ID 27791347)"" href=""#reference-A260127"">2</a></sup></p><p>Ritlecitinib binds covalently to Cys-909 of JAK3, a site where other JAK isoforms have a serine residue. This makes ritlecitinib a highly selective and irreversible JAK3 inhibitor.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ramirez-Marin HA, Tosti A: Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata. Drug Des Devel Ther. 2022 Feb 17;16:363-374. doi: 10.2147/DDDT.S334727. eCollection 2022. (PubMed ID 35210753)"" href=""#reference-A260122"">1</a>,<a class=""reference-popover-link"" data-content=""Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y, Crouse K, Dickinson C, Symanowicz P, Hegen M, Banker ME, Vincent F, Unwalla R, Liang S, Gilbert AM, Brown MF, Hayward M, Montgomery J, Yang X, Bauman J, Trujillo JI, Casimiro-Garcia A, Vajdos FF, Leung L, Geoghegan KF, Quazi A, Xuan D, Jones L, Hett E, Wright K, Clark JD, Thorarensen A: Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol. 2016 Dec 16;11(12):3442-3451. doi: 10.1021/acschembio.6b00677. Epub 2016 Nov 10. (PubMed ID 27791347)"" href=""#reference-A260127"">2</a></sup> Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family. It has been suggested that the dual activity of ritlecitinib toward JAK3 and the TEC kinase family block cytokine signaling as well as the cytolytic activity of T cells, both implicated in the pathogenesis of alopecia areata.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ramirez-Marin HA, Tosti A: Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata. Drug Des Devel Ther. 2022 Feb 17;16:363-374. doi: 10.2147/DDDT.S334727. eCollection 2022. (PubMed ID 35210753)"" href=""#reference-A260122"">1</a></sup>"	P52333|P42680|Q08881|P42681|Q06187|P51813|P08684|P10632|P05177|P11712|P08263|Q16772|P09488|P21266|P46439|P09211|P0CG29|O43708|P10620|Q99735|O14880	285.2	4	2	3	73.9	1.9	0		nan		
Riviciclib		Piramal Enterprises	CHEMBL3545283	CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O	Racemic Mixture	nan	2.0	None		nan	nan	P06493|P11802|P50750	InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1	QLUYMIVVAYRECT-OCCSQVGLSA-N	29165868	|http://www.chemspider.com/Chemical-Structure.29165868.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3969723|http://pubchem.ncbi.nlm.nih.gov/compound/23643976|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934|http://zinc15.docking.org/substances/ZINC000003937395|https://precision.fda.gov/uniisearch/srs/unii/9EK26WE8QN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193086	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						401.1	6	3	3	94.1	3.3	0		CDK1; CDK4; CDK9	CMGC	
Rociletinib		Clovis Oncology	CHEMBL3545308	CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F	Achiral Molecule	nan	3.0	None	AVL-301 | CNX-419 | CO-1686 | CS-1631 | ROCILETINIB	nan	1	P00533	InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)	HUFOZJXAKZVRNJ-UHFFFAOYSA-N	30646712	|http://www.chemspider.com/Chemical-Structure.30646712.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545308|http://pubchem.ncbi.nlm.nih.gov/compound/57335384|http://www.drugbank.ca/drugs/DB11907| http://www.rcsb.org/ligand/8JC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8JC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7966|http://zinc15.docking.org/substances/ZINC000098043800|https://precision.fda.gov/uniisearch/srs/unii/72AH61702G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=149404	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'8JC'	5xdk 5xdl				555.2	8	3	8	111.7	4.8	1		EGFR	Tyr	
Rogaratinib		Bayer	CHEMBL3963485	Cc1cc2cc(sc2c(c1)OC)c3c(c(n4c3c(ncn4)N)CN5CCNC(=O)C5)COC	Achiral Molecule	nan	2.0	None	BAY-1163877 | ROGARATINIB	Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity.	nan	nan	InChI=1S/C23H26N6O3S/c1-13-6-14-8-18(33-22(14)17(7-13)32-3)20-15(11-31-2)16(9-28-5-4-25-19(30)10-28)29-21(20)23(24)26-12-27-29/h6-8,12H,4-5,9-11H2,1-3H3,(H,25,30)(H2,24,26,27)	HNLRRJSKGXOYNO-UHFFFAOYSA-N	58828032	|http://www.chemspider.com/Chemical-Structure.58828032.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3963485|http://pubchem.ncbi.nlm.nih.gov/compound/71611869|http://www.drugbank.ca/drugs/DB15078|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9789|https://precision.fda.gov/uniisearch/srs/unii/98BSN6N516|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=194820	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						466.2	9	2	6	107.0	2.6	0		nan		
Roniciclib		Bayer	CHEMBL4442620	C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O	Single Stereoisomer	nan	2.0	None		nan	nan	P06493|P24941|P11802|P50750	InChI=1S/C18H21F3N4O3S/c1-10(26)11(2)28-16-15(18(19,20)21)9-23-17(25-16)24-12-3-5-13(6-4-12)29(22,27)14-7-8-14/h3-6,9-11,14,22,26H,7-8H2,1-2H3,(H,23,24,25)/t10-,11-,29+/m1/s1	UELYDGOOJPRWGF-SRQXXRKNSA-N	32697590	|http://www.chemspider.com/Chemical-Structure.32697590.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4282338|http://pubchem.ncbi.nlm.nih.gov/compound/71494949|http://www.drugbank.ca/drugs/DB12974| http://www.rcsb.org/ligand/R0N|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/R0N|http://zinc15.docking.org/substances/ZINC000095616570|https://precision.fda.gov/uniisearch/srs/unii/0W9Q8U337A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50468265	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB	'R0N'	5iev				430.1	7	3	7	108.2	4.0	0		CDK1; CDK2; CDK4; CDK9	CMGC	
Ropsacitinib		Pfizer	CHEMBL4459585	Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1	Achiral Molecule	nan	2.0	None	PF-06826647 | ROPSACITINIB	nan	nan	nan	InChI=1S/C20H17N9/c1-27-11-15(9-24-27)17-13-28-18(2-5-23-28)19(26-17)16-10-25-29(12-16)20(3-4-21)6-14(7-20)8-22/h2,5,9-14H,3,6-7H2,1H3/t14-,20-	XPLZTJWZDBFWDE-OYOVHJISSA-N	84492190	|http://www.chemspider.com/Chemical-Structure.84492190.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4459585| http://www.rcsb.org/ligand/UWM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/UWM|https://precision.fda.gov/uniisearch/srs/unii/HY5SOV7O0Q|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=305821	|ChemSpider|ChEMBL|RCSB|PDBe|FDA SRS|BindingDB	'UWM'	6x8g				383.2	9	0	4	113.4	2.5	0		nan		
Ruboxistaurin	Arxxant	Eli Lilly	CHEMBL91829	CN(C)C[C@@H]1CCn2cc(c3c2cccc3)C4=C(c5cn(c6c5cccc6)CCO1)C(=O)NC4=O	Single Stereoisomer	nan	3.0	None	ARXXANT | LY-333531 | RUBOXISTAURIN	nan	nan	nan	InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1	ZCBUQCWBWNUWSU-SFHVURJKSA-N	135727	|http://www.chemspider.com/Chemical-Structure.135727.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL91829|http://pubchem.ncbi.nlm.nih.gov/compound/153999|http://www.drugbank.ca/drugs/DB11829| http://www.rcsb.org/ligand/LY4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LY4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5263|http://zinc15.docking.org/substances/ZINC000003812168|https://precision.fda.gov/uniisearch/srs/unii/721809WQCP|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50128281	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'LY4'	1uu3 2j2i				468.2	6	1	2	68.5	3.5	0		nan		
Ruxolitinib	Jakafi;Jakavi	Incyte Corporation	CHEMBL1789941	c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4	Single Stereoisomer	2011	4.0	US-7598257-B2	INC-424 | INC424 | INCB-018424 | INCB-18424 | INCB018424 | JAKAVI | RUXOLITINIB	Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).	1	P23458|O60674	InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1	HFNKQEVNSGCOJV-OAHLLOKOSA-N	25027389	|http://www.chemspider.com/Chemical-Structure.25027389.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1789941|http://pubchem.ncbi.nlm.nih.gov/compound/25126798|http://www.drugbank.ca/drugs/DB08877| http://www.rcsb.org/ligand/RXT|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/RXT|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688|http://zinc15.docking.org/substances/ZINC43207851|https://precision.fda.gov/uniisearch/srs/unii/82S8X8XX8H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355501	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'RXT'	4u5j 6vgl 6vnk 6wtn 7f3g		"Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Becker H, Engelhardt M, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. (PubMed ID 24756798)"" href=""#reference-A229698"">3</a></sup> which are tyrosine kinases involved in cytokine signalling and hematopoiesis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. (PubMed ID 23061804)"" href=""#reference-A7450"">2</a></sup> Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. (PubMed ID 30069628)"" href=""#reference-A229708"">5</a></sup> Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA: Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma. 2014 Sep;55(9):1968-79. doi: 10.3109/10428194.2013.863307. Epub 2014 Feb 17. (PubMed ID 24206094)"" href=""#reference-A229938"">15</a></sup></p><p>Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA&#39;s approval in 2012.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wasch R: Ruxolitinib. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. (PubMed ID 30069628)"" href=""#reference-A229708"">5</a></sup> In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of <a href=""https://go.drugbank.com/drugs/DB01005"">hydroxyurea</a> and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Drugs.com: Jakafi FDA Approval History"" href=""#reference-L31958"">19</a></sup> The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: OPZELURA (ruxolitinib) cream, for topical use"" href=""#reference-L39125"">23</a></sup> It is being investigated for other inflammatory skin conditions.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A: Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012 Oct;67(4):658-64. doi: 10.1016/j.jaad.2011.12.018. Epub 2012 Jan 24. (PubMed ID 22281165)"" href=""#reference-A229883"">12</a></sup></p><p>Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J: Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26. (PubMed ID 32470486)"" href=""#reference-A229713"">6</a>,<a class=""reference-popover-link"" data-content=""La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosee P: The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020 Jul;34(7):1805-1815. doi: 10.1038/s41375-020-0891-0. Epub 2020 Jun 9. (PubMed ID 32518419)"" href=""#reference-A229718"">7</a></sup> However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Novartis: Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19"" href=""#reference-L31968"">20</a></sup> thus the drug was not approved as a treatment for COVID-19."	O60674|P23458|P52333|P29597|P08684|P11712|P02768	306.2	5	1	4	83.2	3.5	0	86	JAK1; JAK2	Tyr	Y
Samotolisib		Eli Lilly	CHEMBL4297181	C[C@@H](Cn1c2c3cc(ccc3ncc2n(c1=O)C)c4cc(cnc4)C(C)(C)O)OC	Single Stereoisomer	nan	2.0	None	LY 3023414 | LY-3023414 | LY3023414 | SAMOTOLISIB	LY3023414 is a dual inhibitor of phosphoinositide 3-kinase &alpha; (PI3K&alpha;) and the serine/threonine kinase mTOR (mechanistic target of rapamycin), with potential antineoplastic activity.	nan	nan	InChI=1S/C23H26N4O3/c1-14(30-5)13-27-21-18-9-15(16-8-17(11-24-10-16)23(2,3)29)6-7-19(18)25-12-20(21)26(4)22(27)28/h6-12,14,29H,13H2,1-5H3/t14-/m0/s1	ACCFLVVUVBJNGT-AWEZNQCLSA-N	35142771	|http://www.chemspider.com/Chemical-Structure.35142771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297181|http://pubchem.ncbi.nlm.nih.gov/compound/57519748|http://www.drugbank.ca/drugs/DB12167|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8918|http://zinc15.docking.org/substances/ZINC000143116580|https://precision.fda.gov/uniisearch/srs/unii/C88817F47Y	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						406.2	7	1	5	82.2	3.2	0		nan		
Samuraciclib		Imperial College of Science, Technology and Medicine	CHEMBL4297488	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12	Single Stereoisomer	nan	1.5	None	CT-7001 | CT7001 | ICEC-0942 | ICEC0942 | SAMURACICLIB	nan	nan	nan	InChI=1S/C22H30N6O/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29/h3-7,10,13,15,17,19,23,25,29H,8-9,11-12,14H2,1-2H3,(H,24,27)/t17-,19+/m1/s1	YCVGLKWJKIKVBI-MJGOQNOKSA-N	59053821	|http://www.chemspider.com/Chemical-Structure.59053821.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297488|http://pubchem.ncbi.nlm.nih.gov/compound/91844733|http://www.drugbank.ca/drugs/DB16061| http://www.rcsb.org/ligand/I74|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/I74|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9903|http://zinc15.docking.org/substances/ZINC000584905775|https://precision.fda.gov/uniisearch/srs/unii/46D4HS9ODA|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50526797	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'I74'	5jq5 7b5o 7b5q				394.2	7	4	7	86.5	2.8	0		nan		
Sapanisertib		Takeda	CHEMBL3545097	CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N	Achiral Molecule	nan	2.0	None	CB-228 | INK-128 | INK128 | MLN-0128 | MLN0128 | SAPANISERTIB | TAK-228	nan	nan	P42345	InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)	GYLDXIAOMVERTK-UHFFFAOYSA-N	28189069	|http://www.chemspider.com/Chemical-Structure.28189069.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545097|http://pubchem.ncbi.nlm.nih.gov/compound/45375953|http://www.drugbank.ca/drugs/DB11836| http://www.rcsb.org/ligand/FE5|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FE5|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933|http://zinc15.docking.org/substances/ZINC000073069271|https://precision.fda.gov/uniisearch/srs/unii/JGH0DF1U03|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=315477	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'FE5'	6gvf				309.1	8	2	2	121.7	2.4	0		MTOR	Atypical	
Sapitinib		Astrazeneca	CHEMBL2408045	CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl	Achiral Molecule	nan	2.0	None	AZD-8931 | AZD8931 | SAPITINIB	nan	nan	P00533|P04626|Q15303|P21860	InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)	DFJSJLGUIXFDJP-UHFFFAOYSA-N	9663133	|http://www.chemspider.com/Chemical-Structure.9663133.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2408045|http://pubchem.ncbi.nlm.nih.gov/compound/11488320|http://www.drugbank.ca/drugs/DB12183|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7717|http://zinc15.docking.org/substances/ZINC000034587071|https://precision.fda.gov/uniisearch/srs/unii/3499328002|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50437353	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						473.2	7	2	7	88.6	3.8	0		EGFR; ERBB2; ERBB4; ERBB3	Tyr	
Saracatinib		Astrazeneca	CHEMBL217092	CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl	Achiral Molecule	nan	3.0	None	AZ-10353926 | AZD-0530 | AZD0530 | SARACATINIB	nan	1	P12931|P00519	InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)	OUKYUETWWIPKQR-UHFFFAOYSA-N	8477917	|http://www.chemspider.com/Chemical-Structure.8477917.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL217092|http://pubchem.ncbi.nlm.nih.gov/compound/10302451|http://www.drugbank.ca/drugs/DB11805| http://www.rcsb.org/ligand/H8H|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/H8H|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7731|http://zinc15.docking.org/substances/ZINC24811973|https://precision.fda.gov/uniisearch/srs/unii/9KD24QGH76|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=12255	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'H8H'	2h8h 4qmx 5vcx 5vd3 6zgc				541.2	10	1	8	90.4	3.9	1		SRC; ABL1	Tyr	
Savolitinib		Astrazeneca	CHEMBL3334567	C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3	Single Stereoisomer	nan	3.0	None	AZD-6094 | AZD6094 | HMPL-504 | SAVOLITINIB | VOLITINIB	nan	nan	P08581	InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1	XYDNMOZJKOGZLS-NSHDSACASA-N	34501055	|http://www.chemspider.com/Chemical-Structure.34501055.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3334567|http://pubchem.ncbi.nlm.nih.gov/compound/68289010|http://www.drugbank.ca/drugs/DB12048| http://www.rcsb.org/ligand/V0L|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/V0L|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9918|http://zinc15.docking.org/substances/ZINC000149738712|https://precision.fda.gov/uniisearch/srs/unii/2A2DA6857R|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50023342	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'V0L'	5lbw 6sde				345.1	9	0	3	91.6	1.9	0		MET	Tyr	
Selatinib		Qilu Pharmaceutical		CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F		nan	1.0			nan	nan	P00533|P04626	InChI=1S/C29H26ClFN4O3S/c1-39(36)12-11-32-16-23-7-10-27(38-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)37-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)	OAMVGUFHZPRXOM-UHFFFAOYSA-N	30841488	|http://www.chemspider.com/Chemical-Structure.30841488.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3040548|http://pubchem.ncbi.nlm.nih.gov/compound/51348455|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9919|https://precision.fda.gov/uniisearch/srs/unii/6TLR8U8O3C|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=140985	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS|BindingDB						564.1	7	2	11	89.3	6.5	2		EGFR; ERBB2	Tyr	
Seletalisib		UCB	CHEMBL4297648	c1cc2cc(c(nc2c(c1)Cl)c3ccc[n+](c3)[O-])[C@H](C(F)(F)F)Nc4c5c(cccn5)ncn4	Single Stereoisomer	nan	2.0	None	SELETALISIB | UCB-5857 | UCB5857	nan	nan	nan	InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)/t21-/m1/s1	LNLJHGXOFYUARS-OAQYLSRUSA-N	34985875	|http://www.chemspider.com/Chemical-Structure.34985875.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297648|http://pubchem.ncbi.nlm.nih.gov/compound/56928390|http://www.drugbank.ca/drugs/DB12706|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9800|http://zinc15.docking.org/substances/ZINC000144763934|https://precision.fda.gov/uniisearch/srs/unii/64CW205BDD|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50512879	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						482.1	6	1	4	90.5	5.2	1		nan		
Seliciclib		Cyclacel pharmaceuticals	CHEMBL14762	CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1	Single Stereoisomer	nan	2.0	None	AL-39256 | CYC-202 | NSC-701554 | R-ROSCOVITINE | ROSCOVITIN | ROSCOVITINE | SELICICLIB	nan	1	P24941|P50613|P50750	InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N	140922	|http://www.chemspider.com/Chemical-Structure.140922.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL14762|http://pubchem.ncbi.nlm.nih.gov/compound/160355|http://www.drugbank.ca/drugs/DB06195| http://www.rcsb.org/ligand/RRC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/RRC|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6035|http://zinc15.docking.org/substances/ZINC01649340|https://precision.fda.gov/uniisearch/srs/unii/0ES1C2KQ94|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=7533	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'RRC'	1unl 1ygk 2a4l 3ddq 8fp0		R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.	P06493|P24941|P27361|P28482|P50613|P50750|P49674|P35354	354.2	7	3	8	87.9	3.2	0		CDK2; CDK7; CDK9	CMGC	
Selitrectinib		Bayer	CHEMBL4297627	C[C@@H]1CCc2c(cc(cn2)F)[C@H]3CCCN3c4ccn5c(n4)c(cn5)C(=O)N1	Single Stereoisomer	nan	1.5	None	LOXO-195 | SELITRECTINIB	nan	nan	nan	InChI=1S/C20H21FN6O/c1-12-4-5-16-14(9-13(21)10-22-16)17-3-2-7-26(17)18-6-8-27-19(25-18)15(11-23-27)20(28)24-12/h6,8-12,17H,2-5,7H2,1H3,(H,24,28)/t12-,17-/m1/s1	OEBIHOVSAMBXIB-SJKOYZFVSA-N	64853862	|http://www.chemspider.com/Chemical-Structure.64853862.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297627|http://pubchem.ncbi.nlm.nih.gov/compound/129103609|http://www.drugbank.ca/drugs/DB14896|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10314|https://precision.fda.gov/uniisearch/srs/unii/0J45910S3X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50507492	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB						380.2	6	1	0	75.4	2.7	0		nan		
Selonsertib		Gilead Sciences	CHEMBL3916717	Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F	Achiral Molecule	nan	3.0	None	GS-4997 | SELONSERTIB	nan	nan	Q99683	InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)	YIDDLAAKOYYGJG-UHFFFAOYSA-N	44209497	|http://www.chemspider.com/Chemical-Structure.44209497.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3916717|http://pubchem.ncbi.nlm.nih.gov/compound/71245288|http://www.drugbank.ca/drugs/DB14916| http://www.rcsb.org/ligand/NJV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/NJV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9040|http://zinc15.docking.org/substances/ZINC000149387856|https://precision.fda.gov/uniisearch/srs/unii/NS3988A2TC|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50212258	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'NJV'	6oyt				445.2	7	1	6	90.5	4.7	0		MAP3K5	STE	
Selpercatinib	Retevmo	Loxo Oncology	CHEMBL4559134	COC1C=CC(CN2C3CN(CC2C3)C2C=CC(=CN=2)C2=CC(=CN3N=CC(C#N)=C32)OCC(C)(C)O)=CN=1	Achiral Molecule	2020	4.0	US-10112942-B2	LOXO-292 | LY-3527723 | LY3527723 | RET INHIBITOR LOXO-292 | RETEVMO | SELPERCATINIB	On May 2020 FDA approved selpercatinib to treat lung and thyroid cancers.	nan	nan	InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3	XIIOFHFUYBLOLW-UHFFFAOYSA-N	72379991	|http://www.chemspider.com/Chemical-Structure.72379991.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4559134|http://pubchem.ncbi.nlm.nih.gov/compound/134436906|http://www.drugbank.ca/drugs/DB15685|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10318|https://precision.fda.gov/uniisearch/srs/unii/CEGM9YBNGD|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=296429	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS|BindingDB				"Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)"" href=""#reference-A202055"">4</a>,<a class=""reference-popover-link"" data-content=""Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24. (PubMed ID 31988000)"" href=""#reference-A202052"">3</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Retevmo (selpercatinib) capsules"" href=""#reference-L13604"">7</a></sup> Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including <a href=""https://go.drugbank.com/drugs/DB08875"">cabozantinib</a>, <a href=""https://go.drugbank.com/drugs/DB08901"">ponatinib</a>, <a href=""https://go.drugbank.com/drugs/DB00398"">sorafenib</a>, <a href=""https://go.drugbank.com/drugs/DB01268"">sunitinib</a>, and <a href=""https://go.drugbank.com/drugs/DB05294"">vandetanib</a>, have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R, Rolfo C: New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). Curr Oncol Rep. 2020 Apr 16;22(5):48. doi: 10.1007/s11912-020-00909-8. (PubMed ID 32296961)"" href=""#reference-A202049"">2</a>,<a class=""reference-popover-link"" data-content=""Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. (PubMed ID 32083997)"" href=""#reference-A202055"">4</a>,<a class=""reference-popover-link"" data-content=""Solomon BJ, Tan L, Lin JJ, Wong SQ, Hollizeck S, Ebata K, Tuch BB, Yoda S, Gainor JF, Sequist LV, Oxnard GR, Gautschi O, Drilon A, Subbiah V, Khoo C, Zhu EY, Nguyen M, Henry D, Condroski KR, Kolakowski GR, Gomez E, Ballard J, Metcalf AT, Blake JF, Dawson SJ, Blosser W, Stancato LF, Brandhuber BJ, Andrews S, Robinson BG, Rothenberg SM: RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020 Apr;15(4):541-549. doi: 10.1016/j.jtho.2020.01.006. Epub 2020 Jan 24. (PubMed ID 31988000)"" href=""#reference-A202052"">3</a>,<a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Retevmo (selpercatinib) capsules"" href=""#reference-L13604"">7</a></sup></p><p>Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Retevmo (selpercatinib) capsules"" href=""#reference-L13604"">7</a></sup> Selpercatinib is also approved by the European Commission."	P07949|P17948|P35916|P11362|P21802|P22607|P08684|P10632|P08684|Q9HB55|P20815|P24462|P08183|Q9UNQ0|Q96FL8	525.2	10	1	8	112.0	3.3	1		nan		Y
Selumetinib		Astrazeneca	CHEMBL1614701	Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO	Achiral Molecule	2020	4.0	US-7425637-B2	ARRY-142886 | ARRY-886 | AZD-6244 | AZD6244 | SELUMETINIB	On April 2020 FDA approved selumetinib to treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves.	3	Q02750|P36507	InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)	CYOHGALHFOKKQC-UHFFFAOYSA-N	8303141	|http://www.chemspider.com/Chemical-Structure.8303141.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1614701|http://pubchem.ncbi.nlm.nih.gov/compound/10127622|http://www.drugbank.ca/drugs/DB11689| http://www.rcsb.org/ligand/3EW|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3EW|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5665|http://zinc15.docking.org/substances/ZINC31773258|https://precision.fda.gov/uniisearch/srs/unii/6UH91I579U|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50355497	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'3EW'	4u7z 7jut 7juz 7m0t		"Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)"" href=""#reference-A193611"">6</a></sup>Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)"" href=""#reference-A193611"">6</a></sup> However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumors in Phase II trials.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Ciombor KK, Bekaii-Saab T: Selumetinib for the treatment of cancer. Expert Opin Investig Drugs. 2015 Jan;24(1):111-123. doi: 10.1517/13543784.2015.982275. Epub 2014 Nov 11. (PubMed ID 25385055)"" href=""#reference-A193611"">6</a></sup></p><p>Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare with an estimated incidence of 1/3000 individuals.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)"" href=""#reference-A193608"">5</a></sup> It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications including the development of multiple tumors in the nervous system.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC: Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. (PubMed ID 28029918)"" href=""#reference-A193533"">3</a>,<a class=""reference-popover-link"" data-content=""Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)"" href=""#reference-A193608"">5</a></sup> Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered to be relatively uncommon compared to other variants of NF-1.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Tchernev G, Chokoeva AA, Patterson JW, Bakardzhiev I, Wollina U, Tana C: Plexiform Neurofibroma: A Case Report. Medicine (Baltimore). 2016 Feb;95(6):e2663. doi: 10.1097/MD.0000000000002663. (PubMed ID 26871793)"" href=""#reference-A193608"">5</a></sup> Luckily, the use of selumetinib in patients with NF-1 has shown efficacy in shrinking associated tumors and is linked to other positive clinical outcomes.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC: Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. (PubMed ID 28029918)"" href=""#reference-A193533"">3</a></sup>"	Q02750|P36507|P33261|P08684|P11712|P05177|P10632|P05181|P20815|P22309|P35503|P02768|P02763|P19652|P08183|Q9UNQ0	456.0	6	3	6	88.4	3.5	0		MAP2K1; MAP2K2	STE	Y
Semaxanib		Sugen	CHEMBL276711	Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C	Achiral Molecule	nan	3.0	None	NSC-696819 | SEMAXANIB | SEMAXINIB | SU-5416 | SU005416 | SU5416	Investigated for use/treatment in colorectal cancer and lung cancer.	1	P35968	InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-	WUWDLXZGHZSWQZ-WQLSENKSSA-N	4486260	|http://www.chemspider.com/Chemical-Structure.4486260.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL276711|http://pubchem.ncbi.nlm.nih.gov/compound/5329098|http://www.drugbank.ca/drugs/DB06436| http://www.rcsb.org/ligand/X2M|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/X2M|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5056|http://zinc15.docking.org/substances/ZINC12410091|https://precision.fda.gov/uniisearch/srs/unii/71IA9S35AJ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497339	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'X2M'	2x2m		<span class='not-available'>Not Available</span>	P35968|P35354	238.1	1	2	1	44.9	3.1	0		KDR	Tyr	
Serabelisib		Takeda	CHEMBL3935857	c1cc2c(cc1c3ccc4ncc(n4c3)C(=O)N5CCOCC5)nc(o2)N	Achiral Molecule	nan	2.0	None	AGN-PC-0DB6FL | INK1117 | MLN-1117 | MLN1117 | SERABELISIB | TAK-117	nan	nan	nan	InChI=1S/C19H17N5O3/c20-19-22-14-9-12(1-3-16(14)27-19)13-2-4-17-21-10-15(24(17)11-13)18(25)23-5-7-26-8-6-23/h1-4,9-11H,5-8H2,(H2,20,22)	BLGWHBSBBJNKJO-UHFFFAOYSA-N	35143228	|http://www.chemspider.com/Chemical-Structure.35143228.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3935857|http://pubchem.ncbi.nlm.nih.gov/compound/70798655|http://www.drugbank.ca/drugs/DB14935|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8969|http://zinc15.docking.org/substances/ZINC000146965425|https://precision.fda.gov/uniisearch/srs/unii/43J9Q56T3W|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=119531	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						363.1	7	1	2	98.9	2.2	0		nan		
Seralutinib		Gilead Sciences	CHEMBL4650333	COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC	Single Stereoisomer	nan	2.0	None	GB-002 | GB002 | PK-10571 | SERALUTINIB	nan	nan	nan	InChI=1S/C27H27N5O3/c1-17-10-21(14-28-13-17)27(33)31-22-7-5-6-19(11-22)18(2)30-26-16-29-15-23(32-26)20-8-9-24(34-3)25(12-20)35-4/h5-16,18H,1-4H3,(H,30,32)(H,31,33)/t18-/m0/s1	JHJNPOSPVGRIAN-SFHVURJKSA-N	84492190	|http://www.chemspider.com/Chemical-Structure.84492190.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650333|http://pubchem.ncbi.nlm.nih.gov/compound/91663352|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10618|https://precision.fda.gov/uniisearch/srs/unii/3P63ZTE3OY	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS						469.2	7	2	8	98.3	5.3	1		nan		
Silmitasertib		Senhwa Biosciences	CHEMBL1230165	c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O	Achiral Molecule	nan	2.0	None	CX 4945 | CX-4945 | CX-4945 FREE ACID | CX4945 | SILMITASERTIB	nan	1	P68400|P19784	InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)	MUOKSQABCJCOPU-UHFFFAOYSA-N	25057795	|http://www.chemspider.com/Chemical-Structure.25057795.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1230165|http://pubchem.ncbi.nlm.nih.gov/compound/24748573|http://www.drugbank.ca/drugs/DB15408| http://www.rcsb.org/ligand/3NG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3NG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8126|http://zinc15.docking.org/substances/ZINC000058638454|https://precision.fda.gov/uniisearch/srs/unii/C6RWP0N0L2|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50335638	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'3NG'	3nga 3pe1 5o11 6fyl 6fyp 6fyv 6hmb 6isj 6k3l 6khd 6khe 6khf 6p5s 7z1f 7z1g 7z5n				349.1	4	2	3	75.1	4.9	0		CSNK2A1; CSNK2A2	Other	
Simotinib		Advenchen Laboratories	CHEMBL3545235	COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F	Achiral Molecule	nan	3.0	None	SIM-6802 | SIMOTINIB	nan	nan	P00533	InChI=1S/C25H26ClFN4O4/c1-32-21-12-20-17(23(29-15-28-20)30-16-2-3-19(27)18(26)10-16)11-22(21)33-7-6-31-13-24(4-5-24)25(14-31)34-8-9-35-25/h2-3,10-12,15H,4-9,13-14H2,1H3,(H,28,29,30)	OXWUWXCJDBRCCG-UHFFFAOYSA-N	20566604	|http://www.chemspider.com/Chemical-Structure.20566604.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545235|http://pubchem.ncbi.nlm.nih.gov/compound/16735117|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7640|http://zinc15.docking.org/substances/ZINC000137136675|https://precision.fda.gov/uniisearch/srs/unii/58K797D5IK	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS						500.2	8	1	7	78.0	4.4	1		EGFR	Tyr	
Simurosertib		Takeda	CHEMBL4297644	Cc1c(c[nH]n1)c2cc3c(s2)c(=O)[nH]c(n3)C4CC5CCN4CC5	Single Stereoisomer	nan	2.0	None	|TAK-931|TAK931F	nan	nan	nan	InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)	XGVXKJKTISMIOW-UHFFFAOYSA-N	64879789	|http://www.chemspider.com/Chemical-Structure.64879789.html|http://pubchem.ncbi.nlm.nih.gov/compound/71147529	|ChemSpider|PubChem						341.1	5	2	2	77.7	2.8	0		nan		
Sitravatinib		Mirati Therapeutics	CHEMBL3989926	COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F	Achiral Molecule	nan	3.0	None	MG-516 | MG-91516 | MGCD-516 | MGCD516 | SITRAVATINIB	nan	nan	P07949|Q16832|P04629|Q16620|Q16288	InChI=1S/C33H29F2N5O4S/c1-43-15-14-36-18-20-2-8-25(38-19-20)29-17-26-30(45-29)28(10-13-37-26)44-27-9-7-23(16-24(27)35)40-32(42)33(11-12-33)31(41)39-22-5-3-21(34)4-6-22/h2-10,13,16-17,19,36H,11-12,14-15,18H2,1H3,(H,39,41)(H,40,42)	WLAVZAAODLTUSW-UHFFFAOYSA-N	52083477	|http://www.chemspider.com/Chemical-Structure.52083477.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989926|http://pubchem.ncbi.nlm.nih.gov/compound/25212148|http://www.drugbank.ca/drugs/DB15036|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9920|http://zinc15.docking.org/substances/ZINC000164334830|https://precision.fda.gov/uniisearch/srs/unii/CWG62Q1VTB|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50467574	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						629.2	8	3	12	114.5	6.5	2		RET; DDR2; NTRK1; NTRK2; NTRK3	Tyr	
Solcitinib		GlaxoSmithKline	CHEMBL3301606	CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C	Achiral Molecule	nan	2.0	None	G-154578 | G154578 | GLPG-0778 | GLPG-0788 | GLPG0778 | GSK-2586184 | GSK-2586184A | GSK2586184A | SOLCITINIB	nan	nan	P23458	InChI=1S/C22H23N5O2/c1-22(2)12-26(13-22)20(29)16-10-6-14(7-11-16)17-4-3-5-18-23-21(25-27(17)18)24-19(28)15-8-9-15/h3-7,10-11,15H,8-9,12-13H2,1-2H3,(H,24,25,28)	MPYACSQFXVMWNO-UHFFFAOYSA-N	31389944	|http://www.chemspider.com/Chemical-Structure.31389944.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301606|http://pubchem.ncbi.nlm.nih.gov/compound/44603362|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9697|http://zinc15.docking.org/substances/ZINC000118401631|https://precision.fda.gov/uniisearch/srs/unii/3V7GQ1260K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=128101	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						389.2	5	1	4	79.6	3.2	0		JAK1	Tyr	
Sonolisib		Cascadian Therapeutics	CHEMBL411907	CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C	Single Stereoisomer	nan	2.0	None	PX-866 | SONOLISIB	nan	nan	P42336|P42338|P48736	InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1	QIUASFSNWYMDFS-NILGECQDSA-N	8025448	|http://www.chemspider.com/Chemical-Structure.8025448.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL411907|http://pubchem.ncbi.nlm.nih.gov/compound/9849735|http://www.drugbank.ca/drugs/DB12601|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7941|http://zinc15.docking.org/substances/ZINC000029134545|https://precision.fda.gov/uniisearch/srs/unii/987796874T	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						525.2	9	1	8	119.4	3.1	1		PIK3CA; PIK3CB; PIK3CG	Atypical	
Sorafenib	Nexavar	Bayer	CHEMBL1336	CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl	Achiral Molecule	2005	4.0	US-8618141-B2	BAY 43-9006 | BAY-43-9006 | NEXAVAR | SORAFENIB	Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.	2	P15056|P04049|P35916|P35968|P36888|P09619|P10721|P11362|P07949|P17948	InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)	MLDQJTXFUGDVEO-UHFFFAOYSA-N	187440	|http://www.chemspider.com/Chemical-Structure.187440.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1336|http://pubchem.ncbi.nlm.nih.gov/compound/216239|http://www.drugbank.ca/drugs/DB07438| http://www.rcsb.org/ligand/BAX|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/BAX|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5711|http://zinc15.docking.org/substances/ZINC01493878|https://precision.fda.gov/uniisearch/srs/unii/9ZOQ3TZI87|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=16673	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'BAX'	1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2		"Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Iyer R, Fetterly G, Lugade A, Thanavala Y: Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. (PubMed ID 20586710)"" href=""#reference-A255852"">1</a></sup> First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Keating GM, Santoro A: Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. (PubMed ID 19228077)"" href=""#reference-A14794"">3</a></sup>"	P15056|P04049|P35916|P35968|P17948|P36888|P09619|P10721|P11362|P07949|P08684|P11712|P10632|P20815|P24462|P20813|P05177|P33261|P10635|O60656|P22309|P08183|Q9UNQ0|O15439|Q92887|Q15311|Q9Y6L6	464.1	4	3	5	92.3	5.5	1	205.6 °C	BRAF; RAF1; FLT4; KDR; FLT3; PDGFRB; KIT; FGFR1; RET; FLT1	TKL<br>Tyr	Y
Sotrastaurin		Novartis	CHEMBL565612	CN1CCN(CC1)c2nc3ccccc3c(n2)C4=C(C(=O)NC4=O)c5c[nH]c6c5cccc6	Achiral Molecule	nan	2.0	None	AEB-071 | AEB071 | NVP-AEB071 | SOTRASTAURIN	nan	nan	nan	InChI=1S/C25H22N6O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18/h2-9,14,26H,10-13H2,1H3,(H,29,32,33)	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	8472351	|http://www.chemspider.com/Chemical-Structure.8472351.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL565612|http://pubchem.ncbi.nlm.nih.gov/compound/10296883|http://www.drugbank.ca/drugs/DB12369| http://www.rcsb.org/ligand/LW4|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/LW4|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946|http://zinc15.docking.org/substances/ZINC000003973984|https://precision.fda.gov/uniisearch/srs/unii/7I279E1NZ8|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=33971	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'LW4'	3iw4				438.2	6	2	3	94.2	2.4	0		nan		
Spebrutinib		Celgene	CHEMBL3301625	COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F	Achiral Molecule	nan	2.0	None	AVL-292 | BTK INHIBITOR CC-292 | CC-292 | SPEBRUTINIB	nan	nan	Q06187	InChI=1S/C22H22FN5O3/c1-3-20(29)25-16-5-4-6-17(13-16)26-21-19(23)14-24-22(28-21)27-15-7-9-18(10-8-15)31-12-11-30-2/h3-10,13-14H,1,11-12H2,2H3,(H,25,29)(H2,24,26,27,28)	KXBDTLQSDKGAEB-UHFFFAOYSA-N	29361342	|http://www.chemspider.com/Chemical-Structure.29361342.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3301625|http://pubchem.ncbi.nlm.nih.gov/compound/59174488|http://www.drugbank.ca/drugs/DB11764|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7837|http://zinc15.docking.org/substances/ZINC000072319585|https://precision.fda.gov/uniisearch/srs/unii/DRU6NG543J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50161162	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Spebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell, Diffuse, and Leukemia Lymphocytic Chronic B-Cell.	Q06187	423.2	7	3	10	97.4	4.3	0		BTK	Tyr	
Sunitinib	Sutent	Cp Pharmaceuticals	CHEMBL535	CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C	Achiral Molecule	2006	4.0	None	NSC-736511 | NSC-750690 | SU-011248 | SU-11248 | SU011248 | SUNITINIB | SUTENT	For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.	1	P09619|P17948|P10721|P35968|P35916|P36888|P07333|P16234	InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-	WINHZLLDWRZWRT-ATVHPVEESA-N	4486264	|http://www.chemspider.com/Chemical-Structure.4486264.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL535|http://pubchem.ncbi.nlm.nih.gov/compound/5329102|http://www.drugbank.ca/drugs/DB07417| http://www.rcsb.org/ligand/B49|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/B49|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5713|http://zinc15.docking.org/substances/ZINC000003964325|https://precision.fda.gov/uniisearch/srs/unii/V99T50803M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4814	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'B49'	2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 6jok 6m11 6nfy 6nfz 6ng0 6v0x		Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.	P09619|P17948|P10721|P35968|P35916|P36888|P07333|P16234|P08581|P08684|P20815|P24462|O15439|P08183|Q92887|Q9UNQ0	398.2	3	3	7	77.2	3.3	0		PDGFRB; FLT1; KIT; KDR; FLT4; FLT3; CSF1R; PDGFRA	Tyr	Y
Surufatinib		Hutchison MediPharma	CHEMBL4297190	Cc1cc2cc(ccc2[nH]1)Oc3ccnc(n3)Nc4cccc(c4)CS(=O)(=O)NCCN(C)C	Achiral Molecule	nan	3.0	None	HMPL-012 | SULFATINIB | SURUFATINIB	nan	nan	nan	InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)	TTZSNFLLYPYKIL-UHFFFAOYSA-N	57583328	|http://www.chemspider.com/Chemical-Structure.57583328.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297190|http://pubchem.ncbi.nlm.nih.gov/compound/52920501|http://www.drugbank.ca/drugs/DB15106|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9769|http://zinc15.docking.org/substances/ZINC000117218067|https://precision.fda.gov/uniisearch/srs/unii/B2K5L1L8S9	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS						480.2	7	3	10	112.2	3.8	0		nan		
Tafetinib		Nanjing Yoko Biomedical	CHEMBL2180602	CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C	Achiral Molecule	nan	1.0	None	SIM 010603 | SIM-010603 | TAFETINIB	nan	nan	P35968|P35916|P17948	InChI=1S/C24H29FN4O2/c1-4-29(5-2)12-11-26-23(30)20-14(3)27-22-16(20)7-6-8-17(22)21-18-13-15(25)9-10-19(18)28-24(21)31/h9-10,13,27H,4-8,11-12H2,1-3H3,(H,26,30)(H,28,31)/b21-17-	KGSRYTUWXUESJK-FXBPSFAMSA-N	28664989	|http://www.chemspider.com/Chemical-Structure.28664989.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2180602|http://pubchem.ncbi.nlm.nih.gov/compound/56935577|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9921|http://zinc15.docking.org/substances/ZINC000095575309|https://precision.fda.gov/uniisearch/srs/unii/H4X2M2NN5N|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399535	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						424.2	3	3	6	77.2	3.7	0		KDR; FLT4; FLT1	Tyr	
Taletrectinib		Daiichi Sankyo	CHEMBL4650989	C[C@@H](N)COc1ccc(-c2cnc3ccc(N[C@H](C)c4cccc(F)c4)nn23)cc1	Single Stereoisomer	nan	2.0	None	AB-106 | DS-6051 | DS-6051A | TALETRECTINIB	nan	nan	nan	InChI=1S/C23H24FN5O/c1-15(25)14-30-20-8-6-17(7-9-20)21-13-26-23-11-10-22(28-29(21)23)27-16(2)18-4-3-5-19(24)12-18/h3-13,15-16H,14,25H2,1-2H3,(H,27,28)/t15-,16-/m1/s1	HEVHTYMYEMEBPX-HZPDHXFCSA-N	88297530	|http://www.chemspider.com/Chemical-Structure.88297530.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650989|http://pubchem.ncbi.nlm.nih.gov/compound/72202474|https://precision.fda.gov/uniisearch/srs/unii/W4141180YD	|ChemSpider|ChEMBL|PubChem|FDA SRS						405.2	6	2	7	77.5	4.4	0		nan		
Talmapimod		Scios inc	CHEMBL514201	C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F	Single Stereoisomer	nan	2.0	None	SCIO 469 | SCIO-469 | TALMAPIMOD	Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.	1	Q16539	InChI=1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1	ZMELOYOKMZBMRB-DLBZAZTESA-N	8046764	|http://www.chemspider.com/Chemical-Structure.8046764.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL514201|http://pubchem.ncbi.nlm.nih.gov/compound/9871074|http://www.drugbank.ca/drugs/DB05412| http://www.rcsb.org/ligand/469|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/469|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7817|http://zinc15.docking.org/substances/ZINC000034001955|https://precision.fda.gov/uniisearch/srs/unii/B1E00KQ6NT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50266947	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'469'	3hub 3zsh		Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.	Q16539|P01375|P01584|P00403	512.2	5	0	5	65.9	4.0	1		MAPK14	CMGC	
Tamatinib		Rigel Pharmaceuticals		CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C		nan	2.0		R-406 | R940406 | TAMATINIB	nan	1	P43405	InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)	NHHQJBCNYHBUSI-UHFFFAOYSA-N	9388620	|http://www.chemspider.com/Chemical-Structure.9388620.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL475251|http://pubchem.ncbi.nlm.nih.gov/compound/11213558|http://www.drugbank.ca/drugs/DB07159| http://www.rcsb.org/ligand/585|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/585|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7425|http://zinc15.docking.org/substances/ZINC06745792|https://precision.fda.gov/uniisearch/srs/unii/RC3A285J2G|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=60665	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'585'	3fqs 3piy		<span class='not-available'>Not Available</span>	P43405	470.2	10	3	7	128.8	3.6	0		SYK	Tyr	
Tamnorzatinib			CHEMBL4650414	COC1=CC2=NC=CC(OC3C=NC(=CC=3)NC(=O)C3=CC4=C(CCCC4=O)N(C4C=CC=CC=4)C3=O)=C2C=C1OC	Achiral Molecule	nan	1.0	None	|ONO-7475	nan	nan	nan	InChI=1S/C32H26N4O6/c1-40-28-16-21-24(17-29(28)41-2)33-14-13-27(21)42-20-11-12-30(34-18-20)35-31(38)23-15-22-25(9-6-10-26(22)37)36(32(23)39)19-7-4-3-5-8-19/h3-5,7-8,11-18H,6,9-10H2,1-2	WHMMKPWGWNYYFE-UHFFFAOYSA-N	84393657	|http://www.chemspider.com/Chemical-Structure.84393657.html|http://pubchem.ncbi.nlm.nih.gov/compound/90645873|https://precision.fda.gov/uniisearch/srs/unii/0VCB95RHRV	|ChemSpider|PubChem|FDA SRS						562.2	9	1	7	121.6	5.4	2		nan		
Tandutinib		Takeda	CHEMBL124660	CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC	Achiral Molecule	nan	2.0	None	CT 53518 | CT-53518 | CT53518 | MLN-0518 | MLN-518 | NSC-759851 | TANDUTINIB	Investigated for use/treatment in leukemia (myeloid).	nan	P36888|Q9GZP0	InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)	UXXQOJXBIDBUAC-UHFFFAOYSA-N	2302085	|http://www.chemspider.com/Chemical-Structure.2302085.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL124660|http://pubchem.ncbi.nlm.nih.gov/compound/3038522|http://www.drugbank.ca/drugs/DB05465|http://zinc15.docking.org/substances/ZINC000003966243|https://precision.fda.gov/uniisearch/srs/unii/E1IO3ICJ9A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13535	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB				MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. AML patients with FLT3 mutations experience earlier disease relapse and shorter survival rates compared to patients without these mutations. Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration. Phase I/II trials are underway.	P36888|Q9GZP0	562.3	8	1	10	92.3	5.0	2		FLT3; PDGFD	(*)<br>Tyr	
Tanuxiciclib		BeyondBio	CHEMBL5095084	Cc1cc(-c2nc(-c3ccnc(N)c3F)ccc2O)nc(N)n1	Achiral Molecule	nan	-1.0	None		nan	nan	nan	InChI=1S/C15H13FN6O/c1-7-6-10(22-15(18)20-7)13-11(23)3-2-9(21-13)8-4-5-19-14(17)12(8)16/h2-6,23H,1H3,(H2,17,19)(H2,18,20,22)	UQHDKUFLWKTTDL-UHFFFAOYSA-N	115008004	|http://www.chemspider.com/Chemical-Structure.115008004.html|http://pubchem.ncbi.nlm.nih.gov/compound/137150090|https://precision.fda.gov/uniisearch/srs/unii/P5HNG5UF2U	|ChemSpider|PubChem|FDA SRS						312.1	7	3	2	123.8	1.9	0		nan		
Tanzisertib		Celgene	CHEMBL1950289	c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F	Single Stereoisomer	nan	2.0	None	CC-930 | JNK 930 | JNK-930 | TANZISERTIB	nan	1	P45983	InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12-,13-,14-/m0/s1	IBGLGMOPHJQDJB-IHRRRGAJSA-N	28492361	|http://www.chemspider.com/Chemical-Structure.28492361.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1950289|http://www.drugbank.ca/drugs/DB11798| http://www.rcsb.org/ligand/KBI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/KBI|http://zinc15.docking.org/substances/ZINC000102930548|https://precision.fda.gov/uniisearch/srs/unii/M5O06306UO|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50364378	|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|ZINC|FDA SRS|BindingDB	'KBI'	3tti				448.2	8	3	5	97.1	3.7	0		MAPK8	CMGC	
Tarloxotinib		Threshold Pharmaceuticals	CHEMBL4297661	Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-]	Achiral Molecule	nan	2.0	None	TARLOXOTINIB BROMIDE	nan	nan	P00533	InChI=1S/C24H23BrClN9O3.BrH/c1-33-14-30-24(34(37)38)20(33)12-35(2,3)8-4-5-22(36)32-21-10-16-19(11-27-21)28-13-29-23(16)31-15-6-7-18(26)17(25)9-15;/h4-7,9-11,13-14H,8,12H2,1-3H3,(H-,27,28,29,31,32,36);1H/b5-4+;	WAKIMVYUBWMMHJ-FXRZFVDSSA-N	46518771	|http://www.chemspider.com/Chemical-Structure.46518771.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297662|http://pubchem.ncbi.nlm.nih.gov/compound/51038315|https://precision.fda.gov/uniisearch/srs/unii/3Y31FJ8K50	|ChemSpider|ChEMBL|PubChem|FDA SRS						679.0	9	2	9	140.8	1.6	1		EGFR	Tyr	
Taselisib		Hoffmann-La Roche	CHEMBL2387080	Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N	Racemic Mixture	nan	3.0	None	GDC-0032 | RG-7604 | TASELISIB	nan	1	P42336|O00329|P48736	InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)	BEUQXVWXFDOSAQ-UHFFFAOYSA-N	29315044	|http://www.chemspider.com/Chemical-Structure.29315044.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2387080|http://pubchem.ncbi.nlm.nih.gov/compound/51001932|http://www.drugbank.ca/drugs/DB12108| http://www.rcsb.org/ligand/799|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/799|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7794|http://zinc15.docking.org/substances/ZINC000068267049|https://precision.fda.gov/uniisearch/srs/unii/L08J2O299M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50434806	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'799'	5t8f 8exl				460.2	9	1	5	118.7	3.2	0		PIK3CA; PIK3CD; PIK3CG	Atypical	
Tasurgratinib		Eisai	CHEMBL3686884	CNC(=O)n1ccc2cc(Oc3ccnc(NC(=O)c4ccc(C5CCN(CCO)CC5)cc4)c3)c(OCCOC)cc21	Achiral Molecule	nan	2.0	None	E 7090 | E-7090 | E7090 | TASURGRATINIB	nan	nan	nan	InChI=1S/C32H37N5O6/c1-33-32(40)37-14-10-25-19-29(28(21-27(25)37)42-18-17-41-2)43-26-7-11-34-30(20-26)35-31(39)24-5-3-22(4-6-24)23-8-12-36(13-9-23)15-16-38/h3-7,10-11,14,19-21,23,38H,8-9,12-13,15-18H2,1-2H3,(H,33,40)(H,34,35,39)	IBHOLSBDZMIPPT-UHFFFAOYSA-N	58828122	|http://www.chemspider.com/Chemical-Structure.58828122.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3686884|http://pubchem.ncbi.nlm.nih.gov/compound/78323434|http://zinc15.docking.org/substances/ZINC000169711512|https://precision.fda.gov/uniisearch/srs/unii/TN7CUD1NGA|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=142256	|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS|BindingDB						587.3	9	3	11	127.2	4.5	1		nan		
Telatinib		Bayer	CHEMBL2079588	CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl	Achiral Molecule	nan	2.0	None	BAY 57-9352 | BAY-57-9352 | BAY-579352 | TELATINIB	nan	nan	P35968|P35916	InChI=1S/C20H16ClN5O3/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14/h2-10H,11H2,1H3,(H,22,27)(H,24,25)	QFCXANHHBCGMAS-UHFFFAOYSA-N	7984603	|http://www.chemspider.com/Chemical-Structure.7984603.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2079588|http://pubchem.ncbi.nlm.nih.gov/compound/9808844|http://www.drugbank.ca/drugs/DB15393|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10476|http://zinc15.docking.org/substances/ZINC00590964|https://precision.fda.gov/uniisearch/srs/unii/18P7197Q7J|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50399538	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						409.1	7	2	6	102.2	4.0	0		KDR; FLT4	Tyr	
Tenalisib		Rhizen Pharmaceuticals	CHEMBL4297584	CC[C@@H](c1c(c(=O)c2ccccc2o1)c3cccc(c3)F)Nc4c5c([nH]cn5)ncn4	Single Stereoisomer	nan	2.0	None	TENALISIB	nan	nan	nan	InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1	HDXDQPRPFRKGKZ-INIZCTEOSA-N	52083673	|http://www.chemspider.com/Chemical-Structure.52083673.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297584|http://pubchem.ncbi.nlm.nih.gov/compound/86291103|http://www.drugbank.ca/drugs/DB15295|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9907|http://zinc15.docking.org/substances/ZINC000220062787|https://precision.fda.gov/uniisearch/srs/unii/2261HH611H|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50512870	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						415.1	6	2	5	96.7	4.8	0		nan		
Tepotinib		Merck	CHEMBL3402762	CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N	Achiral Molecule	2021	4.0	US-8329692-B2	EMD 1214063 | EMD-1214063 | EMD1214063 | MSC-2156119 | MSC-2156119J | MSC2156119 | TEPOTINIB	On February 2021, FDA approved tepotinib to treat non-small cell lung cancer	1	P08581	InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3	AHYMHWXQRWRBKT-UHFFFAOYSA-N	28637823	|http://www.chemspider.com/Chemical-Structure.28637823.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3402762|http://pubchem.ncbi.nlm.nih.gov/compound/25171648|http://www.drugbank.ca/drugs/DB15133| http://www.rcsb.org/ligand/3E8|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/3E8|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8293|http://zinc15.docking.org/substances/ZINC000043202335|https://precision.fda.gov/uniisearch/srs/unii/1IJV77EI07|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50065457	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'3E8'	4r1v		"Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Markham A: Tepotinib: First Approval. Drugs. 2020 Jun;80(8):829-833. doi: 10.1007/s40265-020-01317-9. (PubMed ID 32361823)"" href=""#reference-A228058"">6</a></sup> It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage PE: The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs. 2014 Oct;32(5):815-24. doi: 10.1007/s10637-014-0107-4. Epub 2014 May 16. (PubMed ID 24832869)"" href=""#reference-A228053"">5</a></sup> gastric cancers,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Sohn SH, Sul HJ, Kim B, Kim BJ, Kim HS, Zang DY: Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3beta, E-Cadherin, and Mucin 5AC and 6 Levels. Int J Mol Sci. 2020 Aug 21;21(17). pii: ijms21176027. doi: 10.3390/ijms21176027. (PubMed ID 32825724)"" href=""#reference-A228033"">2</a></sup> non-small cell lung cancer, and hepatocellular carcinoma.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Markham A: Tepotinib: First Approval. Drugs. 2020 Jun;80(8):829-833. doi: 10.1007/s40265-020-01317-9. (PubMed ID 32361823)"" href=""#reference-A228058"">6</a></sup> MET is a desirable target in the treatment of certain solid tumors as it appears to play a critical role, both directly and indirectly, in the growth and proliferation of tumors in which it is overexpressed and/or mutated.</p><p>Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with <em>MET</em> alterations, and was subsequently granted accelerated approval by the US FDA in February 2021, under the brand name Tepmetko, for the treatment of adult patients with metastatic NSCLC and <em>MET</em> exon 14 skipping alterations.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Tepmetko (tepotinib) tablets for oral use"" href=""#reference-L31443"">7</a>,<a class=""reference-popover-link"" data-content=""PR Newswire: FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations"" href=""#reference-L31473"">9</a></sup> It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""PR Newswire: FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations"" href=""#reference-L31473"">9</a></sup> an advantage that may aid in easing the pill burden often associated with chemotherapeutic regimens. In February 2022, tepotinib was approved for use in Europe.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations"" href=""#reference-L42200"">10</a></sup>"	P08581|Q9Y2I1|P49286|P08684|P10632|P11712|P02768|P02763|P08183|Q9UNQ0|O15245|O15244|Q96FL8|Q86VL8|O95342	492.2	8	0	7	96.9	4.0	0		MET	Tyr	Y
Tesevatinib		Kadmon Corporation	CHEMBL3544983	CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl	Racemic Mixture	nan	3.0	None	EXEL-7647 | KD-019 | KD-020 | KD019 | TESEVATINIB | XL-647 | XL647	nan	nan	P00533|P04626|P35968|P35916|P54760	InChI=1S/C24H25Cl2FN4O2/c1-31-9-14-5-13(6-15(14)10-31)11-33-21-8-19-16(7-20(21)32-2)24(29-12-28-19)30-18-4-3-17(25)22(26)23(18)27/h3-4,7-8,12-15H,5-6,9-11H2,1-2H3,(H,28,29,30)/t13-,14-,15+	HVXKQKFEHMGHSL-QKDCVEJESA-N	32699556	|http://www.chemspider.com/Chemical-Structure.32699556.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3544983|http://www.drugbank.ca/drugs/DB11973|http://zinc15.docking.org/substances/ZINC000114456300|https://precision.fda.gov/uniisearch/srs/unii/F6XM2TN5A1|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50524283	|ChemSpider|ChEMBL|DrugBank|ZINC|FDA SRS|BindingDB				Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.</p><p>Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, tesevatinib retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.	P01133|P54760|P04626	490.1	6	1	6	59.5	5.8	1		EGFR; ERBB2; KDR; FLT4; EPHB4	Tyr	
Theliatinib		Hutchison MediPharma		CN1CC[C@H]2[C@@H]1CN(C2)C(=O)Nc3cc4c(cc3OC)ncnc4Nc5cccc(c5)C#C		nan	1.0		XILIERTINIB	nan	nan	nan	InChI=1S/C25H26N6O2/c1-4-16-6-5-7-18(10-16)28-24-19-11-21(23(33-3)12-20(19)26-15-27-24)29-25(32)31-13-17-8-9-30(2)22(17)14-31/h1,5-7,10-12,15,17,22H,8-9,13-14H2,2-3H3,(H,29,32)(H,26,27,28)/t17-,22+/m1/s1	FSXCKIBROURMFT-VGSWGCGISA-N	68025614	|http://www.chemspider.com/Chemical-Structure.68025614.html|http://pubchem.ncbi.nlm.nih.gov/compound/54759275|http://zinc15.docking.org/substances/ZINC000113384840|https://precision.fda.gov/uniisearch/srs/unii/6ZZ3B7NZ0B	|ChemSpider|PubChem|ZINC|FDA SRS						442.2	6	2	4	82.6	3.5	0		nan		
Tilpisertib		Gilead Sciences	CHEMBL4802154	CC(C)(C)CNC1=C2C=C(C=C(Cl)C2=NC=C1C#N)N[C@@H](C1C=CC=C2C(=O)N(C)C=CC=12)C1=CN(N=N1)C12CC(C1)C2	Single Stereoisomer	nan	2.0	None	TILPISERTIB	nan	nan	nan	InChI=1S/C33H33ClN8O/c1-32(2,3)18-37-28-20(15-35)16-36-29-25(28)10-21(11-26(29)34)38-30(27-17-42(40-39-27)33-12-19(13-33)14-33)23-6-5-7-24-22(23)8-9-41(4)31(24)43/h5-11,16-17,19,30,38H,12-14,18H2,1-4H3,(H,36,37)/t19?,30-,33?/m0/s1	VFGSKBLZRDRHOI-ZAGPDIDGSA-N	115009513	|http://www.chemspider.com/Chemical-Structure.115009513.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4802154|http://pubchem.ncbi.nlm.nih.gov/compound/124181541|https://precision.fda.gov/uniisearch/srs/unii/A8Y5K4G762	|ChemSpider|ChEMBL|PubChem|FDA SRS						592.2	9	2	7	113.5	6.4	2		nan		
Tinengotinib		TransThera Biosciences	CHEMBL4594509	CC1NN=C2NC3C=C(N=CC=3C(=NC2=1)C1C=CC=CC=1Cl)N1CCOCC1	Unknown	nan	2.0	None	|TT-00420	nan	nan	nan	InChI=1S/C20H19ClN6O/c1-12-18-20(26-25-12)23-16-10-17(27-6-8-28-9-7-27)22-11-14(16)19(24-18)13-4-2-3-5-15(13)21/h2-5,10-11H,6-9H2,1H3,(H2,23,25,26)	DQFCVOOFMXEPOC-UHFFFAOYSA-N	115008005	|http://www.chemspider.com/Chemical-Structure.115008005.html|http://pubchem.ncbi.nlm.nih.gov/compound/137279257|http://www.drugbank.ca/drugs/DB17384|https://precision.fda.gov/uniisearch/srs/unii/WZ9TJ0L9Y8	|ChemSpider|PubChem|DrugBank|FDA SRS						394.1	6	2	2	78.4	3.8	0		nan		
Tinlorafenib		Pfizer	CHEMBL5095256	Cc1c(Nc2c(F)ccc(NS(=O)(=O)CCCF)c2Cl)ccc2ncn(C)c(=O)c12	Achiral Molecule	nan	1.0	None	ARRY-461||AR00504461|PF-07284890	nan	nan	nan	InChI=1S/C19H19ClF2N4O3S/c1-11-13(6-7-14-16(11)19(27)26(2)10-23-14)24-18-12(22)4-5-15(17(18)20)25-30(28,29)9-3-8-21/h4-7,10,24-25H,3,8-9H2,1-2H3	VVLVISDSGRHLMB-UHFFFAOYSA-N		|http://www.chemspider.com/Chemical-Structure..html|http://pubchem.ncbi.nlm.nih.gov/compound/155434855	|ChemSpider|PubChem						456.1	6	2	7	93.1	3.9	0		nan		
Tirabrutinib		Ono Pharmaceutical	CHEMBL4071161	CC#CC(=O)N1CCC(C1)n2c3c(c(ncn3)N)n(c2=O)c4ccc(cc4)Oc5ccccc5	Single Stereoisomer	nan	2.0	None	|ONO-4059(FREE BASE)|GS-4059|ONO-4059	nan	nan	nan	InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)	SEJLPXCPMNSRAM-UHFFFAOYSA-N	34979967	|http://www.chemspider.com/Chemical-Structure.34979967.html|http://pubchem.ncbi.nlm.nih.gov/compound/54755435	|ChemSpider|PubChem						454.2	8	1	4	108.3	2.8	0		nan		
Tivantinib		Daiichi Sankyo	CHEMBL2103882	c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5	Single Stereoisomer	nan	3.0	None	ARQ 197 | ARQ-197 | TIVANTINIB	nan	nan	P08581	InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1	UCEQXRCJXIVODC-PMACEKPBSA-N	9669218	|http://www.chemspider.com/Chemical-Structure.9669218.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103882|http://pubchem.ncbi.nlm.nih.gov/compound/11494412|http://www.drugbank.ca/drugs/DB12200| http://www.rcsb.org/ligand/TIV|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/TIV|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948|http://zinc15.docking.org/substances/ZINC000100016063|https://precision.fda.gov/uniisearch/srs/unii/PJ4H73IL17|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50146168	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'TIV'	5cb4		Tivantinib has been investigated in Solid Tumors.	P08581	369.1	3	2	2	66.9	3.6	0		MET	Tyr	
Tivozanib	Fotivda	Aveo Pharmaceuticals	CHEMBL1289494	Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC	Achiral Molecule	2021	4.0	US-6821987-B2	ASP-4130 | AV-951 | FOTIVDA | KIL-8951 | KIL8951 | KRN-951 | TIVOZANIB	On March 2021, FDA approved tivozanib to treat patients with renal cell carcinoma	2	P17948|P35968|P35916	InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)	SPMVMDHWKHCIDT-UHFFFAOYSA-N	8087481	|http://www.chemspider.com/Chemical-Structure.8087481.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1289494|http://pubchem.ncbi.nlm.nih.gov/compound/9911830|http://www.drugbank.ca/drugs/DB11800| http://www.rcsb.org/ligand/AV9|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AV9|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6058|http://zinc15.docking.org/substances/ZINC01489430|https://precision.fda.gov/uniisearch/srs/unii/172030934T|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50331095	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'AV9'	4ase 8bem		"Renal cell carcinoma (RCC) is responsible for 3% of cancer cases<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Pallagani L, Choudhary GR, Himanshu P, Madduri VKS, Singh M, Gupta P, Shrivastava N, Baid G, Meenakshi R, Aasma N, Pareek P, Sanjeev M: Epidemiology and Clinicopathological Profile of Renal Cell Carcinoma: A Review from Tertiary Care Referral Centre. J Kidney Cancer VHL. 2021 Jan 20;8(1):1-6. doi: 10.15586/jkcvhl.2021.154. eCollection 2021. (PubMed ID 33552876)"" href=""#reference-A231314"">2</a></sup> and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Cancer.org: Key Statistics About Kidney Cancer"" href=""#reference-L32529"">10</a></sup> Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: FOTIVDA (tivozanib) capsules, for oral use"" href=""#reference-L32524"">9</a></sup>"	P17948|P35968|P35916|P10721|P09619|P36888|P16234|Q13882|Q02763|P11362|P08581|P08684|P02768|P08183|Q9UNQ0	454.1	7	2	6	107.7	5.6	1	220-233	FLT1; KDR; FLT4	Tyr	Y
Toceranib		Pfizer	CHEMBL13608	Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F	Achiral Molecule	nan	0.0	None	PALLADIA | PHA-291639 | TOCERANIB	nan	nan	O97799	InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-	SRSGVKWWVXWSJT-ATVHPVEESA-N	4486268	|http://www.chemspider.com/Chemical-Structure.4486268.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL13608|http://pubchem.ncbi.nlm.nih.gov/compound/5329106| http://www.rcsb.org/ligand/BWC|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/BWC|http://zinc15.docking.org/substances/ZINC000003989258|https://precision.fda.gov/uniisearch/srs/unii/59L7Y0530C|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4818	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|ZINC|FDA SRS|BindingDB	'BWC'	6m13				396.2	3	3	5	77.2	3.1	0		KIT	KIT	
Tofacitinib	Xeljanz	Pfizer	CHEMBL221959	C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N	Single Stereoisomer	2012	4.0	US-6965027-B2	550 | CP 690550 | CP- 690 550 | CP-690 | CP-690 FREE BASE | CP-690,550 | CP-690,550 FREE BASE | CP-690-550 | CP-690550 | CP-690550 FREE BASE | CP690,550 | CP690550 | TASOCITINIB | TOFACITINIB	For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.	1	P23458|O60674|P52333|P29597	InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1	UJLAWZDWDVHWOW-YPMHNXCESA-N	8102425	|http://www.chemspider.com/Chemical-Structure.8102425.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL221959|http://pubchem.ncbi.nlm.nih.gov/compound/9926791|http://www.drugbank.ca/drugs/DB08895| http://www.rcsb.org/ligand/MI1|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MI1|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5677|http://zinc15.docking.org/substances/ZINC03818808|https://precision.fda.gov/uniisearch/srs/unii/87LA6FU830|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193995	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'MI1'	3eyg 3fup 3lxk 3lxn 4oti		Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate.Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.	P23458|O60674|P52333|P29597|P08684|P33261	312.2	5	1	3	88.9	1.5	0	White crystalline solid. MP: 199-206 °C /Tofacitinib monocitrate/	JAK1; JAK2; JAK3; TYK2	Tyr	Y
Tolebrutinib		Principia Biopharma	CHEMBL4650323	C=CC(=O)N1CCCC(C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5	Single Stereoisomer	nan	3.0	None	PRN-2246 | PRN2246 | SAR-442168 | SAR442168 | TOLEBRUTINIB	nan	nan	nan	InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1	KOEUOFPEZFUWRF-LJQANCHMSA-N	88298633	|http://www.chemspider.com/Chemical-Structure.88298633.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650323|http://pubchem.ncbi.nlm.nih.gov/compound/124111565|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10625|https://precision.fda.gov/uniisearch/srs/unii/8CZ82ZYY9X	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS						455.2	7	1	5	95.4	3.9	0		nan		
Tomivosertib		Effector Therapeutics	CHEMBL4073443	Cc1cc(c(=O)n2c1C(=O)NC23CCCCC3)Nc4cc(ncn4)N	Achiral Molecule	nan	2.0	None	EFT 508 | EFT-508 | EFT508 | TOMIVOSERTIB	Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling	nan	nan	InChI=1S/C17H20N6O2/c1-10-7-11(21-13-8-12(18)19-9-20-13)16(25)23-14(10)15(24)22-17(23)5-3-2-4-6-17/h7-9H,2-6H2,1H3,(H,22,24)(H3,18,19,20,21)	HKTBYUWLRDZAJK-UHFFFAOYSA-N	57617704	|http://www.chemspider.com/Chemical-Structure.57617704.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4073443|http://pubchem.ncbi.nlm.nih.gov/compound/118598754|http://www.drugbank.ca/drugs/DB15219| http://www.rcsb.org/ligand/N45|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/N45|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10167|http://zinc15.docking.org/substances/ZINC000575623807|https://precision.fda.gov/uniisearch/srs/unii/U2H19X4WBV|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50263263	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'N45'	6ck6				340.2	7	3	2	114.9	1.6	0		nan		
Tovorafenib		Sunesis Pharmaceuticals	CHEMBL3348923	CC(C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl	Single Stereoisomer	nan	2.0	None	BIIB-024 | BIIB024 | DAY-101 | DAY101 | MLN-2480 | TAK 580 | TAK-580 | TOVORAFENIB	nan	nan	nan	nChI=1S/C17H12Cl2F3N7O2S/c1-6(28-15(31)12-11(19)13(23)27-5-26-12)16-25-4-9(32-16)14(30)29-10-2-7(17(20,21)22)8(18)3-24-10/h2-6H,1H3,(H,28,31)(H2,23,26,27)(H,24,29,30)/t6-/m1/s1	VWMJHAFYPMOMGF-ZCFIWIBFSA-N	28637796	|http://www.chemspider.com/Chemical-Structure.28637796.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3348923|http://pubchem.ncbi.nlm.nih.gov/compound/25161177|http://www.drugbank.ca/drugs/DB15266| http://www.rcsb.org/ligand/QOP|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QOP|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9977|http://zinc15.docking.org/substances/ZINC000043202464|https://precision.fda.gov/uniisearch/srs/unii/ZN90E4027M|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=209864	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'QOP'	6v34 8f7o				505.0	8	3	5	135.8	4.0	1		nan		
Tozasertib		Merck	CHEMBL572878	Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C	Achiral Molecule	nan	2.0	None	MK-045 | MK-0457 | TOZASERTIB | VX-68 | VX-680	nan	1	O14965|Q96GD4|Q9UQB9	InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)	GCIKSSRWRFVXBI-UHFFFAOYSA-N	4591897	|http://www.chemspider.com/Chemical-Structure.4591897.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL572878|http://pubchem.ncbi.nlm.nih.gov/compound/5494449| http://www.rcsb.org/ligand/VX6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/VX6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5718|http://zinc15.docking.org/substances/ZINC13125756|https://precision.fda.gov/uniisearch/srs/unii/234335M86K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50004205	|ChemSpider|ChEMBL|PubChem|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'VX6'	2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 5wnm 6brj 6gr9				464.2	8	3	7	102.1	3.5	0		AURKA; AURKB; AURKC	Other	
Trametinib	Mekinist	GlaxoSmithKline	CHEMBL2105741	Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5	Achiral Molecule	2013	4.0	US-7378423-B2	GSK-1120212 | GSK1120212 | JTP 74057 | JTP-74057 | MEKINIST | TMT-212 | TMT212 | TRAMETINIB	Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.	3	P15056|Q02750|P36507	InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	9881833	|http://www.chemspider.com/Chemical-Structure.9881833.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103875|http://pubchem.ncbi.nlm.nih.gov/compound/11707110|http://www.drugbank.ca/drugs/DB08911| http://www.rcsb.org/ligand/QOM|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/QOM|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495|http://zinc15.docking.org/substances/ZINC43100709|https://precision.fda.gov/uniisearch/srs/unii/33E86K87QN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50531540	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'QOM'	7jur 7jux 7m0y		"Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Wright CJ, McCormack PL: Trametinib: first global approval. Drugs. 2013 Jul;73(11):1245-54. doi: 10.1007/s40265-013-0096-1. (PubMed ID 23846731)"" href=""#reference-A258298"">4</a>,<a class=""reference-popover-link"" data-content=""Zeiser R: Trametinib. Recent Results Cancer Res. 2014;201:241-8. doi: 10.1007/978-3-642-54490-3_15. (PubMed ID 24756797)"" href=""#reference-A258293"">3</a></sup> It was first approved by the FDA in May 2013 for the treatment of melanoma.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Wright CJ, McCormack PL: Trametinib: first global approval. Drugs. 2013 Jul;73(11):1245-54. doi: 10.1007/s40265-013-0096-1. (PubMed ID 23846731)"" href=""#reference-A258298"">4</a></sup> It was later approved by Health Canada on July 18, 2013 <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Health Canada Approved Drug Products: MEKINIST (Trametinib) Oral Tablets"" href=""#reference-L45588"">9</a></sup> and by the European Commission on June 30, 2014.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""EMA Approved Drug Products: Mekinist (trametinib) Oral Tablets"" href=""#reference-L45583"">8</a></sup> Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with <a href=""https://go.drugbank.com/drugs/DB08912"">dabrafenib</a>, a BRAF inhibitor, for improved therapeutic efficacy. Originally developed by Japan Tobacco, trametinib was initially investigated for treating inflammation, but further studies for this indication were not pursued.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Wright CJ, McCormack PL: Trametinib: first global approval. Drugs. 2013 Jul;73(11):1245-54. doi: 10.1007/s40265-013-0096-1. (PubMed ID 23846731)"" href=""#reference-A258298"">4</a></sup>"	Q02750|P36507|P10632|P08684	615.1	8	2	5	107.1	3.9	1	293-303	BRAF; MAP2K1; MAP2K2	TKL<br>STE	Y
Trilaciclib		G1 Therapeutics	CHEMBL3894860	CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O	Achiral Molecule	2021	4.0	US-8598186-B2;US-8598197-B2	G1T28 | G1T28-1 | TRILACICLIB	On February 2021, FDA approved trilaciclib to mitigate chemotherapy-induced myelosuppression in adult patients with small cell lung cancer	nan	P11802|Q00534	InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)	PDGKHKMBHVFCMG-UHFFFAOYSA-N	58825997	|http://www.chemspider.com/Chemical-Structure.58825997.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3894860|http://pubchem.ncbi.nlm.nih.gov/compound/68029831|http://www.drugbank.ca/drugs/DB15442|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9626|http://zinc15.docking.org/substances/ZINC000143683854|https://precision.fda.gov/uniisearch/srs/unii/U6072DO9XG|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=253928	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: Cosela (Trilaciclib) Intravenous Injection"" href=""#reference-L31828"">6</a></sup> CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Peters G: The D-type cyclins and their role in tumorigenesis. J Cell Sci Suppl. 1994;18:89-96. doi: 10.1242/jcs.1994.supplement_18.13. (PubMed ID 7883799)"" href=""#reference-A229323"">3</a></sup> Trilaciclib was first described in the literature in 2016.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC: Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93. doi: 10.1158/1535-7163.MCT-15-0775. Epub 2016 Jan 29. (PubMed ID 26826116)"" href=""#reference-A229313"">1</a></sup></p><p>Trilaciclib was granted FDA approval on 12 February 2021.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News Release: FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy"" href=""#reference-L31823"">5</a></sup>"	P11802|Q00534|P50750|P24941|Q00535|P50613|P05177|O15244|Q96FL8|Q86VL8|Q9UNQ0|P08183	446.3	8	2	3	91.2	2.7	0		CDK4; CDK6	CMGC	Y
Tucatinib	Tukysa	Array BioPharma	CHEMBL3989868	Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C	Achiral Molecule	2020	4.0	US-7452895-B2	ARRY-380 | IRBINITINIB | ONT-380 | TUCATINIB | TUKYSA	On April 2020, FDA approved tucatinib to treat advanced unresectable or metastatic HER2-positive breast cancer.	nan	P04626	InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)	SDEAXTCZPQIFQM-UHFFFAOYSA-N	34995558	|http://www.chemspider.com/Chemical-Structure.34995558.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3989868|http://pubchem.ncbi.nlm.nih.gov/compound/51039094|http://www.drugbank.ca/drugs/DB11652|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9922|http://zinc15.docking.org/substances/ZINC000068250462|https://precision.fda.gov/uniisearch/srs/unii/234248D0HH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=471617	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Tucatinib is a kinase inhibitor drug used with <a href=""https://go.drugbank.com/drugs/DB00072"">trastuzumab</a> and <a href=""https://go.drugbank.com/drugs/DB01101"">capecitabine</a> in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA News Release: FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast Cancer"" href=""#reference-L12951"">8</a></sup> Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA approved products: Tukysa (tucatinib) oral tablets"" href=""#reference-L12945"">7</a></sup>"	P04626|P21860|P10632|P08684|Q9HB55|P20815|P24462|P04626|Q9UNQ0|P08183|O15244|Q96FL8|Q86VL8	480.2	10	2	5	110.9	5.1	1	230	ERBB2	Tyr	Y
Tunlametinib		Tianjin Binjiang Pharma	CHEMBL5095241	O=C(NOCCO)c1cc2scnc2c(F)c1Nc1ccc(I)cc1F	Achiral Molecule	nan	2.0	None	|HL-085|HL085	nan	nan	nan	InChI=1S/C16H12F2IN3O3S/c17-10-5-8(19)1-2-11(10)21-14-9(16(24)22-25-4-3-23)6-12-15(13(14)18)20-7-26-12/h1-2,5-7,21,23H,3-4H2,(H,22,24)	UFZJUVFSSINETF-UHFFFAOYSA-N	115006753	|http://www.chemspider.com/Chemical-Structure.115006753.html|http://pubchem.ncbi.nlm.nih.gov/compound/71621329|https://precision.fda.gov/uniisearch/srs/unii/IF25NR1PV3	|ChemSpider|PubChem|FDA SRS						491.0	6	3	6	83.5	3.6	0		nan		
Tuspetinib		Hanmi Pharmaceutical	CHEMBL4297980	CC1C=CC2=C(C=1)NC=C2C1=NC(NC2=CC(CN3C[C@H](C)N[C@H](C)C3)=CC(=C2)C2CC2)=NC=C1Cl	Unknown	nan	1.0	None	|HM43239|HM-43239	nan	nan	nan	InChI=1S/C29H33ClN6/c1-17-4-7-24-25(12-31-27(24)8-17)28-26(30)13-32-29(35-28)34-23-10-20(9-22(11-23)21-5-6-21)16-36-14-18(2)33-19(3)15-36/h4,7-13,18-19,21,31,33H,5-6,14-16H2,1-3H3,(H,32,34,35)/t18-,19+	FZLSDZZNPXXBBB-KDURUIRLSA-N	75531294	|http://www.chemspider.com/Chemical-Structure.75531294.html|http://pubchem.ncbi.nlm.nih.gov/compound/135390910|http://www.drugbank.ca/drugs/DB15343|https://precision.fda.gov/uniisearch/srs/unii/C0WUS7XXE9|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=476700	|ChemSpider|PubChem|DrugBank|FDA SRS|BindingDB						500.2	5	3	6	68.9	6.4	2		nan		
Tuvusertib		EMD Serono		CN1C=NC=C1C1C(=CN=CC=1F)NC(=O)C1=C2N=CC(F)=CN2N=C1N		nan	2.0		|1774| 1774	nan	nan	nan	InChI=1S/C16H12F2N8O/c1-25-7-21-5-11(25)12-9(18)3-20-4-10(12)23-16(27)13-14(19)24-26-6-8(17)2-22-15(13)26/h2-7H,1H3,(H2,19,24)(H,23,27)	RBQPCTBFIPVIJN-UHFFFAOYSA-N	75533912	|http://www.chemspider.com/Chemical-Structure.75533912.html|http://pubchem.ncbi.nlm.nih.gov/compound/90199447|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=412025	|ChemSpider|PubChem|BindingDB						370.1	8	2	3	116.0	1.6	0		nan		
Tuxobertinib		Black Diamond Therapeutics	CHEMBL4650279	C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1OCCN1CCOCC1	Achiral Molecule	nan	1.0	None	BDTX-189 | BDTX189 | TUXOBERTINIB	nan	nan	nan	InChI=1S/C29H29ClN6O4/c1-2-28(37)35-25-16-22-24(17-27(25)39-14-11-36-9-12-38-13-10-36)32-19-33-29(22)34-20-6-7-26(23(30)15-20)40-18-21-5-3-4-8-31-21/h2-8,15-17,19H,1,9-14,18H2,(H,35,37)(H,32,33,34)	HIBPKFXWOPYJPZ-UHFFFAOYSA-N	112747183	|http://www.chemspider.com/Chemical-Structure.112747183.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650279|http://pubchem.ncbi.nlm.nih.gov/compound/154824631|https://precision.fda.gov/uniisearch/srs/unii/6CE2107J4T	|ChemSpider|ChEMBL|PubChem|FDA SRS						560.2	9	2	11	110.7	4.8	1		nan		
Ulixertinib		BioMed Valley Discoveries	CHEMBL3590106	CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl	Single Stereoisomer	nan	2.0	None	BVD-523 | BVD-ERK | ULIXERTINIB | VRT-752271	nan	nan	P28482|P27361	InChI=1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1	KSERXGMCDHOLSS-LJQANCHMSA-N	9893722	|http://www.chemspider.com/Chemical-Structure.9893722.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3590106|http://pubchem.ncbi.nlm.nih.gov/compound/11719003|http://www.drugbank.ca/drugs/DB13930| http://www.rcsb.org/ligand/EVK|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/EVK|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9210|http://zinc15.docking.org/substances/ZINC000034642570|https://precision.fda.gov/uniisearch/srs/unii/16ZDH50O1U	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS	'EVK'	6gdq		"Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ: Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib). Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22. (PubMed ID 28939558)"" href=""#reference-A31474"">1</a></sup>. It is currently in clinical trials for the treatment of a wide range of tumors."	P27361|P28482	432.1	4	4	7	90.0	4.7	0		MAPK1; MAPK3	CMGC	
Umbralisib		TG Therapeutics	CHEMBL3948730	C[C@@H](c1c(c(=O)c2cc(ccc2o1)F)c3cccc(c3)F)n4c5c(c(n4)c6ccc(c(c6)F)OC(C)C)c(ncn5)N	Single Stereoisomer	2021	4.0	US-9150579-B2	RP-5264 | RP5264 | TGR 1202 | TGR-1202 BASE | TGR-1202 FREE BASE | UMBRALISIB	On February 2021, FDA approved umbralisib for the treatment of certain patients with marginal zone lymphoma and follicular lymphoma	nan	nan	InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1	IUVCFHHAEHNCFT-INIZCTEOSA-N	34979945	|http://www.chemspider.com/Chemical-Structure.34979945.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3948730|http://pubchem.ncbi.nlm.nih.gov/compound/72950888|http://www.drugbank.ca/drugs/DB14989|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8916|http://zinc15.docking.org/substances/ZINC000141831516|https://precision.fda.gov/uniisearch/srs/unii/38073MQB2A|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=184556	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with <a href=""https://go.drugbank.com/drugs/DB00073"">rituximab</a> (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O&#39;Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. (PubMed ID 29475723)"" href=""#reference-A229363"">1</a></sup> Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Freedman A, Jacobsen E: Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020 Mar;95(3):316-327. doi: 10.1002/ajh.25696. Epub 2019 Dec 22. (PubMed ID 31814159)"" href=""#reference-A229668"">5</a></sup></p><p>On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results from clinical trials. It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA: FDA grants accelerated approval to umbralisib for marginal zone lymphoma and follicular lymphoma"" href=""#reference-L31863"">6</a></sup> Umbralisib inhibits casein kinase, a primary regulator of protein translation, kinase-1ε, distinguishing it from other lymphoma treatments. While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Burris HA 3rd, Flinn IW, Patel MR, Fenske TS, Deng C, Brander DM, Gutierrez M, Essell JH, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Savona MR, O&#39;Connor OA: Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. doi: 10.1016/S1470-2045(18)30082-2. Epub 2018 Feb 20. (PubMed ID 29475723)"" href=""#reference-A229363"">1</a></sup> umbralisib was withdrawn from the market due to safety concerns as the drug was associated with a possible increased risk of death outweighing the benefits.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Drug Safety and Availability: FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns"" href=""#reference-L41930"">10</a></sup>"	P49674|O00329|P00519|P11712|P05177|P08684|P00519|P08183	571.2	8	1	6	109.1	6.7	2	139-142	nan		Y
Upadacitinib	Rinvoq	Abbvie	CHEMBL3622821	CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F	Single Stereoisomer	2019	4.0	US-8962629-B2	ABT-494 | RINVOQ | UPADACITINIB | UPADACITINIB ANHYDROUS | UPADACITINIB HEMIHYDRATE | UPADACITINIB HYDRATE	On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis	nan	P23458	InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1	WYQFJHHDOKWSHR-MNOVXSKESA-N	44210449	|http://www.chemspider.com/Chemical-Structure.44210449.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3622821|http://pubchem.ncbi.nlm.nih.gov/compound/58557659|http://www.drugbank.ca/drugs/DB15091|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9246|http://zinc15.docking.org/substances/ZINC000147180128|https://precision.fda.gov/uniisearch/srs/unii/4RA0KN46E0|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50503287	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				"Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)"" href=""#reference-A189165"">4</a></sup> Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Rivellese F, Lobasso A, Barbieri L, Liccardo B, de Paulis A, Rossi FW: Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors. Curr Med Chem. 2019;26(16):2823-2843. doi: 10.2174/0929867325666180209145243. (PubMed ID 29424301)"" href=""#reference-A189171"">6</a></sup> The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O&#39;Shea JJ: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267. (PubMed ID 29282366)"" href=""#reference-A189168"">5</a></sup> To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and <a href=""https://go.drugbank.com/drugs/DB14845"">filgotinib</a>, were developed.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019. (PubMed ID 31692920)"" href=""#reference-A189165"">4</a></sup></p><p>The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: RINVOQ (upadacitinib) extended-release tablets, for oral use"" href=""#reference-L10896"">9</a></sup> In December 2019, it was additionally approved by the European Commission.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""AbbVie Receives European Commission Approval of RINVOQ™ (upadacitinib) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis"" href=""#reference-L10899"">10</a></sup> Upadacitinib is marketed under the brand name RINVOQ for oral administration.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""FDA Approved Drug Products: RINVOQ (upadacitinib) extended-release tablets, for oral use"" href=""#reference-L10896"">9</a></sup>"	P23458|P08684|P10635|P08183|Q9UNQ0|Q9Y6L6	380.2	4	2	3	78.3	2.9	0	16-19	JAK1	Tyr	Y
Uprosertib		GlaxoSmithKline	CHEMBL3137336	Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN	Single Stereoisomer	nan	2.0	None	AKT INHIBITOR GSK-2141795 | AKT INHIBITOR GSK2141795 | GSK-2141795 | GSK-2141795C | GSK2141795 | GSK2141795C | UPROSERTIB	nan	nan	P31749|P31751|Q9Y243	InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1	AXTAPYRUEKNRBA-JTQLQIEISA-N	32701836	|http://www.chemspider.com/Chemical-Structure.32701836.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3137336|http://pubchem.ncbi.nlm.nih.gov/compound/51042438|http://www.drugbank.ca/drugs/DB11969|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7902|http://zinc15.docking.org/substances/ZINC000043197676|https://precision.fda.gov/uniisearch/srs/unii/ZXM835LQ5E|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50170284	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						428.1	5	2	6	86.1	3.6	0		AKT1; AKT2; AKT3	AGC	
Utatrectinib		Astrazeneca	CHEMBL3545179	C[C@@H](c1ncc(cn1)F)Nc2ccc3c(n2)n(cn3)c4cc([nH]n4)OC(C)C	Single Stereoisomer	nan	1.0	None		nan	nan	nan	InChI=1S/C18H19FN8O/c1-10(2)28-16-6-15(25-26-16)27-9-22-13-4-5-14(24-18(13)27)23-11(3)17-20-7-12(19)8-21-17/h4-11H,1-3H3,(H,23,24)(H,25,26)/t11-/m0/s1	AYOOGWWGECJQPI-NSHDSACASA-N	34950479	|http://www.chemspider.com/Chemical-Structure.34950479.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3659497|http://pubchem.ncbi.nlm.nih.gov/compound/25115967|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10360|http://zinc15.docking.org/substances/ZINC000096167835|https://precision.fda.gov/uniisearch/srs/unii/VNM956Y27V|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=98013	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						382.2	8	2	6	106.4	3.0	0		nan		
Vactosertib		MedPacto	CHEMBL3260567	Cc1cccc(n1)c2c(nc([nH]2)CNc3ccccc3F)c4ccc5ncnn5c4	Achiral Molecule	nan	2.0	None	EW-7197 | TEW 7197 | TEW-7197 | VACTOSERTIB	Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.	nan	nan	InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)	FJCDSQATIJKQKA-UHFFFAOYSA-N	32813335	|http://www.chemspider.com/Chemical-Structure.32813335.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3260567|http://pubchem.ncbi.nlm.nih.gov/compound/54766013|http://www.drugbank.ca/drugs/DB15310|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8107|http://zinc15.docking.org/substances/ZINC000113391423|https://precision.fda.gov/uniisearch/srs/unii/6T4O391P5Y|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50015639	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						399.2	6	2	5	83.8	4.2	0		nan		
Vamotinib		Fusion Pharma	CHEMBL4297478	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1nnc2ccccn12	Achiral Molecule	nan	1.0	None	PF-114 | VAMOTINIB	nan	nan	nan	InChI=1S/C29H27F3N6O/c1-20-6-7-22(17-21(20)9-11-27-35-34-26-5-3-4-12-38(26)27)28(39)33-24-10-8-23(25(18-24)29(30,31)32)19-37-15-13-36(2)14-16-37/h3-8,10,12,17-18H,13-16,19H2,1-2H3,(H,33,39)	SLIVDYMORZGPLW-UHFFFAOYSA-N	68007089	|http://www.chemspider.com/Chemical-Structure.68007089.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297478|http://pubchem.ncbi.nlm.nih.gov/compound/71475839|http://www.drugbank.ca/drugs/DB15396|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9792|http://zinc15.docking.org/substances/ZINC000149048612|https://precision.fda.gov/uniisearch/srs/unii/I8C3R768IZ|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=260151	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						532.2	6	1	4	65.8	4.5	1		nan		
Vandetanib	Caprelsa;Zactima	Ipr Pharmaceuticals	CHEMBL24828	CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br	Achiral Molecule	2011	4.0	US-RE42353-E1	CAPRELSA | GNF-PF-2188 | NSC-744325 | NSC-760766 | VANDETANIB | ZACTIMA | ZD-64 | ZD-6474 | ZD6474	Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.	1.5	P15692|P00533|Q13882|Q02763|P07949	InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)	UHTHHESEBZOYNR-UHFFFAOYSA-N	2338979	|http://www.chemspider.com/Chemical-Structure.2338979.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL24828|http://pubchem.ncbi.nlm.nih.gov/compound/3081361|http://www.drugbank.ca/drugs/DB08764| http://www.rcsb.org/ligand/ZD6|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/ZD6|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5717|http://zinc15.docking.org/substances/ZINC000053683345|https://precision.fda.gov/uniisearch/srs/unii/YO460OQ37K|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=21	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'ZD6'	2ivu		Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.</p><p>On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.	P15692|P00533|Q13882|Q02763|P07949|Q01740|P31513|P08684|P02763|P02768|P33527|Q9UNQ0|O15244|P08183	474.1	6	1	6	59.5	5.0	1		VEGFA; EGFR; PTK6; TEK; RET	(*)<br>Tyr	Y
Varlitinib		Array Biopharma	CHEMBL2103842	C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5	Single Stereoisomer	nan	2.5	None	AR-00334543 | ARRY-334543 | ARRY-543 | ASLAN-001 | ASLAN001 | VARLITINIB	Investigated for use/treatment in cancer/tumors (unspecified).	nan	P00533|P04626	InChI=1S/C22H19ClN6O2S/c1-13-10-31-22(27-13)29-14-2-4-18-16(8-14)21(26-12-25-18)28-15-3-5-19(17(23)9-15)30-11-20-24-6-7-32-20/h2-9,12-13H,10-11H2,1H3,(H,27,29)(H,25,26,28)/t13-/m1/s1	UWXSAYUXVSFDBQ-CYBMUJFWSA-N	25027380	|http://www.chemspider.com/Chemical-Structure.25027380.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2103842|http://pubchem.ncbi.nlm.nih.gov/compound/42642648|http://www.drugbank.ca/drugs/DB05944|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7645|http://zinc15.docking.org/substances/ZINC000013980035|https://precision.fda.gov/uniisearch/srs/unii/846Y8197W1|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50205268	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.	P04626|P00533	466.1	9	2	6	93.5	5.2	1		EGFR; ERBB2	Tyr	
Vatalanib		Novartis	CHEMBL101253	c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4	Achiral Molecule	nan	3.0	None	BAY-86-5127 | CGP-79787 | K-222584 | NVP-PTK787 | PTK-787 | PTK787 | VATALANIB | VATALANIB SUCCINATE | ZK-222584 | ZK222584	Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).	nan	P17948|P35968|P35916	InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)	YCOYDOIWSSHVCK-UHFFFAOYSA-N	133257	|http://www.chemspider.com/Chemical-Structure.133257.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL101253|http://pubchem.ncbi.nlm.nih.gov/compound/151194|http://www.drugbank.ca/drugs/DB04879|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5705|http://zinc15.docking.org/substances/ZINC00007460|https://precision.fda.gov/uniisearch/srs/unii/5DX9U76296|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=4851	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.	P17948|P35968|P35916	346.1	4	1	4	50.7	5.0	1		FLT1; KDR; FLT4	Tyr	
Vebreltinib		Crown Bioscience	CHEMBL4650443	Cn1cc2cc(C(F)(F)c3nnc4ccc(-c5cnn(C6CC6)c5)nn34)c(F)cc2n1	Achiral Molecule	nan	1.0	None	APL-101 | BOZITINIB | CBI-3103 | CBT-101 | PLB-1001 | VEBRELTINIB	nan	nan	nan	InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3	QHXLXUIZUCJRKV-UHFFFAOYSA-N	72388443	|http://www.chemspider.com/Chemical-Structure.72388443.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650443|http://pubchem.ncbi.nlm.nih.gov/compound/72202701|http://www.drugbank.ca/drugs/DB16823|https://precision.fda.gov/uniisearch/srs/unii/2WZP8A9VFN|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=107096	|ChemSpider|ChEMBL|PubChem|DrugBank|FDA SRS|BindingDB						424.1	8	0	4	78.7	3.5	0		nan		
Vecabrutinib		Sunesis Pharmaceuticals	CHEMBL4297640	c1c(cc(cc1N[C@@H]2CCCN(C2=O)[C@H]3CN(CC[C@@H]3C(=O)N)c4c(c(ncn4)N)F)Cl)C(F)(F)F	Single Stereoisomer	nan	1.0	None	BIIB-062 | BSK-4841 | FP-0182 | FP0182 | SNS-062 | VECABRUTINIB	nan	nan	nan	InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1	QLRRJMOBVVGXEJ-XHSDSOJGSA-N	64835225	|http://www.chemspider.com/Chemical-Structure.64835225.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297640|http://pubchem.ncbi.nlm.nih.gov/compound/72547837|http://www.drugbank.ca/drugs/DB16657|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10231|https://precision.fda.gov/uniisearch/srs/unii/PQ7O0OB5GU	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS				Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).	Q06187	529.2	7	3	5	130.5	2.7	1		nan		
Vemurafenib	Zelboraf	Hoffmann-La Roche	CHEMBL1229517	CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F	Achiral Molecule	2011	4.0	US-7504509-B2	PLX-4032 | PLX4032 | RG 7204 | RG-7204 | RO 5185426 | RO-51-85426 | RO-5185426 | VEMURAFENIB | ZELBORAF	Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.	1.5	P15056	InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)	GPXBXXGIAQBQNI-UHFFFAOYSA-N	24747352	|http://www.chemspider.com/Chemical-Structure.24747352.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1229517|http://pubchem.ncbi.nlm.nih.gov/compound/42611257|http://www.drugbank.ca/drugs/DB08881| http://www.rcsb.org/ligand/032|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/032|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5893|http://zinc15.docking.org/substances/ZINC000052509366|https://precision.fda.gov/uniisearch/srs/unii/207SMY3FQT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50396483	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'032'	3og7 4rzv 5hes		"Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R: FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. (PubMed ID 25096067)"" href=""#reference-A31269"">2</a></sup> It exerts its function by binding to the ATP-binding domain of the mutant BRAF.<sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Luke JJ, Hodi FS: Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012 Jan 1;18(1):9-14. doi: 10.1158/1078-0432.CCR-11-2197. Epub  2011 Nov 14. (PubMed ID 22083257)"" href=""#reference-A31270"">3</a></sup> Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. <sup class=""text-reference-group""><a class=""reference-popover-link"" data-content=""Roche news"" href=""#reference-L1012"">8</a></sup>"	P15056|P05177|P10635|P08684|P11712|P10632|P20813|P02768|P02763	489.1	4	2	7	91.9	5.5	1	272°C	BRAF	TKL	Y
Verosudil		Aerie Pharmaceutical	CHEMBL3545065	CN(C)C(c1ccsc1)C(=O)Nc2ccc3c(c2)cc[nH]c3=O	Racemic Mixture	nan	2.0	None	AR-12286 | AR-12286 FREE BASE | VEROSUDIL	nan	nan	nan	InChI=1S/C17H17N3O2S/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21/h3-10,15H,1-2H3,(H,18,21)(H,19,22)	VDYRZXYYQMMFJW-UHFFFAOYSA-N	32742441	|http://www.chemspider.com/Chemical-Structure.32742441.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545065|http://pubchem.ncbi.nlm.nih.gov/compound/66906051|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8911|https://precision.fda.gov/uniisearch/srs/unii/MAF34143WM	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|FDA SRS						327.1	4	2	4	65.2	2.8	0		nan		
Vevorisertib		ArQule	CHEMBL4802156	CN(C1CCN(CC1)C1C=C(C=CC=1)C1=CC=C2N=C(C3C=CC=NC=3N)N(C2=N1)C1C=CC(=CC=1)C1(N)CCC1)C(C)=O	Achiral Molecule	nan	1.0	None	VEVORISERTIB	nan	nan	nan	InChI=1S/C35H38N8O/c1-23(44)41(2)26-15-20-42(21-16-26)28-7-3-6-24(22-28)30-13-14-31-34(39-30)43(33(40-31)29-8-4-19-38-32(29)36)27-11-9-25(10-12-27)35(37)17-5-18-35/h3-4,6-14,19,22,26H,5,15-18,20-21,37H2,1-2H3,(H2,36,38)	NZDSLYATTDIDPH-UHFFFAOYSA-N	115006931	|http://www.chemspider.com/Chemical-Structure.115006931.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4802156|http://pubchem.ncbi.nlm.nih.gov/compound/71138858|https://precision.fda.gov/uniisearch/srs/unii/V6SX910Y31	|ChemSpider|ChEMBL|PubChem|FDA SRS						586.3	8	2	6	119.2	5.5	2		nan		
Vimseltinib		Deciphera Pharmaceuticals	CHEMBL5095202	Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1Oc1ccnc(-c2cnn(C)c2)c1	Achiral Molecule	nan	3.0	None	|DP-6865|DCC-3014	nan	nan	nan	InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)	TVGAHWWPABTBCX-UHFFFAOYSA-N	95499700	|http://www.chemspider.com/Chemical-Structure.95499700.html|http://pubchem.ncbi.nlm.nih.gov/compound/86267612| http://www.rcsb.org/ligand/Z6V|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/Z6V|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11190|https://precision.fda.gov/uniisearch/srs/unii/PX9FTM69BF	|ChemSpider|PubChem|RCSB|PDBe|Guide to Pharmacology|FDA SRS	'Z6V'	7mfc				431.2	9	1	6	99.8	3.6	0		nan		
Vistusertib		Astrazeneca	CHEMBL2336325	C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC	Single Stereoisomer	nan	2.0	None	AZD-2014 | AZD2014 | VISTUSERTIB	nan	nan	P42345	InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1	JUSFANSTBFGBAF-IRXDYDNUSA-N	28294977	|http://www.chemspider.com/Chemical-Structure.28294977.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2336325|http://pubchem.ncbi.nlm.nih.gov/compound/25262792|http://www.drugbank.ca/drugs/DB11925|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7699|http://zinc15.docking.org/substances/ZINC000059258964|https://precision.fda.gov/uniisearch/srs/unii/0BSC3P4H5X|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50429701	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						462.2	8	1	4	92.7	2.5	0		MTOR	Atypical	
Vodobatinib		Sun Pharma Advanced Research Company	CHEMBL4130229	Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1	Achiral Molecule	nan	2.0	None	K-0706 | K0706 | SCO-088 | VODOBATINIB	nan	nan	nan	InChI=1S/C27H20ClN3O2/c1-17-10-12-22(26(32)30-31-27(33)25-18(2)6-5-8-23(25)28)15-20(17)13-11-19-14-21-7-3-4-9-24(21)29-16-19/h3-10,12,14-16H,1-2H3,(H,30,32)(H,31,33)	ZQOBVMHBVWNVBG-UHFFFAOYSA-N	81367338	|http://www.chemspider.com/Chemical-Structure.81367338.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4130229|http://pubchem.ncbi.nlm.nih.gov/compound/89884852|http://www.drugbank.ca/drugs/DB17141|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11191|https://precision.fda.gov/uniisearch/srs/unii/N8Q12KU2SW	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|FDA SRS						453.1	3	2	2	71.1	5.0	0		nan		
Volasertib		Boehringer Ingelheim	CHEMBL1233528	CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C	Single Stereoisomer	nan	3.0	None	BI 6727 | BI-6727 | VOLASERTIB	nan	1	P53350	InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1	SXNJFOWDRLKDSF-STROYTFGSA-N	26327706	|http://www.chemspider.com/Chemical-Structure.26327706.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1233528|http://www.drugbank.ca/drugs/DB12062| http://www.rcsb.org/ligand/IBI|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/IBI|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7947|https://precision.fda.gov/uniisearch/srs/unii/6EM57086EA|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50402023	|ChemSpider|ChEMBL|DrugBank|RCSB|PDBe|Guide to Pharmacology|FDA SRS|BindingDB	'IBI'	3fc2 5v67 5vbr 7lak 7lej 7n7n		Volasertib has been used in trials studying the treatment of Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Monocytic, Acute, among others.	P53350	618.4	9	2	10	106.2	4.3	1		PLK1	Other	
Vorolanib		Tyrogenex	CHEMBL4297587	Cc1c([nH]c(c1C(=O)N[C@H]2CCN(C2)C(=O)N(C)C)C)/C=C\3/c4cc(ccc4NC3=O)F	Single Stereoisomer	nan	2.0	None	VOROLANIB	nan	nan	nan	InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1	KMIOJWCYOHBUJS-HAKPAVFJSA-N	58827733	|http://www.chemspider.com/Chemical-Structure.58827733.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4297587|http://pubchem.ncbi.nlm.nih.gov/compound/59215954|http://www.drugbank.ca/drugs/DB15247|https://precision.fda.gov/uniisearch/srs/unii/YP8G3I74EL	|ChemSpider|ChEMBL|PubChem|DrugBank|FDA SRS						439.2	3	3	3	97.5	2.7	0		nan		
Voruciclib		Piramal Enterprises	CHEMBL3905910	CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O	Single Stereoisomer	nan	2.0	None	P1446A-05 | VORUCICLIB	nan	nan	P11802	InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1	MRPGRAKIAJJGMM-OCCSQVGLSA-N	29165867	|http://www.chemspider.com/Chemical-Structure.29165867.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3905910|http://pubchem.ncbi.nlm.nih.gov/compound/67409219|http://www.drugbank.ca/drugs/DB15157|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9923|http://zinc15.docking.org/substances/ZINC000118905502|https://precision.fda.gov/uniisearch/srs/unii/W66XP666AM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50193104	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						469.1	6	3	3	94.1	4.3	0		CDK4	CMGC	
Voxtalisib		Sanofi	CHEMBL3545366	CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C	Achiral Molecule	nan	2.0	None	SAR-245409 | SAR245409 | VOXTALISIB | XL-765 | XL765	nan	nan	P42336|P42345	InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)	RGHYDLZMTYDBDT-UHFFFAOYSA-N	17279963	|http://www.chemspider.com/Chemical-Structure.17279963.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3545366|http://pubchem.ncbi.nlm.nih.gov/compound/16123056|http://www.drugbank.ca/drugs/DB12400|http://zinc15.docking.org/substances/ZINC000035308805|https://precision.fda.gov/uniisearch/srs/unii/CVL1685GPH|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50519385	|ChemSpider|ChEMBL|PubChem|DrugBank|ZINC|FDA SRS|BindingDB						270.1	6	2	2	102.5	1.1	0		PIK3CA; MTOR	Atypical	
Zabedosertib		Bayer		CC(C)(O)C1=CC2=NN(CCS(C)(=O)=O)C=C2C=C1NC(=O)C1C=CC=C(N=1)C(F)(F)F			2.0						InChI=1S/C20H21F3N4O4S/c1-19(2,29)13-10-15-12(11-27(26-15)7-8-32(3,30)31)9-16(13)25-18(28)14-5-4-6-17(24-14)20(21,22)23/h4-6,9-11,29H,7-8H2,1-3H3,(H,25,28)	OQAMEEFUUFJZRS-UHFFFAOYSA-N	101935510	|http://www.chemspider.com/Chemical-Structure.101935510.html|http://pubchem.ncbi.nlm.nih.gov/compound/121364961|https://precision.fda.gov/uniisearch/srs/unii/N1GRK350ZM|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=395297	|ChemSpider|PubChem|FDA SRS|BindingDB						470.1	7	2	6	114.2	3.0	0		nan	(*)	
Zandelisib		Pathway Therapeutics	CHEMBL4650214	CN1CCC(c2ccccc2CC(C)(C)Nc2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1	Achiral Molecule	nan	3.0	None	ACC-524 | ME-401 | PW-143 | PWT-143 | PWT143 | ZANDELISIB	nan	nan	nan	InChI=1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)	WPFUFWIHMYZXSF-UHFFFAOYSA-N	57617733	|http://www.chemspider.com/Chemical-Structure.57617733.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650214|http://pubchem.ncbi.nlm.nih.gov/compound/66571003|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10627|http://zinc15.docking.org/substances/ZINC000148868634|https://precision.fda.gov/uniisearch/srs/unii/8Z28M5SX0X	|ChemSpider|ChEMBL|PubChem|Guide to Pharmacology|ZINC|FDA SRS						576.3	9	1	8	84.2	5.2	2		nan		
Zanubrutinib	Brukinsa	BeiGene	CHEMBL3936761	C=CC(=O)N1CCC(CC1)C2CCNc3n2nc(c3C(=O)N)c4ccc(cc4)Oc5ccccc5	Single Stereoisomer	2019	4.0	US-9447106-B2		"Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [<a href='javascript:callRef(""ReferenceDisplayForward?referenceId=34570,34571&displayId=1,2"", 960, 600)' title=""1. Robak P, Robak T. (2017) Expert Opin Investig Drugs. 26 (11): 1249-1265; 2. Thompson PA, Burger JA. (2018) Expert Opin Investig Drugs. 27 (1): 31-42"">1-2</a>]."	nan	nan	InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)	RNOAOAWBMHREKO-UHFFFAOYSA-N	60600294	|http://www.chemspider.com/Chemical-Structure.60600294.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3973435|http://pubchem.ncbi.nlm.nih.gov/compound/135905454|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=249900	|ChemSpider|ChEMBL|PubChem|BindingDB						471.2	6	2	6	102.5	4.2	0		nan		Y
Zanzalintinib		Exelixis	CHEMBL5095390	COC1=CC2=NC=CC(OC3C=CC(=CC=3)NC(=O)C3(CC3)C(=O)NC3C=CC(F)=CC=3)=C2C=C1C(=O)NC	Achiral Molecule	nan	3.0	None	|XL-092|ZANZALINTINIB|XL092	nan	nan	nan	InChI=1S/C29H25FN4O5/c1-31-26(35)22-15-21-23(16-25(22)38-2)32-14-11-24(21)39-20-9-7-19(8-10-20)34-28(37)29(12-13-29)27(36)33-18-5-3-17(30)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,35)(H,33,36)(H,34,37)	JSPCKALGNNVYOO-UHFFFAOYSA-N	114641993	|http://www.chemspider.com/Chemical-Structure.114641993.html|http://pubchem.ncbi.nlm.nih.gov/compound/139350422	|ChemSpider|PubChem						528.2	6	3	8	118.7	4.9	1		nan		
Zapnometinib		University of Muenster	CHEMBL4802192	C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)O	Achiral Molecule	nan	2.0	None	PD-0184264	nan	nan	nan	InChI=1S/C13H7ClF2INO2/c14-8-5-6(17)1-4-10(8)18-12-7(13(19)20)2-3-9(15)11(12)16/h1-5,18H,(H,19,20)	XCNBGWKQXRQKSA-UHFFFAOYSA-N	8287717	|http://www.chemspider.com/Chemical-Structure.8287717.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL481949|http://pubchem.ncbi.nlm.nih.gov/compound/10112191|http://zinc15.docking.org/substances/ZINC000022054634|https://precision.fda.gov/uniisearch/srs/unii/4RZD8LK83V	|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS						408.9	2	2	3	49.3	4.7	0		nan		
Zeteletinib		Daiichi Sankyo	CHEMBL5095497	CC(C)(C1C=C(NC(=O)CC2C=NC(=CC=2)C2C=C3C=C(OC)C(=CC3=NC=2)OC)ON=1)C(F)(F)F	Achiral Molecule	nan	1.0	None	|BOS172738 HEMIADIPATE|BOS172738|DS-5010|BOS-172738|DS5010	nan	nan	nan	InChI=1S/C25H23F3N4O4/c1-24(2,25(26,27)28)21-11-23(36-32-21)31-22(33)7-14-5-6-17(29-12-14)16-8-15-9-19(34-3)20(35-4)10-18(15)30-13-16/h5-6,8-13H,7H2,1-4H3,(H,31,33)	KOLQINCWMXQEOF-UHFFFAOYSA-N	115007145	|http://www.chemspider.com/Chemical-Structure.115007145.html|http://pubchem.ncbi.nlm.nih.gov/compound/134391533|https://precision.fda.gov/uniisearch/srs/unii/EP0P7SHM0U|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=475603	|ChemSpider|PubChem|FDA SRS|BindingDB						500.2	7	1	7	99.4	5.3	2		nan		
Zeteletinib 				C1=CC(=CC=C1CCO)OC(F)(F)F		nan	1.0		|BOS172738 HEMIADIPATE|BOS172738|DS-5010|BOS-172738|DS5010	nan	nan	nan	InChI=1S/C9H9F3O2/c10-9(11,12)14-8-3-1-7(2-4-8)5-6-13/h1-4,13H,5-6H2	RILZRCJGXSFXNE-UHFFFAOYSA-N	8926090	|http://www.chemspider.com/Chemical-Structure.8926090.html|http://pubchem.ncbi.nlm.nih.gov/compound/10750766|http://zinc15.docking.org/substances/ZINC25724370	|ChemSpider|PubChem|ZINC						206.1	2	1	3	29.5	2.1	0		nan		
Zimlovisertib		Pfizer	CHEMBL4081711	CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F	Single Stereoisomer	nan	2.0	None	PF 06650833 | PF-06650833 | ZIMLOVISERTIB	nan	nan	nan	InChI=1S/C18H20FN3O4/c1-3-10-13(22-17(24)15(10)19)8-26-18-11-7-14(25-2)12(16(20)23)6-9(11)4-5-21-18/h4-7,10,13,15H,3,8H2,1-2H3,(H2,20,23)(H,22,24)/t10-,13+,15-/m0/s1	JKDGKIBAOAFRPJ-ZBINZKHDSA-N	58805665	|http://www.chemspider.com/Chemical-Structure.58805665.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4081711|http://pubchem.ncbi.nlm.nih.gov/compound/118414016|http://www.drugbank.ca/drugs/DB15143| http://www.rcsb.org/ligand/8CG|http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/8CG|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9667|http://zinc15.docking.org/substances/ZINC000526061587|https://precision.fda.gov/uniisearch/srs/unii/S3F315JJXI|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50239499	|ChemSpider|ChEMBL|PubChem|DrugBank|RCSB|PDBe|Guide to Pharmacology|ZINC|FDA SRS|BindingDB	'8CG'	5uiu				361.1	5	2	6	103.5	1.6	0		nan		
Zipalertinib		Taiho Pharmaceutical	CHEMBL4650281	C=CC(=O)N[C@H]1C=C(C)c2c(-c3cnc4ccccc4c3)c3c(N)ncnc3n2C1	Single Stereoisomer	nan	1.0	None	CLN 081 | CLN-081 | CLN081 | TAS-6417 | TAS6417 | ZIPALERTINIB	nan	nan	nan	InChI=1S/C23H20N6O/c1-3-18(30)28-16-8-13(2)21-19(15-9-14-6-4-5-7-17(14)25-10-15)20-22(24)26-12-27-23(20)29(21)11-16/h3-10,12,16H,1,11H2,2H3,(H,28,30)(H2,24,26,27)/t16-/m0/s1	MKCYPWYURWOKST-INIZCTEOSA-N	71117518	|http://www.chemspider.com/Chemical-Structure.71117518.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL4650281|http://pubchem.ncbi.nlm.nih.gov/compound/117918742	|ChemSpider|ChEMBL|PubChem						396.2	6	2	3	98.7	3.3	0		nan		
Zorifertinib		Astrazeneca	CHEMBL3623290	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	Single Stereoisomer	nan	2.0	None	AZD 3759 | AZD-3759 | AZD3759 | ZORIFERTINIB	nan	nan	nan	InChI=1S/C22H23ClFN5O3/c1-13-11-28(2)7-8-29(13)22(30)32-19-9-14-17(10-18(19)31-3)25-12-26-21(14)27-16-6-4-5-15(23)20(16)24/h4-6,9-10,12-13H,7-8,11H2,1-3H3,(H,25,26,27)/t13-/m1/s1	MXDSJQHFFDGFDK-CYBMUJFWSA-N	38772332	|http://www.chemspider.com/Chemical-Structure.38772332.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3623290|http://pubchem.ncbi.nlm.nih.gov/compound/78209992|http://www.drugbank.ca/drugs/DB14795|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10456|http://zinc15.docking.org/substances/ZINC000221149242|https://precision.fda.gov/uniisearch/srs/unii/67SX9H68W2|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50123453	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB						459.1	7	1	4	79.8	4.3	0		nan		
Zotiraciclib		S*BIO	CHEMBL1944698	CN1C/C=C/CCOc2cccc(c2)-c3ccnc(n3)Nc4cccc(c4)C1	Achiral Molecule	nan	1.0	None	EX 45 | EX45 | SB-1317 | SB-1317 FREE BASE | SB1317 | TG-02 | TG02 | ZOTIRACICLIB	nan	nan	nan	InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+	VXBAJLGYBMTJCY-NSCUHMNNSA-N	20571045	|http://www.chemspider.com/Chemical-Structure.20571045.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1944698|http://pubchem.ncbi.nlm.nih.gov/compound/16739650|http://www.drugbank.ca/drugs/DB16656|http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9095|http://zinc15.docking.org/substances/ZINC000068251500|https://precision.fda.gov/uniisearch/srs/unii/40D08182TT|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50363196	|ChemSpider|ChEMBL|PubChem|DrugBank|Guide to Pharmacology|ZINC|FDA SRS|BindingDB				Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).	P50750|P06241|P06239	372.2	5	1	0	50.3	4.7	0		nan		
Zunsemetinib		Aclaris Therapeutics	CHEMBL3704901	Cc1cnc(-c2ccnc(C(C)(C)O)n2)cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O	Achiral Molecule	nan	2.0	None	ATI 450 | ATI-450 | ATI450 | CDD-450 | CDD450 | ZUNSEMETINIB	nan	nan	nan	InChI=1S/C25H22ClF2N5O3/c1-13-10-30-18(17-5-6-29-24(32-17)25(3,4)35)9-20(13)33-14(2)7-21(22(26)23(33)34)36-12-19-16(28)8-15(27)11-31-19/h5-11,35H,12H2,1-4H3	FQPQMJULRZINPV-UHFFFAOYSA-N	58947940	|http://www.chemspider.com/Chemical-Structure.58947940.html|https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3704901|http://pubchem.ncbi.nlm.nih.gov/compound/86291496|http://zinc15.docking.org/substances/ZINC000220110608|https://precision.fda.gov/uniisearch/srs/unii/AX2VWG0ZCR|http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=175242	|ChemSpider|ChEMBL|PubChem|ZINC|FDA SRS|BindingDB						513.1	8	1	6	103.0	4.4	1		nan		
Zurletrectinib		InnoCare Pharma	CHEMBL5095426	C[C@H]1CNC(=O)Nc2cnn3ccc(nc23)N2C[C@@H](F)C[C@@H]2c2cc(F)cnc2O1	Single Stereoisomer	nan	-1.0	None	|ICP-723	nan	nan	nan	InChI=1S/C19H19F2N7O2/c1-10-6-23-19(29)25-14-8-24-28-3-2-16(26-17(14)28)27-9-12(21)5-15(27)13-4-11(20)7-22-18(13)30-10/h2-4,7-8,10,12,15H,5-6,9H2,1H3,(H2,23,25,29)/t10-,12-,15+/m0/s1	OIBWCYRRWAMTRW-ITDIGPHOSA-N		|http://www.chemspider.com/Chemical-Structure..html|http://pubchem.ncbi.nlm.nih.gov/compound/156371488	|ChemSpider|PubChem						415.2	7	2	0	96.7	2.5	0		nan		
